UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934 (Amendment No.    )

 

 

Filed by the Registrant                               Filed by a Party other than the Registrant  

Check the appropriate box:

 

  Preliminary Proxy Statement
  Confidential, for Use of the Commission Only (as permitted by Rule14a-6(e)(2))
  Definitive Proxy Statement
  Definitive Additional Materials
  Soliciting Material Pursuant to§240.14a-12

 

LOGOLOGO

EXELIXIS, INC.

(Exact name of registrant as specified in its charter)

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

 No fee required.
 Fee computed on table below per Exchange Act Rules14a-6(i)(1) and0-11.
 (1)  

Title of each class of securities to which transaction applies:

 

     

 (2)  

Aggregate number of securities to which transaction applies:

 

     

 (3)  

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

 

     

 (4)  

Proposed maximum aggregate value of transaction:

 

     

 (5)  

Total fee paid:

 

     

 Fee paid previously with preliminary materials.
 Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
 (1)  

Amount Previously Paid:

 

     

 (2)  

Form, Schedule or Registration Statement No.:

 

     

 (3)  

Filing Party:

 

     

 (4)  

Date Filed:

 

     

 

 

 


LOGOLOGO

DEAR FELLOW STOCKHOLDERS,

While we could never have envisioned the magnitude and impact of the COVID-19 pandemic, Exelixis responded well to the challenges presented and never lost focus of its critical mission to help cancer patients recover stronger and live longer. We, writeand the rest of the Board, are incredibly proud of the entire Exelixis team’s ability throughout 2020 to advance the company’s business, while always putting the highest priority on protecting one another’s health and safety and ensuring an uninterrupted supply of Exelixis medicines for the patients that depend upon them. Exelixis’ actions reflect its core values to Be Exceptional, Excel for Patients and Exceed Together.

The success and growth Exelixis achieved in 2020 would be noteworthy in any year, but is even more striking in the context of the pandemic. In particular, we:

Achieved positive top-line results from two pivotal clinical trials, including data that supported U.S. Food and Drug Administration and European Commission approvals of our franchise molecule CABOMETYX® (cabozantinib) in combination with OPDIVO® (nivolumab) as a first-line treatment for patients with advanced renal cell carcinoma in early 2021;

Advanced enrollment in multiple potentially label-enabling trials and initiated three new pivotal studies;

Presented seven data sets from clinical trials evaluating CABOMETYX® in a variety of settings and tumor types;

Progressed our product pipeline by expanding the ongoing phase 1b trial of XL092, in-licensing and readying XL102 and XB002 for clinical development, and advancing our internal programs; and

Expanded our workforce by 25% with the skill and experience required to support our future growth plans, and laid the groundwork necessary to scale sustainably and efficiently, including through the continued expansion of our Alameda headquarters.

Our achievements during the year were supported by a strong foundation of sound governance practices, including the continued evolution of our governance profile to reflect the scale and opportunity of our business. Launched shortly before the onset of the pandemic, the newly established Risk Committee of the Board served as an additional avenue through which management was able to communicate to the Board on the impact of and responses to the COVID-19 pandemic. In addition, the existing Research & Development and Compensation Committees provided important oversight and support for the drug discovery and development activities integral to our progress, and also worked with management to support the company’s efforts to recruit, retain, and cultivate the unified workforce that accomplished so much during the year.

Critical to our success in 2020 was the dedication of our employees and our collective ability to maintain the Exelixis culture of resilience, despite a primarily remote work environment. As a socially responsible company conscious of the expanding racial injustice movement, it was also critical for us to focus on our human capital management strategy and equity, diversity and inclusion initiatives. While there is always work to do, we are proud of our progress and are committed to fostering a culture where every employee feels a sense of belonging to the Exelixis team and our mission.

Exelixis’ accomplishments last year not only create the potential for additional eligible cancer patient communities to benefit from CABOMETYX and the investigational products in our growing pipeline, but we believe they also position us very well to deliver long-term revenue and earnings growth and continue to create value for our stockholders. We remain committed to delivering results for all of our stakeholders, and we thank you for your continued interest in Exelixis, and your confidence in the company’s ability to execute on its mission to accelerate the discovery, development and commercialization of new medicines forsupport.

difficult-to-treat cancers. As we navigate theCOVID-19 pandemic, now more than ever we recognize the critical importance of this company – and more broadly the importance of a strong and innovative biotech industry – in confronting the most serious medical challenges, such as cancer, and developing innovative medicines that can give patients and their familiesWe hope you will join us for the future.

As detailed in the accompanying letter from Michael Morrissey and in our Annual Report, Exelixis’ 25th year was one of strong performance, financially, operationally and strategically. The company produced record annual net product revenues, dramatically increased its understanding of the broad therapeutic potential of cabozantinib, and gained strong momentum pursuing the expansion of its product pipeline through internal discovery andin-licensing activities. These achievements strengthened our foundation, giving us reason to be optimistic as we strive to continue Exelixis’ growth and create value for all of its stakeholders.

During the last year, we also announced the launch of a variety of environmental, social and governance (ESG) initiatives that reflect our ESG values. We appreciate the ongoing dialogue with our stakeholders as we have elicited input from numerous groups regarding the ESG issues that are most material to the company’s current and future activities. We are pleased to highlight that in 2019, the Exelixis Board continued to optimize our corporate governance profile, most notably by amending our Bylaws to provide stockholders with the right to call a special meeting. The Board approved this change following extensive engagement with our stockholders, during which special meetings were identified as critical to the ability of stockholders to act on matters that may arise between annual meetings. We believe this change demonstrates the Board’s dedication to being responsive to stockholder input concerning governance and we remain committed to the ongoing evaluation of our governance profile as Exelixis and its business evolve.

Next up is the Exelixis 20202021 Annual Meeting of Stockholders, which will be held in a virtual format on May 20, 2020,26, 2021, beginning at 10:9:00 a.m. Pacific Time. We have moved to a virtual format dueDue to the emergingongoing public health impact of theCOVID-19 pandemic and to support the health and well-being of our stockholders and employees.employees, we determined it would be appropriate to maintain the virtual format we used for last year’s meeting. You will be able to view the meeting, submit questions and vote online atwww.virtualshareholdermeeting.com/EXEL2020EXEL2021. The following notice of our Annual Meeting contains details of the business to be conducted at the Annual Meeting, as well as information regarding how and when to vote.

We appreciate your attention and hope for the best for you and your families during this challenging period.

Very truly yours,

 

LOGO      LOGO 

Stelios Papadopoulos, PhD

Chair of the Board

  

    Charles Cohen, PhD

    Chair of the Compensation Committee

 

                  


   LOGOLOGO 

1851 Harbor Bay Parkway

Alameda, CA 94502

NOTICEOF ANNUAL MEETING

OF STOCKHOLDERS

To Be Held on May 20, 2020TO BE HELDON MAY 26, 2021

To the Stockholders of Exelixis, Inc.:

NOTICE IS HEREBY GIVEN that the 20202021 Annual Meeting of Stockholders (Annual Meeting) of Exelixis, Inc., a Delaware corporation (Exelixis), will be held on Wednesday, May 20, 2020,26, 2021, at 10:9:00 a.m., Pacific Time. The Annual Meeting will be a completely virtual meeting of stockholders, which will be conducted via live webcast. You will be able to attend the virtual Annual Meeting, andview our list of stockholders as of the record date, submit your questions and vote your shares online during the meeting by visitingwww.virtualshareholdermeeting.com/EXEL2020EXEL2021 and using your16-digit control number to enter the Annual Meeting. In addition, you may submit your questions and vote your shares online in advance of the meetingAnnual Meeting by visitingwww.proxyvote.com and using your16-digit control number. The Annual Meeting will be held for the following purposes:

 

1.

To elect the eleven nominees for director named in the Proxy Statement accompanying this Notice of Annual Meeting to hold office until the next annual meeting of stockholders and until his or her successor is duly elected and qualified or until his or her death, resignation or removal.

 

2.

To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Exelixis’ independent registered public accounting firm for the fiscal year ending January 1,December 31, 2021.

 

3.

To amend and restate the Exelixis 2017 Equity Incentive Plan (2017 Plan) to, among other things, increase the number of shares authorized for issuance by 21,000,000 shares.

4.

To approve, on an advisory basis, the compensation of Exelixis’ named executive officers, as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting.

 

5.4.

To conduct any other business properly brought before the meeting.

These items of business are more fully described in the Proxy Statement accompanying this Notice of Annual Meeting.

You will only be able to attend the virtual Annual Meeting by using your16-digit control number provided on your Notice of Internet Availability of Proxy Materials (Notice of Availability), your proxy cardorcardor your voting instruction form in order to gain access to the virtual Annual Meeting. Therefore, it is important to retain your Notice of Internet Availability of Proxy Materials or a copy of your proxy card or voting instruction form to enable you to gain access to the virtual Annual Meeting. If you are a beneficial owner of shares held in “street name” who did not receive a 16-digit control number via email or on your Notice of Availabilty or voting instruction form, and you wish to attend the Annual Meeting, please follow the specific instructions from your broker, bank or other stockholder of record, including any requirement to obtan a valid legal proxy.

We are mailing to most of our stockholders a Notice of Internet Availability of Proxy Materials (Notice of Availability) instead of a paper copy of thisour Proxy Statement and our Annual Report for the fiscal year ended January 3, 20201, 2021 (Annual Report). The Notice of Availability contains instructions on how to access those documents over the Internet. The Notice of Availability also contains instructions on how to request a paper copy of our proxy materials, including this Proxy Statement, our Annual Report and a form of proxy card or voting instruction form. All stockholders who do not receive a Notice of Availability will receive a paper copy of the proxy materials by mail. We believe that this process will allow us to provide our stockholders with the information they need in a more timely manner, while reducing the environmental impact and lowering the costs of printing and distributing our proxy materials.

The record date for the Annual Meeting is March 23, 2020.29, 2021. Only stockholders of record at the close of business on that date may vote at the meeting or any postponement or adjournment thereof.

 

Important notice regarding the availability of proxy materials for the 20202021 Annual Meeting of Stockholders to be held on May 20, 2020,26, 2021, at 10:9:00 a.m., Pacific Time, via live webcast atwww.virtualshareholdermeeting.com/EXEL2020EXEL2021. You will need your 16-digit control number provided on your Notice of Internet Availability of Proxy Materials, your proxy card or your voting instruction form in order to gain access to the virtual Annual Meeting.

 

The Proxy Statement and Annual Report to stockholders are available atwww.exel-annualstockholdermeeting.com.

 

The Board of Directors recommends that you vote "FOR"“FOR” Proposal Nos. 1-41-3 identified above.

By Order of the Board of Directors

 

LOGO

JEFFREY J. HESSEKIEL

Executive Vice President and General Counsel

Alameda, California

April 9, 202015, 2021


YOUR VOTE IS IMPORTANT

WHETHER OR NOT YOU PLAN TO ATTEND THE VIRTUAL ANNUAL MEETING, TO ENSURE THAT YOU ARE REPRESENTED AT THE MEETING AND TO ENSURE THAT A QUORUM IS PRESENT, WE URGE YOU TO VOTE YOUR PROXY ONLINE, BY TELEPHONE OR BY RETURNING A PROXY CARD BY MAIL AS INSTRUCTED IN THE NOTICE OF AVAILABILITY OF PROXY MATERIALS. EVEN IF YOU HAVE VOTED BY PROXY, YOU MAY STILL VOTE IF YOU ATTEND THE VIRTUAL ANNUAL MEETING. PLEASE NOTE, HOWEVER, THAT IF YOU HOLD YOUR SHARES THROUGH A BROKER, BANK OR OTHER NOMINEE, THEN THAT ENTITY IS THE STOCKHOLDER OF RECORD, AND YOU WILL NEED TO FOLLOW THE INSTRUCTIONS ON THE VOTING INSTRUCTION FORM THEY SEND TO YOU, AND THEY WILL VOTE YOUR SHARES AS YOU DIRECT, DIRECT.


1851 Harbor Bay Parkway

Alameda, CA 94502

PROXY STATEMENT

FOR YOU MUST OBTAINTHE 2021 A PROXY ISSUED IN YOUR NAME FROM THAT ENTITY TO VOTE YOUR SHARES.NNUAL MEETINGOF STOCKHOLDERS

May 26, 2021

Proposals to be voted on at the 2021 Annual Meeting of Stockholders

1.To elect the eleven nominees for director named in the Proxy Statement accompanying this Notice of Annual Meeting to hold office until the next annual meeting of stockholders and until his or her successor is duly elected and qualified or until his or her death, resignation or removal.
2.To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Exelixis’ independent registered public accounting firm for the fiscal year ending December 31, 2021.
3.To approve, on an advisory basis, the compensation of Exelixis’ named executive officers, as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting.
4.To conduct any other business properly brought before the meeting.


Table of Contents

 

TABLE OF CONTENTS

 

Notice of Annual Meeting of Stockholders
Questions and Answers about these Proxy Materials and Voting   1 
Proposal 1: Election of Directors   8 

Corporate Governance

   16 

Board Committees and Meetings

   2021 

Annual Meeting; Attendance

   2526 
Compensation of Directors   2627 

Director Compensation Table

   2829 
Proposal 2: Ratification of Selection of Independent Registered Public Accounting Firm   3031 
Report of the Audit Committee   3233 
Proposal 3: Amendment and Restatement of 2017 Equity Incentive Plan33
Proposal 4: Advisory Vote on the Compensation of the Named Executive OfficerOfficerss   4934 

Required Vote and Board of Directors Recommendation

   4934 
Security Ownership of Certain Beneficial Owners and Management   5035 
Information about our Executive Officers   5338 
Compensation of Executive Officers   5540 

Compensation Discussion and Analysis

   5540 

Executive Summary

   5540 

Objectives of the Compensation Program

   5945 

How We Determine Executive Compensation

   6046 

Compensation Elements

   6450 

Compensation Mix

   6652 

20192020 Compensation Decisions

   6652 

Other Compensation Information

   7564 

Compensation Policies and Practices as They Relate to Risk Management

   7665 

Summary of Compensation

   7766 

Grants of Plan-Based Awards

   7969 

Compensation Arrangements

   8070 

Outstanding Equity Awards at FiscalYear-End

   8171 

Option Exercises and Stock Vested

   8474 

Potential Payments Upon Termination or Change in Control

   8475 

CEO Pay Ratio

   8878 
Compensation Committee Report   8980 
Compensation Committee Interlocks and Insider Participation   8980
Delinquent Section 16(a) Reports80 
Certain Relationships and Related Party Transactions   8980 
Householding of Proxy Materials   9081 
Annual Report of Form10-K   9081 
Other Matters   9081 

 

2020 Proxy Statement    i

2021 Proxy Statement    i


Proxy Statement | Questions and Answers about these Proxy Materials and Voting

 

LOGO

1851 Harbor Bay Parkway

Alameda, CA 94502

PROXY STATEMENT

FORTHE 2020 ANNUAL MEETINGOF STOCKHOLDERS

MAY 20, 2020

QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING

Why am I receiving these materials?

We have made these materials available to you on the Internet or, upon your request, have delivered printed versions of these materials to you by mail because the Board of Directors (the Board), of Exelixis, Inc. (sometimes referred to as “we,” “us,” the “company” or “Exelixis”) is soliciting your proxy to vote at the 20202021 Annual Meeting of Stockholders (Annual Meeting), including at any adjournments or postponements of the meeting. The virtual Annual Meeting will be held on Wednesday, May 20, 2020,26, 2021, at 10:9:00 a.m., Pacific Time, via live webcast atwww.virtualshareholdermeeting.com/EXEL2020EXEL2021. We invite you to attend the virtual Annual Meeting to vote on the proposals described in this Proxy Statement, and you will need your16-digit control number provided on your Notice of Internet Availability of Proxy Materials (described below), your proxy card or your voting instruction form in order to gain access to the virtual Annual Meeting. Therefore, it is important to retain your Notice of Internet Availability of Proxy Materials or a copy of your proxy card or voting instruction form to enable you to gain access to the virtual Annual Meeting. However, you do not need to attend the virtual Annual Meeting to vote your shares. Instead, you may simply complete, sign and return a proxy card, or follow the instructions below or in the Notice of Internet Availability of Proxy Materials to submitvote your proxyshares over the telephone or on the Internet.

We intend to send or make available these materials to stockholders on April 9, 2020.15, 2021.

Why is the Annual Meeting being held as a virtual Annual Meeting?

Due to concerns regarding theCOVID-19 pandemic and to assist in protecting the health and well-being of our stockholders and employees, the Annual Meeting will be held virtually via live webcast on the Internet. WeAfter utilizing a virtual format for our 2020 Annual Meeting of Stockholders, we have designed thea similar virtual format offor the Annual Meeting to ensure that our stockholders who attend virtually will be afforded the same rights and opportunities to participate as they would at anin-person meeting. Accordingly, as stockholders from any location at the world and at no cost, you will be able to listen, submit your questions and vote your shares online regardless of location atwww.virtualshareholdermeeting.com/EXEL2020EXEL2021 by using your16-digit control number provided on your Notice of Internet Availability of Proxy Materials, your proxy card or your voting instruction form that accompanied your proxy materials. In addition, you may submit your questions and vote your shares online in advance of the meeting by visitingwww.proxyvote.com and using your16-digit control number.

The live webcast will begin promptly at 10:9:00 a.m., Pacific Time. We encourage you to access the meeting prior to the start time, as you should allow ample time for thecheck-in procedures.

What is included in these proxy materials?

These proxy materials include:

 

 

The Notice of Annual Meeting;

 

 

The Proxy Statement for the Annual Meeting; and

 

 

Our Annual Report on Form10-K for the fiscal year ended January 3, 2020,1, 2021, as filed withsubmitted to the Securities and Exchange Commission (SEC) on February 25, 202010, 2021 (Annual Report).

If you requested printed versions by mail, these proxy materials also include the proxy card or voting instruction form for the virtual Annual Meeting.

2020 Proxy Statement    1


Why did I receive aone-page notice in the mail regarding Internet availability of proxy materials instead of a full set of printed proxy materials?

Pursuant to rules adopted by the SEC, we have elected to use the Internet as the primary means of furnishing proxy materials to our stockholders this year. This method allows us to deliver the proxy materials to you more quickly, lowers our costs significantly and helps to conserve natural resources. Accordingly, we are sending a Notice of Internet Availability of Proxy Materials (Notice of Availability) to our stockholders who have not asked us to provide proxy materials in printed form. All stockholders receiving a Notice of Availability can request a printed set of proxy materials. Moreover, all stockholders can access the proxy materials atwww.exel-annualstockholdermeeting.com, irrespective of whether they receive a Notice of Availability or a printed copy of the proxy materials. Instructions on how to access the proxy materials on the Internet or how to request a printed copy may be found in the Notice of Availability and in this Proxy Statement.

2021 Proxy Statement    1


In addition, a stockholder may ask to receive proxy materials in printed form by mail or electronically by email on an ongoing basis. We encourage stockholders to take advantage of the option to receive proxy materials electronically by email to help reduce the environmental impact of our annual meeting and to reduce costs associated with the physical printing and mailing of materials. If you choose to receive future proxy materials by email, you will receive an email message next year with instructions containing a link to those materials and a link to the proxy voting website. Your election to receive proxy materials by email will remain in effect until you terminate it.

How can I access the list of stockholders of record?

The list of stockholders of record entitled to vote at the virtual Annual Meeting will be available for 10 days prior to the Annual Meeting for any purpose germane to the Annual Meeting, between the hours of 9:00 a.m. and 5:00 p.m., Pacific Time, at our principal executive offices located at 1851 Harbor Bay Parkway, Alameda, California 94502 by contacting our Corporate Secretary. Due to the COVID-19 pandemic, registered stockholders must make an appointment and must comply with our COVID-19 protocols.

The list of stockholders of record will also be available at and through the conclusion of the Annual Meeting via the virtual meeting website at www.virtualshareholdermeeting.com/EXEL2021.

Who may vote at the Annual Meeting?

Only stockholders of record at the close of business on March 23, 202029, 2021 (the Record Date) will be entitled to vote at the virtual Annual Meeting. On the Record Date, there were 305,733,496313,097,850 shares of common stock outstanding and entitled to vote.

Stockholder of Record: Shares Registered in Your Name

If on March 23, 2020,29, 2021, your shares were registered directly in your name with our transfer agent, Computershare Trust Company, N.A., then you are a stockholder of record. As a stockholder of record, you may vote at the virtual Annual Meeting or vote by proxy. Whether or not you plan to attend the virtual Annual Meeting, we urge you to vote by proxy over the telephone or on the Internet as instructed below, or complete and mail the proxy card if you received printed materials.

Beneficial Owner: Shares Registered in the Name of a Broker, Bank or Other Stockholder of Record (i.e., “Street Name”)

If on March 23, 2020,29, 2021, your shares were held in an account at a brokerage firm, bank, dealer, or other similar organization, then you are the beneficial owner of shares held in “street name,” and these proxy materials are being forwarded to you by that organization. The organization holding your shares is considered to be the stockholder of record for purposes of voting at the virtual Annual Meeting. As a beneficial owner, you have the right to direct your broker, bank or other stockholder of record regarding how to vote the shares in your account, and we invite you to attend the virtual Annual Meeting. Many stockholders of record will provide you with a 16-digit control number via email or in your Notice of Availability or voting instruction form in order to attend and vote your shares at the virtual Annual Meeting. If you did not receive a 16-digit control number via email or on your Notice of Availabilty or voting instruction form, you will receivebe provided with other instructions from your broker, bank or other stockholder of record that must be followed, including any requirement to obtan a valid legal proxy, in order for your broker, bank or other stockholder of record to vote your shares per your instructions. You are also invitedinstructions or to attend the virtual Annual Meeting. However, since you are not the stockholder of record, you may notand vote your shares at the virtual Annual Meeting unless you request andMeeting. Many brokers, banks or other stockholders of record allow a stockholder to obtain a valid legal proxy fromeither online or by mail, and we recommend that you contact your broker, bank or other stockholder of record giving you the right to vote such shares at the virtual Annual Meeting.do so.

What am I voting on?

There are fourthree matters scheduled for a vote at the virtual Annual Meeting. They are as follows:

 

 

Election of the eleven nominees for director named herein to hold office until the next annual meeting of stockholders and until his or her successor is duly elected and qualified or until his or her death, resignation or removal;

 

 

Ratification of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending January 1,December 31, 2021;

Approval of the amendment and restatement of the Exelixis 2017 Equity Incentive Plan (2017 Plan) to, among other things, increase the number of shares authorized for issuance by 21,000,000 shares; and

 

 

Advisory approval of the compensation of our named executive officers, as disclosed in this Proxy Statement.

 

2    Exelixis, Inc.

2    Exelixis, Inc.


Proxy Statement | Questions and Answers about these Proxy Materials and Voting

 

How do I vote?

Whether or not you plan to attend the virtual Annual Meeting, we urge you to vote by proxy to ensure your vote is counted. You may still attend the virtual Annual Meeting and vote even if you have already voted by proxy.

Stockholder of Record: Shares Registered in Your Name

If you are a stockholder of record, you have four ways to vote.

 

LOGO

At Virtual Meeting

    To vote at the virtual Annual Meeting, follow the instructions at www.virtualshareholdermeeting.com/EXEL2020EXEL2021. You will need your16-digit control number provided on your Notice of Internet Availability, of Proxy Materials, your proxy card or your voting instruction form in order to gain access to the virtual Annual Meeting.

LOGO

Via Internet

  

  

To vote on the Internet, go towww.proxyvote.com and follow the instructions provided in the Notice of Availability. You will need your16-digit control number provided on your Notice of Internet Availability, of Proxy Materials, your proxy card or your voting instruction form in order to vote your shares in advance of the meeting. Your vote must be received by 11:59 p.m., Eastern Time, on May 19, 2020,25, 2021, to be counted.

LOGO

By Telephone

    To vote by telephone, request a paper or email copy offollow the proxy materials by following the instructions provided in the Notice of Availability and call the number provided within the proxy materials to transmit your voting instructions. Your vote must be received by 11:59 p.m. Eastern Time, on May 19, 2020,25, 2021, to be counted.
LOGO

By Mail

    To vote by mail, follow the instructions provided in the proxy materials, request a paper copy of the proxy materials by following the instructions provided in the Notice of Availability and then complete, sign and date the proxy card enclosed with the paper copy of the proxy materials and return it promptly in the envelope that will be provided. If you return your signed proxy card to us before the Annual Meeting, we will vote your shares as you direct.

Beneficial Owner: Shares Registered in the Name of Broker, Bank or Other Stockholder of Record (i.e.,Street Name)

If you are a beneficial owner of shares registered in the name of your broker, bank, or other stockholder of record, you should have received the Notice of Availability containing voting instructions from that organization rather than from us. You must follow these instructions for your bank, broker or other stockholder of record to vote your shares per your instructions. Alternatively, many brokers and banks provide the means to grant proxies or otherwise instruct them to vote your shares by telephone and via the Internet.Internet, including by providing you with a 16-digit control number via email or on your Notice of Availability or your voting instruction form. If your shares are held in an account with a broker, bank or other stockholder of record providing such a service, you may grant a proxyinstruct them to vote thoseyour shares by telephone (by calling the number provided in the proxy materials) or over the Internet as instructed by your broker, bank or other stockholder of record. ToIf you did not receive a 16-digit control number via email or on your Notice of Availability or voting instruction form, and you wish to vote prior to or at the virtual Annual Meeting, you must obtain a valid legal proxy from your broker, bank or other stockholder of record. Followfollow the instructions from your broker, bank or other stockholder of record, included with theseincluding any requirement to obtain a valid legal proxy.. Many brokers, banks and other stockholders of record allow a beneficial owner to obtain a valid legal proxy materials,either online or by mail, and we recommend that you contact your broker, bank or other stockholder of record to request a legal proxy.do so.

 

We provide Internet proxy voting to allow you to vote your shares online, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your Internet access, such as usage charges from Internet access providers and telephone companies.

How many votes do I have?

On each matter to be voted upon, you have one vote for each share of common stock you own as of the Record Date, March 23, 2020.29, 2021.

How are proxies voted?

All shares represented by valid proxies received prior to the taking of the vote at the Annual Meeting will be voted and, where a stockholder specifies by means of a proxy a choice with respect to any matter to be acted upon, the shares will be voted in accordance with the stockholder’s instructions.

 

2020 Proxy Statement    3

2021 Proxy Statement    3


If I am a stockholder of record, what happens if I return a proxy card but do not make specific choices?

If you are a stockholder of record and you return a signed and dated proxy card without marking any voting selections, your shares will be voted on the proposals as follows:

 

 

“For” the election of Drs. Cohen, Freire, Garber, Marchesi, Morrissey, Papadopoulos, Poste and Willsey, Messrs. Feldbaum and Wyszomierski and Ms. Smith, as described in Proposal 1;

 

 

“For” the ratification of our selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending January 1,December 31, 2021, as described in Proposal 2;

“For” the approval of the amendment and restatement of the 2017 Plan to, among other things, increase the number of shares authorized for issuance by 21,000,000 shares, as described in Proposal 3; and

 

 

“For” the advisory approval of the compensation of our named executive officers, as described in Proposal 4.3.

If any other matter is properly presented at the Annual Meeting, your proxyholder (one of the individuals named on your proxy card), if permitted, will vote your shares using his best judgment.

If I am a beneficial owner of shares held in street name and I do not provide my broker or bank with voting instructions, what happens?

If you are a beneficial owner of shares registered in the name of your broker, bank or other stockholder of record and you do not provide the broker, bank or other stockholder of record holding your shares with voting instructions, your broker, bank or other stockholder of record will determine if it has the discretionary authority to vote on the particular matter. If you are a beneficial owner whose shares are held of record by a broker and you do not provide voting instructions, your shares will not be voted on any proposal on which the broker does not have discretionary authority to vote. This is called a “brokernon-vote.” In these cases, the broker can register your shares as being present at the Annual Meeting for purposes of determining the presence of a quorum, but will not be able to vote on those matters for which specific authorization is required under the rules of the New York Stock Exchange.

If you are a beneficial owner whose shares are held of record by a broker, your broker has discretionary voting authority under the rules of the New York Stock Exchange to vote your shares on Proposal No. 2 (the ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending January 1,December 31, 2021), even if your broker does not receive voting instructions from you. However, your broker does not have discretionary authority to vote on Proposal No. 1 Proposal No. 3 or Proposal No. 43 without voting instructions from you, in which case a brokernon-vote will occur, and your shares will not be voted on Proposal No. 1 Proposal No. 3 or Proposal No. 4.3.

Who is paying for this proxy solicitation?

We are soliciting proxies and will bear the entire cost of soliciting proxies, including the preparation, printing and mailing of the Notice of Availability, the Notice of Annual Meeting, the Proxy Statement, the proxy card and any additional information furnished to stockholders. We have engaged Morrow Sodali LLC, located at 470 West Ave, Stamford, Connecticut 06902, to assist in the solicitation of proxies from shareholders for a fee of $13,000 plus reimbursement of customaryout-of-pocket expenses. Copies of solicitation materials will be furnished to banks, brokerage houses, fiduciaries and custodians holding in their names shares of our common stock beneficially owned by others to forward to such beneficial owners. We may reimburse persons representing beneficial owners of our common stock for their costs of forwarding solicitation materials to such beneficial owners. Original solicitation of proxies by mail may be supplemented by telephone, telegram or personal solicitation by our directors, officers or other regular employees. No additional compensation will be paid to directors, officers or other regular employees for such services.

What does it mean if I receive more than one Notice of Availability or proxy card?

If you receive more than one Notice of Availability or proxy card, your shares are registered in more than one name or are registered in different accounts. Please follow the instructions on each Notice of Availability or proxy card to ensure that all of your shares are voted.

 

4    Exelixis, Inc.

4    Exelixis, Inc.


Proxy Statement | Questions and Answers about these Proxy Materials and Voting

 

Can I change my vote after submitting my proxy?

Yes. You can revoke your proxy at any time before the final vote at the Annual Meeting. You may revoke your proxy in the following ways:

Stockholder of Record: Shares Registered in Your Name

 

Your proxy may be revoked by filing with the Secretary of Exelixis at our principal executive office, Exelixis, Inc., 1851 Harbor Bay Parkway, Alameda, California 94502, either (1) a written notice of revocation or (2) a duly executed proxy card bearing a later date.

 

 

Your proxy may also be revoked by granting a subsequent proxy by telephone or on the Internet (your latest telephone or Internet proxy is the one that is counted).

 

 

Your proxy may also be revoked by attending the virtual Annual Meeting and voting online via the live webcast. Attendance at the Annual Meeting will not, by itself, revoke your proxy.

Beneficial Owner: Shares Registered in the Name of Broker, Bank or Other Stockholder of Record

 

If your shares are held by your broker or bank as nominee or agent, you should follow the instructions provided by your broker or bank to revoke any prior voting instructions.instructions, which may include attending the virtual Annual Meeting and voting online via the live webcast.

What is the quorum requirement for the Annual Meeting?

A majority of the outstanding shares entitled to vote at the virtual Annual Meeting must be present or represented by proxy at the Annual Meeting to hold a valid meeting. This is called a “quorum.” As this is a virtual Annual Meeting, holders of record attending via the live webcast will be deemed to be present at the virtual Annual Meeting.

If you are a stockholder of record, your shares will be counted towards the quorum only if you vote at the virtual Annual Meeting or have properly voted by proxy on the Internet, by telephone or by submitting a proxy card by mail. You may vote “For,” “Against” or “Abstain” with respect to Proposal Nos. 1, 2 3 and 4.3. Abstentions will be counted towards the number of shares considered to be present at the meeting for purposes of determining whether a quorum is present.

If you are a beneficial owner holding your shares in “street name” then only the broker, bank or other stockholder of record can vote your shares unless you obtain a valid legal proxy from the broker, bank or other stockholder of record.record, or are otherwise provided with a separate means to vote your shares (such as a 16-digit control number provided via email or on your Notice of Availability or voting instruction form). See “If I am a beneficial owner of shares held in street name and I do not provide my broker or bank with voting instructions, what happens?” above. Shares represented by “brokernon-votes” will be counted in determining whether there is a quorum present.

Votes will be counted by the inspector of election appointed for the Annual Meeting. If there is no quorum, either the chairperson of the Annual Meeting or the holders of a majority of shares present or represented by proxy at the Annual Meeting may adjourn the Annual Meeting to another date.

How many votes are needed to approve each proposal, how are votes counted, and how are abstentions and brokernon-votes treated?

 

 

Proposal1-Election of Directors: Directors in an uncontested election, such as this one, are elected by a majority of the votes cast. Accordingly, each of the eleven nominees must receive “For” votes from the holders of a majority of the votes cast with respect to such director (i.e., the number of shares voted “For” a director must exceed the number of shares voted “Against” that director). Abstentions and brokernon-votes if any, are not counted for purposes of electing directors and will have no effect on the results of this vote.

 

 

Proposal2-Ratification of Ernst & Young LLP:The affirmative vote of a majority of shares present or represented by proxy at the Annual Meeting and entitled to vote on the proposal is required to ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending January 1,December 31, 2021. Abstentions will have the effect of votes against this proposal. Brokers generally have discretionary authority to vote on the ratification of our independent accounting firm; thus, we do not expect any brokernon-votes on this proposal.

Proposal3-Approval of the Amendment and Restatement of the 2017 Plan:The affirmative vote of a majority of shares present or represented by proxy at the Annual Meeting and entitled to vote on the proposal is required to amend and restate the 2017 Plan to, among other things, increase the number of shares authorized for issuance by 21,000,000 shares. Abstentions will be counted toward the tabulation of votes cast on the proposal and will have the same effect as votes against thisthe proposal. Brokernon-votes, if any, will have no effect and will not be counted towards the vote total.

 

2020 Proxy Statement    5


 

Proposal4-Advisory3-Advisory Vote on Executive Compensation: The affirmative vote of a majority of shares present or by represented proxy at the Annual Meeting and entitled to vote on the proposal is required to approve thenon-binding, advisory vote on executive compensation. Abstentions will be counted toward the tabulation of votes

2021 Proxy Statement    5


cast on the proposal and will have the same effect as votes against this proposal. Brokernon-votes will have no effect and will not be counted towards the vote total. Since the vote is advisory, it is not binding on the Board or on us. Nevertheless, the views expressed by our stockholders, whether through this vote or otherwise, are very important to the Compensation CommitteeBoard and the Boardmanagement team and, accordingly, the Compensation Committee and Board intend to consider the results of this vote in making determinations in the future regarding executive compensation arrangements. Your vote will serve as an additional tool to guide the Compensation Committee and Board in continuingas they continue to improve the alignment of our executive compensation programs with business objectives and performance and with the interests of our stockholders.

Do I have dissenters’ rights?

No. We are organized as a corporation under Delaware law. Under the Delaware General Corporation Law, our stockholders are not entitled to dissenters’ rights with respect to any of the proposals set forth in this Proxy Statement and we will not independently provide the stockholders with any such rights.

How can I find out the results of the voting at the Annual Meeting?

We expect to announce preliminary voting results at the Annual Meeting. In addition, final voting results will be published in a current report on Form8-K that we expect to file within four business days after the Annual Meeting. If final voting results are not available to us in time to file a Form8-K within four business days after the Annual Meeting, we intend to file aForm 8-K to publish preliminary results and, within four business days after the final results are known to us, file an additional Form8-K to publish the final results.

Will other matters be voted on at the Annual Meeting?

We are not aware of any matters to be presented at the Annual Meeting other than those described in this Proxy Statement. If any other matters not described in the Proxy Statement are properly presented at the meeting, proxies will be voted in accordance with the best judgment of the proxyholders.

What proxy materials are available on the Internet?

This Proxy Statement and our Annual Report are available atwww.exel-annualstockholdermeeting.com.

What is the deadline for submitting stockholder proposals for the 20212022 Annual Meeting?

To be considered for inclusion in the 20212022 proxy materials, your proposal must be submitted in writing by December 11, 2020,[16], 2021, to Exelixis’ Secretary at Exelixis, Inc., 1851 Harbor Bay Parkway, Alameda, California 94502, and you must comply with all applicable requirements of Rule14a-8 promulgated under the Securities Exchange Act of 1934, as amended (Exchange Act). However, if our 20212022 Annual Meeting of Stockholders is held before April 20, 2021,26, 2022, or after June 19, 2021,25, 2022, then the deadline will be a reasonable time prior to the time that we make our proxy materials available to our stockholders, either online or in printed form.

If you wish to submit a proposal or nominate a director at the 20212022 Annual Meeting of Stockholders, but you are not requesting that your proposal or nomination be included in next year’s proxy materials, you must submit your proposal in writing, in the manner set forth in our Bylaws, to Exelixis’ Secretary at Exelixis, Inc., 1851 Harbor Bay Parkway, Alameda, California 94502, to be received no earlier than the close of business on February 19, 2021,25, 2022, and no later than the close of business on March 21, 2021.27, 2022. However, if our 20212022 Annual Meeting of Stockholders is held before April 20, 2021,26, 2022, or after June 19, 2021,25, 2022, then you must notify Exelixis’ Secretary, in writing, not earlier than the close of business on the 90th day prior to the date of the 20212022 Annual Meeting of Stockholders and not later than the close of business on the later of (i) the 60th day prior to the date of the 20212022 Annual Meeting of Stockholders or (ii) if we publicly announce the date of the 20212022 Annual Meeting of Stockholders fewer than 70 days prior to the date of the 20212022 Annual Meeting of Stockholders, the 10th day following the day that we first make such public announcement of the date of the 20212022 Annual Meeting of Stockholders. We also advise you to review our Bylaws, which contain additional requirements about advance notice of stockholder proposals and director nominations. The chairperson of the 20212022 Annual Meeting of Stockholders may determine, if the facts warrant, that a matter has not been properly brought before the meeting and, therefore, may not be considered at the meeting. In

6    Exelixis, Inc.


Proxy Statement | Questions and Answers about these Proxy Materials and Voting

addition, unless prohibited by Rule14a-4(c) promulgated under the Exchange Act, our management will have discretionary authority to vote all shares for which it has proxies for any such stockholder proposal or director nomination, including in opposition to such stockholder proposal or director nomination.

6    Exelixis, Inc.


Proxy Statement | Questions and Answers about these Proxy Materials and Voting

How may I obtain a printed copy of the Proxy Materials?

Instructions on how to obtain a printed copy of the proxy materials are set forth in the Notice of Availability.

Forward-Looking Statements

This Proxy Statement contains forward-looking statements, including, without limitation, statements related to: Exelixis’ expectations that its employees and partners will commit to the highest standards of ethical behavior and maintain values and principles that reflect both global awareness and sustainability; Exelixis’ dedication of financial resources to offer patients high-quality cancer treatments and commitment to providing patients with access to Exelixis medicines; Exelixis’ strategies for quality monitoring and compliance in developing its products; Exelixis’ potential to attain future environmental stability; Exelixis’ ongoing efforts towards the achievement of key priorities and anticipated milestones for 20202021 and 2021, including generatingtop-line data frombeyond; Exelixis’ expectation that the combination of CABOMETYX and OPDIVO will be a key clinical trials, completing enrollmentdriver of ongoing studies, initiating new pivotal trials,revenue growth; Exelixis’ plans to file with the FDA for accelerated approval of the combination of cabozantinib and progressingatezolizumab in an mCRPC indication, if warranted by the data; the potential for Exelixis to add clinical-stage assets to itsmid-stage and early product pipeline; the anticipated organizational growth of Exelixis; Exelixis’ market strategiesstrategic planning for potential future commercial indications for cabozantinib, the further development of XL092 and other potential business development assets; Exelixis’ plans to initiate variouspre-clinical studies in the first half of 2020; and other statements that are not historical fact. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis’ current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the continuing COVID-19 global pandemic and its impact on our research and development operations, including our ability to initiate new clinical trials andExelixis’ clinical trial, sites, enroll clinical trial patients, conduct trials per protocol,drug discovery and conduct drug research and discovery operations and relatedcommercial activities; the degree of market acceptance of CABOMETYX and other Exelixis products in the indications for which they are approved and in the territories where they are approved, and Exelixis and its partners’ abilitiesability to obtain or maintain coverage and reimbursement for these products; the effectiveness of CABOMETYX and other Exelixis products in comparison to competing products; the level of costs associated with Exelixis’ commercialization, research and development, in-licensing or acquisition of product candidates, and other activities; Exelixis’ ability to maintain and scale adequate sales, marketing, market access and product distribution capabilities for its products or to enter into and maintain agreements with third parties to do so; the availability of data at the referenced times; the potential failure of cabozantinib and other Exelixis product candidates, both alone and in combination with other therapies, to demonstrate safety and/or efficacy in clinical testing; uncertainties inherent in the drug discovery and product development process; Exelixis’ dependence on its relationships with its collaboration partners, including their pursuit of regulatory approvals for partnered compounds in new indications, their adherence to their obligations under relevant collaboration agreements and the level of their investment in the resources necessary to complete clinical trials or successfully commercialize partnered compounds in the territories where they are approved; complexities and the unpredictability of regulatory review and approval processes in the USU.S. and elsewhere, including the risk that regulatory authorities may not approve Exelixis’ products as treatments for the indications in which approval has been sought, if at all;elsewhere; Exelixis’ continuing compliance with applicable legal and regulatory requirements; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating cabozantinib and other Exelixis products; Exelixis’ dependence on third-party vendors for the development, manufacture and supply of its products;products and product candidates; Exelixis’ ability to protect its intellectual property rights; market competition, including the potential for competitors to obtain approval for generic versions of Exelixis’ marketed products; changes in economic and business conditions; and other factors discussed under the caption “Risk Factors” in Exelixis’ Annual Report onForm 10-K filed withsubmitted to the SEC on February 25, 2020,10, 2021, and in Exelixis’ future filings with the SEC. All forward-looking statements in this Proxy Statement are based on information available to Exelixis as of the date of this Proxy Statement, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law.

 

2020 Proxy Statement    7

2021 Proxy Statement    7


PROPOSAL 1

ELECTIONOF DIRECTORS

Prior to the 2019 Annual Meeting of Stockholders, ourOur Certificate of Incorporation and Bylaws provided that the Board was divided into three classes, with each class having a three-year term. At the 2019 Annual Meeting of Stockholders, our stockholders approved an amendment to our Certificate of Incorporation to declassify the Board to provide for the annual election of each director bydirector. There are currently eleven directors on the Annual Meeting. Accordingly, beginning with the Annual Meeting, each director is to be considered for election by our stockholders for a term expiring at the next annual meeting of stockholders; theBoard, and all eleven director nominees listed belowdirectors have been nominated and are standing forre-election this year:

 

Director Nominees

    Age     Position  Director
Since
 

Charles Cohen, Ph.D.

     69     Director   1995 

Carl B. Feldbaum, Esq.

     76     Director   2007 

Maria C. Freire, Ph.D.

     65     Director   2018 

Alan M. Garber, M.D., Ph.D.

     64     Director   2005 

Vincent T. Marchesi, M.D., Ph.D.

     84     Director   2001 

Michael M. Morrissey, Ph.D.

     59     President and Chief Executive Officer   2010 

Stelios Papadopoulos, Ph.D.

     71     Chair of the Board   1994 

George Poste, DVM, Ph.D., FRS

     75     Director   2004 

Julie Anne Smith

     49     Director   2016 

Lance Willsey, M.D.

     58     Director   1997 

Jack L. Wyszomierski

     64     Director   2004 

Dr. Scangos is not standing forre-election at the Annual Meeting and will resign from the Board effective as of the Annual Meeting. As a result, effective at the Annual Meeting, the number of directors constituting the Board will be reduced from twelve to eleven. We acknowledge with gratitude Dr. Scangos’ long-term service on the Board and his invaluable contributions to Exelixis.

    

Director Nominees

    Age     Position  Director
Since
 

Charles Cohen, Ph.D.

     70     Independent Director   1995 

Carl B. Feldbaum, Esq.

     77     Independent Director   2007 

Maria C. Freire, Ph.D.

     66     Independent Director   2018 

Alan M. Garber, M.D., Ph.D.

     65     Independent Director   2005 

Vincent T. Marchesi, M.D., Ph.D.

     85     Independent Director   2001 

Michael M. Morrissey, Ph.D.

     60     President and Chief Executive Officer   2010 

Stelios Papadopoulos, Ph.D.

     72     Independent Chair of the Board   1994 

George Poste, DVM, Ph.D., FRS

     76     Independent Director   2004 

Julie Anne Smith

     50     Independent Director   2016 

Lance Willsey, M.D.

     59     Independent Director   1997 

Jack L. Wyszomierski

     65     Independent Director   2004 

If elected at the Annual Meeting, each of these director nominees would serve until the next annual meeting of stockholders and until the director’s successor is elected and has qualified, or, if sooner, until the director’s death, resignation or removal.

As this is an uncontested election, each director will be elected by a majority of the votes cast with respect to that director. A majority of the votes cast means that the number of shares voted “for” a director must exceed the number of votes cast “against” that director. Abstentions and brokernon-votes will have no effect on the election of directors. If any nominee becomes unavailable for election as a result of an unexpected occurrence, your shares will be voted for the election of such substitute nominee as the Board, after receiving the recommendation of the Nominating and Corporate Governance Committee of the Board, may propose. Each person nominated for election has agreed to serve if elected, and we have no reason to believe that any nominee will be unable to serve.

Majority Voting Standard and Resignation Policy

Our Corporate Governance Guidelines require that all director nominees set forth in this Proxy Statement have tendered an irrevocable resignation as a director conditioned upon: (i) such director failing to receive a majority of the votes cast at the Annual Meeting; and (ii) acceptance by the Board of such resignation. If a director nominee who is serving as a director at the time of the election does not receive a majority of the votes cast at the Annual Meeting, then the Board will take the following actions:

 

The Nominating and Corporate Governance Committee will act to determine whether to recommend to the Board that it accept the director’s conditional resignation. In making their respective decisions, the Nominating and Corporate Governance Committee and the Board will evaluate the best interests of Exelixis and its stockholders and shall consider all factors and information deemed relevant by the respective body. The director who tenders his or her conditional resignation shall not participate in the Nominating and Corporate Governance Committee’s recommendation or Board action regarding whether to accept the conditional resignation of such director.

 

8    Exelixis, Inc.


Proposal 1 | Election of Directors

The Board will act on the Nominating and Corporate Governance Committee’s recommendation within ninety days following certification of the stockholder vote.

 

If the Board determines not to accept the conditional resignation of a director, the Board will promptly disclose its decision-making process and decision to reject the conditional resignation in a Form8-K furnished to the SEC.

8    Exelixis, Inc.


Proposal 1 | Election of Directors

Board Independence, Diversity and Skills

The Board regularly evaluates the skills and experiences that it believes are desirable to be represented on the Board and best align with our strategic vision and business and operations. Below are certain qualifications, skills and experiences of our current directors that contribute the Board’s effectiveness as a whole.

 

LOGO

LOGO

In addition, set forth below is biographical information for each nominee for election to our Board at the Annual Meeting. Incorporated within each biography is a description of the specific qualifications, skills and experiences of each nominee that led our Board to conclude that the individual should serve as a director as of the date of this Proxy Statement.

 

2020 Proxy Statement    9

2021 Proxy Statement    9


Director Nominees

 

 

Charles Cohen, Ph.D.

Independent Biotechnology Investor

Former Chief Executive Officer, Perform Biologics, Inc. and On Target Therapeutics, LLC

 

  

Director since 1995

 

Age 6970

 

Key Qualifications and Expertise:

Our Board concluded that Dr. Cohen should continue to serve as a director of Exelixis due to his training as a scientist, his knowledge and experience with respect to the biotechnology, pharmaceutical and healthcare industries, his broad leadership experience resulting from service on various boards and as a chief executive officer, and his knowledge and experience with respect to finance matters.

 

Committee Assignments:

 

•   Audit Committee

 

•   Compensation Committee (chair)

 

•   Research & Development Committee

 

Other Current Public Company Boards:

 

•   None

 

Charles Cohen, Ph.D., has been a director since November 1995. Dr. Cohen is an independent investor and from March 2015 to May 2019, he served as Chief Executive Officer and as a member of the board of directors of Perform Biologics, Inc., a privately held biotechnologystart-up company. Previously, Dr. Cohen served as Chief Executive Officer and as a member of the board of directors of On Target Therapeutics, LLC, a privately held biotechnologystart-up company, from June 2015 to June 2017. From May 2007 to December 2015, Dr. Cohen was a managing director of Synthesis Capital (formerly Advent Healthcare Ventures), a venture capital firm. From 2003 to 2007, Dr. Cohen was Vice President of Advent International, a global private equity firm. From 2000 to 2002, Dr. Cohen was the Chief Executive Officer of Cellzome AG, a post-genomics biotechnology company. Prior to that time, Dr. Cohenco-founded Creative BioMolecules, Inc., a biotechnology company, in 1982 and was one of its directors and its Chief Executive Officer from 1985 to 1995. Dr. Cohen served as a member of the board of directors of the following publicly held companies: Anadys Pharmaceuticals, Inc., a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C, from 2000 to 2005; and Anesiva, Inc., a biopharmaceutical company focused on the development and commercialization of novel pharmaceutical products for pain management from 2005 to 2007. Dr. Cohen also served as the Chairman of the Supervisory Board of Cellzome AG, prior to its acquisition by GlaxoSmithKline in May 2012, and as the Chief Executive Officer of several other companies. Dr. Cohen received his B.A. from the State University of New York at Buffalo and his Ph.D. from New York University School of Medicine.

 

Carl B. Feldbaum, Esq.

President Emeritus, Biotechnology Innovation Organization

 

  

Director since 2007

 

Age 7677

 

Key Qualifications and Expertise:

Our Board concluded that Mr. Feldbaum should continue to serve as a director of Exelixis due to his training as an attorney, his knowledge and experience with respect to the biotechnology, pharmaceutical and healthcare industries, his broad leadership experience resulting from service on various boards and as an executive officer and his knowledge and experience with policymaking, regulatory issues and other governmental matters.

 

Committee Assignments:

 

•   Nominating and Corporate Governance Committee

 

•   Risk Committee (chair)

 

Other Current Public Company Boards:

 

•   None

 

Carl B. Feldbaum, Esq., has been a director since February 2007. Mr. Feldbaum serves as a member emeritus of the board of directors of BIO Ventures for Global Health, anon-profit organization, and is president emeritus of the Biotechnology Innovation Organization (BIO), which is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. Mr. Feldbaum served as president of BIO from 1993 until his retirement in 2005. Prior to joining BIO, Mr. Feldbaum was chief of staff to Senator Arlen Specter of Pennsylvania. He also was president and founder of Palomar Corporation, a national security “think tank” in Washington, D.C. Before founding Palomar Corporation, Mr. Feldbaum was Assistant to the Secretary of Energy and served as the Inspector General for defense intelligence in the U.S. Department of Defense. Mr. Feldbaum served as a member of the board of directors of the following publicly held companies: Actelion, Ltd, a biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs (acquired by Johnson & Johnson in 2017), from 2005 to 2015; Trovagene, Inc., a precision medicine biotechnology company focused on the development of oncology therapeutics for improved cancer care, from 2014 to 2015; and Connetics Corporation, a specialty pharmaceutical company focused on the development and commercialization of innovative therapeutics for the dermatology market, from 2005 until its acquisition by Stiefel Laboratories, Inc. in 2006. Mr. Feldbaum holds an A.B. in Biology from Princeton University and a J.D. from the University of Pennsylvania Law School.

 

10    Exelixis, Inc.

10    Exelixis, Inc.


Proposal 1 | Director Nominees

 

Maria C. Freire, Ph.D.

President and Executive Director, Foundation for the National Institutes of Health

 

  

Director since 2018

 

Age 6566

 

Key Qualifications and Expertise:

Our Board concluded that Dr. Freire should continue to serve as a director of Exelixis due to her training as a scientist, her knowledge and experience with respect to medical research, the pharmaceutical industry and government healthcare policymaking, as well as her leadership experience in the public sector.

 

Committee Assignments:

 

•   Nominating and Corporate Governance Committee

 

•   Research & Development Committee

 

•   Risk Committee

 

Other Current Public Company Boards:

 

•   Alexandria Real Estate Equities, serving on the Nominating & Corporate Governance Committee and the Science & Technology Committee (chair)

 

Maria C. Freire, Ph.D., has been a director since April 2018. Since November 2012, Dr. Freire has served as President and Executive Director and as a member of the board of directors of the Foundation for the National Institutes of Health. From March 2008 to November 2012, she served as President and as a member of the board of directors of the Albert and Mary Lasker Foundation. Prior to joining the Lasker Foundation, Dr. Freire served as President and Chief Executive Officer of the Global Alliance for TB Drug Development from 2001 to 2008 and Director of the Office of Technology Transfer at the National Institutes of Health from 1995 to 2001. Dr. Freire has served on the board of directors of Alexandria Real Estate Equities, Inc. a publicly held urban office real estate investment trust uniquely focused on collaborative life science and technology campuses, since April 2012, and has previously served on the boards of numerous national and international organizations, including the Science Board of the U.S. Food and Drug Administration, the World Health Organization Commission on Intellectual Property Rights, Innovation and Public Health and the United Nations Secretary General’s High Level Panel on Access to Medicines. Dr. Freire is also a member of the National Academy of Medicine and the Council on Foreign Relations, and she is the recipient of numerous awards, including a 2017 Gold Stevie Award for “Woman of the Year,” the U.S. Department of Health and Human Services Secretary’s Award for Distinguished Service, the Arthur S. Fleming Award and the Bayh-Dole Award. Dr. Freire holds a Ph.D. in Biophysics from the University of Virginia and a B.S. from the Universidad Peruana Cayetano Heredia in Lima, Peru.

 

Alan M. Garber, M.D., Ph.D.

Provost of Harvard University

 

  

Director since 2005

 

Age 6465

 

Key Qualifications and Expertise:

Our Board concluded that Dr. Garber should continue to serve as a director of Exelixis due to his training as a physician and economist, his knowledge and experience with respect to the life sciences, healthcare and pharmaceutical industries, and his knowledge and experience with policymaking, regulatory issues and other governmental matters.

 

Committee Assignments:

 

•   Nominating and Corporate Governance Committee (chair)

 

•   Research & Development Committee

 

Other Current Public Company Boards:

 

•   Vertex Pharmaceuticals Incorporated, serving on the Audit & Finance Committee and the Scientific & Technology Committee

 

Alan M. Garber, M.D., Ph.D., has been a director since January 2005. He became Provost of Harvard University, Mallinckrodt Professor of Health Care Policy at Harvard Medical School, and a Professor in the Harvard Kennedy School of Government and in the Department of Economics at Harvard in September 2011. Before moving to Harvard, from 1998 until August 2011, he was the Henry J. Kaiser Jr. Professor, a Professor of Medicine, and a Professor (by courtesy) of Economics, Health Research and Policy, and of Economics in the Graduate School of Business at Stanford University. Dr. Garber also served as the Director of the Center for Primary Care and Outcomes Research and the Center for Health Policy at Stanford. During his tenure at Stanford University, Dr. Garber also served as a Senior Fellow at the Freeman Spogli Institute for International Studies and as a staff physician at the VA Palo Alto Health Care System. Dr. Garber has served as a member of the board of directors of Vertex Pharmaceuticals Incorporated, a publicly held biotechnology company focused on developing and commercializing therapies for the treatment of cystic fibrosis, since June 2017. In addition, Dr. Garber is a one of several co-founders and serves as the chair of the board of directors for the Center for Advanced Biological Innovation and Manufacturing, a public benefit limited liability company in the Boston metro area created to encourage collaboration among multiple institutions, with the ultimate aim of promoting the development and production of cell and gene therapies, biologics, immunotherapies and other emerging technologies that can benefit patients. Dr. Garber is a member of the National Academy of Medicine, the American Society of Clinical Investigation, the Association of American Physicians and the American Academy of Arts and Sciences. He is a Fellow of the American College of Physicians, the Royal College of Physicians and the American Association for the Advancement of Science. Dr. Garber is also a Research Associate with the National Bureau of Economic Research and served as founding Director of its Health Care Program for nineteen years. He has also served as a member of the National Advisory Council on Aging at the National Institutes of Health, as a member of the Board of Health Advisers of the Congressional Budget Office and as Chair of the Medicare Evidence Development and Coverage Advisory Committee at the Centers for Medicare and Medicaid Services. Dr. Garber previously served on the editorial board of a number of acclaimed scientific journals and has received numerous awards and honors. Dr. Garber holds an A.B. summa cum laude, an A.M. and a Ph.D., all in Economics, from Harvard University, and an M.D. with research honors from Stanford University.

 

2020 Proxy Statement    11

2021 Proxy Statement    11


Vincent T. Marchesi, M.D., Ph.D.

Professor of Pathology and Cell Biology, Yale University

 

  

Director since 2001

 

Age 8485

 

Key Qualifications and Expertise:

Our Board concluded that Dr. Marchesi should continue to serve as a director of Exelixis due to his training as a physician and scientist and his research and experience in the fields of healthcare and life sciences, with a particular focus on biotechnology.

 

Committee Assignments:

 

•   Compensation Committee

 

•   Research & Development Committee

 

Other Current Public Company Boards:

 

•   None

 

Vincent T. Marchesi, M.D., Ph.D., has been a director since May 2001. Since 1973, Dr. Marchesi has been a Professor of Pathology and Cell Biology at Yale University and, since 1991, the Director of the Boyer Center for Molecular Medicine at Yale University. In 1982, Dr. Marchesico-founded Molecular Diagnostics, Inc., a diagnostic development company. Dr. Marchesi was formerly Chair of Pathology at theYale-New Haven Hospital. Dr. Marchesi holds an M.D. from Yale University and a Ph.D. from Oxford University, and is a member of the National Academy of Sciences and the Institute of Medicine.

 

Michael M. Morrissey, Ph.D.

President and Chief Executive Officer, Exelixis, Inc.

 

  

Director since 2010

 

Age 5960

 

Key Qualifications and Expertise:

Our Board concluded that Dr. Morrissey should continue to serve as a director of Exelixis due to his leadership role as the President and Chief Executive Officer of Exelixis. Beyond his role as Exelixis’ principal executive officer, the Board also considered Dr. Morrissey’s extensive qualifications, including his training as a scientist, his significant knowledge and experience with respect to the biotechnology, healthcare and pharmaceutical industries, comprehensive leadership background resulting from service as an executive in the biotechnology industry, and his ability to bring historic knowledge and continuity to the Board.

 

Committee Assignments:

 

•   None

 

Other Current Public Company Boards:

 

•   None

 

Michael M. Morrissey, Ph.D., has served as a director and as Exelixis’ President and Chief Executive Officer since July 2010. Dr. Morrissey has held positions of increasing responsibility at Exelixis since he joined the company in February 2000, including serving as President of Research and Development from January 2007 until July 2010. From 1991 to 2000, Dr. Morrissey held several positions at Berlex Biosciences, last holding the position of Vice President, Discovery Research. Earlier in his career, Dr. Morrissey served as a Senior Scientist and Project Team Leader in Medicinal Chemistry at CIBA-Geigy Corporation. Since 2020, Dr. Morrissey has served as a member of the board of directors of XWPharma Incorporated, a privately held, clinical-stage biopharmaceutical company dedicated to the discovery and development of therapeutics that apply novel platform chemistry to time-regulated neurobiology. He is the author of numerous scientific publications in medicinal chemistry and drug discovery and an inventor on 70 issued U.S. patents and 25 additional published U.S. patent applications. Dr. Morrissey holds a B.S. (Honors) in Chemistry from the University of Wisconsin and a Ph.D. in Chemistry from Harvard University.

 

12    Exelixis, Inc.

12    Exelixis, Inc.


Proposal 1 | Director Nominees

 

Stelios Papadopoulos, Ph.D.

Co-Founder and Chair of the Board, Exelixis, Inc.

 

  

Director since 1994

 

Age 7172

 

Key Qualifications and Expertise:

Our Board concluded that Dr. Papadopoulos should continue to serve as a director of Exelixis due to his training as a scientist, his knowledge and experience with respect to the biotechnology, healthcare and pharmaceutical industries, his broad leadership experience resulting from extensive service on various boards, his knowledge and experience with respect to finance matters, and his ability to bring historic knowledge and continuity to the Board.

 

Committee Assignments:

 

•   Audit Committee

 

•   Research & Development Committee

 

Other Current Public Company Boards:

 

•   Biogen Inc. (chair), serving on the Corporate Governance Committee

 

•   Regulus Therapeutics, Inc. (chair), serving on the Audit Committee and the Nominating and Governance Committee

•   Eucrates Biomedical Acquisition Corp. (chair)

 

Stelios Papadopoulos, Ph.D., aco-founder of Exelixis, has been a director since December 1994 and the Chair of the Board since January 1998. Dr. Papadopoulos retired as Vice Chairman of Cowen & Co., LLC in August 2006 after six years as an investment banker with the firm, where he focused on the biotechnology and pharmaceutical sectors. Prior to joining Cowen & Co., he spent 13 years as an investment banker at PaineWebber, Incorporated, where he was most recently Chairman of PaineWebber Development Corp., a PaineWebber subsidiary focusing on biotechnology. He joined PaineWebber in April 1987 from Drexel Burnham Lambert, where he was a Vice President in the Equity Research Department covering the biotechnology industry. Prior to Drexel, he was a biotechnology analyst at Donaldson, Lufkin & Jenrette. Before coming to Wall Street in 1985, Dr. Papadopoulos was on the faculty of the Department of Cell Biology at New York University Medical Center. Dr. Papadopoulos was aco-founder of Anadys Pharmaceuticals, Inc., a publicly held biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C, acquired byHoffmann-La Roche Inc. in November 2011. Dr. Papadopoulos served as a member of the board of directors of Anadys Pharmaceuticals from 2000 to 2011 and as its chairman in 2011, prior to its acquisition. Dr. Papadopoulos has also served as a member of the board of directors of threefour other publicly held companies: Biogen, Inc., a biopharmaceutical company focused on the treatment of serious diseases, since 2008 and as its chairman since 2014; Regulus Therapeutics Inc., a biopharmaceutical company focused on the development of medicines targeting microRNAs, since 2008, and as its chairman since 2013; Eucrates Biomedical Acquisition Corp., a special purpose acquisition company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, and as its chairman, since 2020; and BG Medicine, Inc., a diagnostics company focused on the development and commercialization of cardiovascular diagnostic tests, from 2003 until 2018. Dr. Papadopoulos was alsoco-founder and member of the board of directors of Cellzome Inc., a privately held drug discovery company acquired by GlaxoSmithKline in May 2012. In thenot-for-profit sector, Dr. Papadopoulos is aco-founder and Chairman of Fondation Santé, a member of the board of visitors of Duke Medicine, and a member of the Global Advisory Board of the Duke Institute for Health Innovation. Dr. Papadopoulos holds an M.S. in Physics, a Ph.D. in Biophysics and an M.B.A. in Finance, all from New York University.

 

George Poste, DVM, Ph.D., FRS

Chief Scientist, Complex Adaptive Systems Initiative

 

  

Director since 2004

 

Age 7576

 

Key Qualifications and Expertise:

Our Board concluded that Dr. Poste should continue to serve as a director of Exelixis due to his training as a scientist, his knowledge and experience with respect to the life sciences, healthcare and pharmaceutical industries, his broad leadership experience resulting from service on various boards, and his knowledge and experience with policymaking, regulatory issues and other governmental matters.

 

Committee Assignments:

 

•   Research & Development Committee (chair)

 

•   Risk Committee

 

Other Current Public Company Boards:

 

•   None

 

George Poste, DVM, Ph.D., FRS, has been a director since August 2004. Since February 2009, Dr. Poste has been the Chief Scientist at Complex Adaptive Systems Initiative and Regents’ Professor and Del E. Webb Professor of Health Innovation at Arizona State University. From May 2003 to February 2009, Dr. Poste served as the director of the Biodesign Institute at Arizona State University. Dr. Poste has served as the Chief Executive Officer of Health Technology Networks, a consulting company that specializes in the application of genomic technologies and computing in healthcare, since 2000. From 1992 to 1999, he was the Chief Science and Technology Officer and President, R&D, of SmithKline Beecham Corporation, a pharmaceutical company (later merged into GlaxoSmithKline plc). Dr. Poste served on the Defense Science Board of the U.S. Department of Defense from 2001 to 2010 and is a member of other organizations dedicated to advancing defenses against bioweapons and biowarfare. Dr. Poste serveshas served as a member of the board of directors of Caris Life Sciences, a privately held medical diagnostics company, since 2009. Previously, Dr. Poste served as a member of the board of directors of Monsanto Company, a publicly held provider of agricultural products and solutions, from February 2003 until its acquisition by Bayer Aktiengesellschaft in June 2018, and as theNon-Executive Chairman of Orchid Cellmark, Inc., a publicly held DNA forensics company, from April 2000 until its acquisition by the Laboratory CorporateCorporation of America in August 2009. Dr. Poste is a Fellow of the Royal Society, the UK Academy of Medical Sciences, Hoover Institution, Stanford University, and various other prestigious organizations and has been awarded honorary doctorates from several universities. Dr. Poste holds a DVM in veterinary medicine and a Ph.D. in Virology from the University of Bristol, England and Board Certification in Pathology from the Royal College of Pathologists.

 

2020 Proxy Statement    13

2021 Proxy Statement    13


Julie Anne Smith

President and Chief Executive Officer, EscapeESCAPE Bio Inc.

 

  

Director since 2016

 

Age 4950

 

Key Qualifications and Expertise:

Our Board concluded that Ms. Smith should continue to serve as a director of Exelixis due to her knowledge and experience with respect to biotechnology, healthcare and pharmaceutical industries and her broad leadership experience resulting from service as an executive in the pharmaceutical industry.

 

Committee Assignments:

 

•   Audit Committee

 

•   Compensation Committee

 

Other Current Public Company Boards:

 

•   NoneStoke Therapeutics, Inc., serving on the Compensation Committee

 

Julie Anne Smith has been a director since September 2016. Since August 2018, Ms. Smith has served as President and Chief Executive Officer and as a member of the board of directors of EscapeESCAPE Bio Inc., a privately held, biotechnologyclinical-stage biopharmaceutical company developing novel, precisely targeted therapiestherapeutics for patients with genetically defined neurodegenerative diseases. From July 2017 until June 2018, Ms. Smith served as President and Chief Executive Officer and as a member of the board of directors of Nuredis, Inc., a privately held biotechnology company developing novel therapies to treat inherited neurodegenerative diseases caused by nucleotide repeat expansions.company. Prior to Nuredis, she served as President and Chief Executive Officer of Raptor Pharmaceutical Corp., a publicly held biopharmaceutical company focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases, from January 2015 until the company’s acquisition by Horizon Pharma plc in October 2016, where she also served as Executive Vice President and Chief Operating Officer from 2012 to 2014. From 2008 to 2012, Ms. Smith served as Chief Commercial Officer of Enobia Pharmaceuticals prior to the company’s acquisition by Alexion Pharmaceuticals, Inc. Previously, Ms. Smith served as Vice President of Commercial at Jazz Pharmaceuticals plc from 2006 to 2008, as Vice President, Global Marketing at Genzyme General from 2001 to 2005, and helped to establish the operations and business development function for the biotechstart-up, Novazyme Pharmaceuticals, from 2000 to 2001. Ms. Smith began her industry career at Bristol-Myers Squibb Company in 1996. Ms. Smith has served onas a member of the board of directors of Stoke Therapeutics, Inc., a publicly held biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely unregulating protein expression, since June 2020. Previously, Ms. Smith served as a member of the board of directors of Audentes Therapeutics, Inc. a publicly held, clinical stageclinical-stage biotechnology company focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects, from December 2016 until its acquisition by Astellas Pharma Inc. in January 2020, and previously, Ms. Smith wasas a Director on the Health and Emerging Companies Sections of the BIO board. Ms. Smith holds a B.S. in biological and nutritional sciences from Cornell University.

 

Lance Willsey, M.D.

Founding Partner, DCF Capital

 

  

Director since 1997

 

Age 5859

 

Key Qualifications and Expertise:

Our Board concluded that Dr. Willsey should continue to serve as a director of Exelixis due to his skill as a physician, his knowledge and experience with respect to the life sciences and healthcare industries, and his knowledge and experience with respect to finance matters.

 

Committee Assignments:

 

•   Compensation Committee

 

•   Research & Development Committee

 

Other Current Public Company Boards:

 

•   None

 

Lance Willsey, M.D., has been a director since April 1997. Dr. Willsey was a founding partner of DCF Capital, a hedge fund focused on investing in the life sciences, from July 1998 to March 2002, and currently is a consultant to institutional investors in the field of oncology. Since 2000, Dr. Willsey has served on the Visiting Committee of the Department of Genitourinary Oncology at the Dana-Farber Cancer Institute at Harvard Medical School. From July 1997 to July 1998, Dr. Willsey served on the Staff Department of Urologic Oncology at the Dana-Farber Cancer Institute. From July 1996 to July 1997, Dr. Willsey served on the Staff Department of Urology at Massachusetts General Hospital at Harvard University School of Medicine, where he was a urology resident from July 1992 to July 1996. From 2000 to 2010, Dr. Willsey served a member of the board of directors of Exact Sciences Corporation, a publicly held molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer. Dr. Willsey holds a B.S. in Physiology from Michigan State University and an M.S. in Biology and an M.D., both from Wayne State University.

 

14    Exelixis, Inc.

14    Exelixis, Inc.


Proposal 1 | Director Nominees

 

Jack L. Wyszomierski

Former Executive Vice President and Chief Financial Officer,

VWR International, LLC

 

  

Director since 2004

 

Age 6465

 

Key Qualifications and Expertise:

Our Board concluded that Mr. Wyszomierski should continue to serve as a director of Exelixis due to his extensive financial reporting, accounting and finance experience, as well as his experience in the healthcare and life sciences industries. These qualities have also formed the basis for the Board’s decision to appoint Mr. Wyszomierski as a member and Chair of the Audit Committee.

 

Committee Assignments:

 

•   Audit Committee (chair)

 

•   Nominating and Corporate Governance Committee

 

Other Current Public Company Boards:

 

•   XOMA Corporation, serving on the Audit Committee, the Compensation Committee (chair) and the Nominating and Corporate Governance Committee

 

•   Athersys, Inc., serving on the Audit Committee the Compensation Committee and the Nominations Committee

 

•   SiteOne Landscape Supply, Inc., serving on the Audit Committee and the Nominating & Corporate Governance Committee (chair)

 

Jack L. Wyszomierski, has been a director since February 2004. From June 2004 to June 2009, Mr. Wyszomierski served as the Executive Vice President and Chief Financial Officer of VWR International, LLC, a supplier of laboratory supplies, equipment and supply chain solutions to the global research laboratory industry. From 1982 to 2003, Mr. Wyszomierski held positions of increasing responsibility within the finance group at Schering-Plough Corporation, a health care company, culminating with his appointment as Executive Vice President and Chief Financial Officer in 1996. Prior to joining Schering-Plough, he was responsible for capitalization planning at Joy Manufacturing Company, a producer of mining equipment, and was a management consultant at Data Resources, Inc. Mr. Wyszomierski has served: as a member of the board of directors of XOMA Corporation, a publicly held company that licenses novel antibody therapeutics,biotech royalty aggregator, since August 2010; as a member of the board of directors of Athersys, Inc., a publicly held company engaged in the discovery and development of therapeutic product candidates, since June 2010; as a member of the board of directors of Solenis LLC, a privately held manufacturer of chemical products, since August 2014; and as a member of the board of directors of SiteOne Landscape Supply, Inc., a publicly held company that distributes landscape supply products, since April 2016. Mr. Wyszomierski previously served as a member of the board of directors of: Unigene Laboratories, Inc., a publicly held biopharmaceutical company, from April 2010 to July 2013; and AssuraMed Holding, Inc., a privately held distributor of home healthcare products, from January 2011 until its acquisition by Cardinal Health Inc. in March 2013. Mr. Wyszomierski holds a M.S. in Industrial Administration and a B.S. in Administration, Management Science and Economics from Carnegie Mellon University.

 

THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” EACH NAMED NOMINEE.

 

2020 Proxy Statement    15

2021 Proxy Statement    15


Corporate Governance

 

Please note that information found on, or accessible through, our website is not a part of, and is not incorporated into, this Proxy Statement.

Corporate Governance Guidelines

We have adopted written Corporate Governance Guidelines, which may be viewed atwww.exelixis.com under the caption “Investors & Media—Corporate Governance—Corporate Governance Documents.” This document covers, among other topics, director independence, board composition, structure and functioning, director selection criteria, committees of the board, board and board committee evaluations, overboarding guidelines and our majority voting policy. Our Board regularly reviews, and modifies from time to time, our Corporate Governance Guidelines, Board committee charters and Board practices.

Corporate Code of Conduct

We have adopted a Corporate Code of Conduct, which functions as our Code of Ethics under the SEC rules and applies to all directors, officers and employees, including the principal executive officer and principal financial/accounting officer. The Corporate Code of Conduct is posted on our website atwww.exelixis.com under the caption “Investors & Media—Corporate Governance—Corporate Governance Documents.” We intend to satisfy the disclosure requirement under Item 5.05 ofForm 8-K regarding an amendment to, or waiver from, a provision of this Corporate Code of Conduct by posting such information on our website, at the address and location specified above and, to the extent required by the listing standards of the Nasdaq Stock Market, by filing a Current Report on Form8-K with the SEC, disclosing such information.

Our Corporate Code of Conduct reflects our corporate values and describes how our officers, directors, employees and contractors are expected to conduct themselves when representing Exelixis. It also underscores our commitment to strive to comply with laws that regulate our business activities as a biotechnology company. Our employees receive regular training on our Corporate Code of Conduct, which includes consequences of taking actions that would constitute a violation of our Corporate Code of Conduct.

Included in our Corporate Code of Conduct are procedures for employees to report potential violations to our Ethics Committee, which is chaired by our Chief Executive Officer and includes other members of our senior management team. To ensure our employees feel comfortable raising good faith questions or concerns with respect to our Corporate Code of Conduct or our other policies, these reports can be made confidentially (or anonymously) via our Ethics Hotline, and we maintain a strict policy against any retaliation or discrimination towards an employee who makes such a report. The Board, through the Audit Committee, regularly receives reports of disclosures made through the Ethics Hotline, as well as any concerns raised to the Ethics Committee or otherwise submitted through our internal compliance reporting system. The Audit Committee will beis responsible for the oversight of such matters, or as appropriate, will assign such oversight to another committee of the Board.

Director Independence

We have adopted standards for director independence pursuant to Nasdaq listing standards, which require that a majority of the members of a listed company’s board of directors qualify as “independent,” as affirmatively determined by the board of directors. An “independent director” means a person other than an officer or employee of Exelixis or one of our subsidiaries, or another individual having a relationship that, in the opinion of the Board, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. Consistent with these considerations, after review of all relevant transactions or relationships between each director, or any of his or her family members, and Exelixis, its senior management or its independent registered public accounting firm, the Board has affirmatively determined that Drs. Cohen, Freire, Garber, Marchesi, Papadopoulos, Poste Scangos and Willsey, Messrs. Wyszomierski and Feldbaum and Ms. Smith, who are eleventen of the twelveeleven members of the Board, represent a majority of the Board and are independent under applicable SEC rules and the Nasdaq listing standards. Dr. Morrissey, our President and Chief Executive Officer, is not independent by virtue of his employment with Exelixis. In addition, the Board has also determined that: (i) all directors who serve on the Audit, Compensation and Nominating and Corporate Governance Committees are independent under applicable Nasdaq listing standards; and (ii) all members of the Audit Committee meet the independence requirements under the Exchange Act.

Special Note Regarding Independence of Dr. Papadopoulos. Dr. Papadopoulos is considered a “co-founder” of Exelixis as a result of financial contributions he made during the earliest part of its history and his role in assembling and advising the

16    Exelixis, Inc.


Proposal 1 | Corporate Governance

scientists who ultimately served as the company’s earliest management team. However, he has never been employed by us or otherwise involved with any daily business operations and, moreover, Exelixis’ management team today is composed of entirely different individuals from the company’s earliest management team. Accordingly, the Board has determined that Dr. Papadopoulos is independent under applicable SEC rules and the Nasdaq listing standards and is qualified to serve as our Chair and on our Audit Committee, as the Board believes that he has no interest, business or other relationship (including no family relationships) that could, or could reasonably be perceived to, materially interfere with his ability to act in the best interests of Exelixis.

Board Leadership Structure

The Board does not have a formal policy on whether the role of Chair and Chief Executive Officer should be separate or combined. Our Corporate Governance Guidelines provide that the Board will select its Chair and the Chief Executive Officer

16    Exelixis, Inc.


Proposal 1 | Corporate Governance

in the manner it considers to be in the best interests of our company. Currently, we have an independent Chair of the Board separate from the Chief Executive Officer. The Board believes this bifurcated structure provides for independent oversight of management and strong Board leadership, while allowing for the effective management of company affairs. The Board believes that if the positions of Chair and Chief Executive Officer are combined, the appointment of a lead independent director would be necessary for effective governance. Accordingly, our Corporate Governance Guidelines provide that if the roles are combined, the independent directors of the Board must appoint a lead independent director. Our Corporate Governance Guidelines further provide that the lead independent director would: (i) preside at all meetings of the Board at which the Chair is not present, including executive sessions of the independent directors; (ii) have the authority to call meetings of the independent directors; (iii) serve as the principal liaison on Board-wide issues between the independent directors and the Chair; and (iv) have such other authority and duties as the Board may from time to time determine. The Board believes that this flexible approach provides it with the ability to establish a leadership structure that, based upon its judgment, is in the best interests of our company and those of our stockholders at any given time.

Role of the Board in Risk Oversight

Management is responsible for assessing, managing and mitigating the various risks associated with our business and operational activities, including, without limitation, strategic, operational, financial, regulatory and cyber-securitycybersecurity risks that may exist from time to time. Management has implemented appropriate risk management structures, policies and procedures, and manages our risk exposure on aday-to-day basis. In accordance with our Corporate Governance Guidelines, the Board, both directly and through its committees (including the Risk Committee formed in December 2019), oversees the proper functioning of our internal risk management processes. In their specific risk oversight roles, the Board and the Risk Committee evaluate whether management has reasonable controls in place to address material risks currently facing our company and those we may face in the future. The Board, the Risk Committee and other committees meet at regularly scheduled and special meetings throughout the year at which management reports to the Board concerning the results of its risk management activities, as well as external changes that may change the levels of business risk to which we are exposed.

The Board delegates certain of its risk oversight responsibilities to its various committees as follows:

 

 

OurRisk Committee assists the Board with oversight of our internal risk management framework, policies, guidelines and infrastructure, and, if called for, its administration of government and other investigations and material litigation matters. The Risk Committee receives reports from management’s Ethics Committee and also oversees management in the dispatch of its responsibility to administer our various compliance programs, including, but not limited to, data privacy (including cyber-security), drug safety, healthcare compliance and quality management. Finally, the Risk Committee oversees our business and operational risks that are not specifically allocated to the Board or another committee of the Board. The Risk Committee provides periodic reports to the full Board.

OurAudit Committee oversees the management of risks relating to financial reporting or fraud, securities trading and tax matters. Our Audit Committee also reviews any proposed related party transactions to ensure we do not engage in transactions that would create a conflict of interest or result in harm to us.

 

 

OurCompensation Committee periodically assesses our compensation policies and practices, including structuring and reviewing our executive compensation programs, in order to determine whether any such policies or practices are reasonably likely to have a material adverse effect on us. Our Compensation Committee also assists the Board in its oversight of our human capital management function.

 

 

OurNominating and Corporate Governance Committee oversees our governance practices and the management of related risks, including director independence and Board composition and succession of both the Board and CEO, and the development and administration of our Code of Conduct.

 

 

OurResearch & Development Committee evaluates risks associated with the scientific discovery process, preclinical and clinical development programs, to the extent not within the purview of the Risk Committee’s oversight of our compliance programs.

Our Risk Committee assists the Board with oversight of our internal risk management framework, policies, guidelines and infrastructure, and, if called for, its administration of government and other investigations and

2021 Proxy Statement    17


material litigation matters. The Risk Committee receives reports from management’s Ethics Committee and also oversees management in the dispatch of its responsibility to administer our various compliance programs, including, but not limited to, data privacy (including cybersecurity), drug safety, healthcare compliance and quality management. Finally, the Risk Committee oversees our business and operational risks that are not specifically allocated to the Board or another committee of the Board. The Risk Committee provides periodic reports to the full Board.

Senior management presents the full Board with frequent business updates during monthly teleconferences, at which time the Board provides management with feedback, makes recommendations and, as needed, issues directives to address our risk exposure.

 

2020 Proxy Statement    17


BOARD OVERSIGHT OF COVID-19 IMPACT AND COMPANY RESPONSES

As a result of the COVID-19 global pandemic, management provided regular reports to both the Risk Committee and the full Board regarding potential and actual impacts of the pandemic on our clinical trial, drug discovery and commercial activities, as well as our general business operations. Included in these reports were the various strategies and mitigation efforts undertaken by management to maintain business continuity while protecting the health and safety of employees, contractors and patients that rely on our critical cancer medicines. Both the Risk Committee and the full Board will continue to receive information from management relating to the effects of the COVID-19 pandemic on the company, its operations and employees on a frequent and regular basis for the foreseeable future.

Prohibitions on Derivative, Hedging, Monetization and Other Transactions

We maintain an insider trading policy that applies to directors and employees, including our executive officers, which prohibits certain transactions in our stock, including short sales, puts, calls or other transactions involving derivative securities, hedging or monetization transactions, purchases of Exelixis securities on margin or borrowing against an account in which Exelixis securities are held, or, subject to the following exception, pledging Exelixis stock as collateral for a loan. There are no exceptions to these prohibitions, other than the pledging of Exelixis stock as collateral for a loan, which requires prior approval of Exelixis’ Securities Compliance Committee (comprising senior members of our legal and finance teams). Before granting the exception, the Securities Compliance Committee will require such director or employee to establish his or her financial capacity to repay the loan without resort to the pledged securities, and the pledged securities may not be sold without the advance written consent of the Securities Compliance Committee. As of the date of this Proxy Statement, no shares of Exelixis stock are pledged by any of our directors or executive officers.

Corporate Responsibility and Sustainability

Exelixis’ mission is to help cancer patients recover stronger and live longer. As we strive to extend and improve cancer patients’ lives, we recognize the need also to contribute positively to society as a whole. To that end, Exelixis expects that its employees will commit to the highest standards of ethical behavior and maintain values and principles that reflect both global awareness and sustainability. This entails integrating environmental, social and governance (ESG) considerations directly into our research and development projects, business operations and investment processes as we strive to create sustained value for all our stakeholders by translating science into impact for patients and all those we serve.

18    Exelixis, Inc.


Proposal 1 | Corporate Governance

We seek to achieve these commitments through a number of initiatives, including those listed below:

Our Governance and Compliance

 

LOGOLOGO

At Exelixis, we recognize that good governance, corporate responsibility and accountability are critical to our quest to develop medicines in our ongoing mission to treat and defeat cancer. We embed strong compliance practices and oversight into our scientific and business activities with the goal that these business activities be conducted in a legal and ethical manner and in the best interests of all Exelixis’ stakeholders, in particular, the patients we serve.

Program Highlights:

 

Strong internal governance structure relies upon the management-level Ethics Committee and its subcommittees, overseen by the Board-level Risk Committee

 

Requirement for systematic and regularperiodic reporting to senior management and our Board of Directors on matters relating to our Corporate Code of Conduct, including responding to and escalating key issues and concerns as needed

 

  Commitment to high standards and ethics across all departments and company stakeholders, as reflected by our internal policies, including ourPolicy for Recoupment of Variable Compensation (Clawback Policy)

Comprehensive training programs covering various compliance matters and utilizing both live (in-person or virtual) classroom sessions and interactive online modules.
 

 

Access to Health

 

LOGOLOGO

At Exelixis, we aim to bevalue being exceptional in what we do and how we lead, excelling for patients by going the extra mile to care for them and exceeding together as a business and contributor to the scientific community. We dedicate substantial financial resources and work tirelessly in our efforts to offer patients high-quality, safe and effective cancer treatments. Moreover, once our products are available, we have a firm, voluntary commitmentour goal is to ensure that no patient prescribed an Exelixis medicine will go without it due to lack of insurance or inability to pay.

Program Highlights:

 

Long history of dedicated research and development efforts, focused on creating better treatments for patients

 

Thoughtful pricing decisions that account for patient access (including discounting and rebates for certain group purchases), reinvestment designed to improve our drugs and production costs

 

Exelixis Access Services (EASE), a comprehensive resource that providesco-pay assistance, allows qualifying uninsured or underinsured patients to receive medication free of charge and connects patients with healthcare providers to assist with their treatment
 

 

18    Exelixis, Inc.

2021 Proxy Statement    19


Proposal 1 | Corporate Governance

 

Taking Responsibility for Our Products

 

LOGOLOGO

The well-being of patients is one of oura top priorities.priority for us. Our Corporate Code of Conduct holds every Exelixis employee accountable to safe and ethical standards of work and behavior, and is designed to ensure our products are developed in compliance with Good Practice quality guidelines. As a core tenetreflection of Exelixis values, product responsibility is monitored by teams with a direct chain of reporting to our Ethics Commmittee and overseen by our Board of Directors. This process is designed to allow us to escalate and address issues quickly and holistically.

Program Highlights:

 

Robust qualityQuality assurance program designed to ensure safe and ethical development and manufacturing practices

 

Transparency withInitiatives designed to provide transparency to clinical patients regarding important study considerations and pseudonymization of all patient data designed to protect sensitive personal information

 

Anticounterfeiting and serialization practices designed to safeguard product integrity in our supply chain and system to manage product recalls (should one become necessary)
 

 

Environmental

 

LOGOLOGO

Exelixis is committed to conducting business in a way that respects our environment and the Earth’s changing climate, and that is also consistent with providing a high stateserving the well-being of wellness for our patients, employees and all our stakeholders. To date, weWe have already incorporated many environmentally sustainable practices into certain of our facilities and operations, and we plan to invest inincorporate more of these practices as we continue to grow.

Program Highlights:

 

ImplementationContinued implementation of more energy-efficient systems in our headquarters and use of renewable energy sources, including for additional office space currently under construction

 

Employee commuter programs designed to take cars ofoff the road, and therebyas well as electric vehicle charging stations, which together reduce emission of greenhouse gases

 

Waste reduction practices with an emphasis on recycling by employees and a commitment to adherence to applicable laws and regulations that govern anythe handling and disposal of hazardous materials
 

 

Human Capital Management and Workforce Diversity

 

LOGOLOGO

Our mission to help cancer patients recover stronger and live longer depends on the talent and dedication of our employees. Therefore, weWe therefore invest in building their collective strength as a team by hiring the best qualified candidates available and fostering growth opportunities for individuals. At Exelixis, we value being exceptional in what we do and how we lead, excelling for patients by going the extra mile to care for them and exceeding together as a business and contributor to the scientific community.

Program Highlights:

 

Integrate our strong corporate values into our new hire interview process, performance evaluations and promotion criteria

 

Support of diversity in our workforce (with 44%48% and 46% of management and executivemanagerial roles held by non-whites and women, respectively, as of the end of fiscal 2019)2020) and insistence upon anti-discrimination in hiring and promotion practices

 

RegularComprehensive safety measures in response to COVID-19 pandemic, combined with regular inspections and training to promote general workplace safety and low rate of accidents

 

Competitive benefits programs to recruit and retain talented employees and a collaborative workplace culture that embodiesfosters individual development while embodying our corporate values
 

 

Further information about our ESG programs and sustainability efforts is available on our website atwww.exelixis.com under the caption “Impact—Environmental, Social and Governance.”

 

2020 Proxy Statement    19

20    Exelixis, Inc.


Proposal 1 | Corporate Governance

Stockholder Communications with the Board

The Board welcomes communications from Exelixis’ stockholders. Stockholders may communicate with the Board by sending a written communication to “Exelixis, Inc., Board of Directors c/o Corporate Secretary, 1851 Harbor Bay Parkway, Alameda, California 94502.” Stockholders may also communicate with the Board by facsimile at(650) 837-7951 or bye-mail at info@exelixis.com, with each of the foregoing sent with “Attn: Board of Directors” in the “Subject” line.

Each communication must set forth the name and address of the stockholder as it appears in the Exelixis’ records (and, if the stock is held by a nominee, the name and address of the beneficial owner of the stock). After confirming the stock ownership of the author of the communication, the Corporate Secretary will review and evaluate the communication, and shall have the authority to and will screen out communications from stockholders that are not directly related to the duties and responsibilities of the Board. The Corporate Secretary may also disregard duplicative communications. If deemed directly related to the duties and responsibilities of the Board, the Corporate Secretary will forward the communication, depending on the subject matter, to the Chair of the Nominating and Corporate Governance Committee, the Chair of the Audit Committee, the Chair of the Board, the independent directors, or the full Board, as deemed appropriate.

Stockholder Outreach

We maintain a robust program for stockholder outreach to elicit a better understanding of the concerns and perspectives of our stockholder base, and we have implemented the feedback received from our stockholders into our executive compensation program, governance practices and other areas of our business. For additional details about our stockholder outreach efforts during fiscal 2019,2020, please see “Compensation Discussion and Analysis—How We Determine Executive Compensation—Stockholder Outreach.”

Stock Ownership Guidelines forNon-Employee Directors

We maintain Stock Ownership Guidelines for our directors and Named Executive Officers (as defined below) to further align their financial interests with those of our stockholders, as well as to promote sound corporate governance. For ournon-employee directors, we amended our Stock Ownership Guidelines in February 2021 to provide an ownership target equalof the value equivalent to 5 times the annual cash Board retainer, an increase from the prior target of the lesser of athe value equivalent to three3 times the annual cash Board retainer or 3,000 shares. Allnon-employee directors are expected to achieve their stock ownership targets within five years of becoming subject to these guidelines. The policy includes procedures for granting exemptions in the case of severe financial hardship. Ownership targets for our Named Executive Officers (including those serving on our Board) are described below under  “Compensation Discussion and Analysis—Other Compensation Information—Stock Ownership Guidelines.”

In determining ownership levels for eachnon-employee director under our Stock Ownership Guidelines, credit is provided for shares held outright (including shares owned through trusts, the Amended and Restated Exelixis, Inc. 401(k) Plan (401(k) Plan), or by a spouse), as well as 50% of the number of vested, but unexercised, stock options. No credit is provided for RSUs (as defined below) until they vest. The values for all shares determined to be held by ournon-employee directors and Named Executive Officers are based on the200-day average stock price as of the measurement date. As of February 10, 2020,5, 2021, all of ournon-employee directors had met the required ownership targets.

Board Committees and Meetings

 

The Board held seven meetings and acted by unanimous written consent one time during 2019,2020, and all of our directors other than Dr. Scangos attended at least 75% of the total meetings of the Board and of the committees on which they served. Dr. Scangos’ absences were due principally to scheduling conflicts with certain activities and meetings in connection with the initial public offering of Vir Biotechnology, Inc. (Vir), for which Dr. Scangos serves as Chief Executive Officer and as a member of the Vir Board of Directors. In February 2020, Dr. Scangos provided us with notice that he will retire from the Board at the end of his current term, which expires at the Annual Meeting. The independent directors met four times in regularly scheduled executive sessions.

From January 2019 until December 2019,During 2020, the Board had fourfive standing committees: the Audit Committee; the Compensation Committee; the Nominating and Corporate Governance Committee; and the Research & Development Committee; and the Risk Committee. On

 

20    Exelixis, Inc.

2021 Proxy Statement    21


Proposal 1 | Board Committees and Meetings

December 5, 2019, the Board established a Risk Committee to assist the Board in its oversight of management’s responsibility to assess, manage and mitigate risks associated with our business and operational activities. Committee membership in 20192020 was as follows:

 

                                                                                                                                            

Board Member

  Audit
Committee
 

Compensation

Committee

  Nominating
and Corporate
Governance
Committee
  

Research &

Development
Committee

  Risk
Committee*
  Audit
Committee
  

Compensation

Committee

  Nominating
and Corporate
Governance
Committee
  

Research &

Development
Committee

  Risk
Committee
 

Charles Cohen, Ph.D.

  Member Chair     Member     Member*  Chair   

 

  Member   

 

 

Carl B. Feldbaum, Esq.

    Member**  Member     Chair   

 

   

 

  Member   

 

  Chair
 

Maria C. Freire, Ph.D.

       Member  Member  Member   

 

   

 

  Member  Member  Member
 

Alan M. Garber, M.D., Ph.D.

       Chair  Member      

 

   

 

  Chair  Member   

 

 

Vincent T. Marchesi, M.D., Ph.D.

    Member     Member      

 

  Member   

 

  Member   

 

 

Stelios Papadopoulos, Ph.D.

  Member       Member     Member*   

 

   

 

  Member   

 

 

George Poste, DVM, Ph.D., FRS

       Member***  Chair  Member   

 

   

 

   

 

  Chair  Member
 

George A. Scangos, Ph.D.^

          Member  Member   

 

   

 

   

 

  Member  Member
 

Julie A. Smith

  Member Member           Member*  Member   

 

   

 

   

 

 

Lance Willsey, M.D.

    Member     Member      

 

  Member   

 

  Member   

 

 

Jack L. Wyszomierski

  Chair****    Member        Chair*   

 

  Member   

 

   

 

Number of Meetings Held in Fiscal 2019

  5 9  2  3  0
 

Number of Meetings Held in Fiscal 2020

  4  11  3  4  2

 

*

On December 5, 2019, Drs. Freire, Poste and Scangos and Mr. Feldbaum were appointed to the Risk Committee, and Mr. Feldbaum was appointed as Chair. The Risk Committee did not hold any meetings in 2019.

**

On December 5, 2019, Mr. Feldbaum transitioned off of the Compensation Committee.

***

On December 5, 2019, Dr. Poste transitioned off of the Nominating and Corporate Governance Committee.

****

Designated by the Board as an “audit committee financial expert.”

^

Dr. Scangos isdid not standingstand forre-election at the 2020 Annual Meeting of Stockholders and will resignresigned from the Board effective as of the Annual Meeting.May 20, 2020.

Audit Committee

 

The Audit Committee assists the Board in overseeing our financial reporting process and ensuring the integrity of our financial statements. The Audit Committee is composed entirely of independent directors and performs several functions, including:

 

•  Evaluating the performance, qualifications, compensation and continued engagement of the independent registered public accounting firm, as well as resolving any disagreements between the independent registered public accounting firm and management

 

•  Reviewing our tax strategy, the status of any material tax audits and proceedings and any other material tax matters

•  Reviewing, providing oversight of, and approving related person transactions

 

•  Reviewing the financial statements for inclusion in our Annual Report on Form10-K and preparing the Audit Committee’s report for inclusion in our Proxy Statement or Annual Report onForm 10-K

•  Establishing procedures to receive and address complaints regarding accounting, internal accounting controls or auditing matters

 

•  Reviewing the results of the annual audit and the results of our quarterly financial statement reviews with management and the independent registered public accounting firm

•  Overseeing our management of risks relating to financial reporting or fraud, securities trading and tax matters

 

•  Serving as the Qualified Legal Compliance Committee within the meaning of Rule 205.2(k) of Title 17, Chapter II of the Code of Federal Regulations

•  Maintaining compliance with SEC and Nasdaq rules applicable to audit committees

 

•  Reviewing and approving our decisions to enter into certain swaps and other derivatives transactions, as well as our overall hedging strategy

2020 Proxy Statement    21


The Board has determined that Mr. Wyszomierskieach member of the Audit Committee is an “audit committee financial expert” as defined in applicable SEC rules. Although Mr. Wyszomierski, the Chair of our Audit Committee, also serves as a director and a member of the audit committee for three other publicly traded companies, he attended all Exelixis Board and Audit Committee meetings during 2020 and makes himself generally available to assit or advise Exelixis management.

22    Exelixis, Inc.


Proposal 1 | Board Committees and Meetings

The Audit Committee’s report is set forth in “Report of the Audit Committee” below. The Audit Committee has a written charter, which is available on our website atwww.exelixis.com under the caption “Investors & Media—Corporate Governance—Committee Composition and Charters.”

Compensation Committee

 

The Compensation Committee assists the Board in overseeing our compensation policies, plans and programs. The Compensation Committee is composed entirely of independent directors and performs several functions, including:

 

•  Reviewing and determining the compensation to be paid to executive officers

  

•  Reviewing our Compensation Discussion and Analysis and preparing the Compensation Committee’s report for inclusion in our Proxy Statement

•  Addressing any conflict of interest with any compensation adviser engaged by management or the Compensation Committee

  

•  Establishing general policies relating to compensation and benefits of employees, including executive officers

•  Evaluating director compensation and recommending any changes to the Board for approval

  

•  Administering the issuance of equity awards under our stock plans

•  Assisting the Board in its oversight of our policies and strategies relating to our human capital management function.function, including reruiting, retention, career development and progression, non-CEO management succession, diversity and employment practices

  

•  Assessing compensation policies and practices in order to determine whether they are reasonably likely to have a material adverse effect on us.

The Compensation Committee’s report is set forth in “Compensation Committee Report” below. Information on the Compensation Committee’s processes and procedures for consideration of executive compensation are addressed in “Compensation Discussion and Analysis” below. For information regarding our processes and procedures for the consideration and determination of director compensation, please see “Compensation of Directors” below. The Compensation Committee has a written charter, which is available on our website atwww.exelixis.com under the caption “Investors & Media—Corporate Governance—Committee Composition and Charters.” In accordance with its charter, the Compensation Committee also may delegate any of its authority or responsibility to the Chair of the Compensation Committee or to a subcommittee composed of one or more members of the Compensation Committee and/or other members of the Board and/or officers of Exelixis.

Compensation Consultants.The Compensation Committee retained Compensia, Inc. (Compensia),Radford, a national compensation consulting firm serving technology and life sciences companies, as its external compensation consultant to assist the Compensation Committee in its duties related to executive andnon-employee director compensation from March 2019 until November 2019. Compensia did not perform any work for us other than the executive compensation andnon-employee director compensation consulting services provided to the Compensation Committee andduring 2020. In this capacity, Radford reported directly to the Compensation Committee or through its Chair. Fees paid to Compensia in 2019 did not exceed $120,000. Beginning in November 2019, the Compensation Committee retained Radford, a compensation consulting firm serving technology and life sciences companies, to succeed Compensia as the Compensation Committee’s external compensation consultant with respect to future executive andnon-employee director compensation matters. In addition, at the direction of the Compensation Committee, management retained Radford, principally to provide benchmark and industry compensation data for executive and broad-based compensation analyses. In consideration for compensation related services provided during 20192020 we paid Radford an aggregate of $18,176.$219,737. Radford also provided our management with access to the Radford Global Life Sciences Survey, Radford Global Technology Survey, Radford Global Sales Survey, and Radford U.S. Benefits Survey and similar materials, for which we paid Radford an aggregate of $27,405$28,857 in 2019.2020. Radford is an Aon Hewitt company and an affiliate of Aon Risk Services which provided insurance brokerage services to us during 20192020 at a total cost of $205,000. See “Compensation Discussion and Analysis” for more information regarding the Compensation Committee’s engagement of Compensia and Radford.

 

22    Exelixis, Inc.

2021 Proxy Statement    23


Proposal 1 | Board Committees and Meetings

 

Nominating and Corporate Governance Committee

 

The Nominating and Corporate Governance Committee oversees all aspects of our corporate governance functions on behalf of the Board. The Nominating and Corporate Governance Committee is composed entirely of independent directors and performs several functions, including:

 

•  Overseeing our governance practices, including reviewing and recommending to the Board for approval any changes to our corporate governance framework

  

•  Ensuring effective communication between the Board, its committees and management, as well developing and administering policies and procedures for stockholders’ communications to the Board

•  Conducting periodic assessments of the performance of the Board and its committees and compliance with SEC and Nasdaq requirements for independence and expertise

  

•  Facilitating our CEO Succession Plan in the event our Chief Executive Officer is no longer able to serve in that position

•  Identifying, reviewing and evaluating candidates to serve as directors and recommending qualified candidates to the Board

  

•  Developing a set of Corporate Governance Guidelines, as well as administering our Corporate Code of Conduct

In addition, as part of its oversight of our governance practices, the Nominating and Corporate Governance Committee oversees management in its preparation of public disclosures pertaining to our ESG programs and sustainability efforts. The Nominating and Corporate Governance Committee has a written charter, which is available on our website atwww.exelixis.com under the caption “Investors & Media—Corporate Governance—Committee Composition and Charters.”

Director Qualifications; Diversity. The Nominating and Corporate Governance Committee does not have a fixed set of minimum qualifications for candidates for membership on the Board. Instead, in considering candidates for directorship, the Nominating and Corporate Governance Committee will generally consider all relevant factors, including the candidate’s applicable expertise and demonstrated excellence in his or her field, the usefulness of such expertise to us, the availability of the candidate to devote sufficient time and attention to the affairs of Exelixis, the existence of any relationship that would interfere with the exercise of the candidate’s independent judgment, and the candidate’s demonstrated character and judgment. In addition, the Board believes that its members should reflect a diversity of viewpoints, background, experience and other characteristics such as gender and race. Accordingly, when evaluating candidates for nomination as new directors, the Nominating and Corporate Governance Committee will seek to considerconsiders (and will ask any search firm that it engages to provide) a set of candidates who would contribute to Board diversity, including both women and individuals from historically underrepresented communities of color who meet the relevant business and search criteria. Both the Nominating and Corporate Governance Committee and full Board evaluate the effectiveness of this diversity policy as part of their periodic performance assessments. In the director candidate review process, the Nominating and Corporate Governance Committee evaluates prospective candidates for directorship in the context of the existing membership of the Board (including the qualities and skills of the existing directors), our operating requirements and the long-term interests of our stockholders.

The Nominating and Corporate Governance Committee regularly evaluates the needs of the Board with respect to skills and experiences that may be filled by a new director candidate. In addition, the Nominating and Corporate Governance Committee is authorized to access external resources as it deems necessary or appropriate to fulfill its defined responsibilities, including engagement of executive search firms to help identify director candidates.

Director Nominations.The Nominating and Corporate Governance Committee considers and assesses all candidates recommended by our directors, officers and stockholders. Evaluations of candidates generally involve a review of background materials, internal discussions and interviews with selected candidates as appropriate. If, after its review, the Nominating and Corporate Governance Committee supports a candidate, it would recommend the candidate for consideration by the full Board. The Nominating and Corporate Governance Committee considers stockholder recommendations for directors using the same criteria as potential nominees recommended by the members of the Nominating and Corporate Governance Committee or others. The Nominating and Corporate Governance Committee has not received any recommended nominations from any stockholder holding 5% or more of our common stock in connection with the Annual Meeting.

24    Exelixis, Inc.


Proposal 1 | Board Committees and Meetings

Stockholders who wish to recommend individuals for consideration by the Nominating and Corporate Governance Committee to become nominees for election to the Board may do so by delivering a written recommendation to the Nominating and Corporate Governance Committee within the timeframe specified in our Bylaws that is applicable to matters

2020 Proxy Statement    23


to be brought before an annual meeting of stockholders as set forth under “Questions and Answers About These Proxy Materials and Voting” above. Such communications should be sent to the following address: Exelixis, Inc., 1851 Harbor Bay Parkway, Alameda, California 94502, Attn: Nominating and Corporate Governance Committee of the Board. Submissions must include (a) the name, age, business address and residence address of such person, (b) the principal occupation or employment of such person, (c) the class and number of shares of the corporation which are beneficially owned by such person, (d) a description of all arrangements or understandings between the stockholder and each nominee and any other person or persons (naming such person or persons) pursuant to which the nominations are to be made by the stockholder, (e) a statement whether such person, if elected, intends to comply with our Corporate Governance Guidelines, including with respect to matters relating to the election of directors, and (f) any other information relating to such person that is required to be disclosed in solicitations of proxies for election of directors, or is otherwise required, in each case pursuant to Regulation 14A under the 1934 Act (including without limitation such person’s written consent to being named in the proxy statement, if any, as a nominee and to serving as a director if elected).

Performance Assessments. The Nominating and Corporate Governance Committee performs periodic assessments of the performance of the Board and its committees. As part of this process, each director, under the direction of the Nominating and Corporate Governance Committee, completes an annual assessment questionnaire for the full Board and each committee on which such director serves to evaluate, on anonymous basis,anonymously, the overall performance of the Board and its committees and identify areas for improvement. The factors considered in the annual assessment questionnaires include, but are not limited to: the appropriateness of the size of the Board; whether the directors possess the skills and expertise appropriate for the company; the effectiveness of the Board’s selection criteria for new director candidates (including with respect to the Board’s diversity policy); the overall effectiveness of and efficient use of time at Board and committee meetings; and the process for management to report important information to committees or the full Board, as appropriate. Directors areThe annual assessment questionnaires also given theprovide each director with an opportunity to provide open-ended responses with respect to ways to improve Board and/or committee performance. In addition, as part of the performance assessment process during certain years, each director will interview with an independent legal counsel to the Board to discuss his or her perspectives about the Board’s performance, as well as corporate governance goals and potential risks facing the company, and summaries of these interviews are then reported to the Board. The Nominating and Corporate Governance Committee and the full Board also seek regular input from management and external advisors as part of the ongoing performance assessment process.

Research & Development Committee

 

The Research & Development Committee assists the Board in overseeing various scientific matters related to our drug discovery and preclinical and clinical development programs. The Research & Development Committee is composed entirely of independent directors and performs several functions, including:

 

•  Overseeing our clinical development program and internal drug discovery activities

  

•  Evaluating and discussing trends in the oncology treatment landscape and potential effects on our pipeline strategy and other business needs

•  Reviewing the progress of preclinical assets that we havein-licensed or acquired and evaluating potential future business development opportunities

  

•  Advising the Board on other matters of scientific importance as the Board, in consultation with management, may designate from time to time

2021 Proxy Statement    25


Risk Committee

 

The Risk Committee of the Board assists the Board in overseeing management’s responsibility to assess, manage and mitigate risks associated with our business and operational activities. The Risk Committee is composed entirely of independent directors and performs several functions, including:

 

•  Reviewing our overall risk management framework and infrastructure designed to identify, assess, manage and mitigate our material risks

  

•  Overseeing management’s administration of our various compliance programs, including, but not limited to, those relating to data privacy (including cyber-security)cybersecurity), drug safety, healthcare compliance and quality management

•  Reviewing the policies, guidelines and practices aimed at the management of business and operational risks

  

•  Overseeing management’s administration of government and other investigations and material litigation matters

24    Exelixis, Inc.


Proposal 1 | Board Committees and Meetings

•  Overseeing management’s identification, assessment and management of our business and operational risks not specifically allocated to the Board or another committee of the Board, and obtaining periodic reports from our Ethics Committee

  

•  Evaluating and discussing trends in the relevant areas of risk management and advising the Board on best practices with respect to risk management strategy and implementation

Annual Meeting; Attendance

 

The Board does not have a formal policy with respect to the attendance of its members at Annual Meetings of Stockholders. Dr.Drs. Papadopoulos, Cohen and Morrissey was the only member of the Boardwere in attendance at the 20192020 Annual Meeting of Stockholders.

 

2020 Proxy Statement    25

26    Exelixis, Inc.


Compensation of Directors

COMPENSATION OF DIRECTORS

Overview of Director Compensation

The compensation program for ournon-employee directors is intended to be competitive and fair so that we can attract optimal talent to our Board and recognize the time and effort required of a director given the size and complexity of our operations. In accordance with its charter, our Compensation Committee is responsible for recommending to the Board for approval the annual compensation for ournon-employee directors and acts on behalf of the Board in discharging the Board’s responsibilities with respect to overseeing our compensation policies fornon-employee directors. To assist with the Compensation Committee’s and the Board’s review, ourthe Compensation Committee’s external compensation consultant prepares a comprehensive annual assessment of ournon-employee director compensation program. The assessment includes benchmarking director compensation against the same 20192020 peer group used for executive compensation purposes, an update in recent trends in director compensation and a review of related corporate governance best practices.

Recent Changes to Director Compensation

In February 2019, the Board approved changes to thenon-employee director compensation program following consideration of market data prepared by the Compensation Committee’s independent compensation adviser, and the recommendation of the Compensation Committee. The primary goal of these changes was to balance our ability to attract and retain the highest quality directors while aligning the program with the interests of our stockholders. As such, the Board sought to align the total compensation for ournon-employee directors with those in the 60th percentile of our same 2019 peer group used for executive compensation purposes. The Board also sought to ensure that the pay structure appropriately reflected the scope of responsibilities and level of contribution provided by ournon-employee directors. Among the changes to the program in 2019 were the following:

For the cash component of ournon-employee director compensation program, the annual retainers payable to eachnon-employee director for service on the Audit Committee and Compensation Committee were each increased by $2,000 compared to 2018. However, the additional annual retainers payable to the Chairs of the Audit Committee and Compensation Committee were each reduced by $2,000 compared to 2018, such that each Chair’s total annual retainer for service on the Audit Committee or Compensation Committee, as applicable, was the same in 2019 as in 2018. In addition, the annual retainer payable to the Chair of the Board was increased by $1,000 compared to 2018.

For the equity component of ournon-employee director compensation program, the dollar value of the annual awards ournon-employee directors are eligible to receive was increased to $400,000. In addition, with respect to nonstatutory stock options granted as part of each annual award, such options are immediately exercisable, but shares issued upon early exercise are subject to a repurchase right and will vest as to 100% of the underlying shares on the first anniversary of the grant date, rather than monthly in equal parts over aone-year period during as with such options granted in 2018.

These changes were effective beginning with the first quarter of fiscal 2019.

In addition, at our 2017 Annual Meeting of Stockholders, our stockholders approved a limit on the amount ofnon-employee director compensation under our 2017 Plan. The aggregate value of all compensation granted or paid to any individual solely for service as a non-employee director of the Board of Directors may not exceed (a) $750,000 in total value with respect to any calendar year after a non-employee director is first appointed or elected to the Board or (b) $1,500,000 in total value with respect to the calendar year during which a non-employee director is first appointed or elected to the Board, in each case calculating the value of any stock awards based on the grant date fair value of such awards for financial reporting purposes. This limit was not intended to serve as an increase in the annual amount ofnon-employee director compensation; rather, this action was approved for the purpose of limiting the amount of compensation the Board can approve fornon-employee directors each year.

Cash Compensation Arrangements

Eachnon-employee director receives an annual cash retainer for his or her service on the Board, as well as an additional annual cash retainer if he or she serves as the Chair of the Board, on a committee or as the chair of a committee. In addition, ournon-employee directors receive meeting fees for attendance at each Board meeting or at each of their respective committee meetings in excess of thepre-determined number of meetings for the fiscal year, which is included in the full description of the 20192020 cash compensation arrangements for ournon-employee directors in the table below.

26    Exelixis, Inc.


Compensation of Directors

The table below provides information regarding the cash compensation arrangements for ournon-employee directors for 2019.2020. Dr. Morrissey receives no compensation in his capacity as a member of the Board.

 

Service

  Fee Type  

Cash    

Compensation ($)    

Board

  Retainer Fee    50,000        
  Additional Chair Retainer Fee    31,000        
  Meeting Fee (1)(2)    2,500        

Audit Committee

  Retainer Fee    12,000        
  Additional Chair Retainer Fee    13,000        
  Meeting Fee (1)(3)    1,000        

Compensation Committee

  Retainer Fee    10,000        
  Additional Chair Retainer Fee    10,000        
  Meeting Fee (1)(3)    1,000        

Nominating & Corporate Governance Committee

  Retainer Fee    5,000        
  Additional Chair Retainer Fee    10,000        
  Meeting Fee (1)(4)    1,000        

Research & Development Committee

  Retainer Fee    5,000        
  Additional Chair Retainer Fee    10,000        
Meeting Fee (1)(4)1,000        

Risk Committee

Retainer Fee5,000        
Additional Chair Retainer Fee10,000        
   Meeting Fee (1)(4)    1,000        

 

(1)

Meeting for which minutes are generated count toward the meeting threshold to determine when Meeting Fees are to be paid.

(2)

Meeting Fee paid for all meetings in excess of eight meetings.

(3)

Meeting Fee paid for all meetings in excess of seven meetings.

(4)

Meeting Fee paid for all meetings in excess of four meetings.

All cash compensation is paid to each director in arrears on a quarterly basis for services performed during the prior fiscal quarter.

2021 Proxy Statement    27


Equity Compensation Arrangements

Ournon-employee directors are also eligible to receive equity as part of their Board service, including an initial award upon joining the Board and an annual award on the day following each annual meeting of stockholders. Grants to ournon-employee directors are made under our 2017 Equity Incentive Plan (2017 Plan), pursuant to theNon-Employee Director Equity Compensation Policy, as amended (2017 Directors’(Directors’ Policy), as adopted by the Board. To address changes in the trading price of our common stock, we utilize a value-based approach for determining the number of shares subject tonon-employee director equity awards. Under the terms of the 2017 Directors’ Policy, the aggregate value of eachone-time initial award is $680,000, and the aggregate value of each annual award is $400,000. The value of each initial award and annual award is then divided approximately evenly between a nonstatutory stock option and a restricted stock unit (RSU) award. However, effective as of February 2020, eachnon-employee director may instead elect to receive the full value of his or her annual award in the form of either RSUs or nonstatutory stock options.

Under the 2017 Directors’ Policy, the total number of options and RSUs granted as part of each initial award and annual award is determined using a formula based upon the Black-Scholes Merton option pricing model and the average of the daily closing sale prices of our common stock for the trading days during the30-day calendar period ending on (and including) the last calendar day immediately prior to the relevant grant date. The value of each award, as determined in accordance with the 2017 Directors’ Policy, may be greater or lesser than the grant date fair value computed for financial reporting purposes and reflected in the “DirectorDirector Compensation Table”Table below. This is a result of the different calculation employed to determine the grant date fair value, which uses a formula based upon the Black-Scholes Merton option pricing model and the closing sale price of our common stock on the grant date.

Options granted under the 2017 Plan in accordance with the 2017 Directors’ Policy are not incentive stock options under the Internal Revenue Code of 1986, as amended (the Code). The exercise price of each initial and annual stock option granted under the 2017 Plan is equal to 100% of the fair market value of a share of common stock on the grant date. Under the terms of the 2017 Directors’ Policy, theone-time initial options are immediately exercisable, but shares issued upon early exercise are subject to a repurchase right and will vest at the rate of 25% of the underlying shares on the first anniversary of the grant date and monthly thereafter over the next three years. The annual options are immediately exercisable, but shares issued upon early exercise are subject to a repurchase right and will vest at the rate of 100% of the underlying shares on the first anniversary of the grant date.

2020 Proxy Statement    27


As long as thenon-employee director continues to serve with us or with an affiliate of ours, the options continue to vest and be exercisable during their terms, and shares issued upon early exercise continue to vest. When the option holder’s service terminates, we have the right to repurchase any unvested shares acquired upon exercise of the option at the original exercise price without interest. The post-termination exercise period for the vested portion of options granted to ournon-employee directors is generally set to terminate the earlier of three years after anon-employee director’s service terminates or the remainder of the term of the option, as described in the form of option agreement fornon-employee directors under the 2017 Plan (not to exceed seven years from the date of grant).

The initial RSU awards vest at the rate of 25% of the underlying shares on each of the first four anniversaries of the grant date, and the annual RSU awards vest at the rate of 100% of the underlying shares on the first anniversary of the grant date, in each case so long as thenon-employee director continues to serve with us or with an affiliate of ours.

In the event of a change in control, 100% of thenon-employee director’s outstanding and unvested equity awards will immediately vest, and any applicable repurchase rights we may have will terminate.

Reimbursement of Expenses

The members of the Board are eligible for reimbursement of certain expenses incurred in connection with their attendance at Board meetings and their service on the Board in accordance with our policy.

Meaningful Limits on Director Compensation

The aggregate value of all compensation granted or paid to any individual solely for service as a non-employee director may not exceed (a) $750,000 in total value with respect to any calendar year after a non-employee director is first appointed or elected to the Board or (b) $1,500,000 in total value with respect to the calendar year during which a non-employee director is first appointed or elected to the Board, in each case calculating the value of any stock awards based on the grant date fair value of such awards for financial reporting purposes. These limits on non-employee director compensation were approved by our stockholders and are included in our 2017 Plan.

28    Exelixis, Inc.


Compensation of Directors

Director Compensation Table

 

The following table shows compensation information for ournon-employee directors for the fiscal year ended January 3, 2020.1, 2021.

Director Compensation for Fiscal 20192020

 

  Fees Earned or
Paid in  Cash
($)
   Stock Awards
($)(1)
   Option Awards
($)(2)
     

Total

($)

 
  Fees Earned or
Paid in  Cash
($)
   Stock Awards
($)(1)
   Option Awards
($)(2)
     

Total

($)

 

Charles Cohen, Ph.D.

   88,000        380,780      468,780    91,000        358,410      449,410 

Carl B. Feldbaum, Esq.

   66,000        380,780      446,780    70,000        358,410      428,410 

Maria C. Freire, Ph.D.

   60,000    203,967   184,260     448,227    65,000    190,263    180,149      435,412 

Alan M. Garber, M.D., Ph.D.

   70,000        380,780      450,780    70,000        358,410      428,410 

Vincent T. Marchesi, M.D., Ph.D.

   67,000    203,967    184,260      455,227    69,000    190,263    180,149      439,412 

Stelios Papadopoulos, Ph.D.

   98,000    203,967    184,260      486,227    98,000    382,546          480,546 

George Poste, DVM, Ph.D., FRS

   70,000    203,967    184,260      458,227    70,000    382,546          452,546 

George A. Scangos, Ph.D.

   55,000        380,780      435,780 

George A. Scangos, Ph.D.(3)

   30,000              30,000 

Julie A. Smith

   73,000        380,780      453,780    76,000    382,546          458,546 

Lance Willsey, M.D.

   65,000        380,780      445,780    68,000        358,410      426,410 

Jack L. Wyszomierski

   80,000    203,967    184,260      468,227    80,000    190,263    180,149      450,412 

 

(1)

On May 23, 2019,21, 2020, each of Drs. Freire, Marchesi, Papadopoulos and Poste, Ms. Smith and Mr. Wyszomierski were granted an RSU award pursuant to the 2017 Directors’ Policy, whichPolicy. Each of Drs. Papadopoulos and Poste, and Ms. Smith elected to receive 100% of their annual award in the form of RSU awards. RSU awards granted to Drs. Freire and Marchesi and Mr. Wyszomierski accounted for approximately 50% of the total value of their annual award. Amounts shown in this column reflect the grant date fair value of the RSU award as computed in accordance with Financial Accounting Standards Board (FASB), Accounting Standards Codification Topic 718 (ASC 718). See “Equity Compensation Arrangements” above for a description of the RSU awards made tonon-employee directors on May 23, 2019.21, 2020.

 

  

Only one RSU award was granted to each of Drs. Freire, Marchesi, Papadopoulos and Poste, Ms. Smith and Mr. Wyszomierski during fiscal 20192020 and, accordingly, the grant date fair value of that RSU award is reflected in the table. The aggregate number of shares subject to all RSUs held by each of thesenon-employee directors as of January 3, 2020,1, 2021, is as follows: Dr. Freire—20,90714,788 Dr. Marchesi—10,317;7,728; Dr. Papadopoulos—10,317;15,538; Dr. Poste—10,317;15,538; Ms. Smith—15,538 and Mr. Wyszomierski—10,317.7,728. None of the othernon-employee directors received any RSU awards during fiscal 2019,2020, and none of the othernon-employee directors held any outstanding RSU or other stock awards as of January 3, 2020.1, 2021.

28    Exelixis, Inc.


Compensation of Directors

 

(2)

On May 23, 2019, each21, 2020, seven of our non-employee director wasdirectors were granted an option to purchase our common stock pursuant to the 2017 Directors’ Policy. Each of Drs. Cohen, Garber Scangos and Willsey, and Mr. Feldbaum and Ms. Smith elected to receive 100% of their annual award in the form of options to purchase our common stock, while each of Drs. Freire Marchesi, Papadopoulos and PosteMarchesi, and Mr. Wyszomierski elected to receive approximately 50% of their annual award in the form of options to purchase our common stock and approximately 50% of their annual award in the form of an RSU award. Amounts shown in this column reflect the aggregate grant date fair value for the option awards granted in fiscal 20192020 as computed in accordance with FASB ASC 718. The assumptions used to calculate the value of option awards are set forth in Note 8 of the Notes to Consolidated Financial Statements included in our Annual Report on Form10-K for the fiscal year ended January 3, 2020, filed with1, 2021, submitted to the SEC on February  25, 2020.10, 2021. See “Equity Compensation Arrangements” above for a description of the option grants made tonon-employee directors on May 23, 2019.21, 2020. There can be no assurance that the options will ever be exercised (in which case no value will actually be realized by the director) or that the value on exercise of stock options will be equal to the grant date fair value shown in this column.

 

  

Only one stock option award was granted to eachnon-employee director of Drs. Cohen, Freire , Garber, Marchesi and Willsey and Messrs. Feldbaum and Wyszomierski during fiscal 20192020 and, accordingly, the grant date fair value of that stock option is reflected in the table. The aggregate number of shares subject to all stock options held by each of our currentnon-employee directors as of January 3, 2020,1, 2021, is as follows: Dr. Cohen—377,695;248,049; Mr. Feldbaum—266,845;228,049; Dr. Freire—64,748;

2021 Proxy Statement    29


80,204; Dr. Garber—304,255;248,049; Dr. Marchesi—198,198;103,650; Dr. Papadopoulos—333,985;168,194; Dr. Poste—187,856; Dr. Scangos—268,985;128,194; Ms. Smith—139,919; Dr. Willsey—368,441;248,049; and Mr. Wyszomierski—275,597.183,650.

(3)

Dr. Scangos did not stand for re-election at the 2020 Annual Meeting of Stockholders and resigned from the Board effective as of May 20, 2020. As of January 1, 2021, Dr. Scangos did not hold any options to purchase shares of our common stock or any outstanding RSU awards. The compensation paid to Dr. Scangos in 2020 reflects the portions of his annual cash retainers for his service as a director and as a member of the Research & Development Committee and Risk Committee earned during the first two quarters of fiscal 2020.

 

2020 Proxy Statement    29

30    Exelixis, Inc.


Proposal 2 | Ratification of Selection of Independent Registered Public Accounting Firm

PROPOSAL 2

RATIFICATIONOF SELECTIONOF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The Audit Committee of the Board has selected Ernst & Young LLP as Exelixis’ independent registered public accounting firm for the fiscal year ending January 1,December 31, 2021. The Board, on behalf of the Audit Committee, has further directed that management submit the selection of the independent registered public accounting firm for ratification by the stockholders at the Annual Meeting. Ernst & Young LLP has audited our financial statements for each of the nineteentwenty fiscal years in the period ended January 3, 2020.1, 2021. Representatives of Ernst & Young LLP are expected to be present at the Annual Meeting. They will have an opportunity to make a statement if they so desire and will be available to respond to appropriate questions.

Neither our Bylaws nor other governing documents or law require stockholder ratification of the selection of Ernst & Young LLP as Exelixis’ independent registered public accounting firm. However, the Board is submitting the selection of Ernst & Young LLP to the stockholders for ratification as a matter of good corporate governance. If the stockholders fail to ratify the selection, the Audit Committee of the Board will reconsider whether or not to retain that firm. Even if the selection is ratified, the Audit Committee of the Board in its discretion may direct the appointment of a different independent registered public accounting firm at any time during the year if they determine that such a change would be in the best interests of Exelixis and its stockholders.

The affirmative vote of the holders of a majority of the shares present or represented by proxy at the Annual Meeting and entitled to vote at the Annual Meetingon this proposal is required to ratify the selection of Ernst & Young LLP. Abstentions will be counted toward the tabulation of votes cast on proposals presented to the stockholdersthis proposal and will have the same effect as a votevotes against this proposal. Brokers generally have discretionary authority to vote on the ratification of our independent accounting firm; thus, we do not expect any brokerBroker non-votes, on this proposal.if any, will have no effect.

 

THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR"“FOR” PROPOSAL 2.

Principal Accountant Fees and Services

The aggregate fees billed by Ernst & Young LLP for the last two fiscal years for the services described below are as follows:

 

  Fiscal Year Ended   Fiscal Year Ended 
      
  January 3,
2020
   December 28,
2018
   January 1,
2021
   January 3,
2020
 

Audit fees (1)

  $2,004,195   $1,914,430   $2,076,000   $2,004,195 

Audit-related fees (2)

   66,000    155,200    80,000    66,000 

Tax Compliance Fees (3)

   226,600     

Tax fees:

   477,736    515,748 

Tax compliance fees (3)

   132,200    226,600 

Other tax fees (4)

   289,148    416,273    345,536    289,148 

All other fees (5)

   8,255    3,230    6,010    8,255 

Total Fees

  $2,594,198   $2,489,133   $2,639,746   $2,594,198 

 

(1)

“Audit fees” consist of fees billed for professional services rendered for the audit of our consolidated financial statements and review of the interim consolidated financial statements included in quarterly reports and services that are normally provided by Ernst & Young LLP in connection with statutory and regulatory filings and other engagements such as consents and review of documents filed with the SEC.

 

(2)

“Audit-related fees” consist of fees billed for assurance and related services that are reasonably related to the performance of the audit or review of our consolidated financial statements and are not reported under “Audit fees.” During fiscal 20192020 and 20182019 these services included consultations relating to various transactions.

 

(3)

“Tax compliance fees” consist of fees for tax compliance and tax preparation.

 

(4)

“Other tax fees” consist of fees for tax advice and tax planning.

 

(5)

“All other fees” consist of fees for products and services other than the services described above. During fiscal 20192020 and 2018,2019, these fees related to anon-line subscription to an Ernst & Young LLP database.

 

30    Exelixis, Inc.

2021 Proxy Statement    31


Proposal 2 | Ratification of Selection of Independent Registered Public Accounting Firm

 

All fees described above werepre-approved by the Audit Committee. The Audit Committee has determined that the rendering of the services other than audit services by Ernst & Young LLP is compatible with maintaining the independence of the independent registered public accounting firm.

Pre-Approval of Services

During 20192020 and 2018,2019, the Audit Committee of the Boardpre-approved the audit andnon-audit services to be performed by Exelixis’ independent registered public accounting firm, Ernst & Young LLP.Non-audit services are defined as services other than those provided in connection with an audit or a review of our financial statements. The Audit Committeepre-approves all audit andnon-audit services rendered by Ernst & Young LLP. The Audit Committee generallypre-approves specified services in the defined categories of audit services, audit-related services, tax services and all other services up to specified amounts.Pre-approval may also be given as part of the Audit Committee’s approval of the scope of the engagement of the independent registered public accounting firm or on an individual explicitcase-by-case basis before the independent auditor is engaged to provide each service. The Audit Committee or its Chair, whom the Audit Committee has designated as aone-person subcommittee withpre-approval authority,pre-approved all audit fees, audit-related fees, tax fees and other fees in 20192020 and 2018.2019. Anypre-approvals by the subcommittee must be and were presented to the Audit Committee at its next scheduled meeting.

 

2020 Proxy Statement    31

32    Exelixis, Inc.


Report of the Audit Committee

REPORTOFTHE AUDIT COMMITTEE

The material in this report is not “soliciting material,” is not deemed “filed” with the Securities and Exchange Commission and is not deemed to be incorporated by reference in any filing of Exelixis under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.

In connection with the audited consolidated financial statements for the fiscal year ended January 3, 2020,1, 2021, of Exelixis, Inc. (“Exelixis”), the Audit Committee of the Board of Directors of Exelixis has:

(1) reviewed and discussed the audited financial statements for the fiscal year ended January 3, 2020,1, 2021, with management of Exelixis;

(2) discussed with Ernst & Young LLP, Exelixis’ independent registered public accounting firm (“Ernst & Young”), the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board (“PCAOB”); and the SEC; and

(3) received the written disclosures and the letter from Ernst & Young required by the applicable requirements of the PCAOB regarding Ernst & Young’s communications with the Audit Committee concerning independence, and has discussed with Ernst & Young that accounting firm’s independence.

Based on the foregoing, the Audit Committee has recommended to the Board of Directors that the audited financial statements be included in Exelixis’ Annual Report on Form10-K for the fiscal year ended January 3, 2020.1, 2021.

Audit Committee:

Jack L. Wyszomierski, Chair

Charles Cohen

Stelios Papadopoulos

Julie A. Smith

 

32    Exelixis, Inc.

2021 Proxy Statement    33


Proposal 3 | Amendment and Restatement of 2017 Equity Incentive Plan

 

PROPOSAL 3

AMENDMENTAND RESTATEMENTOF 2017 EQUITY INCENTIVE PLAN

The Compensation Committee approved an amendment and restatement of the 2017 Plan in March 2020, subject to approval by our stockholders. For purposes of this Proposal 3, we refer to the 2017 Plan, as amended and restated by the Compensation Committee in March 2020, as the “Amended 2017 Plan.” We are asking our stockholders to approve the Amended 2017 Plan at the Annual Meeting.

The Amended 2017 Plan contains the following material changes from the 2017 Plan:

Subject to adjustment for certain changes in our capitalization, the aggregate number of shares of our common stock that may be issued under the Amended 2017 Plan will not exceed 45,453,064 shares (plus the Prior Plans’ Returning Shares (as defined below), as such shares become available from time to time), which is an increase of 21,000,000 shares over the aggregate number of shares of our common stock that may be issued under the 2017 Plan.

The 2017 Plan provides for accelerated vesting of outstanding awards in the event of (i) certain corporate transactions involving Exelixis in which the surviving or acquiring corporation (or its parent company) does not assume, continue or substitute for such awards, (ii) certain control acquisitions involving Exelixis that are not approved by the Board or Compensation Committee, and (iii) certain involuntary terminations of service that occur within one month before, as of, or within 13 months after a change in control of Exelixis. The Amended 2017 Plan retains such provisions, but specifies that (a) the provision regarding certain corporate transactions involving Exelixis will also apply to a change in control of Exelixis and (b) for purposes of such acceleration, with respect to any such awards that are subject to performance-based vesting conditions or requirements, vesting will be deemed to be satisfied at the target level of performance.

Why We Are Asking Our Stockholders to Approve the Amended 2017 Plan

We are seeking stockholder approval of the Amended 2017 Plan to increase the number of shares available for the grant of stock options, RSU awards and other awards to our employees and directors, which will enable us to have a competitive equity incentive program to compete with our peer group for key talent.

Approval of the Amended 2017 Plan by our stockholders will allow us to continue to grant stock options and RSU awards at levels determined appropriate by the Board or Compensation Committee, which determination takes into account the impact of such awards on stockholder dilution. The Amended 2017 Plan will also allow us to utilize a broad array of equity incentives in order to secure and retain the services of our employees and directors, and to provide long-term incentives that align the interests of our employees and directors with the interests of our stockholders.

Requested Share Increase

Subject to adjustment for certain changes in our capitalization, if this Proposal 3 is approved by our stockholders, we will have 21,000,000 new shares available for grant under the Amended 2017 Plan after the Annual Meeting.

Due to the inherent unpredictability of clinical trial outcomes and of regulatory approval processes, we are not presently able to forecast the rate at which we will utilize equity awards as a tool for attracting and retaining talent. Taking these factors into consideration, the Board determined that our request for 21,000,000 new shares under the Amended 2017 Plan is an appropriate amount that we believe a majority of our institutional investors would support.

Why You Should Vote to Approve the Amended 2017 Plan

Equity Awards Are an Important Part of Our Compensation Philosophy

The Board believes that our future success depends, in large part, on our ability to maintain a competitive position in attracting, retaining and motivating employees and directors. The Board believes that the grant of equity awards is a key element underlying our ability to attract, retain and motivate employees and directors, and better aligns the interests of our employees and directors with those of our stockholders. The Amended 2017 Plan will allow us to continue to provide equity-based incentives to our employees and directors. Therefore, the Board believes that the Amended 2017 Plan is in the best interests of Exelixis and our stockholders and recommends a vote in favor of this Proposal 3.

2020 Proxy Statement    33


We Have Experienced and Expect to Continue to Experience Substantial Growth in Our Business

Recent progress in our product development programs has driven growth in the number of our employees. As of December 28, 2018, we had 485 employees, compared to 618 employees as of January 3, 2020, and 645 employees as of the Record Date, March 23, 2020.

The Board believes that the Amended 2017 Plan is necessary to ensure that the number of shares available for issuance pursuant to equity awards will be sufficient to allow us to continue to attract, retain and motivate the services of talented individuals essential to our long-term growth and financial success. The Board strongly believes that the grant of equity awards is a key element underlying our ability to attract, retain and motivate our employees, including our executives, and our directors, and is a substantial contributing factor to our success and the growth of our business. We have relied significantly on equity awards in the form of stock options and RSU awards to attract, retain and motivate key employees, and we believe that equity awards are necessary for us to remain competitive in the marketplace for executive talent and other employees.

We Manage Our Equity Award Use Carefully and Dilution Is Reasonable

We believe that equity awards such as stock options and RSU awards are a vital part of our overall compensation program, and we grant awards to substantially all of our employees. However, we recognize that this compensation philosophy dilutes existing stockholders, and, therefore, we must responsibly manage the growth of our equity compensation program. We are committed to monitoring our equity compensation share reserve carefully, including our “burn rate,” to ensure that we maximize stockholders’ value by granting the appropriate number of equity awards necessary to attract, retain and motivate our employees and directors.

The Size of Our Share Reserve Increase Request Is Reasonable

Subject to adjustment for certain changes in our capitalization, if this Proposal 3 is approved by our stockholders, we will have 21,000,000 new shares available for grant under the Amended 2017 Plan after the Annual Meeting (for a total of approximately 26,386,694 shares available for grant under the Amended 2017 Plan after the Annual Meeting (based on the number of shares available for grant under the 2017 Plan as of March 4, 2020) (plus the Prior Plans’ Returning Shares (as defined below), as such shares become available from time to time)).

The Board believes that our request for 21,000,000 new shares under the Amended 2017 Plan is necessary to provide an appropriate amount of equity awards for attracting, retaining, and motivating our employees and directors in accordance with our business plans, and is an amount that we believe a majority of our institutional investors would support.

The Amended 2017 Plan Combines Compensation and Governance Best Practices

The Amended 2017 Plan includes provisions that are designed to protect our stockholders’ interests and to reflect corporate governance best practices including:

No liberal share counting or recycling. The following shares will not become available again for issuance under the Amended 2017 Plan: (i) shares that are reacquired or withheld (or not issued) by us to satisfy the exercise or purchase price of a stock award; (ii) shares that are reacquired or withheld (or not issued) by us to satisfy a tax withholding obligation in connection with stock options or stock appreciation rights; (iii) shares repurchased by us on the open market with the proceeds of the exercise price of a stock option or stock appreciation right; and (iv) the gross number of shares subject to a stock appreciation right in the event that such stock appreciation right is settled in shares.

Fungible share counting. The Amended 2017 Plan contains a “fungible share counting” structure, whereby the number of shares available for issuance under the Amended 2017 Plan will be reduced by: (i) one share for each share issued pursuant to a stock option or stock appreciation right with an exercise price that is at least 100% of the fair market value of our common stock on the date of grant (Appreciation Award) granted under the Amended 2017 Plan; and (ii) 1.5 shares for each share issued pursuant to a stock award that is not an Appreciation Award (Full Value Award) granted under the Amended 2017 Plan. As part of such fungible share counting structure, the number of shares available for issuance under the Amended 2017 Plan will be increased by: (i) one share for each share that becomes available again for issuance under the terms of the Amended 2017 Plan subject to an Appreciation Award and (ii) 1.5 shares for each share that becomes available again for issuance under the terms of the Amended 2017 Plan subject to a Full Value Award.

34    Exelixis, Inc.


Proposal 3 | Amendment and Restatement of 2017 Equity Incentive Plan

Minimum vesting requirements. The Amended 2017 Plan provides that no award may vest until at least 12 months following the date of grant of the award; provided, however, that shares up to 5% of the aggregate number of shares that may be issued under the Amended 2017 Plan may be issued pursuant to awards which do not meet such vesting requirements.

Maximum seven-year term for stock options and stock appreciation rights. The Amended 2017 Plan provides that no stock option or stock appreciation right may have a term longer than seven years.

Restrictions on dividends. The Amended 2017 Plan provides that (i) no dividends or dividend equivalents may be paid with respect to any shares subject to an award before the date such shares have vested, (ii) any dividends or dividend equivalents that are credited with respect to any such shares will be subject to all of the terms and conditions applicable to such shares under the terms of the applicable award agreement (including any vesting conditions), and (iii) any dividends or dividend equivalents that are credited with respect to any such shares will be forfeited to us on the date such shares are forfeited to or repurchased by us due to a failure to vest.

Awards subject to forfeiture/clawback. Awards granted under the Amended 2017 Plan will be subject to recoupment in accordance with (i) the Clawback Policy and (ii) any clawback policy that we are required to adopt pursuant to the listing standards of any national securities exchange or association on which our securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. In addition, the Board may impose other clawback, recovery or recoupment provisions in an award agreement, including a reacquisition right in respect of previously acquired shares or other cash or property upon the occurrence of cause. For additional information on the Clawback Policy, please see “Compensation Discussion and Analysis—Other Compensation Information—Clawback Policy.

Repricing not allowed. The Amended 2017 Plan prohibits the repricing of outstanding stock options and stock appreciation rights and the cancellation of any outstanding stock options or stock appreciation rights that have an exercise price greater than the then-current fair market value of our common stock in exchange for cash or other awards under the Amended 2017 Plan without prior stockholder approval.

No liberal change in control definition. The change in control definition in the Amended 2017 Plan is not a “liberal” definition. A change in control transaction must actually occur in order for the change in control provisions in the Amended 2017 Plan to be triggered.

Limit onnon-employee director compensation. The maximum number of shares subject to stock awards granted during any calendar year to any of ournon-employee directors, taken together with any cash fees paid by Exelixis to suchnon-employee director during such calendar year, may not exceed $750,000 in total value, or $1,500,000 in total value with respect to the calendar year in which the individual is first appointed or elected to the Board (calculating the value of any such stock awards based on the grant date fair value of such stock awards for financial reporting purposes).

Overhang

The following table provides certain additional information regarding our equity incentive program.

  As of March 4, 2020

Total number of shares of common stock subject to outstanding stock options

19,855,357

Weighted-average exercise price of outstanding stock options

$10.20

Weighted-average remaining term of outstanding stock options

3.17 years

Total number of shares of common stock subject to outstanding full value awards

9,114,878

Total number of shares of common stock available for grant under the 2017 Plan (1)

5,386,694
  As of Record Date

Total number of shares of common stock outstanding

305,733,496

Per-share closing price of common stock as reported on Nasdaq Global Select Market

$15.34

(1)

As of March 4, 2020, there were no shares of common stock available for grant under any of our equity incentive plans other than the 2017 Plan, as described in this table.

2020 Proxy Statement    35


Burn Rate

The following table provides detailed information regarding the activity related to our equity incentive plans for fiscal years 2019, 2018 and 2017.

    Fiscal Year
2019
   Fiscal Year
2018
   Fiscal Year
2017
 

Total number of shares of common stock subject to time-based vesting stock options granted

   1,310,696    2,930,108    2,166,110 

Total number of shares of common stock subject to performance-based vesting stock options vested

            

Total number of shares of common stock subject to time-based vesting full value awards granted

   1,988,857    1,826,294    2,137,817 

Total number of shares of common stock subject to performance-based vesting full value awards vested

   141,004         

Weighted-average number of shares of common stock outstanding

   302,584,000    297,892,000    293,588,000 

Adjusted Burn Rate (1)

   1.84%    2.21%    2.19% 

Unadjusted Burn Rate (2)

   1.14%    1.60%    1.47% 

(1)

Adjusted Burn Rate is calculated as: (shares subject to time-based vesting stock options granted + shares subject to performance-based vesting stock options vested + 2 (shares subject to time-based vesting full value awards granted + shares subject to performance-based vesting full value awards vested))/weighted average common stock outstanding. For purposes of this calculation, shares subject to time-based vesting full value awards granted and shares subject to performance-based vesting full value awards vested are increased by a 2.0x volatility multiplier for each of fiscal years 2017-2019. The share reserve under the 2017 Plan is reduced by 1.5 shares for each share issued pursuant to a full value award.

(2)

Unadjusted Burn Rate is calculated as: (shares subject to time-based vesting stock options granted + shares subject to performance-based vesting stock options vested + shares subject to time-based vesting full value awards granted + shares subject to performance-based vesting full value awards vested)/weighted average common stock outstanding.

Stockholder Approval

If this Proposal 3 is approved by our stockholders, the Amended 2017 Plan will become effective as of the date of the Annual Meeting. In the event that our stockholders do not approve this Proposal 3, the Amended 2017 Plan will not become effective and the 2017 Plan will continue to be effective in accordance with its terms.

Description of the Amended 2017 Plan

The material features of the Amended 2017 Plan are described below. The following description of the Amended 2017 Plan is a summary only and is qualified in its entirety by reference to the complete text of the Amended 2017 Plan. Stockholders are urged to read the actual text of the Amended 2017 Plan in its entirety.

Purpose

The Amended 2017 Plan is designed to secure and retain the services of our employees, directors and consultants, provide incentives for our employees, directors and consultants to exert maximum efforts for the success of Exelixis and our affiliates, and provide a means by which our employees, directors and consultants may be given an opportunity to benefit from increases in the value of our common stock.

Successor to 2014 Plan

The Amended 2017 Plan is intended to be the successor to the Exelixis, Inc. 2014 Equity Incentive Plan (2014 Plan).

36    Exelixis, Inc.


Proposal 3 | Amendment and Restatement of 2017 Equity Incentive Plan

Types of Awards

The terms of the Amended 2017 Plan provide for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, other stock awards, and performance awards that may be settled in cash, stock, or other property.

Shares Available for Awards

Subject to adjustment for certain changes in our capitalization, the aggregate number of shares of our common stock that may be issued under the Amended 2017 Plan (Share Reserve) will not exceed 45,453,064 shares (which is the sum of (i) 453,064 shares (the number of unallocated shares that were available for grant under the 2014 Plan as of the effective date of the 2017 Plan), (ii) 24,000,000 additional shares that were reserved as of the effective date of the 2017 Plan, and (iii) 21,000,000 newly requested shares), plus the Prior Plans’ Returning Shares, as such shares become available from time to time.

The “Prior Plans’ Returning Shares” are shares subject to outstanding stock awards granted under any of the following plans (which we refer to as the “Prior Plans” for purposes of this Proposal 3): the 2014 Plan, the Exelixis, Inc. 2000 Equity Incentive Plan, the Exelixis, Inc. 2000Non-Employee Directors’ Stock Option Plan, the Exelixis, Inc. 2011 Equity Incentive Plan, and the Exelixis, Inc. 2016 Inducement Award Plan, in each case that, from and after the effective date of the 2017 Plan, (i) expire or terminate for any reason prior to exercise or settlement, (ii) are forfeited, cancelled or otherwise returned to us because of the failure to meet a contingency or condition required for the vesting of such shares, or (iii) other than with respect to outstanding Appreciation Awards granted under the Prior Plans, are reacquired or withheld (or not issued) by us to satisfy a tax withholding obligation in connection with a stock award.

The number of shares of our common stock available for issuance under the Amended 2017 Plan will be reduced by (i) one share for each share of common stock issued pursuant to an Appreciation Award granted under the Amended 2017 Plan, and (ii) 1.5 shares for each share of common stock issued pursuant to a Full Value Award granted under the Amended 2017 Plan.

If (i) any shares of common stock subject to a stock award granted under the Amended 2017 Plan are not issued because the stock award expires or otherwise terminates without all of the shares covered by the stock award having been issued or is settled in cash, (ii) any shares of common stock issued pursuant to a stock award granted under the Amended 2017 Plan are forfeited back to or repurchased by us because of the failure to meet a contingency or condition required for the vesting of such shares, or (iii) with respect to a Full Value Award granted under the Amended 2017 Plan, any shares of common stock are reacquired or withheld (or not issued) by us to satisfy a tax withholding obligation in connection with the award, then such shares (which we refer to as the “Amended 2017 Plan Returning Shares” for purposes of this Proposal 3) will again become available for issuance under the Amended 2017 Plan. For each Amended 2017 Plan Returning Share or Prior Plans’ Returning Share subject to a Full Value Award, the number of shares of common stock available for issuance under the Amended 2017 Plan will increase by 1.5 shares.

Any shares of common stock reacquired or withheld (or not issued) by us to satisfy the exercise or purchase price of a stock award granted under the Amended 2017 Plan or a Prior Plan will no longer be available for issuance under the Amended 2017 Plan, including any shares subject to a stock award that are not delivered to a participant because the stock award is exercised through a reduction of shares subject to the stock award. Any shares reacquired or withheld (or not issued) by us to satisfy a tax withholding obligation in connection with an Appreciation Award granted under the Amended 2017 Plan or a Prior Plan, or any shares repurchased by us on the open market with the proceeds of the exercise price of an Appreciation Award granted under the Amended 2017 Plan or a Prior Plan will no longer be available for issuance under the Amended 2017 Plan. In the event that a stock appreciation right granted under the Amended 2017 Plan or a Prior Plan is settled in shares of common stock, the gross number of shares subject to such stock appreciation right will no longer be available for issuance under the Amended 2017 Plan.

Eligibility

All of our (including our affiliates’) employees,non-employee directors and consultants are eligible to participate in the Amended 2017 Plan and may receive all types of awards other than incentive stock options. Incentive stock options may be granted under the Amended 2017 Plan only to our (including our affiliates’) employees.

As of the Record Date, we (including our affiliates) had 645 employees, 11non-employee directors and 54 consultants. However, Dr. Scangos, who is not standing forre-election at the Annual Meeting and will resign from the Board effective as of the Annual Meeting, will not be eligible to receive awards as anon-employee director under the Amended 2017 Plan. In addition, we currently do not expect to grant any awards to our consultants under the Amended 2017 Plan.

2020 Proxy Statement    37


Individual Award Limits

Under the Amended 2017 Plan, subject to adjustment for certain changes in our capitalization, no participant will be eligible to be granted during any calendar year more than: (i) a maximum of 5,000,000 shares of our common stock subject to stock options, stock appreciation rights and other stock awards whose value is determined by reference to an increase over an exercise or strike price of at least 100% of the fair market value of our common stock on the date of grant; (ii) a maximum of 5,000,000 shares of our common stock subject to performance stock awards; and (iii) a maximum of $10,000,000 subject to performance cash awards.

Non-Employee Director Compensation Limit

The maximum number of shares of our common stock subject to stock awards granted during any calendar year to any of ournon-employee directors, taken together with any cash fees paid by Exelixis to suchnon-employee director during such calendar year, will not exceed $750,000 in total value, or $1,500,000 in total value with respect to the calendar year in which the individual is first appointed or elected to the Board (calculating the value of any such stock awards based on the grant date fair value of such stock awards for financial reporting purposes).

Administration

The Amended 2017 Plan will be administered by the Board, which may in turn delegate authority to administer the Amended 2017 Plan to a committee. The Board has delegated concurrent authority to administer the Amended 2017 Plan to the Compensation Committee, but may, at any time, revest in itself some or all of the power delegated to the Compensation Committee. The Board and the Compensation Committee are each considered to be a Plan Administrator for purposes of this Proposal 3. Subject to the terms of the Amended 2017 Plan (including certain minimum vesting requirements (see “Minimum Vesting Requirements” below)), the Plan Administrator may determine the recipients, the types of awards to be granted, the number of shares of our common stock subject to or the cash value of awards, and the terms and conditions of awards granted under the Amended 2017 Plan, including the period of their exercisability and vesting. The Plan Administrator also has the authority to provide for accelerated exercisability and vesting of awards. Subject to the limitations set forth below, the Plan Administrator also determines the fair market value applicable to a stock award and the exercise or strike price of stock options and stock appreciation rights granted under the Amended 2017 Plan.

The Plan Administrator may also delegate to one or more officers the authority to designate employees who are not officers to be recipients of certain stock awards and the number of shares of our common stock subject to such stock awards. Under any such delegation, the Plan Administrator will specify the total number of shares of our common stock that may be subject to the stock awards granted by such officer. The officer may not grant a stock award to himself or herself.

Repricing; Cancellation andRe-Grant of Awards

Under the Amended 2017 Plan, the Plan Administrator does not have the authority to reprice any outstanding stock option or stock appreciation right by reducing the exercise or strike price of the stock option or stock appreciation right or to cancel any outstanding stock option or stock appreciation right that has an exercise or strike price greater than the then-current fair market value of our common stock in exchange for cash or other awards without obtaining the approval of our stockholders. Such approval must be obtained within 12 months prior to such an event.

Minimum Vesting Requirements

Under the Amended 2017 Plan, no award may vest until at least 12 months following the date of grant of the award; provided, however, that shares up to 5% of the Share Reserve may be issued pursuant to awards which do not meet such vesting requirements.

Dividends and Dividend Equivalents

The Amended 2017 Plan provides that dividends or dividend equivalents may be paid or credited with respect to any shares of our common stock subject to an award, as determined by the Board and contained in the applicable award agreement; provided, however, that (i) no dividends or dividend equivalents may be paid with respect to any such shares before the date such shares have vested, (ii) any dividends or dividend equivalents that are credited with respect to any such shares will be subject to all of the terms and conditions applicable to such shares under the terms of the applicable award agreement (including any vesting conditions), and (iii) any dividends or dividend equivalents that are credited with respect to any such shares will be forfeited to us on the date such shares are forfeited to or repurchased by us due to a failure to vest.

38    Exelixis, Inc.


Proposal 3 | Amendment and Restatement of 2017 Equity Incentive Plan

Section 162(m) Transition Relief for Performance-Based Compensation

Under Section 162(m) of the Code, compensation paid to any publicly held corporation’s “covered employees” (as defined under Section 162(m) of the Code) that exceeds $1 million per taxable year for any covered employee is generallynon-deductible. Certain provisions in the Amended 2017 Plan refer to the “performance-based compensation” exception to the $1 million deductibility limit under Section 162(m) of the Code. Pursuant to the Tax Cuts and Jobs Act, this exception was repealed with respect to taxable years beginning after December 31, 2017. However, an award may still be eligible for this exception if, among other requirements, it is intended to qualify, and is eligible to qualify, as “performance-based compensation” under Section 162(m) of the Code pursuant to the transition relief provided by the Tax Cuts and Jobs Act for remuneration provided pursuant to a written binding contract which was in effect on November 2, 2017 and which was not modified in any material respect on or after such date. For purposes of this Proposal 3, the term “Section 162(m) Transition Relief” refers to such transition relief. Accordingly, the provisions in the Amended 2017 Plan which refer to the “performance-based compensation” exception under Section 162(m) of the Code will only apply to any award that is intended to qualify, and is eligible to qualify, as “performance-based compensation” under Section 162(m) of the Code pursuant to the Section 162(m) Transition Relief and, therefore, such provisions are not applicable to any other awards granted under the Amended 2017 Plan. However, even if an award is intended to qualify as “performance-based compensation” under Section 162(m) of the Code, no assurance can be given that the award will in fact qualify for the Section 162(m) Transition Relief or the “performance-based compensation” exception under Section 162(m) of the Code.

Stock Options

Stock options may be granted under the Amended 2017 Plan pursuant to stock option agreements. The Amended 2017 Plan permits the grant of stock options that are intended to qualify as incentive stock options, or ISOs, and nonstatutory stock options, or NSOs.

The exercise price of a stock option granted under the Amended 2017 Plan may not be less than 100% of the fair market value of the common stock subject to the stock option on the date of grant and, in some cases (see “Limitations on Incentive Stock Options” below), may not be less than 110% of such fair market value.

The term of stock options granted under the Amended 2017 Plan may not exceed seven years and, in some cases (see “Limitations on Incentive Stock Options” below), may not exceed five years. Except as otherwise provided in a participant’s stock option agreement or other agreement with us or one of our affiliates, if a participant’s service relationship with us or any of our affiliates (referred to in this Proposal 3 as “continuous service”) terminates (other than for cause and other than upon the participant’s death or disability), the participant may exercise any vested stock options for up to three months following the participant’s termination of continuous service. Except as otherwise provided in a participant’s stock option agreement or other agreement with us or one of our affiliates, if a participant’s continuous service terminates due to the participant’s disability or death (or the participant dies within a specified period, if any, following termination of continuous service), the participant, or his or her beneficiary, as applicable, may exercise any vested stock options for up to 12 months following the participant’s termination due to the participant’s disability or for up to 18 months following the participant’s death. Except as explicitly provided otherwise in a participant’s stock option agreement or other written agreement with us or one of our affiliates, if a participant’s continuous service is terminated for cause (as defined in the Amended 2017 Plan), all stock options held by the participant will terminate upon the participant’s termination of continuous service and the participant will be prohibited from exercising any stock option from and after such termination date. Except as otherwise provided in a participant’s stock option agreement or other agreement with us or one of our affiliates, the term of a stock option may be extended if the exercise of the stock option following the participant’s termination of continuous service (other than for cause and other than upon the participant’s death or disability) would be prohibited by applicable securities laws or if the sale of any common stock received upon exercise of the stock option following the participant’s termination of continuous service (other than for cause) would violate our insider trading policy. In no event, however, may a stock option be exercised after its original expiration date.

Acceptable forms of consideration for the purchase of our common stock pursuant to the exercise of a stock option under the Amended 2017 Plan will be determined by the Plan Administrator and may include payment: (i) by cash, check, bank draft or money order payable to us; (ii) pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board; (iii) by delivery to us of shares of our common stock (either by actual delivery or attestation); (iv) by a net exercise arrangement (for NSOs only); or (v) in other legal consideration approved by the Plan Administrator.

Subject to certain minimum vesting requirements (see “Minimum Vesting Requirements” above), stock options granted under the Amended 2017 Plan may become exercisable in cumulative increments, or “vest,” as determined by the Plan

2020 Proxy Statement    39


Administrator at the rate specified in the stock option agreement. Shares covered by different stock options granted under the Amended 2017 Plan may be subject to different vesting schedules as the Plan Administrator may determine.

The Plan Administrator may impose limitations on the transferability of stock options granted under the Amended 2017 Plan in its discretion. Generally, a participant may not transfer a stock option granted under the Amended 2017 Plan other than by will or the laws of descent and distribution or, subject to approval by the Plan Administrator, pursuant to a domestic relations order or an official marital settlement agreement. However, the Plan Administrator may permit transfer of a stock option in a manner that is not prohibited by applicable tax and securities laws. In addition, subject to approval by the Plan Administrator, a participant may designate a beneficiary who may exercise the stock option following the participant’s death. Notwithstanding the foregoing, no stock option may be transferred to any financial institution without prior stockholder approval.

Limitations on Incentive Stock Options

The aggregate fair market value, determined at the time of grant, of shares of our common stock with respect to ISOs that are exercisable for the first time by a participant during any calendar year under all of our stock plans may not exceed $100,000. The stock options or portions of stock options that exceed this limit or otherwise fail to qualify as ISOs are treated as NSOs. No ISO may be granted to any person who, at the time of grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any affiliate unless the following conditions are satisfied:

the exercise price of the ISO must be at least 110% of the fair market value of the common stock subject to the ISO on the date of grant; and

the term of the ISO must not exceed five years from the date of grant.

Subject to adjustment for certain changes in our capitalization, the aggregate maximum number of shares of our common stock that may be issued pursuant to the exercise of ISOs under the Amended 2017 Plan is 50,000,000 shares.

Stock Appreciation Rights

Stock appreciation rights may be granted under the Amended 2017 Plan pursuant to stock appreciation right agreements. Each stock appreciation right is denominated in common stock share equivalents. The strike price of each stock appreciation right will be determined by the Plan Administrator, but will in no event be less than 100% of the fair market value of the common stock subject to the stock appreciation right on the date of grant. Subject to certain minimum vesting requirements (see “Minimum Vesting Requirements” above), the Plan Administrator may also impose restrictions or conditions upon the vesting of stock appreciation rights that it deems appropriate. The appreciation distribution payable upon exercise of a stock appreciation right may be paid in shares of our common stock, in cash, in a combination of cash and stock, or in any other form of consideration determined by the Plan Administrator and set forth in the stock appreciation right agreement. The term of stock appreciation rights granted under the Amended 2017 Plan may not exceed seven years. Stock appreciation rights will be subject to the same conditions upon termination of continuous service and restrictions on transfer as stock options under the Amended 2017 Plan.

Restricted Stock Awards

Restricted stock awards may be granted under the Amended 2017 Plan pursuant to restricted stock award agreements. A restricted stock award may be granted in consideration for cash, check, bank draft or money order payable to us, the participant’s services performed for us or any of our affiliates, or any other form of legal consideration acceptable to the Plan Administrator. Subject to certain minimum vesting requirements (see “Minimum Vesting Requirements” above), shares of our common stock acquired under a restricted stock award may be subject to forfeiture to or repurchase by us in accordance with a vesting schedule to be determined by the Plan Administrator. Rights to acquire shares of our common stock under a restricted stock award may be transferred only upon such terms and conditions as are set forth in the restricted stock award agreement; provided, however, that no restricted stock award may be transferred to any financial institution without prior stockholder approval. Upon a participant’s termination of continuous service for any reason, any shares subject to restricted stock awards held by the participant that have not vested as of such termination date may be forfeited to or repurchased by us.

40    Exelixis, Inc.


Proposal 3 | Amendment and Restatement of 2017 Equity Incentive Plan

RSU Awards

RSU awards may be granted under the Amended 2017 Plan pursuant to RSU award agreements. Payment of any purchase price may be made in any form of legal consideration acceptable to the Plan Administrator. A RSU award may be settled by the delivery of shares of our common stock, in cash, in a combination of cash and stock, or in any other form of consideration determined by the Plan Administrator and set forth in the RSU award agreement. Subject to certain minimum vesting requirements (see “Minimum Vesting Requirements” above), RSU awards may be subject to vesting in accordance with a vesting schedule to be determined by the Plan Administrator. Except as otherwise provided in a participant’s RSU award agreement, RSUs that have not vested will be forfeited upon the participant’s termination of continuous service for any reason.

Performance Awards

The Amended 2017 Plan allows us to grant performance stock and cash awards.

A performance stock award is a stock award that is payable (including that may be granted, may vest, or may be exercised) contingent upon the attainment ofpre-determined performance goals during a performance period. A performance stock award may require the completion of a specified period of continuous service. Subject to certain minimum vesting requirements (see “Minimum Vesting Requirements” above), the length of any performance period, the performance goals to be achieved during the performance period, and the measure of whether and to what degree such performance goals have been attained will be determined by the Compensation Committee, except that the Plan Administrator also may make any such determinations to the extent that the award is not intended to qualify as performance-based compensation under Section 162(m) of the Code. In addition, to the extent permitted by applicable law and the performance stock award agreement, the Plan Administrator may determine that cash may be used in payment of performance stock awards.

A performance cash award is a cash award that is payable contingent upon the attainment ofpre-determined performance goals during a performance period. A performance cash award may require the completion of a specified period of continuous service. Subject to certain minimum vesting requirements (see “Minimum Vesting Requirements” above), the length of any performance period, the performance goals to be achieved during the performance period, and the measure of whether and to what degree such performance goals have been attained will be determined by the Compensation Committee, except that the Plan Administrator also may make any such determinations to the extent that the award is not intended to qualify as performance-based compensation under Section 162(m) of the Code. The Plan Administrator may specify the form of payment of performance cash awards, which may be cash or other property, or may provide for a participant to have the option for his or her performance cash award to be paid in cash or other property.

Performance goals under the Amended 2017 Plan will be based on any one or more of the following performance criteria: (1) earnings (including earnings per share and net earnings); (2) earnings before interest, taxes and depreciation; (3) earnings before interest, taxes, depreciation and amortization; (4) total stockholder return; (5) return on equity or average stockholder’s equity; (6) return on assets, investment, or capital employed; (7) stock price; (8) margin (including gross margin); (9) income (before or after taxes); (10) operating income; (11) operating income after taxes;(12) pre-tax profit; (13) operating cash flow; (14) sales or revenue targets; (15) increases in revenues or product revenues; (16) expenses and cost reduction goals; (17) improvement in or attainment of working capital levels; (18) economic value added (or an equivalent metric); (19) market share; (20) cash flow; (21) cash flow per share; (22) share price performance; (23) debt reduction; (24) implementation or completion of projects or processes; (25) customer satisfaction; (26) stockholders’ equity; (27) capital expenditures; (28) debt levels; (29) operating profit or net operating profit; (30) workforce diversity; (31) growth of net income or operating income; (32) billings; and (33) to the extent that an award is not intended to comply with Section 162(m) of the Code, other measures of performance selected by the Plan Administrator.

Performance goals may be based on a company-wide basis, with respect to one or more business units, divisions, affiliates or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Under the Amended 2017 Plan, unless specified otherwise by the Compensation Committee (or, if not required for compliance with Section 162(m) of the Code, the Plan Administrator) (i) in the award agreement at the time the award is granted or (ii) in such other document setting forth the performance goals at the time the performance goals are established, the Compensation Committee (or, if not required for compliance with Section 162(m) of the Code, the Plan Administrator) will appropriately make adjustments in the method of calculating the attainment of performance goals for a performance period: (1) to exclude restructuring and/or other nonrecurring charges; (2) to exclude exchange rate effects, as applicable, fornon-U.S. dollar denominated performance goals; (3) to exclude the effects of changes to generally accepted accounting principles; (4) to exclude the effects of any statutory adjustments to

2020 Proxy Statement    41


corporate tax rates; and (5) to exclude the effects of any items that are “unusual” in nature or occur “infrequently” as determined under generally accepted accounting principles. In addition, the Compensation Committee (or, if not required for compliance with Section 162(m) of the Code, the Plan Administrator) retains the discretion to reduce or eliminate the compensation or economic benefit due upon the attainment of any performance goals and to define the manner of calculating the performance criteria it selects to use for a performance period.

Other Stock Awards

Other forms of stock awards valued in whole or in part by reference to, or otherwise based on, our common stock may be granted either alone or in addition to other stock awards under the Amended 2017 Plan. Subject to the terms of the Amended 2017 Plan (including certain minimum vesting requirements (see “Minimum Vesting Requirements” above)), the Plan Administrator will have sole and complete authority to determine the persons to whom and the time or times at which such other stock awards will be granted, the number of shares of our common stock to be granted and all other terms and conditions of such other stock awards.

Clawback Policy

Awards granted under the Amended 2017 Plan will be subject to recoupment in accordance with (i) the Clawback Policy and (ii) any clawback policy that we are required to adopt pursuant to the listing standards of any national securities exchange or association on which our securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. In addition, the Plan Administrator may impose other clawback, recovery or recoupment provisions in an award agreement as the Plan Administrator determines necessary or appropriate, including a reacquisition right in respect of previously acquired shares of our common stock or other cash or property upon the occurrence of cause. For additional information on the Clawback Policy, please see “Compensation Discussion and Analysis—Other Compensation Information—Clawback Policy.

Changes to Capital Structure

In the event of certain capitalization adjustments, the Plan Administrator will appropriately adjust: (i) the class(es) and maximum number of securities subject to the Amended 2017 Plan; (ii) the class(es) and maximum number of securities that may be issued pursuant to the exercise of ISOs; (iii) the class(es) and maximum number of securities that may be awarded to any participant pursuant to the individual award limits under the Amended 2017 Plan; and (iv) the class(es) and number of securities and price per share of stock subject to outstanding stock awards.

Corporate Transaction and Change in Control

The following applies to stock awards under the Amended 2017 Plan in the event of a corporate transaction (as defined in the Amended 2017 Plan) or a change in control (as defined in the Amended 2017 Plan) (each of which we refer to as a “Transaction” for purposes of this Proposal 3), unless otherwise provided in a participant’s stock award agreement or other written arrangement with us or one of our affiliates or in any director compensation policy.

In the event of a Transaction, any stock awards outstanding under the Amended 2017 Plan may be assumed, continued or substituted for by any surviving or acquiring corporation (or its parent company), and any reacquisition or repurchase rights held by us with respect to the stock award may be assigned to the successor (or its parent company). If the surviving or acquiring corporation (or its parent company) does not assume, continue or substitute for such stock awards, then (i) with respect to any such stock awards that are held by participants whose continuous service has not terminated prior to the effective time of the Transaction (Current Participants), the vesting (and exercisability, if applicable) of such stock awards will be accelerated in full (and with respect to any such stock awards that are subject to performance-based vesting conditions or requirements, vesting will be deemed to be satisfied at the target level of performance) to a date prior to the effective time of the Transaction (contingent upon the effectiveness of the Transaction), and such stock awards will terminate if not exercised (if applicable) at or prior to the effective time of the Transaction, and any reacquisition or repurchase rights held by us with respect to such stock awards will lapse (contingent upon the effectiveness of the Transaction), and (ii) any such stock awards that are held by persons other than Current Participants will terminate if not exercised (if applicable) prior to the effective time of the Transaction, except that any reacquisition or repurchase rights held by us with respect to such stock awards will not terminate and may continue to be exercised notwithstanding the Transaction.

In the event a stock award will terminate if not exercised prior to the effective time of a Transaction, the Plan Administrator may provide that the holder of such stock award may not exercise such stock award but instead will receive a payment equal

42    Exelixis, Inc.


Proposal 3 | Amendment and Restatement of 2017 Equity Incentive Plan

in value to the excess (if any) of (i) the value of the property the participant would have received upon exercise of such stock award immediately prior to the effective time of the Transaction over (ii) any exercise price payable in connection with such exercise.

For purposes of the Amended 2017 Plan, a corporate transaction generally will be deemed to occur in the event of the consummation of: (i) a sale, lease or other disposition of all or substantially all of our assets; (ii) an acquisition by a person, entity or group of the beneficial ownership of our securities representing at least 50% of the combined voting power entitled to vote in the election of our directors; (iii) a merger, consolidation or similar transaction in which we are not the surviving corporation; or (iv) a reverse merger, consolidation or similar transaction in which we are the surviving corporation but shares of our outstanding common stock are converted into other property by virtue of the transaction.

For purposes of the Amended 2017 Plan, a change in control generally will be deemed to occur in the event of the consummation of: (i) a sale, lease or other disposition of all or substantially all of our assets; (ii) an acquisition by a person, entity or group of the beneficial ownership of our securities representing at least 50% of the combined voting power entitled to vote in the election of our directors other than by virtue of a merger, consolidation or similar transaction; (iii) a merger, consolidation or similar transaction in which we are not the surviving corporation; or (iv) a reverse merger, consolidation or similar transaction in which we are the surviving corporation but shares of our outstanding common stock are converted into other property by virtue of the transaction.

Control Acquisition

The following applies to stock awards under the Amended 2017 Plan in the event of a control acquisition (as defined in the Amended 2017 Plan), unless otherwise provided in a participant’s stock award agreement or other written arrangement with us or one of our affiliates or in any director compensation policy.

In the event of a control acquisition that was not approved by the Plan Administrator prior to the consummation of such transaction, the vesting (and exercisability, if applicable) of any stock awards that are held by Current Participants will be accelerated in full (and with respect to any such stock awards that are subject to performance-based vesting conditions or requirements, vesting will be deemed to be satisfied at the target level of performance) to a date prior to the effective time of the control acquisition (contingent upon the effectiveness of the control acquisition), and any reacquisition or repurchase rights held by us with respect to such stock awards will lapse (contingent upon the effectiveness of the control acquisition).

For purposes of the Amended 2017 Plan, a control acquisition generally will be deemed to occur in the event of the consummation of an acquisition by a person, entity or group of the beneficial ownership of our securities representing at least 50% of the combined voting power entitled to vote in the election of our directors.

Change in Control

The following applies to stock awards under the Amended 2017 Plan in the event of a change in control (as defined in the Amended 2017 Plan), unless otherwise provided in a participant’s stock award agreement or other written arrangement with us or one of our affiliates or in any director compensation policy.

If a change in control occurs and within one month before, as of, or within 13 months after, the effective time of such change in control, a participant’s continuous service terminates due to an involuntary termination (not including death or disability) without cause (as defined in the Amended 2017 Plan) or due to a voluntary termination with good reason (as defined in the Amended 2017 Plan), then the vesting (and exercisability, if applicable) of such participant’s stock awards will be accelerated in accordance with the vesting schedule applicable to such stock awards as if (i) with respect to any such stock awards that are subject to vesting conditions or requirements based solely on such participant’s continuous service, such participant’s continuous service had continued for 12 months following the date of termination, and (ii) with respect to any such stock awards that are subject to performance-based vesting conditions or requirements, vesting has been satisfied at the target level of performance. Any such acceleration will occur on the date of termination, or if later, the effective date of the change in control.

Plan Amendments and Termination

The Plan Administrator will have the authority to amend or terminate the Amended 2017 Plan at any time. However, except as otherwise provided in the Amended 2017 Plan or an award agreement, no amendment or termination of the Amended 2017 Plan may materially impair a participant’s rights under his or her outstanding awards without the participant’s consent. We will obtain stockholder approval of any amendment to the Amended 2017 Plan as required by applicable law and listing

2020 Proxy Statement    43


requirements. No incentive stock options may be granted under the Amended 2017 Plan after the tenth anniversary of the date the 2017 Plan was adopted by our Board.

U.S. Federal Income Tax Consequences

The following is a summary of the principal United States federal income tax consequences to participants and us with respect to participation in the Amended 2017 Plan. This summary is not intended to be exhaustive and does not discuss the income tax laws of any local, state or foreign jurisdiction in which a participant may reside. The information is based upon current federal income tax rules and therefore is subject to change when those rules change. Because the tax consequences to any participant may depend on his or her particular situation, each participant should consult the participant’s tax adviser regarding the federal, state, local and other tax consequences of the grant or exercise of an award or the disposition of stock acquired the Amended 2017 Plan. The Amended 2017 Plan is not qualified under the provisions of Section 401(a) of the Code and is not subject to any of the provisions of the Employee Retirement Income Security Act of 1974. Our ability to realize the benefit of any tax deductions described below depends on our generation of taxable income as well as the requirement of reasonableness, the provisions of Section 162(m) of the Code and the satisfaction of our tax reporting obligations.

Nonstatutory Stock Options

Generally, there is no taxation upon the grant of an NSO if the stock option is granted with an exercise price equal to the fair market value of the underlying stock on the grant date. Upon exercise, a participant will recognize ordinary income equal to the excess, if any, of the fair market value of the underlying stock on the date of exercise of the stock option over the exercise price. If the participant is employed by us or one of our affiliates, that income will be subject to withholding taxes. The participant’s tax basis in those shares will be equal to their fair market value on the date of exercise of the stock option, and the participant’s capital gain holding period for those shares will begin on that date.

Subject to the requirement of reasonableness, the provisions of Section 162(m) of the Code and the satisfaction of a tax reporting obligation, we will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the participant.

Incentive Stock Options

The Amended 2017 Plan provides for the grant of stock options that are intended to qualify as “incentive stock options,” as defined in Section 422 of the Code. Under the Code, a participant generally is not subject to ordinary income tax upon the grant or exercise of an ISO. If the participant holds a share received upon exercise of an ISO for more than two years from the date the stock option was granted and more than one year from the date the stock option was exercised, which is referred to as the required holding period, the difference, if any, between the amount realized on a sale or other taxable disposition of that share and the participant’s tax basis in that share will be long-term capital gain or loss.

If, however, a participant disposes of a share acquired upon exercise of an ISO before the end of the required holding period, which is referred to as a disqualifying disposition, the participant generally will recognize ordinary income in the year of the disqualifying disposition equal to the excess, if any, of the fair market value of the share on the date of exercise of the stock option over the exercise price. However, if the sales proceeds are less than the fair market value of the share on the date of exercise of the stock option, the amount of ordinary income recognized by the participant will not exceed the gain, if any, realized on the sale. If the amount realized on a disqualifying disposition exceeds the fair market value of the share on the date of exercise of the stock option, that excess will be short-term or long-term capital gain, depending on whether the holding period for the share exceeds one year.

For purposes of the alternative minimum tax, the amount by which the fair market value of a share of stock acquired upon exercise of an ISO exceeds the exercise price of the stock option generally will be an adjustment included in the participant’s alternative minimum taxable income for the year in which the stock option is exercised. If, however, there is a disqualifying disposition of the share in the year in which the stock option is exercised, there will be no adjustment for alternative minimum tax purposes with respect to that share. In computing alternative minimum taxable income, the tax basis of a share acquired upon exercise of an ISO is increased by the amount of the adjustment taken into account with respect to that share for alternative minimum tax purposes in the year the stock option is exercised.

We are not allowed a tax deduction with respect to the grant or exercise of an ISO or the disposition of a share acquired upon exercise of an ISO after the required holding period. If there is a disqualifying disposition of a share, however, we will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the participant, subject to the

44    Exelixis, Inc.


Proposal 3 | Amendment and Restatement of 2017 Equity Incentive Plan

requirement of reasonableness and the provisions of Section 162(m) of the Code, and provided that either the employee includes that amount in income or we timely satisfy our reporting requirements with respect to that amount.

Restricted Stock Awards

Generally, the recipient of a restricted stock award will recognize ordinary income at the time the stock is received equal to the excess, if any, of the fair market value of the stock received over any amount paid by the recipient in exchange for the stock. If, however, the stock is not vested when it is received (for example, if the employee is required to work for a period of time in order to have the right to sell the stock), the recipient generally will not recognize income until the stock becomes vested, at which time the recipient will recognize ordinary income equal to the excess, if any, of the fair market value of the stock on the date it becomes vested over any amount paid by the recipient in exchange for the stock. A recipient may, however, file an election with the Internal Revenue Service, within 30 days following his or her receipt of the stock award, to recognize ordinary income, as of the date the recipient receives the award, equal to the excess, if any, of the fair market value of the stock on the date the award is granted over any amount paid by the recipient for the stock.

The recipient’s basis for the determination of gain or loss upon the subsequent disposition of shares acquired from a restricted stock award will be the amount paid for such shares plus any ordinary income recognized either when the stock is received or when the stock becomes vested.

Subject to the requirement of reasonableness, the provisions of Section 162(m) of the Code and the satisfaction of a tax reporting obligation, we will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the recipient of the restricted stock award.

RSU Awards

Generally, the recipient of an RSU award structured to comply with the requirements of Section 409A of the Code or an exemption from Section 409A of the Code will recognize ordinary income at the time the stock is delivered equal to the excess, if any, of the fair market value of the stock received over any amount paid by the recipient in exchange for the stock. To comply with the requirements of Section 409A of the Code, the stock subject to a restricted stock unit award may generally only be delivered upon one of the following events: a fixed calendar date (or dates), separation from service, death, disability or a change in control. If delivery occurs on another date, unless the restricted stock unit award otherwise complies with or qualifies for an exemption from the requirements of Section 409A of the Code, in addition to the tax treatment described above, the recipient will owe an additional 20% federal tax and interest on any taxes owed.

The recipient’s basis for the determination of gain or loss upon the subsequent disposition of shares acquired from an RSU award will be the amount paid for such shares plus any ordinary income recognized when the stock is delivered.

Subject to the requirement of reasonableness, the provisions of Section 162(m) of the Code and the satisfaction of a tax reporting obligation, we will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the recipient of the RSU award.

Stock Appreciation Rights

Generally, if a stock appreciation right is granted with an exercise price equal to the fair market value of the underlying stock on the grant date, the recipient will recognize ordinary income equal to the fair market value of the stock or cash received upon such exercise. Subject to the requirement of reasonableness, the provisions of Section 162(m) of the Code, and the satisfaction of a tax reporting obligation, we will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the recipient of the stock appreciation right.

Section 162(m) of the Code

Under Section 162(m) of the Code, compensation paid to any publicly held corporation’s “covered employees” (as defined under Section 162(m) of the Code) that exceeds $1 million per taxable year for any covered employee is generallynon-deductible. Prior to the enactment of the Tax Cuts and Jobs Act, compensation that qualified as “performance-based compensation” under Section 162(m) of the Code was not subject to this deduction limitation. Pursuant to the Tax Cuts and Jobs Act, this exception for “performance-based compensation” under Section 162(m) of the Code was repealed with respect to taxable years beginning after December 31, 2017, except that certain transition relief is provided for remuneration provided pursuant to a written binding contract which was in effect on November 2, 2017 and which was not modified in any material respect on or after such date. As a result, compensation paid to any of our “covered employees” in excess of

2020 Proxy Statement    45


$1 million per taxable year generally will not be deductible unless, among other requirements, it is intended to qualify, and is eligible to qualify, as “performance-based compensation” under Section 162(m) of the Code pursuant to the transition relief described above. Because of certain ambiguities and uncertainties as to the application and interpretation of Section 162(m) of the Code, as well as other factors beyond the control of the Compensation Committee, no assurance can be given that any award granted under the Amended 2017 Plan will be eligible for such transition relief and, therefore, eligible for the “performance-based compensation” exception under Section 162(m) of the Code.

New Plan Benefits under Amended 2017 Plan

Amended 2017 Plan

Name and position

  Dollar value     Number of shares 

Michael M. Morrissey, Ph.D.
President and Chief Executive Officer

   (1     (1

Gisela M. Schwab, M.D.
President, Product Development and Medical Affairs and Chief Medical Officer

   (1     (1

Christopher J. Senner
Executive Vice President and Chief Financial Officer

   (1     (1

Jeffrey J. Hessekiel, J.D.
Executive Vice President and General Counsel

   (1     (1

Peter Lamb, Ph.D.
Executive Vice President, Scientific Strategy and Chief Scientific Officer

   (1     (1

All current executive officers as a group

   (1     (1

All current directors who are not executive officers as a group

  $
 
4,000,000 per
calendar year
 
 
     (2

All employees, including all current officers who are not executive officers, as a group

   (1     (1

(1)

Awards granted under the Amended 2017 Plan to our executive officers and other employees are discretionary and are not subject to set benefits or amounts under the terms of the Amended 2017 Plan, and the Board and the Compensation Committee have not granted any awards under the Amended 2017 Plan subject to stockholder approval of this Proposal 3. Accordingly, the benefits or amounts that will be received by or allocated to our executive officers and other employees under the Amended 2017 Plan are not determinable.

(2)

Awards granted under the Amended 2017 Plan to ournon-employee directors are discretionary and are not subject to set benefits or amounts under the terms of the Amended 2017 Plan. However, pursuant to our equity compensation policy fornon-employee directors, each of our currentnon-employee directors (except Dr. Scangos, who is not standing forre-election at the Annual Meeting) automatically will be granted annual awards in the form of a stock option and RSU award (or in the form of a stock option or RSU award only, if elected by such individual) on the day following each of our annual meetings of stockholders, provided that such individual is anon-employee director on such date. The total dollar value of eachnon-employee director’s annual awards will be $400,000. The number of shares of our common stock subject to each such award will be based on the valuation methodology established by the Board, which is in part based on the fair market value of our common stock during the30-calendar day period prior to the grant date and, therefore, is not determinable at this time. On and after the date of the Annual Meeting, any such awards will be granted under the Amended 2017 Plan if this Proposal 3 is approved by our stockholders. For additional information regarding our equity compensation policy fornon-employee directors, see the “Compensation of Directors” section above.

46    Exelixis, Inc.


Proposal 3 | Amendment and Restatement of 2017 Equity Incentive Plan

Plan Benefits under 2017 Plan

The following table sets forth, for each of the individuals and the various groups indicated, the total number of shares of our common stock subject to awards that have been granted (even if not currently outstanding) under the 2017 Plan since its approval by our stockholders in 2017 through March 4, 2020.

Name and position

Number of shares

Michael M. Morrissey, Ph.D.
President and Chief Executive Officer

1,920,436

Gisela M. Schwab, M.D.
President, Product Development and Medical Affairs and Chief Medical Officer

704,454

Christopher J. Senner
Executive Vice President and Chief Financial Officer

619,424

Jeffrey J. Hessekiel, J.D.
Executive Vice President and General Counsel

551,939

Peter Lamb, Ph.D.
Executive Vice President, Scientific Strategy and Chief Scientific Officer

636,982

All current executive officers as a group

5,003,744

All current directors who are not executive officers as a group

970,080

Each nominee for election as a director

    Charles Cohen, Ph.D.

97,299

    Carl B. Feldbaum, Esq.

97,299

    Maria C. Freire, Ph.D.

97,122

    Alan M. Garber, M.D., Ph.D.

97,299

    Vincent T. Marchesi, M.D., Ph.D.

72,291

    Michael M. Morrissey, Ph.D.

1,920,436

    Stelios Papadopoulos, Ph.D.

72,291

    George Poste, DVM, Ph.D., FRS

72,291

    Julie Anne Smith

97,299

    Lance Willsey, M.D.

97,299

    Jack L. Wyszomierski

72,291

Each associate of any executive officers, current directors or director nominees

Each other person who received or is to receive 5% of awards

All employees, including all current officers who are not executive officers, as a group

11,589,449

2020 Proxy Statement    47


Equity Compensation Plan Information

The following table provides certain information about our common stock that may be issued upon the exercise of stock options and other rights under all of our existing equity compensation plans as of January 3, 2020, which consists of our 2000Non-Employee Directors’ Stock Option Plan (the Director Plan), our 2000 Employee Stock Purchase Plan (the ESPP), our 2011 Equity Incentive Plan (the 2011 Plan), the 2014 Plan, our 2016 Inducement Award Plan (the 2016 Plan) and the 2017 Plan:

Plan Category

  

Number of securities
to be issued  upon
exercise of outstanding

options, warrants and
rights (a)

   

Weighted-average
exercise price of
outstanding

options, warrants and

rights (b)

     Number of securities remaining
available for future issuance
under equity compensation
plans (excluding securities
reflected in column (a)) (c)
 

Equity compensation plans approved by stockholders (1)

   29,030,468    $  6.86(2)      10,497,315 

Equity compensation plans not approved by stockholders (3)

   213,014    $15.76(4)       

Total

   29,243,482    $  6.93      10,497,315 

(1)

Equity plans approved by our stockholders include the Director Plan, the 2011 Plan, the 2014 Plan, the 2017 Plan and the ESPP. As of January 3, 2020, a total of 4,238,999 shares of our common stock remained available for issuance under the ESPP, and up to a maximum of 465,480 shares of our common stock may be purchased in the current purchase period. The shares issuable pursuant to our ESPP are not included in the number of shares to be issued pursuant to rights outstanding or the weighted-average exercise price of such rights as of January 3, 2020, as those numbers are not known.

(2)

The weighted-average exercise price takes into account the shares subject to outstanding RSUs, including such awards with performance conditions which have no exercise price. The weighted-average exercise price, excluding such outstanding RSUs, is $9.83.

(3)

Represents shares of our common stock issuable pursuant to the 2016 Plan. As of January 3, 2020, no shares of our common stock remained available for additional grants under the 2016 Plan. In November 2016, the Board adopted the 2016 Plan pursuant to which we reserved 1,500,000 shares of our common stock for issuance under the 2016 Plan. The only persons eligible to receive grants of Awards under the 2016 Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) and the related guidance under Nasdaq IM5635-1—that is, generally, a person not previously an employee or director of Exelixis, or following a bona fide period ofnon-employment, as an inducement material to the individual’s entering into employment with Exelixis. An “Award” is any right to receive Exelixis common stock pursuant to the 2016 Plan, consisting of nonstatutory stock options, stock appreciation rights, restricted stock awards, RSUs, or any other stock award.

(4)

The weighted-average exercise price takes into account the shares subject to outstanding RSUs, which have no exercise price. The weighted-average exercise price, excluding such outstanding RSUs, is $19.41.

Required Vote and Board of Directors Recommendation

The affirmative vote of the holders of a majority of the shares present or represented by proxy and entitled to vote at the Annual Meeting is required to approve the Amended 2017 Plan. Abstentions will be counted toward the tabulation of votes cast on the proposal and will have the same effect as votes against this proposal. Brokernon-votes will have no effect and will not be counted towards the vote total.

THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” PROPOSAL 3.

48    Exelixis, Inc.


Proposal 4 | Advisory Vote on the Compensation of the Named Executive Officers

PROPOSAL 4

ADVISORY VOTE OONN TTHEHE COMPENSATION OOFF TTHEHE NAMED EXECUTIVE OFFICERS

Our stockholders are entitled to vote to approve, on an advisory basis, the compensation, as disclosed in this Proxy Statement, of our Chief Executive Officer, Chief Financial Officer and the other executive officers appearing in the table entitled “Summary Compensation Table” later in this Proxy Statement (collectively, the Named Executive Officers). This vote is not intended to address any specific item of compensation, but rather the overall compensation of our Named Executive Officers and the philosophy, policies and practices described in this Proxy Statement.

The Board encourages our stockholders to review the compensation tables and read the disclosures set forth in the “CompensationCompensation Discussion and Analysis”Analysis section of this Proxy Statement that describe our executive compensation program and the compensation of our Named Executive Officers for fiscal 2019.2020. For the reasons described in this Proxy Statement, the Board believes that our executive compensation program strongly aligns with the interests of our stockholders, effectively ties executive compensation with our performance and results in the attraction and retention of highly talented executives.

Accordingly, the Board recommends that our stockholders vote FOR the following resolution:

RESOLVED, that the compensation paid to the Named Executive Officers, as disclosed pursuant to Item 402 of RegulationS-K, including the Compensation Discussion and Analysis, compensation tables and narrative discussion, is hereby APPROVED.”

Required Vote and Board of Directors Recommendation

 

Advisory approval of Proposal 43 requires the affirmative vote of a majority of the shares present or represented by proxy at the Annual Meeting and entitled to vote on this proposal. Abstentions will be counted toward the tabulation of votes cast on the proposal and will have the same effect as votes against this proposal. Brokernon-votes, if any, will have no effect.

Our stockholders have expressed a preference, and our Board has determined, to hold an advisory vote on executive compensation annually. We are presenting this Proposal 43 as required by Section 14A of the Exchange Act. Our Board believes that approval of Proposal 43 is in our best interests and the best interests of our stockholders for the reasons stated above. Because the vote is advisory, it is not binding on the Board or on us. Nevertheless, the views expressed by our stockholders, whether through this vote or otherwise, are very important to managementthe Board and the Boardmanagement team and, accordingly, the Compensation Committee and Board intend to consider the results of this vote in making determinations in the future regarding executive compensation arrangements. Your vote will serve as an additional tool to guide the Compensation Committee and Board in continuingas they continue to improve the alignment of our executive compensation programs with business objectives and performance and with the interests of our stockholders. Unless our Board changes the frequency of future advisory votes on executive compensation, the next advisory vote on executive compensation will be held at the 20212022 Annual Meeting of Stockholders.

 

THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” PROPOSAL 4.3.

 

2020 Proxy Statement    49

34    Exelixis, Inc.


Security Ownership of Certain Beneficial Owners and Management

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth certain information regarding the ownership of our common stock as of February 28, 2020,2021, (except as noted) by: (i) each director and nominee for director; (ii) each of the executive officers named in theSummary Compensation Table; (iii) all current executive officers and directors of Exelixis as a group; and (iv) all those known by us to be beneficial owners of more than five percent of our common stock.

 

    Beneficially Owned (1)     Beneficially Owned (1) 

Name of Beneficial Owner

    Number of
Shares of
Common Stock
     Percentage
of Total
     Number of
Shares of
Common Stock
     Percentage
of Total
 

Executive Officers and Directors

               

 

     

 

Michael M. Morrissey, Ph.D. (2)

     2,942,639      1.0     2,206,563      * 

Gisela M. Schwab, M.D. (3)

     1,606,944      *      1,389,159      * 

Christopher J. Senner (4)

     785,993      *      778,861      * 

Jeffrey J. Hessekiel, J.D. (5)

     920,737      *      722,307      * 

Peter Lamb, Ph.D. (6)

     1,155,890      * 

Patrick J. Haley (6)

     491,517      * 

Charles Cohen, Ph.D. (7)

     398,674      *      389,424      * 

Carl B. Feldbaum, Esq. (8)

     275,366      *      216,570      * 

Maria C. Freire, Ph.D. (9)

     79,745      *      109,048      * 

Alan M. Garber, M.D., Ph.D. (10)

     266,128      *      260,767      * 

Vincent T. Marchesi, M.D., Ph.D. (11)

     270,365      *      162,037      * 

Stelios Papadopoulos, Ph.D. (12)

     1,376,236      *      1,341,553      * 

George Poste, DVM, Ph.D., FRS (13)

     290,331      *      270,648      * 

George A. Scangos, Ph.D. (14)

     1,255,611      * 

Julie A. Smith (15)

     140,682      * 

Lance Willsey, M.D. (16)

     736,714      * 

Jack L. Wyszomierski (17)

     395,806      * 

All current directors, executive officers as a group (17 persons) (18)

     13,336,913      4.2

Julie A. Smith (14)

     140,682      * 

Lance Willsey, M.D. (15)

     632,464      * 

Jack L. Wyszomierski (16)

     373,731      * 

All current directors, executive officers as a group (16 persons) (17)

     10,480,854      3.3

5% Stockholders

               

 

     

 

BlackRock, Inc. (19)

55 East 52nd Street

New York, New York 10055

     31,834,126      10.4

The Vanguard Group (20)

100 Vanguard Blvd.

Malvern, Pennsylvania 19355

     28,111,171      9.2

Renaissance Technologies LLC (21)

800 Third Avenue

New York, New York 10022

     17,953,926      5.9

BlackRock, Inc. (18)

55 East 52nd Street

New York, New York 10055

     31,387,574      10.0

The Vanguard Group (19)

100 Vanguard Blvd.

Malvern, Pennsylvania 19355

     28,470,067      9.1

Renaissance Technologies LLC (20)

800 Third Avenue

New York, New York 10022

     21,682,651      6.9

T. Rowe Price Associates, Inc. (21)

100 E. Pratt Street

Baltimore, Maryland 21202

     17,588,494      5.6

 

*

Less than one percent.

 

(1)

This table is based upon information supplied by executive officers and directors and upon information gathered by us about principal stockholders known to us. Unless otherwise indicated in the footnotes to this table and subject to community property laws where applicable, we believe that each of the stockholders named in this table has sole voting and investment power with respect to the shares indicated as beneficially owned. Applicable percentages are based on 305,494,563312,817,909 shares outstanding on February 28, 2020,2021, adjusted as required by rules promulgated by the SEC. The percentage of beneficial ownership as to any person as of a particular date is calculated by dividing the number of

2021 Proxy Statement    35


shares beneficially owned by such person, which includes the number of shares as to which such person has the right to

50    Exelixis, Inc.


Security Ownership of Certain Beneficial Owners and Management

acquire voting or investment power within 60 days of February 28, 2020,2021, by the sum of the number of shares outstanding as of such date plus the number of shares as to which such person has the right to acquire voting or investment power within 60 days of February 28, 2020.2021. Consequently, the denominator for calculating beneficial ownership percentages may be different for each beneficial owner.

 

(2)

Includes 322,1271,059,683 shares held by Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended. Also includes 2,602,7841,129,152 shares Dr. Morrissey has the right to acquire pursuant to options exercisable within 60 days of February 28, 2020.2021. Also includes 17,728 shares held by Dr. Morrissey under our 401(k) Plan, determined based upon information provided in plan statements.

 

(3)

Includes 1,322,4361,004,765 shares Dr. Schwab has the right to acquire pursuant to options exercisable within 60 days of February 28, 2020.2021. Also includes 14,880 shares held by Dr. Schwab under our 401(k) Plan, determined based upon information provided in plan statements.

 

(4)

Includes 711,811627,890 shares Mr. Senner has the right to acquire pursuant to options exercisable within 60 days of February 28, 2020.2021. Also includes 2,723 shares held by Mr. Senner under our 401(k) Plan, determined based upon information provided in plan statements.

 

(5)

Includes 718,727268,515 shares Mr. Hessekiel has the right to acquire pursuant to options exercisable within 60 days of February 28, 2020.2021. Also includes 999 shares held by Mr. Hessekiel under our 401(k) Plan, determined based upon information provided in plan statements.

 

(6)

Includes 1,056,31123,539 shares Dr. Lambheld by Mr. Haley’s spouse. Also includes 382,663 shares Mr. Haley has the right to acquire pursuant to options exercisable within 60 days of February 28, 2020.2021. Also includes 17,10510,648 shares held by Dr. LambMr. Haley under our 401(k) Plan, determined based upon information provided in plan statements.

 

(7)

Includes 332,695208,049 shares Dr. Cohen has the right to acquire pursuant to options exercisable within 60 days of February 28, 2020, 42,6412021, 30,750 of which would be subject to repurchase by us, if so exercised.

 

(8)

Includes 266,845208,049 shares Mr. Feldbaum has the right to acquire pursuant to options exercisable within 60 days of February 28, 2020, 42,6412021, 30,750 of which would be subject to repurchase by us, if so exercised.

 

(9)

Includes 3,530 shares issuable pursuant to RSUs that will vest within 60 days of February 28, 20202021 and 64,74880,204 shares Dr. Freire has the right to acquire pursuant to options exercisable within 60 days of February 28, 2020, 35,9312021, 22,516 of which would be subject to repurchase by us, if so exercised.

 

(10)

Includes 217,299248,049 shares Dr. Garber has the right to acquire pursuant to options exercisable within 60 days of February 28, 2020, 42,6412021, 30,750 of which would be subject to repurchase by us, if so exercised.

 

(11)

Includes 198,198103,650 shares Dr. Marchesi has the right to acquire pursuant to options exercisable within 60 days of February 28, 2020, 20,6342021, 15,456 of which would be subject to repurchase by us, if so exercised.

 

(12)

Includes 333,985168,194 shares Dr. Papadopoulos has the right to acquire pursuant to options exercisable within 60 days of February 28, 2020, 20,634 of which would be subject to repurchase by us, if so exercised.2021.

 

(13)

Includes 187,85688,194 shares Dr. Poste has the right to acquire pursuant to options exercisable within 60 days of February 28, 2020, 20,634 of which would be subject to repurchase by us, if so exercised.2021.

 

(14)

Includes 8,963 shares held by Dr. Scangos and Leslie S. Wilson, as Trustees of The Jennifer Wilson Scangos Trust, and 8,963 shares held by Dr. Scangos and Leslie S. Wilson, as Trustees of The Katherine Wilson Scangos Trust. Also includes 268,985 shares Dr. Scangos has the right to acquire pursuant to options exercisable within 60 days of February 28, 2020, 42,641 of which would be subject to repurchase by us, if so exercised. Also includes 5,669 shares held by Dr. Scangos under our 401(k) Plan, determined based upon information provided in plan statements.

(15)

Includes 139,919 shares Ms. Smith has the right to acquire pursuant to options exercisable within 60 days of February 28, 2020, 50,5882021.

(15)

Includes 208,049 shares Dr. Willsey has the right to acquire pursuant to options exercisable within 60 days of February 28, 2021, 30,750 of which would be subject to repurchase by us, if so exercised.

 

(16)

Includes 368,441183,650 shares Dr. WillseyMr. Wyszomierski has the right to acquire pursuant to options exercisable within 60 days of February 28, 2020, 42,6412021, 15,456 of which would be subject to repurchase by us, if so exercised.

 

(17)

Includes 275,597 shares Mr. Wyszomierski has the right to acquire pursuant to options exercisable within 60 days of February 28, 2020, 20,634 of which would be subject to repurchase by us, if so exercised.

(18)

Total number of shares includes 3,840,7064,560,196 shares of common stock held by our current directors and executive officers as of February 28, 2020,2021, and entities affiliated with such directors and executive officers. Also includes 3,530 shares issuable pursuant to RSUs that will vest within 60 days of February 28, 2020.2021. Also includes 9,422,9255,853,045 shares our directors and executive officers have the right to acquire pursuant to options exercisable within 60 days of February 28,

2020 Proxy Statement    51


2020, 381,360 2021, 176,428 of which would be subject to repurchase by us, if so exercised. Also includes 69,75264,083 shares held by our current directors and executive officers under our 401(k) Plan, determined based upon information provided in plan statements.

 

(19)
36    Exelixis, Inc.


Security Ownership of Certain Beneficial Owners and Management

(18)

BlackRock, Inc. reported that it has sole voting power over 30,675,30730,304,654 of such shares and that it has sole dispositive power over all of the shares. Blackrock, Inc. also reported that Blackrock Fund Advisors beneficially owns 5% or more of our outstanding common stock. The information is based solely on a Schedule 13G/A, filed with the SEC on February 4, 2020,January 27, 2021, which provides information only as of December 31, 2019,2020, and, consequently, the beneficial ownership of BlackRock may have changed between December 31, 20192020 and February 28, 2020.2021.

 

(20)(19)

The Vanguard Group reported that it has sole voting power over 163,124 of such shares, shared voting power over 60,919217,705 of thesesuch shares, sole dispositive power over 27,926,76828,003,214 of such shares and shared dispositive power over 184,403466,853 of such shares. The information is based solely on a Schedule 13G/A, filed with the SEC on February 12, 2020,10, 2021, which provides information only as of December 31, 2019,2020, and, consequently, the beneficial ownership of Vanguard may have changed between December 31, 20192020 and February 28, 2020.2021.

 

(21)(20)

These shares are beneficially owned by Renaissance Technologies LLC (RTC), and Renaissance Technologies Holdings Corporation (RTHC), the majority owner of RTC. RTC reported that it and RTHC each have sole voting power over 21,520,637 of such shares and sole dispositive power over all of the shares. The information is based solely on a Schedule 13G/A filed with the SEC on February 11, 2021, which provides information only as of December 31, 2020, and, consequently, the beneficial ownership of RTC and RTHC may have changed between December 31, 2020 and February 28, 2021.

(21)

T. Rowe Price Associates, Inc. reported that it has sole voting power over 3,195,069 of such shares and sole dispositive power over all of the shares. The information is based solely on a Schedule 13G filed with the SEC on February 12, 2020,16, 2021, which provides information only as of October 8, 2019,December 31, 2020, and, consequently, the beneficial ownership of RTC and RTHCT. Rowe Price Associates may have changed between October 8, 2019December 31, 2020 and February 28, 2020.2021.

 

52    Exelixis, Inc.

2021 Proxy Statement    37


Executive Officers

 

INFORMATION ABOUT OUR EXECUTIVE OFFICERS

The following chart sets forth certain information regarding our executive officers as of March 23, 2020:29, 2021:

 

Name

  Age  Position

Michael M. Morrissey, Ph.D. (1)

  5960  President and Chief Executive Officer

Gisela M. Schwab, M.D.

  6364  President, Product Development and Medical Affairs and Chief Medical Officer

Christopher J. Senner

  5253  Executive Vice President and Chief Financial Officer

Patrick J. Haley

  4445  Executive Vice President, Commercial

Jeffrey J. Hessekiel, J.D.

  5152  Executive Vice President and General Counsel

Peter Lamb, Ph.D.

  5960  Executive Vice President, Scientific Strategy and Chief Scientific Officer

 

(1)

Please see “Director Nominees” in this Proxy Statement for Dr. Morrissey’s biography.

 

Gisela M. Schwab, M.D.

President, Product Development and Medical Affairs and Chief Medical Officer

 

 

Gisela M. Schwab, M.D., has served as President, Product Development and Medical Affairs and Chief Medical Officer since February 2016. Previously she served as Executive Vice President and Chief Medical Officer from January 2008 to February 2016 and as Senior Vice President and Chief Medical Officer from September 2006 to January 2008. From 2002 to 2006, she held the position of Senior Vice President and Chief Medical Officer at Abgenix, Inc., a human antibody-based drug development company. She also served as Vice President, Clinical Development, at Abgenix from 1999 to 2001. Prior to working at Abgenix, from 1992 to 1999, she held positions of increasing responsibility at Amgen Inc., most recently as Director of Clinical Research and Hematology/Oncology Therapeutic Area Team Leader. From August 2011 through July 2014, Dr. Schwab served as a member of the board of directors of Topotarget A/S, a publicly held biopharmaceutical company. She has served as a member of the board of directors of Cellerant Therapeutics, Inc., a privately held biopharmaceutical company, since June 2012, and as a member of the board of directors of Genocea Biosciences, Inc., a publicly held biopharmaceutical company, since February 2020,2020. Previously, Dr. Schwab served as a member of the board of directors of Topotarget A/S, a publicly held biopharmaceutical company, from August 2011 through July 2014, and as a member of the board of directors of Nordic Nanovector A.S. (Nordic), a Norwegian biotechnology company, sincefrom March 2015. Dr. Schwab will be stepping down from the Nordic board of directors at Nordic’s next Annual General Meeting in April2015 through June 2020. She received her Doctor of Medicine degree from the University of Heidelberg, trained at the University of Erlangen-Nuremberg and the National Cancer Institute and is board certified in internal medicine and hematology and oncology.

 

Christopher J. Senner

Executive Vice President and Chief Financial Officer

 

 

Christopher J. Senner, has served as Executive Vice President and Chief Financial Officer (and in such capacity, as our principal financial officer and principal accounting officer, as defined under applicable securities laws) since July 2015. Prior to joining Exelixis, Mr. Senner served as Vice President, Corporate Finance for Gilead Sciences, Inc., a biopharmaceutical company, from March 2010 to July 2015, where he was accountable for controllership, tax, treasury and corporate and operational financial planning. Mr. Senner previously spent eighteen years at Wyeth, a pharmaceutical company acquired by Pfizer Inc. in 2009, in a variety of financial roles with increasing responsibility, most notably as Chief Financial Officer of Wyeth’s U.S. pharmaceuticals business and the BioPharma Business Unit. Since 2019, Mr. Senner has served as a member of the board of directors of Cortexyme, Inc., a publicly held clinical-stage biopharmaceutical company. Mr. Senner holds a B.S. in Finance from Bentley College.

 

P.J.Patrick J. Haley

Executive Vice President, Commercial

 

 

P.J.Patrick J. Haley, has served as the company’s Executive Vice President, Commercial since February 2020 and has held positions of progressive commercial leadership since September 2010, serving as Senior Vice President, Commercial from December 2016 to February 2020, Vice President, Commercial from November 2014 to November 2016, Executive Director, Sales & Marketing from September 2013 to October 2014, Senior Director, Marketing from March 2012 to August 2013, and as Director, Marketing from September 2010 to February 2012. Prior to joining Exelixis, from 2007 to 2010, he held positions of increasing responsibility at Genentech, Inc., on the Avastin marketing team, most recently Group Product Manager. Between 2003 and 2007, Mr. Haley served in various sales and marketing roles at Amgen, Inc. He served as an analyst at PWC Securities, Lehman Brothers and Accenture from 1998 to 2001. Mr. Haley holds a Masters of Business Administration from University of Michigan, Ross School of Business, and a Bachelor of Arts in Art History and Medieval and Renaissance Studies from Duke University.

 

2020 Proxy Statement    53

38    Exelixis, Inc.


Information About Our Executive Officers

Jeffrey J. Hessekiel, J.D.

Executive Vice President and General Counsel

 

 

Jeffrey J. Hessekiel, J.D., has served as Executive Vice President and General Counsel since February 2014 and as its Secretary from October 2014 to September 2017. From 2012 to 2014, he held the position of Senior Counsel at Arnold & Porter Kaye Scholer LLP, where he advised emerging growth and public companies, primarily in the life sciences sector, on complex legal issues connected with strategic transactions, healthcare compliance programs and investigations, and regulatory matters. Prior to working with Arnold & Porter, from 2002 to 2012, he held positions of increasing responsibility at Gilead Sciences, Inc., most recently as Chief Compliance & Quality Officer where he was responsible for the creation and management of Gilead’s Corporate Compliance & Quality department. From 1998 to 2002, Mr. Hessekiel held the position of Associate, working on both litigation and corporate matters for Wilson Sonsini Goodrich and Rosati PC. Mr. Hessekiel also worked as an Associate focusing on litigation matters for Heller Ehrman LLP from 1996 to 1998. Prior to joining Heller Ehrman LLP, Mr. Hessekiel also worked for several internationalnon-governmental organizations. Mr. Hessekiel received his J.D. from The George Washington University Law School and is admitted to practice in California. Mr. Hessekiel received a B.A. in Political Science from Duke University.

 

Peter Lamb, Ph.D.

Executive Vice President, Scientific Strategy and Chief Scientific Officer

 

 

Peter Lamb, Ph.D., has served as Executive Vice President, Scientific Strategy and Chief Scientific Officer since February 2016. Previously, he served as Executive Vice President, Discovery Research and Chief Scientific Officer from September 2009 to February 2016, as Senior Vice President, Discovery Research and Chief Scientific Officer from January 2007 until September 2009, as Vice President, Discovery Pharmacology from December 2003 until January 2007 and as Senior Director, Molecular Pharmacology and Structural Biology from October 2000 until December 2003. Prior to joining Exelixis, from June 1992 until September 2000, Dr. Lamb held positions of increasing responsibility at Ligand Pharmaceuticals, a pharmaceutical company, most recently serving as Director of Transcription Research. Dr. Lamb has held post-doctoral research fellowships at the Carnegie Institution, Department of Embryology, with Dr. S.L. McKnight and the University of Oxford with Dr. N.J. Proudfoot, working in the field of gene regulation. He has authored numerous articles in the fields of gene expression, signal transduction and oncology, and is an author on multiple issued and pending U.S. patents. He has a Ph.D. in Molecular Biology from the ICRF/University of London and a B.A. in Biochemistry from the University of Cambridge.

 

54    Exelixis, Inc.

2021 Proxy Statement    39


Compensation of Executive Officers | Compensation Discussion and Analysis

 

COMPENSATION OF EXECUTIVE OFFICERS

Compensation Discussion and Analysis

 

This Compensation Discussion and Analysis (CD&A) explains the strategy, design, and decision-making related to our compensation programs and practices for our principal executive officer, our principal financial officer and our three other most highly compensated executive officers, who we refer to collectively as our Named Executive Officers. This CD&A is intended to provide perspective on the information contained in the tables that follow this discussion. For fiscal 2019,2020, our Named Executive Officers were:

 

Named Executive Officers

  

Title

Michael M. Morrissey, Ph.D.

  President and Chief Executive Officer

Gisela M. Schwab, M.D.

  President, Product Development and Medical Affairs and Chief Medical Officer

Christopher J. Senner

  Executive Vice President and Chief Financial Officer

Jeffrey J. Hessekiel, J.D.

  Executive Vice President and General Counsel

Peter Lamb, Ph.D.Patrick J. Haley

  Executive Vice President, Scientific Strategy and Chief Scientific OfficerCommercial

While the principal purpose of this CD&A is to discuss the compensation of our Named Executive Officers, many of the programs discussed apply to other members of senior management who, together with the Named Executive Officers, are collectively referred to as our executive officers.

Executive Summary

Our Business

We are an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines fordifficult-to-treat cancers. Since we were founded in 1994, four products resulting from our discovery efforts have progressed through clinical development, received regulatory approval and established a commercial presence in various geographies around the world. Two are derived from cabozantinib, our flagship molecule, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Our cabozantinib products are: CABOMETYX® (cabozantinib) tablets, approved for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company’s OPDIVO® (nivolumab), and previously treated hepatocellular carcinoma (HCC); and COMETRIQ® (cabozantinib) capsules, approved for progressive, metastatic medullary thyroid cancer. For these types of cancer, cabozantinib has become or is becoming a standard of care. The two other products resulting from our discovery efforts are: COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO® (esaxerenone), an oral,non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).Limited.

Our COVID-19 Response

In January 2020, prior to the onset of the COVID-19 pandemic, we outlined a series of strategic priorities and anticipated milestones for the year, including generating top-line data from important clinical trials, completing enrollment of ongoing studies, initiating new pivotal trials and progressing our mid- and early-stage product pipeline. As the COVID-19 pandemic crisis quickly developed in the early part of the year and imposed challenges on our business, we remained determined to make 2020 a period of focused execution and achievement for Exelixis. We rapidly devised and implemented COVID-19 response plans across all facets of the organization in order to mitigate the impact of the pandemic on our business, our employees and the patients who rely on our medicines. We called on our team’s collective resilience, focus and commitment to making every day count, as we continued in our efforts on behalf of cancer patients.

Workplace Safety. We were able to mitigate the risk of transmission of the virus by reducing the number of employees working on-site at our Alameda headquarters, while simultaneously implementing enhanced safety and social distancing protocols and an on-site testing program. Despite displacement of most of our staff to their home offices, we maintained efficiencies in our workstreams and organizational cohesion by expanding the use of technology systems, increasing the frequency and clarity of communications from executive management, and finding ways to improve coordination across business units. In the context of these adjustments, we were also able to expand our workforce by 25% from 617 to 773 employees.

40    Exelixis, Inc.


Compensation of Executive Officers | Compensation Discussion and Analysis

Clinical Trials. We convened a COVID-19 task force to meet daily and evaluate means to moderate the impact of the pandemic on site activation, patient screening and enrollment, as well as help prevent material delays to our clinical trials through an ongoing assessment of the pandemic’s impact. Wherever possible, we took proactive steps in compliance with guidance issued by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and other regulatory agencies to support the safety of our patients and their access to treatment, as well as to maintain the high quality of our clinical trials.

Commercial Activities. We maintained engagement with healthcare professionals and our ability to educate and respond to questions about our products by transitioning our sales force from in-person promotional activities to primarily telephonic and virtual interactions.

Supply Chain. Notwithstanding global supply chain risks posed by the COVID-19 pandemic, we took advantage of our longstanding practice of maintaining substantial inventories of drug substance and drug product and were able to safeguard the timely production and delivery of our products by working closely with third-party contract manufacturers, distributors and suppliers, as well as collaboration partners.

Pipeline Expansion. We mitigated the impact of periods when the COVID-19 pandemic forced lab closures by making efficient use of available third-party laboratory resources for early-stage drug discovery work, and once we were able to partially reopen our labs, we prioritized critical late-stage drug discovery activities.

20192020 Financial Performance Highlights1

Despite the challenges posed by the COVID-19 pandemic, we delivered strong financial results in fiscal 2020, increasing total revenues by 2% year-over-year and ending fiscal 2020 with a healthy cash and investments balance of over $1.5 billion. Other key financial highlights from fiscal 2020 include:

 

13% 

Year over year  

total revenue growth  

We delivered strong financial results in fiscal 2019, increasing total revenues by 13% year over year and ending fiscal 2019 with a healthy cash and investments balance of $1.4 billion. We also continued to execute on our tactical plan to generate product and collaboration revenues to reinvest in our business and drive the expansion and depth of our product offerings. Other key financial highlights from fiscal 2019 include:

Cabozantinib franchise net product revenues of $760.0 million, resulting in our seventh consecutive year of record net product revenues;$741.6 million;

 

Total revenues of $967.8$987.5 million, reflecting both strong product demand and significant financial contributions generated from our collaborations;

 

Total operating expenses of $598.3$877.5 million, up 44%47% from the prior fiscal year, underscoring our commitment to investing in our product pipeline, while exercising disciplined expense management; and

 

A thirdfourth full year of operating profit, resulting in diluted earnings per share of $1.02.$0.35.

$1.4B 

Year-end cash and  

investments balance  

$1.02 

Diluted earnings  

per share  

 

1

Amounts included in 20192020 Financial Performance Highlights are calculated in accordance with U.S. Generally Accepted Accounting Principles.

 

2020 Proxy Statement    55

2021 Proxy Statement    41


20192020 Corporate Performance Highlights

 

4

Commercial products
resulting from
Exelixis’ discovery
efforts

9

Ongoing potentially
label-enabling
clinical trials evaluating
cabozantinib

20  

Ongoingdiscovery
programs
from
internal and
collaborative efforts

In fiscal 2019, we continuedLOGO

LOGO

We were able to continue to drive growth during fiscal 2020 in spite of the COVID-19 pandemic. We executed commercially by executing ondevising new strategies to maintain engagement with prescribers despite restricted in-person access; we succeeded in the clinic by adjusting the operation of our strategy to make CABOMETYX the tyrosine kinase inhibitor of choice for patients with RCC, to build our product portfolio through cabozantinib label-enabling clinical trials in compliance with established protocols, always placing the highest priority on patient safety; and to create new product opportunities through internalwe created opportunity with drug discovery by advancing our research where it could be done safely and externalby supplementing it with research collaborations and development efforts.in-licensing arrangements. Key highlights of our corporate performance included:include:

Navigation of Regulatory Pathways Toward Approval of CABOMETYX as Part of a Combination Regimen to Treat Patients with Advanced RCC

Following acceptance of our supplemental New Drug Application (sNDA) in August 2020, on January 22, 2021, the FDA approved CABOMETYX in combination with OPDIVO as a first-line treatment for patients with advanced RCC, the most common form of kidney cancer.

FDA approval was based on the results from Checkmate -9ER, a phase 3 pivotal trial evaluating the combination regimen compared with sunitinib in previously untreated advanced or metastatic RCC, which read out positively in April 2020. The compelling results from CheckMate -9ER, which revealed that the combination of CABOMETYX and OPDIVO significantly improved progression-free survival, overall survival, objective response rate and quality of life compared to sunitinib, are expected to be a key driver of revenue growth in 2021 and beyond.

To make the combination regimen available to eligible RCC patients outside of the U.S, we worked closely with our collaboration partners Ipsen Pharma SAS (Ipsen) and Takeda Pharmaceutical Company Limited (Takeda) on their respective regulatory strategies. In October 2020, Takeda submitted a supplemental application to the Japanese Ministry of Labour, Health and Welfare (MHLW) to manufacture and market the combination of CABOMETYX and OPDIVO as a treatment for patients with advanced RCC, and in March 2021, Ipsen received regulatory approval from the European Commission for the combination of CABOMETYX and OPDIVO as a first-line treatment for advanced RCC.

Successful Commercialization of CABOMETYX for Advancedin Approved RCC in an Increasingly Competitive Marketand HCC Indications

 

 

In the U.S., we continued to promote CABOMETYX within its labeled RCC and HCC indications and educate physicians on itsthe product’s unique clinical profile. These efforts helped drive continued strong product demand in 20192020 despite increased competition from therapies that combine an immune checkpoint inhibitor (ICI) with another targeted agent to treat cancer.

 

 

In markets outside of the U.S., we worked closely with our partnerpartners Ipsen Pharma SAS (Ipsen)and Takeda in support of itstheir respective regulatory strategystrategies and commercialization efforts for CABOMETYX as a treatment for advanced RCC.CABOMETYX. As a result of additional approvals in 51 territories outside of the U.S. as of the end of fiscal 2019,, CABOMETYX has continued to grow both in sales revenues and the number of RCC and HCC patients benefiting from its clinical effect in 2019. With respect to the Japanese market, our partner Takeda Pharmaceutical Company Limited (Takeda) achieved an important regulatory milestone in April 2019 with its application to the Japanese Ministry of Health, Labour and Welfare (MHLW) for Manufacturing and Marketing Approval of CABOMETYX as a treatment for patients with unresectable and metastatic RCC in Japan, for which Takeda received approval in March 2020.

Expansion of CABOMETYX Label for the Treatment for Patients with HCC Who Have Previously Been Treated with Sorafenib

On January 14, 2019, the FDA approved CABOMETYX as a treatment for patients with HCC who have been previously treated with sorafenib, an aggressive anddifficult-to-treat cancer that represents a significant unmet medical need. Utilizing the strength of our existing commercial and medical affairs organizations, in addition to our well-established distribution network, we were immediately prepared to offer CABOMETYX to all eligible HCC patients in the U.S. who may benefit from this treatment option.

 

 

In an effortthe Japanese market, our partner Takeda achieved two important regulatory milestones, including approval from the Japanese MHLW to help make CABOMETYX available to eligible HCC patients outside of the U.S, we worked closely with our collaboration partners Ipsenmanufacture and Takeda on their regulatory strategies, which culminated in multiple regulatory approvals throughout the world formarket CABOMETYX as a treatment for patients with previously treated HCC, including by Health Canadacuratively unresectable or metastatic RCC in November 2019. Takeda also made significant progress on an HCC bridging study it conducted in support of its JanuaryMarch 2020 application to the Japanese MHLW for Manufacturing and Marketing Approval of CABOMETYX as a treatment for patients with unresectable HCC whothat progressed after prior systemic therapycancer chemotherapy in Japan.November 2020.

 

56    Exelixis, Inc.

42    Exelixis, Inc.


Compensation of Executive Officers | Compensation Discussion and Analysis

 

Achievement of Positive Results from Potential Label-Enabling Clinical Trials and Further Evaluation of Cabozantinib in Multiple Potentially Label-Enabling ClinicalPhase 3 Pivotal Trials

 

 

In supportDecember 2020, we announced positive top-line results from COSMIC-311, our pivotal phase 3 trial evaluating cabozantinib versus placebo in patients with radioactive iodine-refractory differentiated thyroid cancer (DTC). The trial met its co-primary endpoint of our effortsdemonstrating significant improvement in progression-free survival with a hazard ratio of 0.22, providing evidence of cabozantinib’s efficacy as a monotherapy in this patient population, and shortly after year-end, the FDA granted Breakthrough Therapy Designation to cabozantinib as a potential treatment for this indication.

To expand the late-stage development of cabozantinib both alone and in combination with other therapies, we initiatedcompleted enrollment for COSMIC-312, a phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab, an anti-PD-L1 ICI developed by F. Hoffmann-La Roche Ltd. (Roche), versus sorafenib in previously untreated advanced HCC in August 2020.

To reinforce our efforts in RCC, we substantially advanced the enrollment of COSMIC-313, a phase 3 pivotal trial evaluating the triplet combination of cabozantinib, nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk RCC, and substantially advanced the enrollment of the ongoing phase 3 pivotal trialsCOSMIC-311, evaluating cabozantinib in patients with radioactive iodine-refractory differentiated thyroid cancer, andCOSMIC-312, evaluating cabozantinib in combination with atezolizumab versus sorafenib in previously untreated advanced HCC.RCC.

 

 

Building upon encouraging clinical activity observed inEncouraging results from an interim analysis of the metastatic castration-resistant prostate cancer (mCRPC) cohort of COSMIC-021, our phase 1b trial evaluating the combination of cabozantinib and atezolizumab in patients with locally advanced or metastatic solid tumors, were presented at the American Society of Clinical Oncology’s Genitourinary Cancer Symposium in February 2020. Based on regulatory feedback, we entered intointend to file with the FDA for accelerated approval in an mCRPC indication in 2021, if such a jointstrategy continues to be warranted by the emerging clinical research agreement with Roche fordata.

Also based on the purpose of further evaluating the combinationencouraging clinical activity observed in a late-stage setting, includingCOSMIC-021, in June and July 2020 we initiated three planned phase 3 pivotal trials in advancedcollaboration with Roche, CONTACT-01, CONTACT-02 and CONTACT-03, evaluating the combination of cabozantinib with atezolizumab in patients with metastatic non-small cell lung cancer (NSCLC), metastatic castration-resistant prostate cancer (mCRPC)mCRPC and RCC.advanced RCC, respectively.

Expansion of Product Pipeline Beyond the Cabozantinib Franchise

 

 

In January 2019, the FDA acceptedWe made substantial progress on our investigational new drug (IND) application forevaluation of XL092, a next-generation oral TKItyrosine kinase inhibitor, including generating data that supports the expansion of XL092’s clinical development and enrolling the first compound to advance from our reinitiated discovery operations,patient in the combination arm of the phase 1 trial evaluating the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of XL092, both alone and in February 2019 we initiated a phase 1 dose escalation trial to evaluate the compound’s pharmacokinetics, safety and tolerabilitycombination with atezolizumab in patients with advanced solid tumors.

 

 

As partIn December 2020, the FDA accepted our investigational new drug (IND) application for XL102, a potent, selective and orally bioavailable covalent inhibitor of our strategycyclin-dependent kinase 7, and shortly after year-end, we initiated a phase 1 trial designed to expand our product pipeline through thein-license of attractive, early-stage oncology assets, in May 2019 we entered into an exclusive optionevaluate XL102’s safety, tolerability, pharmacokinetics and license agreement with Iconic Therapeutics, Inc. (Iconic) to advance an innovative next-generation antibody-drug conjugates (ADC) program for cancer,preliminary anti-tumor activity, both as a single agent and in July 2019 we entered into an exclusive collaboration, option and license agreementcombination with Aurigene Discovery Technologies Limited (Aurigene) to license as many as six programs to discover and develop small molecules asother anti-cancer therapies for cancer.in patients with locally-advanced or metastatic solid tumors.

 

 

Significant milestones were reachedIn December 2020, we exercised our exclusive option for XB002, the lead oncology antibody-drug conjugates (ADC) program under our research collaboration agreements with Daiichi SankyoIconic Therapeutics, Inc. and Genentech, including regulatory approval of MINNEBRO forsubsequently filed an IND with the treatment of hypertensionFDA in Japan and the achievement of positivetop-line results for IMspire150, the phase 3 pivotal trial evaluating the combination of cobimetinib with atezolizumab and vemurafenib in patients with previously untreated BRAF V600 mutant melanoma.March 2021.

Successful Management of Organizational Growth and Expansion of Corporate Headquarters

 

 

In supportan effort to expand our pipeline to encompass a variety of promising therapeutic modalities, in September 2020 we entered into two collaboration and license agreements with NBE-Therapeutics AG (NBE) and entities affiliated with Catalent, Inc. (together, Catalent), each focused on the executiondevelopment of our planned cabozantinib development activities and resumption of internal discovery efforts, we increased hiring activities, and as ofADCs that have the end of fiscal 2019, had 617 full-time employees (FTEs), a 27% year-over-year increase of our employee population. To enable the effective management of this growth, we continuedpotential to implement new and/or improved operational and financial systems, procedures and controls, and expanded employee training and development efforts.become anti-cancer therapies.

 

 

In contemplation ofJuly 2020, we achieved a significant milestone under our continued organizational growth, we expanded our corporate headquarters by approximately 94,000 square feet of laboratorycollaboration agreement with Genentech, when the FDA approved COTELLIC® (cobimetinib) in combination with TECENTRIQ® (atezolizumab) and office space and entered into abuild-to-suit lease for approximately 220,000 square feet of office space located adjacent to our existing corporate headquarters in Alameda. We have committed to a 100% carbon-neutral energy footprintZELBORAF®(vemurafenib) for the operationtreatment of our new building.patients with previously untreated BRAF V600 mutation positive advanced melanoma.

 

2020 Proxy Statement    57

2021 Proxy Statement    43


20192020 Executive Compensation Program Highlights

Following several yearsThe unprecedented nature of growth2020 for Exelixis, as well as for all of our stakeholders, required an equally unprecedented response from our management team and evolution,the entire Exelixis organization. From the onset of the COVID-19 pandemic, we have developed intomoved decisively to protect our patients, our employees, and our business, and to ensure a fully integrated biotechnology companyreliable supply of our critical cancer medicines for the patients who depend upon them. Despite the challenges of this unforeseeable global public health crisis, we were nevertheless able to achieve mission-critical research, development, commercial and created a strong foundation from which we intendoperational objectives established by the Compensation Committee prior to continuethe onset of the pandemic. We were also able to create value for all of our stakeholders. Building upon this foundation, in 2019, we achieved significant research, development and financial milestones that helped position us to be able to deliver upon our goal ofstockholders by driving the expansion and depth of our commercial and investigational product offerings.offerings, growing our revenues and improving our future business prospects through important partnerships with emerging biotech companies. The Compensation Committee believes that the 20192020 compensation of all our employees, including our Named Executive Officers, reflectsis appropriate not only due to the achievement of thesecritical milestones under exceedingly difficult conditions, but will also to continue to encourage appropriatetheir extraordinary efforts towards the achievement of our key priorities and anticipated milestones for 2020in 2021 and 2021, including generatingtop-line data from key clinical trials, completing enrollmentbeyond. In consideration of ongoing studies, initiating new pivotal trials, and progressing ourmid-stage and early product pipeline. In light of the company’s performance as summarized above, the Board and Compensation Committee took the following key actions with respect to 20192020 compensation for our employees, including our Named Executive Officers:

 

Key Compensation Actions

  

Description

Approved Salary Increases for Named Executive Officers

  

In February 2019,2020, the Compensation Committee increased base salaries for all but one of our Named Executive Officers by between 4.0% and 6.5%5.0% over salaries for 2018.2019. Mr. Haley received a base salary increase of 10.2% in connection with his promotion to the level of Executive Vice President in February 2020.

ImplementedMaintained a 100% Performance-Based
Long-Term Incentive Program
(LTIP)

  

In September 2019,2020, as part of our ongoing equitylong-term incentive compensation program, the Compensation Committee granted 100% performance-based RSU awards (PSUs). A 100% PSU approach strongly aligns our Named Executive Officers’ compensation with the interests of our stockholders because the PSUs only vest upon the achievement of aclinical and regulatory milestonemilestones critical to our future long-term growth.

Applied an Objective Framework to DetermineDid Not Adjust Performance Targets for LTIP or Annual Cash Bonus Plan

Notwithstanding the challenges imposed by the COVID-19 pandemic on our business, the Compensation Committee did not adjust the performance targets for either our LTIP or our Annual Cash Bonus Plan. Rather, the Compensation Committee believed that the established programs were appropriate and that the performance targets remained critical business objectives for the company.

Approved Annual Cash Bonuses that areThat Are Aligned withWith Strong Company Performance

  

In February 2020,2021, the Compensation Committee approved the payment of cash bonuses in amounts between 110%114% and 114%144% of each Named Executive Officer’s 20192020 target cash bonus amounts. These decisions reflected the Compensation Committee’s assessment of our strong corporate performance, including the overall achievement of ourpre-determined 2019 2020 corporate goals, and the individual contribution of each Named Executive Officer toward achievement of our corporate goals, including contributions toward departmental achievements in eachgoals. In its decision-making, the Compensation Committee considered the unforeseen burden of the COVID-19 pandemic on our operations and the extraordinary response taken by our Named Executive Officer’s areaOfficers to mitigate its impact on the various facets of responsibilityour organization, while simultaneously achieving critical business milestones under exceptionally challenging conditions. The Compensation Committee believed it was important to recognize this extraordinary effort to secure the retention of our Named Executive Officers, whose leadership is critical to our ability to maintain business continuity during these challenging times and to achieve our future objectives. Accordingly, the Compensation Committee decided to exercise discretion afforded to it under the Annual Cash Bonus Plan to increase the corporate performance factor from 108% to 120%. Understanding that droveour 2020 achievements would not have been possible without the achievementsupport of our entire organization, the Compensation Committee also approved a bonus pool for employees who did not participate in the Annual Cash Bonus Plan in an amount equal to 120% of the aggregate target cash bonus amounts for all such corporate goals.employees.

 

58    Exelixis, Inc.

44    Exelixis, Inc.


Compensation of Executive Officers | Compensation Discussion and Analysis

 

Compensation Practices and Governance Highlights

 

Pay for Performance

  

  We link the compensation of our Named Executive Officers to the achievement of our corporate goals and stock price appreciation.performance.

Stockholder Alignment

  

  We use long-term equity incentives to align the interests of our Named Executive Officers with those of our stockholders.

Alignment of Compensation Metrics and Corporate Strategy

  

  Our Compensation Committee establishes long-term incentive compensation programs based on metrics that are aligned with our corporate strategy and designed to build value for our stockholders.

Compensation Governance

  

  Our Compensation Committee is made up entirely of independent directors and engages an independent compensation consultant to advise on executive compensation matters.

Stockholder Feedback

  

  We value the feedback of our stockholders and solicit it on a regular basis, including through an annual stockholder vote to approvalapprove oursay-on-pay proposal.

Recoupment (or Clawback) Policy

  

  We adopted themaintain a Clawback Policy that permits the company to recoup variable compensation from senior level employees, including our Named Executive Officers, in the event of misconduct that causes material harm to the company.

Annual Cash Bonus Amounts Subject to
Payment Maximums

  

  Our annual cash bonus programAnnual Cash Bonus Plan sets a cap of 200% on the payouts of target bonus payments for individual and/or corporate performance.

Equity Plan Features

  

  Applies a maximum7-year term for stock options.

 

  Prohibits repricing of underwater stock options without prior stockholder approval.

 

  The 2017 Plan also includes minimum vesting requirements of no less than one year for all types of awards, subject to limited exceptions.

Stock Ownership Guidelines

  

  We apply stock ownership guidelines to directors and executive officers to further align their interests with those of our stockholders.

Change in Control Provisions

  

  Does not include excessive change in control or severance payments.

 

  Provides “double-trigger” change in control benefits.

 

  Does not include taxgross-ups on severance or change in control benefits.

Perquisites, Retirement and Pension Benefits

  

  Our Named Executive Officers do not receive excessive perquisites or post-termination retirement or pension benefits that are not available to all employees generally.

Prohibition on Hedging and Margin Loans

  

  We prohibit hedging and purchases on margin by executive officers and directors.

Meaningful Limits on Pledging

  

  We limit pledging of our common stock by executive officers and directors to circumstances where the individual can clearly demonstrate the financial capacity to repay the loan without resorting to the pledged securities. No executive officers or directors pledged our common stock during 2019.2020.

Compensation Risk Assessment

  

  Our Compensation Committee conducts an annual risk assessment of our compensation policies and practices to ensure that our programs are not reasonably likely to have a material adverse effect on us.

Objectives of the Compensation Program

The primary goals of our executive compensation program are to:

 

 

Provide market-competitive compensation that attracts, retains and motivates our executive officers to achieve our short- and long-term business objectives;

 

2020 Proxy Statement    59

2021 Proxy Statement    45


 

Align our executive officers’ compensation with the interests of our stockholders; and

 

 

Reward our executive officers for success in achieving our corporate goals.

The success of any biotechnology company depends in large part upon the quality of its work force. Therefore, we believe it is critical to our business that we retain our core team of highly qualified employees, including our Named Executive Officers. As a testament to the high demand for their services in the marketplace, large pharmaceutical and biotechnology companies and strong local competitors have pursued our executives and other highly skilled employees. In light of this competitive pressure, each year we design our executive compensation program to help attract, motivate and retain highly qualified individuals with relevant experience in the biotechnology industry to manage the varied aspects of our growing business operations. We believe the twelve-year average tenure of our Named Executive Officersexecutive officers and the strength of our corporate and financial performance following the first FDA approval of CABOMETYX in April 2016 are evidence of what we believe to be the effectiveness of our compensation program with respect to retention and building value for our stockholders.

How We Determine Executive Compensation

Role of the Compensation Committee, Compensation Consultants and Executive Officers in Compensation Decisions

Role of the Compensation Committee

The Compensation Committee is responsible for evaluating and approving the compensation packages offered to our Named Executive Officers. When appropriate, the Compensation Committee will solicit the input of, or present its recommendations on compensation matters for consideration and approval to, the full Board. The Compensation Committee acts on behalf of the Board in discharging the Board’s responsibilities with respect to overseeing our compensation policies, plans and programs, and establishing and reviewing general policies relating to compensation and benefits of our employees. The Compensation Committee also administers our equity and other incentive plans. The Compensation Committee does not delegate any of its functions to others in determining executive compensation.

Role of Compensation Consultants

Under its charter, the Compensation Committee has the authority to obtain the advice and assistance from external advisors to assist it in the performance of its duties. In accordance with this authority, the Compensation Committee engages external advisors to advise on executive officer compensation, including base salaries, bonus targets and equity compensation, as well as director compensation. These advisors also prepare industry compensation data, assist with the development of our peer group, and advise the Compensation Committee on best industry practices and relevant changes to regulations that may impact the Compensation Committee’s decision-making process with regard to executive officer and director compensation determinations. For 20192020 compensation matters, the Compensation Committee retained the consulting firm Compensia,Radford, to advise and assist with the following:

 

 

Development of a peer group to be used in the evaluation of 20192020 executive and director compensation determinations.

 

 

Documentary support, including peer group and industry data with respect to base salaries, target annual cash bonuses and equity compensation.

 

 

A market analysis of executive officer compensation compared to our peer group, which market analysis was reviewed with the Compensation Committee and used to guide 20192020 base salary and bonus target decisions for our Named Executive Officers.

 

 

A market analysis of long-term incentive compensation of our executive officers compared to our peer group, which market analysis was reviewed with the Compensation Committee and used to guide 20192020 long-term equity compensation determinations.

The Compensation Committee assessed the independence of CompensiaRadford pursuant to SEC rules and concluded that the work performed by CompensiaRadford for the Compensation Committee did not raise any conflicts of interest.

Role of Executive Officers

Dr. Morrissey, our President and Chief Executive Officer, also participates in the Compensation Committee’s deliberations with respect to Named Executive Officer compensation other than his own; he is not present during deliberations and voting concerning his compensation. Each year, Dr. Morrissey and other senior management develop annual corporate goals and performance targets for long-term incentive awards for the company, which are reviewed and, subject to their input, approved by the Compensation Committee.

 

6046    Exelixis, Inc.


Compensation of Executive Officers | Compensation Discussion and Analysis

 

Compensation Committee Process

In setting the level of salary, annual cash bonus and long-term incentive compensation for our Named Executive Officers, the Compensation Committee typically considers various factors, including:

 

 

the performance of the company during the prior year;

 

 

the contribution of each Named Executive Officer toward achievement of our corporate goals, including contributions toward departmental achievements in each Named Executive Officer’s area of responsibility that drove the achievement of such corporate goals during the prior year;goals;

 

 

the criticality of each Named Executive Officer’s skill set and relative expected future contributions to our business;

 

 

the growing complexity of our business and expanding workforce resulting in increased workloads and responsibilities of our Named Executive Officers;

 

 

the appropriate mix of compensation for each Named Executive Officer;

 

 

the historical salary, cash bonus and percentage of vested versus unvested equity awards held by each Named Executive Officer; and

 

 

market data, which include competitive information relating to compensation levels for comparable positions in the biotechnology and life sciences sector and for our specific peer group.

The Compensation Committee balances each of these factors, as applicable in any given year, against our cash resources and the critical need to prioritize clinical development and pipeline expansion investments over other expenditures, as well as our aggregate equity burn rate. For 2020, due to the risk of the COVID-19 pandemic to our business and the extraordinary response of our Named Executive Officers to mitigate that risk, the Compensation Committee considered the importance of recognizing this effort to secure the retention of our Named Executive Officers, whose leadership is critical to our ability to maintain business continuity during these challenging times and achieve our future business objectives. Using this process, our Compensation Committee strives to ensure that our executive compensation program as a whole is competitive.

Stockholder Outreach

An integral part of the review process for our executive compensation program isare our stockholder outreach initiative, aimed at elicitinginitiatives, pursuant to which we elicit and obtain a better understanding of the concerns and perspectives of our stockholder base.stockholders.

 

 

Range of Governance and Business Topics Discussed with Stockholders During 20192020

    COVID-19 Response

    Human Capital Managment

    Equity, Diversity and Inclusion

    ESG Disclosures

 

    Executive Compensation

 

    ESG Disclosures

    Special Meeting Requests

    Business StrategyBoard Independence, Composition, Tenure and Execution

    Board Refreshment

 

    Risk Oversight

Each year, during the period following the filing of our Proxy Statement with the SEC and the date of our annual meeting, we engage with our stockholders to seek support for our annual meeting proposals and request feedback regarding governance matters. This outreach effort also provides us with the opportunity to gather our stockholders’ opinions concerning the executive compensation programmeasures that are in the best interest of our stockholders and other governance matters.to reaffirm our commitment to align pay and performance. Participants at these meetings typically include members of the management team and the Chair of our Compensation Committee, depending on availability. Stockholder feedback is then reported to the appropriate committee and/or the entire Board for consideration. During this period in 2019,the Fall each year, we reachedagain reach out to stockholders representing more than 44% of our outstanding shares at that time. Participants at these meetings included members of the management team and the Chair of our Compensation Committee, depending on availability. This outreach effort provided the opportunity to discuss executive compensation measures that are in the best interest of our stockholders and to convey our commitment to align pay and performance.

After our 2019 Annual Meeting, we again reached out to stockholders holding more than 51% of our outstanding shares at that time to solicit additional feedback on the designmatters critical to our stockholders’ evaluation of our executive compensationgovernance profile. Participants in the Fall 2020 stockholder outreach program discuss governance practices and obtain input on our ESG disclosure plans. Membersincluded members of the management team, as well as either the Chair of our Board and/or

2020 Proxy Statement    61


the Compensation Committee, participated in these meetings.Committee. These conversations provided us with the opportunity to discuss the extraordinary efforts taken by management to mitigate the impact of the COVID-19 pandemic on our business, as well as our equity, diversity and inclusion initiatives. It also yielded constructive feedback with respect to stockholder views on ESG disclosures, executive compensation programs and board independence, tenure and refreshment, all of which was summarized and reported to the Compensation Committee and the Board as a whole. Infor consideration in its ongoing evaluation of this feedback, the Compensation Committee designed a 100% performance-based long-term incentive compensation program, the Board provided our stockholders with the right to call a special meeting, subject to certain ownership requirements and procedures, and we published our ESG disclosures on our website atwww.exelixis.com under the caption “Impact—Environmental, Social and Governance.”governance profile.

2021 Proxy Statement    47


We intend to continue to engage with our stockholders throughout the year, and we invite you to reach out with any comments or questions at any time. Please see our website atwww.exelixis.com under the caption “Investors & Media—Contact IR” for the appropriate contact information.

Stockholder Advisory Vote on Executive Compensation

We provide our stockholders the opportunity to cast an annual advisory vote on our executive compensation program, and the Compensation Committee takes the results of this vote into account when determining compensation of the company’s Named Executive Officers. At our annual meeting of stockholders held in May 2019,2020, approximately 98%97% of the votes present and entitled to vote voted in favor of thesay-on-pay proposal. Our Compensation Committee considered these votes to be an endorsement of the Compensation Committee’s policies and practices.

Competitive Assessment

A key objective of our executive compensation program is to ensure that the overall compensation packages we offer our executive officers remain competitive with the packages offered by companies with which we compete for executive talent. The Compensation Committee consults with its independent compensation consultant, to develop a peer group of companies to serve as the basis for comparing our executive compensation program to the market.

Peer Group Development Process and How We Used the Data

The Compensation Committee reviews and makes adjustments to the composition of the peer group on an annual basis, or more often as deemed necessary, to account for changes in both our business and the businesses of the companies in the peer group. The Compensation Committee does not have a specific target compensation level for the Named Executive Officers. Instead, we review data concerning practices at our peer group companies and within the general biotechnology market as a reference point to assist in developing programs that will attract and retain exceptional talent and drive company performance.

In developing the 20192020 peer group, the Compensation Committee considered the significantcontinued evolution of our business and meaningful developments in comparison to the 20182019 peer group companies. It also considered what other companies might make suitable additions to the 20192020 list. The key qualitative and quantitative considerations that influenced the development of the 20192020 peer group were:

 

 

industry—including, biotechnology and pharmaceutical companies;

 

 

therapeutic area, including companies with an oncology product focus, while avoiding the inclusion of companies marketing solely orphan and rare disease drugs;

 

 

stage of business, as reflected by the existence of at least one marketed product;

 

 

locationthe size of headquarters and the organization to reflect organizational complexity;

whether the company is traded on a major U.S. exchange;

 

 

market capitalization between 0.25x—4.0x0.3x—3.0x of our then-current market capitalization (approximately $1.2$1.5 billion—approximately $20.0$15.0 billion); and

 

 

revenues between 0.3x—5.0x0.5x—2.5x of our then revenues (approximately $225$500 million—approximately $3.7$2.5 billion). Due to the limited number of companies identified by the scope criteria that had comparable revenues, the Compensation Committee continued to use a wide revenue range.

 

62    Exelixis, Inc.

48    Exelixis, Inc.


Compensation of Executive Officers | Compensation Discussion and Analysis

 

Following this analysis, the Compensation Committee, in consultation with management and Compensia,Radford, identified the following 2120 publicly-traded, U.S—based biotechnology/pharmaceutical companies as our peer group to be used in reviewing compensation for 2019:2020:

 

Fiscal 20192020 Peer Group

ACADIA Pharmaceuticals Inc.

Blueprint Medicines CorporationNektar Therapeutics

Agios Pharmaeuticals,Pharmaceuticals, Inc.

 HalozymeCorcept Therapeutics Inc.Incorporated Nektar TherapeuticsNeurocrine Biosciences, Inc.

Alkermes Public Limited Company

 Incyte CorporationHorizon Therapeutics Public Limited Company Neurocrine Biosciences, Inc.Novocure Ltd.

Alnylam Pharmaceuticals, Inc.

 Ionis Pharmaceuticals, Inc.Incyte Corporation OPKO Health,Sarepta Therapeutics, Inc.

Array BioPharma Inc.BeiGene, Ltd.

 IronwoodIonis Pharmaceuticals, Inc. Sarepta Therapeutics,Seagen, Inc.

BioMarin Pharmaceutical Inc.

 Ironwood Pharmaceuticals, Inc.United Therapeutics Corporation

bluebird bio, Inc.

Jazz Pharmaceuticals Public Limited Company Seattle Genetics, Inc.

Blueprint Medicines Corporation

Ligand Pharmaceuticals IncorporatedSupernus Pharmaceuticals, Inc.

Corcept Therapeutics Incorporated

Loxo Oncology, Inc.United Therapeutics Corporation

Positioning Relative to 20192020 Peers

(as of November 2018)2019)

LOGOLOGO

Percentile Rank

Of these 20 companies, 14 companies (Alkermes(Agios Pharmaceuticals, Inc. Alkermes Public Limited Company, Alnylam Pharmaceuticals, Inc. BioMarin Pharmaceutical Inc., Blueprint Medicines Corporation, Corcept Therapeutics Incorporated, Halozyme Therapeutics, Inc., Incyte Corporation, Ionis Pharmaceuticals, Inc., Ironwood Pharmaceuticals, Inc., Jazz Pharmaceuticals Public Limited Company, Ligand Pharmaceuticals Incorporated, Nektar Therapeutics, OPKO Health,Neurocrine Biosciences, Inc., Seattle Genetics,Sarepta Therapeutics, Inc., Supernus Pharmaceuticals,Seagen, Inc., and United Therapeutics Corporation) were in our 20182019 peer group. The Compensation Committee did not include in our 20192020 peer group fivesix companies (Bioverativ(Array BioPharma Inc., ClovisHalozyme Therapeutics, Inc., Ligand Pharmaceuticals Incorporated, Loxo Oncology, Inc., Juno Therapeutics, Inc., TESARO,OPKO Health, Inc. and The Medicines Company)Supernus Pharmaceuticals, Inc.) that were in our 20182019 peer group, because they were either acquired or had a market capitalization or revenues that fell below the selection criteria.

 

2020 Proxy Statement    63

2021 Proxy Statement    49


Compensation Elements

Our executive compensation program generally consists of three principal components: base salary; annual cash bonus; and long-term incentive compensation. A description and objective(s) for each element of compensation, which may vary from year to year, is set forth below:

 

Element

 

Description

 

Objective(s)

Annual Base Salary

 Fixed cash compensation to recognize each Named Executive Officer’s role and responsibilities. Provide an appropriate and competitive base level of current cash income for Named Executive Officers.

Annual Cash Bonus

 Variable cash compensation based on corporate performance, including achievement againstpre-determined corporate goals and the individual contributions of each Named Executive Officer toward the achievement of such corporate goals. 

Align our Named Executive Officers’ compensation with our annual corporate goals.

 

Rewards Named Executive Officers for overall achievement of ourpre-determined 2019 corporate goalsperformance and for executive officers other than our CEO, their individual contributions toward achievement of our corporate goals, including contributions toward departmental achievements in each Named Executive Officer’s area of responsibility that drove the achievement of such corporate goals.critical business objectives.

 

Long-Term Incentive Compensation

 

RSUs (or PSUs, if performance-based)performance-

based)

 Variable share-based compensation, subject to either performance-based vesting or time-based vesting based on the achievement of key corporate goals. 

Align the interests of our Named Executive Officers with those of our stockholders.

 

Motivate our Named Executive Officers to achieve long-term corporate performance objectives.

 

Promote retention, including during periods of stock price volatility common to biotechnology companies.

 

Stock Options

 

Variable share-based compensation whereby value is derived from appreciation in stock price.

 

Align the interests of our Named Executive Officers with those of our stockholders.

 

Motivate our Named Executive Officers to pursue our critical business objectives, because stock options only have value if the value of our company as reflected by our stock price increases over time.

As explained under “20192020 Compensation Decisions—20192020 Long-Term Incentive Awards in more detail below, for 2019,2020, the Compensation Committee determined that an entirely performance-based equity program consisting solely of PSUs would be the most appropriate incentive structure for our Named Executive Officers in 20192020 to reward performance over time and achieve our retention objective; accordingly, no stock options or time-based RSUs were granted to our Named Executive Officers under our long-term incentive compensation program for 2020. As explained under “—2020 Compensation Decisions—2020 Long-Term Incentive Awardsin 2019.more detail below, in February 2020, Mr. Haley received a time-based RSU award in connection with his promotion to Executive Vice President, Commercial.

50    Exelixis, Inc.


Compensation of Executive Officers | Compensation Discussion and Analysis

Other Compensation and Benefits

In addition to the primary elements of compensation described above, all of our employees, including our Named Executive Officers are also eligible to participate, on the same basis as other employees, in our 401(k) Plan, our employee stock purchase plan (ESPP) and other benefit programs generally available to all employees. These programs are intended to providetax-beneficial ways to save toward retirement, promote health and wellness and encourage stock ownership. Our Named Executive Officers are also eligible to participate in our Change in Control and Severance Benefit Plan, a compensation program that incentivizes our Named Executive Officers to remain with our company, and objectively evaluate

64    Exelixis, Inc.


Compensation of Executive Officers | Compensation Discussion and Analysis

and facilitate an acquisition of our company should consideration of such a transaction be determined appropriate by the Board and in the best interests of our stockholders. The Compensation Committee believes that considered together, these benefits are critical for retaining and motivating these leaders and are consistent with compensation arrangements provided in the competitive market for executive talent.

 

Element

  

Description

401(k) Plan

  Named Executive Officers contribute their own funds, as salary deductions, on apre-tax orafter-tax basis, subject to plan and government limits. For 2019,2020, we matchedpre-tax and Roth 401(k) contributionsdollar-for-dollar up to $8,500, in the form of Exelixis common stock.$10,000. As of January 2020,2021, we increased the annual match to $10,000$11,000 per calendar year and have transitioned to making the match in cash rather than Exelixis common stock going forward.year.

Employee Stock Purchase Plan

  Our ESPP allows for Named Executive Officers to purchase shares of our common stock at a price equal to the lower of 85% of the closing price on the first day of thesix-month offering period or 85% of the closing price on the final day of such offering period, subject to specified limits.

Health Care, Dental and Vision Benefits

  Subject to applicable laws, these health and welfare benefits are available to all eligible employees, including our Named Executive Officers.

Change in Control and Severance Benefit
Plan (1)

  

A double-trigger plan, in which each participant receives plan benefits only if the participant is terminated without cause or is constructively terminated in connection with a change in control. We adopted a double-trigger plan because it protects the participants from post-change in control events that are not related to the participants’ performance, encourages them to stay throughout a transition period in the event of a change in control, and does not provide for benefits for a participant who remains with the surviving company in a comparable position.

 

To ensure our best interests, the plan requires a release of claims against us as a condition to receiving any severance benefits.

 

(1)

A description of the Change in Control and Severance Benefit Plan is set forth below under the heading “Potential Payments Upon Termination or Change in Control.

 

2020 Proxy Statement    65

2021 Proxy Statement    51


Compensation Mix

The Compensation Committee has not established formal policies or guidelines for allocating compensation between annual and long-term incentive compensation, or between cash andnon-cash compensation. Instead, through our compensation program, the Compensation Committee seeks to align pay and performance. To that end, a significant portion of our Named Executive Officers’ compensation is “at risk” because it is variable, performance-based and in large part dependent on the success of our company.At-risk compensation for 20192020 included PSUs, RSUs and annual incentive cash bonuses, which annual incentive cash bonuses relate to the Compensation Committee’s assessment of theour overall corporate performance, including achievement ofagainst ourpre-determined 2019 2020 corporate goals under difficult conditions, and, other than for Dr. Morrissey, the Compensation Committee’s consideration of the individual contributions of each Named Executive Officer toward the achievement of our corporate goals, including contributions toward departmental achievements in each Named Executive Officer’s area of responsibility that drove the achievement of such corporate goals. The following charts highlight the 20192020 pay mix for our Chief Executive Officer and all of our other Named Executive Officers as a group.

 

Chief Executive Officer

Pay Mix

91%90% of CEO 20192020 Compensation is Considered Variable and At-Risk

  

All Other Named Executive Officers (as a group)

Pay Mix

82%84% of All Other Named Executive Officers (as a group) 20192020
Compensation is Considered Variable and At-Risk

LOGOLOGO  LOGOLOGO

20192020 Compensation Decisions

20192020 Base Salaries

In considering the appropriate level of base salaries for our Named Executive Officers for 2019,2020, the Compensation Committee did not apply a formula, but rather employed a holistic analysis of multiple relevant factors using its professional judgment and experience, emphasizing the following:

 

 

the individual contribution of the Named Executive Officer to our exceptional 20182019 research, development, regulatory, pipeline expansion and financial achievements, as explained in more detail below;

 

 

the criticality of each Named Executive Officer’s skill set and relative expected future contributions to our business;

 

 

the growing complexity of our business resulting in increased workloads and responsibilities of each of our Named Executive Officers;

 

 

other competing business priorities forthe competitive position of each Named Executive Officer’s base salary relative to similarly situated executives at our company that require substantial investment;2020 peer group companies; and

 

 

the particularly challengingfiercely competitive hiring market for life sciencesciences companies in the San Francisco Bay Area.

 

66    Exelixis, Inc.

52    Exelixis, Inc.


Compensation of Executive Officers | Compensation Discussion and Analysis

 

The Compensation Committee considered the base salaries of similarly situated executives at our 2019 peer group companies for an understanding of whether our compensation program is competitively positioned to retain our highly qualified Named Executive Officers. Following such analysis, in February 2019,2020, the Compensation Committee determined that each Named Executive Officer should receive an increase in his or her base salary for 20192020 as follows:

 

Name

    2018 Base
Salary
     2019 Base
Salary
   Percentage
Increase
     2019 Base
Salary
     2020 Base
Salary
   Percentage
Increase
 

Michael M. Morrissey, Ph.D. (1)

    $955,060     $1,017,140    6.5    $1,017,140     $1,067,997    5.0

Gisela M. Schwab, M.D. (2)

    $680,520     $717,949    5.5    $717,949     $750,257    4.5

Christopher J. Senner (3)

    $601,020     $628,067    4.5    $628,067     $653,189    4.0

Jeffrey J. Hessekiel, J.D. (4)

    $536,597     $558,061    4.0    $558,061     $580,384    4.0

Peter Lamb, Ph.D. (5)

    $497,525     $552,401    5.0

Patrick J. Haley (5)

    $462,956     $510,000    10.2

 

(1)

Dr. Morrissey’s base salary increase reflects the strength of our overall corporate performance during 2018,2019, including the progress of our discovery programs, our clinical and regulatory achievements and the commercial success of CABOMETYX. Dr. Morrissey’s leadership was also viewed as critical to achieving our goalkey priorities for 2020, including maximizing clinical development opportunities for CABOMETYX and advancing a pipeline of becoming a fully integrated biotechnology company.potential new medicines.

 

(2)

Dr. Schwab’s base salary increase reflects her strong leadership of our product development and medical affairs organizations and her performance with respect to the achievement of our product development goals in 2018,2019, particularly with respect to the FDA’s approval of CABOMETYX as a treatment for patients with HCC, who have been previously treated with sorafenib, the initiation and management of multiple potentially label-enabling clinical trials of cabozantinib in combination with immunotherapy agents and support of cabozantinib worldwide regulatory filings by collaboration partners. Dr. Schwab’s leadership was also viewed as critical to our ability to execute on our 20192020 product development goals, including with respect to regulatory filings, late-stage clinical trial initiation, the continued broad evaluation of cabozantinib and XL092 and anticipated organizational growth.

 

(3)

Mr. Senner’s base salary increase reflects his leadership of our finance organization and his performance with respect to the achievement of our financial goals in 2018,2019, particularly with respect to the management of operating expenses and long-range planning.positioning the business to support future growth. Mr. Senner’s leadership was also viewed as critical to our ability to execute on our 20192020 business development, technology infrastructure and fiscal management objectives.

 

(4)

Mr. Hessekiel’s base salary increase reflects his leadership of our legal, compliance and compliancegovernment affairs organizations and his performance with respect to the achievement of our business and legal goals in 2018,2019, particularly with respect to his appropriate management of business risks through a well-established compliance program.and the establishment of Exelixis’ brand recognition within the U.S. government to support our business and the interests of patients. Mr. Hessekiel’s leadership was also viewed as critical to the management of our Abbreviated New Drug Application (ANDA) litigation against MSN Pharmaceuticals, Inc. (MSN) and our ability to ensure the continued strength of our compliance program during a period of anticipatedrapid growth.

 

(5)

Dr. Lamb’sMr. Haley’s base salary increase is primarily related to his promotion to Executive Vice President, Commercial and reflects his leadership of our research and discoverycommercial organization, andincluding his performance with respect to the achievementgeneration of our pipeline development goals, particularly with respect torecord cabozantinib net product revenues in 2019 and the progress on the license and collaboration agreement with Invenra, Inc. (Invenra) and our internal discovery efforts resulting in the FDA’s acceptancesuccessful commercial launch of our IND applicationCABOMETYX for XL092. Dr. Lamb’sHCC . Mr. Haley’s leadership was also viewed as critical to our efforts to expand our product pipeline beyond cabozantinib.commercially execute on any future potential indications for cabozantinib, if approved by the FDA.

20192020 Annual Cash Bonuses

Rigorous Process for Determining Annual Cash Bonus

Our Annual Cash Bonus Plan is an annual incentive program designed to provide our senior management team, including our Named Executive Officers, with incentives and rewards for working to achieve the strongest possible performance againstpre-determinedcorporate goals,performance, while also enhancing our ability to attract and retain highly talented individuals. Under our Annual Cash Bonus Plan, Named Executive Officers are eligible to receive an annual performance-based cash bonus award, the amount of which is based on apre-set target percentage of the Named Executive Officer’s annual base salary earned during the year. The Compensation Committee is responsible for establishing the bonus target percentages, as well as the relative percentage contributions of corporate performance and individual performance. For each Named Executive Officer, the amount of the cash bonus award for each fiscal year depends upon our overall corporate performance, including the achievement of applicable corporate goals established by the Compensation Committee for that year, and, as applicable, the Compensation Committee’s consideration of the individual contributions of each Named Executive Officer toward the achievement of our corporate goals andgoals. Under appropriate circumstances, the departmental achievements in each Named Executive Officer’s area of responsibility that drove the achievement of suchCompensation Committee may use discretion to acknowledge progress toward

 

2020 Proxy Statement    67

2021 Proxy Statement    53


corporate goals.

achievement of a goal when factors outside of our control rendered a performance target impossible or impractical to achieve. The corporate goals under the Annual Cash Bonus Plan may be based on criteria such as the following: sales or commercial goals; research, development and clinical activities; financial metrics, including revenues, cash flow and net income, cash balance, operating expenses and stock price performance;metrics; hiring, retention development of plans and other operational goals; commercial, clinical and strategic collaborations and alliance management; acquisitions and licensing or partnering transactions; manufacturing and supply goals; quality goals; regulatory goals; compliance and government affairs and public policy goals. Individual performance may be assessed by the Compensation Committee based on the Named Executive Officer’s contributions toward the achievement of our corporate goals and departmental goals, recommended by the Chief Executive Officer and approved by the Compensation Committee, for the Named Executive Officer’s area of responsibility. Taking these factors into account, the Compensation Committee assigns an individual performance percentage for each Named Executive Officer, other than Dr. Morrissey. For any year, the achieved corporate performance percentage and/or individual performance percentage may exceed 100% in the event the targeted level of achievement of the applicable goals is exceeded,, provided that neither percentage may exceed 200%.

20192020 Bonus Targets

Bonus targets (expressed as a percentage of base salary) are based on the seniority of the applicable position. They are reviewed annually by the Compensation Committee, taking into consideration competitive market data and the criticality of the role for the organization, and adjusted if deemed appropriate by the Compensation Committee. InFollowing such review, in February 2019,2020, the Compensation Committee determined 2019 target annual cash bonuses should remain at the same levels as 2018bonus targets for alleach Named Executive Officers,Officer for 2020 as reflected in the table below. The Compensation Committee’s decision regarding 2019 target bonuses was based on its assessment that the percentages of base salaries previously established were appropriate and continued to align us competitively with our 2019 peer group.follows:

 

Named Executive Officer

  20192020 Bonus
Target
 

Michael M. Morrissey, Ph.D. (1)

   100

Gisela M. Schwab, M.D. (2)

60

Christopher J. Senner (3)

   50

ChristopherJeffrey J. SennerHessekiel, J.D. (3)

   4550

JeffreyPatrick J. Hessekiel, J.D.Haley (3)

   45

Peter Lamb, Ph.D.

4550

(1)

In February 2020, following a review of a market analysis prepared by Radford, the Compensation Committee determined that Dr. Morrissey’s 2020 bonus target should remain at the same level as 2019. The Compensation Committee’s decision regarding Dr. Morrissey’s 2020 bonus target was based on its assessment that the previously established target was both appropriate and reflective of the critical importance of his leadership toward driving the company’s achievement of its 2020 business and financial objectives, and also continued to align competitively with our 2020 peer group.

(2)

A review of the market analysis for Dr. Schwab indicated that her existing bonus target was aligned at the 50th percentile of market peers. However, in addition to reviewing market data, the Compensation Committee also considered (i) the ambitious goals for both the cabozantinib clinical development program and the advancement of our early-stage product pipeline during 2020 and (ii) the criticality of Dr. Schwab’s ability to influence our achievement of those objectives while serving in her leadership role as President of the Product Development and Medical Affairs organization. With such consideration, the Compensation Committee approved an increase to Dr. Schwab’s 2020 bonus target to 60% from 50% in 2019.

(3)

A review of the market analysis for Messrs. Senner, Hessekiel and Haley indicated that each of their existing bonus targets were aligned at or below the 25th percentile of market peers. In order to better align their bonus targets with those of peer executives at the companies in our 2020 peer group and in recognition of their ability to influence future company performance and achievement of our 2020 business and financial objectives, the Compensation Committee approved an increase to each of Messrs. Senner, Hessekiel and Haley’s 2020 bonus target to 50% from 45% in 2019.

20192020 Corporate Goal Development and Weighting

In connection with establishing the bonus program for 2019,2020, the Compensation Committee reviewed management’s proposed commercial,discovery, business development, product development, pipeline development,commercial, and finance, legal and business operations goals and recommended them to the Board for approval. In February 2019,2020, prior to the onset of the COVID-19 pandemic, the Board then reviewed and approved the proposed companycorporate goals for 2019,2020, as identified in the table below. In selecting these goals, the Compensation Committee and the Board believed that they were appropriate drivers for our business, as they provided a balance between the efforts necessary to continue the successful commercialization of CABOMETXCABOMETYX in its approved RCC and HCC

54    Exelixis, Inc.


Compensation of Executive Officers | Compensation Discussion and Analysis

indications, further our cabozantinib development program and expandadvance our early-stage product pipeline, all while maintaining a strong financial position, which together would enhance stockholder value. At the time the 20192020 corporate goals were set, the Compensation Committee and management believed that such goals were challenging and achieving them would require not only continued strong commercial performance, research and product development success, and prudent fiscal and legal management, but also a high level of effort and execution on the part of our Named Executive Officers.

68    Exelixis, Inc.


Compensation of Executive Officers | Compensation Discussion and Analysis

The Compensation Committee also applied a performance weighting to each goal relative to the overall performance of the company to reflect the prioritization of key business objectives. Target and maximum achievement levels were defined for certain goals and, depending on the level of achievement, Named Executive Officers were eligible to receive a payout ranging from 0% to 150% for such goal. Additionally, a weighting between corporate performance and individual performance was also applied for each Named Executive Officer to reflect the level of impact such individual would be able to make on the overall corporate performance. The relative weighting for each corporate goal and corporate versus individual performance is as follows:

 

Corporate Goals

  

Weighting

(%)

     

Named Executive Officer

  

Weighting of

Corporate

Goals

   

Weighting of

Individual

Performance

Assessment

   

Weighting

(%)

      

Named Executive Officer

  

Weighting of

Corporate

Goals

   

Weighting of

Individual

Performance

Assessment

 

Discovery

   20   

Michael M. Morrissey, Ph.D.

   100   0

Business/Corporate Development

   10   

Gisela M. Schwab, M.D.

   70   30

Product Development

   40   

Christopher J. Senner

   70   30

Commercial

   40 

 

 

Michael M. Morrissey, Ph.D.

   100   0   20   

Jeffrey J. Hessekiel, J.D.

   70   30

Product Development

   30 

 

 

Gisela M. Schwab, M.D.

   60   40

Pipeline Development

   20 

 

 

Christopher J. Senner

   60   40

Finance, Legal and Facilities

   10 

 

 

Jeffrey J. Hessekiel, J.D.

   50   50

Finance, Legal and Business Operations

   10   

Patrick J. Haley

   70   30

Total

   100        

Peter Lamb, Ph.D.

   60   40   100          

20192020 Performance Evaluation

During 2019,2020, management reported regularly to the Compensation Committee and the Board on the status of the company’s performance against theseour 2020 goals, including in formal meetings in February, May, September and December. Included in these reports were details regarding the impact of the COVID-19 pandemic on our progress toward achievement of the 2020 goals and the focus of our Named Executive Officers to mitigate the pandemic’s impacts. Notwithstanding the extent of these challenges and disruptions, the Compensation Committee did not adjust the performance targets because, regardless of the pandemic, these targets remained critical business objectives for the company.

2021 Proxy Statement    55


In February 2020,2021, the Compensation Committee evaluated the company’s performance in relation to the 20192020 goals, as well as other than for Dr. Morrissey,the individual contributions of each Named Executive Officer’s individual contribution toOfficer (other than Dr. Morrissey) toward the achievement of those goals. After consideration of such performance,In conducting its evaluation, the Compensation Committee concludedprioritized its ongoing commitment to maintain a pay program that 2019 was a year of meaningful accomplishments during whichboth motivates and retains our high-quality management team and pays for performance that generates long-term stockholder value. To these ends, the company largely achieved eachCompensation Committee took into consideration the unprecedented nature of the goals, as further described inCOVID-19 pandemic, and despite its heavy operational burden on our business, our ability to make progress toward and achieve critical business objectives that will drive the table below.growth of our commercial business and the expansion and depth of our product offerings. Examples of operational burdens imposed by the COVID-19 pandemic and the extraordinary efforts taken by our organization, led by our Named Executive Officers, to mitigate the impact on our business include:

 

   

PERFORMANCE OBJECTIVES

 

 

ACHIEVEMENTS

 

 

TARGET %

 

 

PAYOUT %   

 

    Commercial

    
  

 

Exceed cabozantinib franchise net product revenue target established by the Board

 

 

 

   Generated cabozantinib franchise net product revenues of $760 million during 2019.

 

40%

 

40%  

 

 

Implement a comprehensive and rigorous launch strategy for CABOMETYX for second-line+ HCC indication while continuing growth in RCC

 

 

 

   Successfully launched CABOMETYX in approved HCC indication while growing demand in an increasingly competitive RCC market.

 

 

 

Provide commercial evaluation and assessments of new assets from strategic and business development activity and for cabozantinib lifecycle management

 

 

 

   Completed initial lifecycle indication prioritization onCOSMIC-021 indications.

 

   Conducted strategic evaluation of mCRPC, NSCLC, and other markets for cabozantinib and other potential business development assets.

 

LOGO

The Compensation Committee particularly focused on the following progress made toward the execution of our 2020 corporate goals:

 

2020 Proxy Statement    69


   

PERFORMANCE OBJECTIVES

 

 

ACHIEVEMENTS

 

 

TARGET %

 

 

PAYOUT %   

 

    Product Development and Medical Affairs

    
 

 

Achieve approval of supplemental New Drug Application for CABOMETYX as a treatment for patients with previously treated HCC in January 2019 and support the launch for the new indication with market access support, educational efforts and customer service

 

 

 

   FDA approved CABOMETYX as a treatment for patients with HCC who have previously been treated with sorafenib on January 14, 2019.

 

   Met all Medical Affairs operational performance metrics, including those regarding field interactions with key opinion leaders and continuing medical education events.

 

30%

 

40%  

 

 

Initiate at least 2 new cabozantinib phase 3 studies

 

 

 

   InitiatedCOSMIC-313 in June 2019.

 

   Supported the initiation of PDIGREE, in May 2019 through our Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute’s Cancer Therapy Evaluation Program(NCI-CTEP).

 

 

 

AdvanceCOSMIC-311 andCOSMIC-312 by initiating at least 75% of planned countries as sites

 

 

 

   Activated 88% of planned countries and 83% of identified sites forCOSMIC-311.

 

   Activated 88% of planned countries and 77% of identified sites forCOSMIC-312.

 

 

 

Continue to explore cabozantinib alone or in combination with other therapies through a broad lifecycle management program; support the start of at least twelve new investigator-sponsored trials orNCI-CTEP studies and the continued progress of CABINET and randomized phase 2 trials evaluating cabozantinib in RCC, NSCLC and endometrial cancer

 

 

 

   Established a cross company filing team and initiated planning workstreams with Bristol-Myers Squibb Company pending results for CheckMate 9ER.

 

   Yielded encouraging initial data from the mCRPC and NSCLC cohorts ofCOSMIC-021 and amended the trial protocol to expand the patient enrollment in such cohorts and add new mCRPC cohorts.

 

   Entered into an agreement with Roche to further evaluate the combination of cabozantinib and atezolizumab in patients with locally advanced or metastatic solid tumors, including in three planned phase 3 pivotal trials in advanced NSCLC, mCRPC and RCC.

 

   Facilitated the initiation of 13 investigator sponsored trials in the U.S., as well as the continued progress of CTEP-sponsored randomized trials in RCC, NSCLC, neuroendocrine tumors and endometrial cancer.

 

 

 

Add additional FTEs to support Development and Medical Affairs plans and ensure continuous process improvements to enable expeditious and compliant trial execution

 

 

 

 

   Hired all planned FTEs per the 2019 budget.

  

 

Support cabozantinib worldwide regulatory filings by collaboration partners

 

 

 

   Supported Ipsen’s receipt of worldwide CABOMETYX regulatory approvals by providing filing documents and assistance in responding to regulatory inquiries.

 

   Assisted Takeda with its April 2019 and January 2020 regulatory applications to the Japanese MHLW for Manufacturing and Marketing Approval of CABOMETYX as a treatment for patients with RCC and HCC respectively.

 

Discovery: Entering 2020, our Discovery team was highly focused on expanding our product pipeline beyond cabozantinib by moving product candidates through lead optimization to development candidate status and ultimately to IND filing. However, when Alameda County’s COVID-19 shelter-in-place orders restricted access to the new state-of-the art laboratory facilities, our Discovery team was forced to overhaul its plans. The team focused its efforts on a limited number of product candidates that it believed offered the greatest potential for success in the clinic. By combining this prioritization strategy with efficient oversight of global third-party contractors conducting preclinical development work and close coordination with research collaboration partners to maximize productivity under the circumstances, our Discovery team was still able to achieve or make substantial progress toward each of its 2020 business objectives.

 

70    Exelixis,

Business Development: Our Business Development team did not waver from its focus on the identification and execution of transactions that facilitate the expansion of our product pipeline despite unique market conditions created in part by the COVID-19 pandemic. As the pandemic progressed, the market dynamics enabled biotechnology companies in possession of early-stage clinical assets to gain unprecedented access to the capital markets, leading to tremendous inflation in the values of clinical-stage companies and in-licensing targets previously identified by our Business Development team. In response, the team shifted its focus to early-stage pre-clinical assets and coordinated with our Discovery and Finance teams to complete multiple in-licensing transactions to access critical ADC technology platforms from NBE and Catalent in 2020, and related technologies from Adagene, Inc. (Adagene) and WuXi Biologic (WuXi) in early 2021, enabling us to build capacity and depth in this critical area of drug discovery more rapidly than

56    Exelixis, Inc.


Compensation of Executive Officers | Compensation Discussion and Analysis

 

   

PERFORMANCE OBJECTIVES

 

 

ACHIEVEMENTS

 

 

TARGET %

 

 

PAYOUT %   

 

    Pipeline Development

    
 

 

Determine the recommended phase 2 dose for XL092 and initiate single agent cohort expansions

 

 

 

   Enrolled dose escalation cohorts in the phase 1 trial evaluating XL092 and amended the trial protocol to introduce tablets.

 

 20% 15%  
 

 

Advance two small molecules (internal or partnered) to development candidate (DC) status and initiate good laboratory practice (GLP) toxicology studies for one DC

 

 

 

   Identified XL265 as a DC for the TAM kinase program with a GLP toxicology study to be initiated in the first half of 2020.

 

   Progress made toward identification of a second DC, anticipated to be selected in the first half of 2020 pending additional profiling.

 

 

 

Advance one biotherapeutic program to cell line development stage

 

 

 

   Lead program progressing under collaboration with Invenra delayed.

 

 

 

Complete two early-stage oncologyin-licensing deals

 

 

 

   Executed an exclusive option and license agreement with Iconic to advance an innovative next-generation ADC program for cancer and an exclusive collaboration, option and license agreement with Aurigene toin-license programs to discover and develop small molecules as therapies for cancer.

 

  

 

Complete buildout of internal discovery team per 2019 budget and reinitiate high throughput screening

 

 

 

   Hired all planned FTEs per the 2019 budget.

 

   Completed three high throughput screens.

    Finance, Legal and Facilities

      
 

 

Manage cash balance and operating expenses within budget established by the Board

 

 

 

   Managed operating expenses to $598.3 million and ended fiscal 2019 with a cash and investments balance of $1.4 billion.

 

 10% 15%  
 

 

Integrate and implement compliance into all aspects of organizational activities

 

 

 

   Completed all planned monitoring activities. Compliance programs operated effectively across the enterprise, with appropriate ongoing oversight.

 

 

 

Build Exelixis brand recognition within U.S. Government to support our business and the interests of patients

 

 

 

   Engaged with Congress and the Administration on legislative, regulatory and policy matters, including a novel policy initiative related to drug pricing.

 

 

 

Develop and implement business continuity management and facilities growth plans that support long range planning

 

 

 

   Increased campus footprint by approximately 94,000 square feet to serve as additional laboratory and office space.

 

   Entered into abuild-to-suit lease for approximately 220,000 square feet on the property adjacent to our existing corporate headquarters.

 

     
      100% 110%   
previously anticipated. Notwithstanding this shift, our Business Development team continued to pursue clinical-stage assets for our product pipeline and progressed numerous clinical-stage business development opportunities to term sheet status, thereby maximizing the potential for execution on this business objective in 2021.

Commercial: With healthcare professionals acutely focused on modifying their medical practices to adjust for the COVID-19 pandemic, our Commercial team proved itself highly capable of adapting to changing market conditions in order to remain engaged with healthcare professionals and continue to promote CABOMETYX in its approved RCC and HCC indications. The sales force transitioned from in-person to primarily telephonic and virtual interactions and remained productive throughout the course of the year, ultimately delivering revenues within the range of financial guidance we provided in early January 2020 before disruptions due to the pandemic began and building CABOMETYX into the market leading second-line agent for RCC. Beyond sales and marketing activities, our Commercial team’s research analytics and market evaluation activities also contributed significantly to our corporate development and planning activities, and the strategic direction of our XL092 development plan.

Product Development: Our 2020 product development goals were already bold and substantial before the COVID-19 pandemic; however, when the pandemic hit, it markedly increased the challenges faced by our Product Development team. Our clinical trials are conducted across the globe, and in virtually every region, our Product Development team experienced and largely overcame challenges to patient screening and enrollment activity, delays in new treatment site activations, and heavy restrictions on the access to treatment sites required by study protocols to monitor clinical trial progress and administration. Despite these disruptions to the core development activities that drive future regulatory and commercial success, and the effort required to mitigate their impact on the business, our Product Development team substantially progressed our broad cabozantinib development program through the achievement and presentation of clinical trial results from multiple clinical trials evaluating cabozantinib, both alone and in combination with ICIs. Included among those trials were positive top-line results from two label-enabling studies, CheckMate -9ER and COSMIC-311, which helped position us to execute on our long-term cabozantinib franchise net product revenue goals. In addition to the achievement and management of clinical trial results, our Product Development team successfully navigated the challenges of the COVID-19 pandemic to progress or complete enrollment for multiple other potentially label-enabling studies, including COSMIC-021, COSMIC-312 and COSMIC-313, and initiated three new phase 3 pivotal trials in collaboration with Genentech. On the regulatory front, the achievements continued with the filing of our sNDA for CABOMETYX in combination with OPDIVO as a first-line treatment for patients with advanced RCC, which was reviewed under the FDA’s Real-Time Oncology Review pilot program and received Fast Track designation. In addition, in order to contribute to speedy and ultimately successful regulatory filings outside of the U.S., our Product Development team also extensively supported our partners Ipsen and Takeda as they navigated regulatory approval pathways for CABOMETYX in their respective territories.

Business Operations: Our successful business execution in 2020 would not have been possible without the talent and hard work of the employees that were sourced and integrated by a Human Resources team focused on our critical mission to expand the organization with talented new employees. While relying on an entirely remote interview and integration process, in just one year we grew our employee base by 25% and maintained a turnover rate that was consistently below average for the U.S. life sciences industry generally, as well as for life sciences companies located in Northern California, despite the fierce competition for biotechnology employees and many people choosing to move out of the San Francisco Bay Area following the onset of the COVID-19 pandemic. Throughout the year, our Business Operations team remained highly focused on plans to safely return our growing employee population to the office following the ongoing pandemic. While the state and county mandated shelter-in-place order in the first quarter of 2020 resulted in the delay of construction activity for all of our buildings, the delays proved to be inconsequential for the business due to our remote work policy implemented in March 2020 to protect the health and safety of our employees. Nonetheless, our Business Operations team continued to work closely with our landlords and contractors throughout the year and by year-end achieved all construction related objectives included in our 2020 corporate goals.

Following its evaluation, the Compensation Committee concluded that 2020 was a year of meaningful accomplishments. In appropriate circumstances, the Compensation Committee exercised its discretion to acknowledge progress made toward achievement of certain performance targets that, due to the COVID-19 pandemic and related market conditions, were rendered impossible or impractical to fully achieve during 2020. As a reflection of these considerations, the Compensation Committee set the bonus payout for the corporate performance metric at 120% of the target incentive amount, which exceeded the achievement reflected in the table below by 12%.

2021 Proxy Statement    57


   PERFORMANCE OBJECTIVES ACHIEVEMENTS TARGET % ACHIEVEMENT %
    Discovery    
 

Target (100%): Submit IND applications to FDA for two of three lead product candidates

 

Maximum (150%): Submit and receive notification of acceptance of IND for three lead product candidates

 

›   Submitted IND for XL102.

 

   Submitted IND for XB002 (March 2021).

 10% 7.5%
 

Target (100%): Advance one internally developed and one partnered program to Development Candidate status (DC)

 

Maximum (150%): Advance two internally developed and two partnered programs to DC status

 

   Declared XL265, XL114 and one additional internal compound DCs.

 7% 9%
  

Target (100%): Advance four early stage partnered programs with Aurigene to lead optimization decision

 

Maximum (150%): Advance one additional partnered program to DC status

 

   Advanced three programs into lead optimization decision and progressed one additional program toward lead optimization decision.

 3% 2%
    Business/Corporate Development    
  

Target (100%): Acquire or in-license one clinical -stage asset

 

Maximum (150%): Acquire or in-license two clinical -stage assets or one clinical -stage asset with near-term market entry and a target threshold for peak sales

 

   Executed a collaboration and license agreement with NBE and Catalent to discover and develop ADCs.

 

   Executed transactions with Adagene and WuXi (January and March 2021, respectively).

 

   Progressed numerous clinical-stage business development projects to term sheet status.

 

 10% 0%
    Product Development and Medical Affairs    
 

Target (100%): Achieve and manage disclosure of results for five key clinical trials evaluating cabozantinib

 

Maximum (150%): Achieve and manage disclosure of results for three additional key clinical trials evaluating cabozantinib where results are event-based

 

   Top-line results from CheckMate -9ER and COSMIC-311.

 

   Presented data from COSMIC-021 cohorts (CRPC, Bladder, NSCLC, clear cell RCC and non-clear cell RCC) and CheckMate 040 at various medical conferences.

 

   Top-line results from CANTATA.

 

   Top-line results from EXAMINER (February 2021).

 

 16% 23.5%
 

Target (100%): Complete trial enrollment of COSMIC-312 and currently existing cohorts of COSMIC-021

 

Maximum (150%): Complete trial enrollment of COSMIC-311 by year end and COSMIC-312 by the second quarter of 2020

 

 

   Completed enrollment of COSMIC-312 based on original protocol in June 2020.

 

   Near complete enrollment of COSMIC-021.

 

   Stopped enrollment of COSMIC-311 (due to positive efficacy).

 6% 8.5%
 

Target (100%): Initiate three CONTACT pivotal trials

 

Maximum (150%): Initiate three CONTACT pivotal trials during the first half of 2020

 

 

   Initiated CONTACT-01 and CONTACT-02 in June 2020.

 

   Initiated CONTACT-03 (July 2020).

 5% 7%
  

Target (100%): Advance enrollment of COSMIC-313 by initiating 95% of planned countries and sites and initiate combination cohorts of phase 1 XL092 clinical trial

 

Maximum (150%): Enroll 629 patients in COSMIC-313

 

 

   Enrolled 745 patients in COSMIC-313, following activation of 100% of planned countries and 97% of sites.

 

   Initiated XL092 combination cohorts with atezolizumab.

 6% 9%

58    Exelixis, Inc.


Compensation of Executive Officers | Compensation Discussion and Analysis

   PERFORMANCE OBJECTIVES ACHIEVEMENTS TARGET % ACHIEVEMENT %
 

Target (100%): File sNDA for CABOMETYX as a first-line treatment for patients with advanced RCC by the end of the third quarter of 2020

 

Maximum (150%): File sNDA for CABOMETYX as a first-line treatment for patients with advanced RCC by August 2020

 

   Filed sNDA for CABOMETYX for first-line advanced RCC in August 2020.

 5% 7.5%
 Target (100%): Support cabozantinib worldwide regulatory filings by collaboration partners 

   Supported Ipsen’s worldwide CABOMETYX regulatory approvals, including its application to the EMA for the combination of CABOMETYX and OPDIVO in RCC.

 

   Assisted Takeda with its applications to the Japanese MHLW for approvals of CABOMETYX in HCC and RCC (in combination with OPDIVO).

 1% 1%
  Target (100%): Ensure continuous process improvements to enable expeditious and compliant trial execution 

   Completed extensive process and technology improvements and upgrades for key clinical trial systems.

 

   Grew and restructured the Product Development organization commensurate with the expanding number and scope of development programs.

 

   Identified and integrated key informatic/analytics leader into the Product Development organization.

 

1%

 1%
    Commercial    
 

Target (100%): Meet cabozantinib franchise net product revenue target established by the Board

Maximum (150%): Exceed 105% of cabozantinib franchise net product revenue target established by the Board

 

   Generated cabozantinib franchise net product revenues of $741.6 million.

 15% 15%
 

Target (100%): Achieve launch readiness by October 2020 for CABOMETYX in first-line RCC

Maximum (150%): Execute organizational planning and launch readiness for all potential future indications in 2021 and beyond

 

   Commercial organization achieved launch readiness in August 2020.

 

   Completed broad commercial reorganization to facilitate potential launches in RCC, HCC, mCRPC and DTC.

 4% 6%
  Target (100%): Provide commercial evaluation and assessment of new assets from strategic and busines development activity and for cabozantinib lifecycle management 

   Conducted strategic evaluations of potential assets identified for acquisition or in-licensing.

 

   Supported XL092 strategic planning to enable a robust and broad development plan.

 1% 1%
    Finance, Legal and Business Operations    
 

Target (100%): Successfully manage the initial stage of the ANDA litigation against MSN

 

Maximum (150%): Early settlement of ANDA litigation against MSN

 

   Vigorously prosecuted our ANDA infringement litigation against MSN.

 2% 2%
 Target (100%): Manage cash balance and operating expenses within budget established by the Board 

   Managed operating expenses to $877.5 million and ended fiscal 2020 with a cash and investments balance of $1.54 billion.

 2% 2%
 Target (100%): Complete upgrade of SAP to S/4 HANA platform 

   Completed upgrade of SAP to S/4 HANA platform.

 1% 1%
 Target (100%): Complete build-out of Building 1601 by the first quarter of 2020; substantially advance build-out of Building 1701 and initiate construction on Building 1951 

   Completed build-out of Building 1601 (June 2020).

 

   Substantially progressed construction of Building 1701.

 

   Initiated construction on Building 1951.

 1% 1%

2021 Proxy Statement    59


   PERFORMANCE OBJECTIVES ACHIEVEMENTS TARGET % ACHIEVEMENT %
 

Target (100%): Achieve year-end headcount of 769 full-time employees (FTEs)

 

Maximum (150%): Achieve an overall turnover rate of less than 10%

 

   Achieved headcount of 773 FTEs.

 

   Achieved annual overall turnover rate of 10.6%.

 2% 2%
 Target (100%): Integrate and implement compliance into all aspects of organizational activities 

   Completed all planned monitoring activities, as adjusted for COVID-19 restrictions.

 

   Compliance programs operated effectively across the enterprise, with appropriate monitoring and oversight.

 1% 1%
 Target (100%): Build Exelixis brand recognition within U.S. Government to support our business and the interests of patients 

   Conducted bi-partisan engagement with Congress, resulting in positive associations with the Exelixis brand.

 

   Participated in development of academic white paper focused on the disparate impact of the 340B drug discount program on small to mid-size innovative drug companies.

 1% 1%
   100% 108%

Individual Performance Assessments of our Named Executive Officers other than the CEO

The Compensation Committee also recognized the individual contributions of each Named Executive Officer, other than Dr. Morrissey, toward achievement of the 2019 corporate goals, as well as the departmental achievements in each Named Executive Officer’s area of responsibility that drove the achievement of such2020 corporate goals. In evaluating the individual contributions of each Named

Executive Officer, the Compensation Committee determined that all Named Executive Officers performed above expectations and considered the following contributions from each in such determination:

 

 

Dr. Schwab’s overall leadership of our product development and medical affairs organizations and her performance with respect to the achievement of our product development goals in 2019,2020, particularly regardingregarding: the FDA’s approvalfiling of the sNDA for CABOMETYX in combination with OPDIVO as a treatment for patients with HCC previously treated with sorafenib,advanced RCC under the FDA’s Real-Time Oncology Review pilot program; achievement of positive top-line results for COSMIC-311; the initiation ofCOSMIC-313 CONTACT-01, CONTACT-02 and CONTACT-03 and management of other potentially label-enabling clinical trials, including COSMIC-312, COSMIC-313 and COSMIC-021; support of cabozantinib worldwide regulatory filings by collaboration partnerspartners; and the oversight of a rapidly growing Product Development organization. The Compensation Committee gave specific weight to the criticality of Dr. Schwab’s performance with respect to the advancementmanagement of our clinical trial programs during the cabozantinib development programCOVID-19 pandemic and itstheir strategic importance to Exelixis’ growth potential.the continued success of the Exelixis business.

 

 

Mr. Senner’s overall leadership of our finance organization and his performance with respect to the achievement of our financial goals in 2019,2020, particularly regardingregarding: our disciplined expense management andmanagement; his role in positioning position the company to be able to execute on future strategic initiatives.initiatives; and the successful upgrade of our SAP system to the S/4 HANA platform. The Compensation Committee also considered the expansion of Mr. Senner’s responsibilities to lead the Information Technology organization and implement initiatives to further enhance our technology infrastructure.

 

2020 Proxy Statement    71


 

Mr. Hessekiel’s overall leadership of our legal and compliance organizations and his performance with respect to the achievement of our business and legal goals in 2019,2020, particularly regardingregarding: the advanced preparations forgrowth in the volume and managementcomplexity of our patent infringement lawsuit against MSN Pharmaceuticals, Inc., as well asbusiness agreements and arrangements; the continued integrationrapid adjustments made to our compliance program in order to maintain an effective oversight function following the evaluation of new methods of interactions with healthcare professionals due to the COVID-19 pandemic; and implementationour level of compliance throughout a rapidly expanding organization.organizational preparedness for potential shifts in healthcare regulations applicable to our business.

 

 

Dr. Lamb’sMr. Haley’s overall leadership of our research and discoveryCommercial organization and his performance with respect to the achievement of our pipeline developmentcommercial goals in 2019,2020, particularly regardingregarding: the rebuildingcontinued strong CABOMETYX demand in 2020 and building the brand into the leading second line agent in RCC despite increased competition in the indications for which CABOMETYX is approved; early achievement of our discovery organization andre-initiation of high throughput screening, research progress madelaunch readiness for CABOMETYX in combination with respect to potential development candidates, the FDA’s acceptance of our INDOPDIVO as a treatment for XL092first-line advanced RCC; and the executionreorganization of our licensethe Commercial team to achieve scalability for future potential launches in RCC, HCC, mCRPC and collaboration agreements with Iconic and Aurigene. The Compensation Committee also considered Dr. Lamb’s contributions to the advancement of Exelixis’ information technology and cyber-security programs.DTC.

60    Exelixis, Inc.


Compensation of Executive Officers | Compensation Discussion and Analysis

In consideration of the foregoing, in February 2020, pursuant to the terms and conditions of the Annual Cash Bonus Plan,2021, the Compensation Committee approved annual cash bonus payments for each Named Executive Officer as reflected in the table below.

 

Name

 

2019

Base

Salary

 

2019

Target

Award

(%)

 

2019

Corporate

Performance

Weighting

(%)

 

2019

Approved

Corporate

Performance

(%)

 

2019

Individual

Performance

Weighting

(%)

 

2019

Individual

Performance

(%)

 

2019

Annual Cash

Bonus Payout

(% of Target

Award)

 

2019

Annual

Cash Bonus

Payout

($)

  

2020

Base

Salary

 

2020

Target

Award

(%)

 

2020

Corporate

Performance

Weighting

(%)

 

2020

Approved

Corporate

Performance

(%)

 

2020

Individual

Performance

Weighting

(%)

 

2020

Individual

Performance

(%)

 

2020

Annual Cash

Bonus Payout

(% of Target

Award)

 

2020

Annual

Cash Bonus

Payout

($)

 

Michael M. Morrissey, Ph.D.

 $1,017,140   100  100  110  N/A   N/A   110 $1,118,854  $1,067,997   100  100  120  N/A   N/A   120 $1,281,596 

Gisela M. Schwab, M.D.

 $717,949   50  60  110  40  120  114 $409,231  $750,257   60  70  120  30  200  144 $648,222 

Christopher J. Senner

 $628,067   45  60  110  40  110  110 $310,893  $653,189   50  70  120  30  135  125 $406,610 

Jeffrey J. Hessekiel, J.D.

 $558,061   45  50  110  50  110  110 $276,240  $580,384   50  70  120  30  100  114 $330,819 

Peter Lamb, Ph.D.

 $522,401   45  60  110  40  110  110 $258,589 

Patrick J. Haley

 $510,000   50  70  120  30  100  114 $290,700 

20192020 Long-Term Incentive Awards

 

Because ofConsistent with our goal to align executive compensation andwith performance that advances our critical business objectives, a significant portion of the Named Executive Officers’ total compensation typically has consisted of, and is expected to continue to consist of, equity-based awards. In evaluating the mix of equity awards for 2019,2020, the Compensation Committee considered market trends, as well as feedback from stockholders and proxy advisory firms, and determined that an entirely performance-based program consisting solely of PSUs would be the most appropriate incentive structure for our Named Executive Officers to reward performance over time and achieve our retention objectives.    LOGOLOGO

Determination of September 20192020 Performance Target for Long-Term Incentive Awards

The Compensation Committee seeks to develop long-term incentive compensation programs based on metrics that are aligned with our corporate strategy and designed to build value for our stockholders. TheAccordingly, the PSUs granted to Named Executive Officers in 20192020 vest upon or following achievement of the following performance targets:

2020 PSU Grant #1

positive top-line results of one or more clinical trials evaluating a product for which we own, or have licensed to a collaboration partner, development or commercialization rights, that provides data that can reasonably support regulatory evaluation of safety and efficacy to determine the risk/benefit profile of the product

2020 PSU Grant #2

the approval by the FDA for the commercial sale and marketing of one or more products for which we hold,own, or have licensed to a collaboration partner, development andor commercialization rights, in the U.S. in one or more new indications or an indication for which the product has previously received FDA approval, if such product is intended to treat a new, additional or expanded set of patients or is part of a combination therapy. therapy

The Compensation Committee selected thisthese performance targettargets because it representedthey represent the most critical business objectiveobjectives for which the Named Executive Officers are responsible, thereby linking executive compensation with our long-term growth strategy.

Depending onFor each 2020 PSU award, the level of achievement of such performance goal, Named Executive Officers are eligible to vest up to a maximum of 200% of the target number of shares of Exelixis common stock subject to the PSU.PSU award. Failure to achieve thea performance target by December 31, 20212024 will result in forfeiture of 100% of the applicable 2020 PSU award.

 

72    Exelixis, Inc.

2021 Proxy Statement    61


Compensation of Executive Officers | Compensation Discussion and Analysis

Vesting Percentage of Performance

 

         0%               100%               150%               200%  
     
    Failure to Achieve:Achievement on January 1, 2022 or later      Target Achievement:Achievement between January 1, 2021 and December 31, 2021      Early Achievement:Achievement on December 31, 2020 or earlier      

Over Achievement:Achievement with respect to more than one new indication on or before December 31, 2021

 

  
        0%       50%       100%       

150%

         200%  
      
   Failure to Achieve: Achievement on or after January 1, 2025        

Threshold Achievement: Achievement with respect to one performance

target on or before December 31, 2024

 

        Target Achievement: Achievement with respect to two performance targets on or before December 31, 2024        

Partial Over Achievement: Achievement with respect to three

performance targets on or before December 31, 2024

        

Early Achievement: Achievement with respect to at least two performance targets on or before December 31, 2022

 

 

Over Achievement: Achievement with respect to more than three performance targets on or before December 31, 2024

 

  

The 2019Upon achievement of a performance target, the Compensation Committee will certify the applicable level of achievement and determine the number of shares that are entitled to vest based on such achievement, which will be equal to the target number of shares subject to the applicable 2020 PSU awardsaward multiplied by the applicable vesting percentage (“2020 PSU Certified Shares”). Each 2020 PSU award will vest as to 50% of the original number of shares subject to the award2020 PSU Certified Shares upon the Compensation Committee’s certification that we have achieved the performance goal and 50% of the original number of shares subject to the award2020 PSU Certified Shares on the first quarterly vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following theone-year anniversary of the Compensation Committee’s certification.

Potential PSU Payouts

(% of Target)

 

 

LOGOLOGO

Vesting of these PSUs will cease upon termination of service as an employee for any reason. Pursuant to the terms of the award agreements, following certain change in control events wherein the PSU awards are assumed by the surviving entity, the PSU awards will convert to time-based vesting, and vestas though the target number of shares subject to each PSU award had been subject to a vesting schedule pursuant to which the shares would have vested annually over a three-yearfour-year period following the grant date.date (with any portion that would have vested on or prior to the change in control event under such vesting schedule becoming vested on the date of the change in control event and any portion that is unvested following the date of the change in control event vesting in accordance with such vesting schedule). The purpose of this conversion feature is to account for the fact that the goal may not be achievable in the context of the newly formed organization. In addition, the Named Executive Officers are party to our Change in Control and Severance Benefit Plan, which provides for acceleration of vesting of the award in the event of certain specified change in control events involving us, as further described under the caption “Potential Payments Upon Termination or Change in Control” below.

Determination of Long-Term Incentive Awards

When determining the appropriate value of equity incentive awards, the Compensation Committee asked CompensiaRadford to provide guidance with respect to implementing a program that would incentivize our Named Executive Officers to achieve key company priorities and increase stockholder value over the long-term, while maintaining competitive market practices and being mindful of the company’s equity burn rate.

62    Exelixis, Inc.


Compensation of Executive Officers | Compensation Discussion and Analysis

As part of the decision-making process, the Compensation Committee considered the challenges of managing a rapidly expanding organization, as well as our need to retain a cohesive management team to facilitate the achievement of product development and pipeline expansion objectives, while supporting the continued commercial success of CABOMETYX, that would position the company for future success. The Compensation Committee also believed it was important that the value of the equity awards continue to reflect the individual performance of each Named Executive Officer during the fiscal year to

2020 Proxy Statement    73


date and the criticality of each Named Executive Officer’s skill set and expected future contributions to our business. Taking these factors into consideration and applying Compensia’sRadford’s market analysis of long-term incentive compensation of our Named Executive Officers compared to our 20192020 peer group, the Compensation Committee determined that the aggregate value of the aggregate equity awards granted to each of our Named Executive Officers should be between the 50th and 75th percentile of market peers and in September 2019, approved the grantsaggregate grant amounts to the Named Executive Officers summarized in the table below. The actual number of PSUs granted to each executive officer werewas determined by dividing the value the Compensation Committee intended to deliver by the30-day average trailing stock price (as of a date shortly before the grant date)July 31, 2020), and this number of PSUs was then allocated equally between Performance Target #1 (Positive Top-Line Results) and Performance Target #2 (Regulatory Approvals).A 30-day average share price was used, rather than a single day share price, in order to provide a more stabilized share value less susceptible to possible swings in the market.

 

Name

  Number of Shares
Subject to 2019
PSUs – Target
Achievement
   Number of Shares
Subject to 2019
PSUs – Early
Achievement
   Number of Shares
Subject to 2019
PSUs – Over
Achievement
     

Number of Shares
Subject to 2019 PSUs  –

Early Achievement
& Over Achievement

  Number of Shares
Subject to 2020
PSUs – Threshold
Achievement
 Number of Shares
Subject to 2020
PSUs – Target
Achievement
 Number of Shares
Subject to 2020
PSUs – Partial
Over
Achievement
 Number of Shares
Subject to 2020
PSUs – Early/
Over
Achievement
 Maximum
Number of Shares
Subject to 2020 PSUs
 

Michael M. Morrissey, Ph.D.

   448,574    672,861    897,148      897,148   188,005   376,010   564,015   752,020   752,020 

Gisela M. Schwab, M.D.

   142,586    213,879    285,172      285,172   65,135   130,270   195,405   260,540   260,540 

Christopher J. Senner

   118,821    178,231    237,642      237,642   65,135   130,270   195,405   260,540   260,540 

Jeffrey J. Hessekiel, J.D.

   118,821    178,231    237,642      237,642   57,900   115,800   173,700   231,600   231,600 

Peter Lamb, Ph.D.

   142,586    213,879    285,172      285,172 

Patrick J. Haley

  57,900   115,800   173,700   231,600   231,600 

Promotion Grant to Mr. Haley

In February 2020, Mr. Haley was promoted to Executive Vice President, Commercial. In connection with Mr. Haley’s promotion, the Compensation Committee granted him a time-based RSU award for 35,000 shares having a target award value of $650,300. Mr. Haley’s RSUs will vest as to 25% of the original number of shares subject to his RSU award on each May 15th with a final vesting date of May 15, 2024. Vesting of these RSUs will cease upon Mr. Haley’s termination of service for any reason.

2018 Long-Term Incentive Awards Achievements Table

In 2018, the Compensation Committee granted PSUs to Named Executive Officers allocated among five separate awards that only vest upon the achievement of certain commercial, clinical development and pipeline expansion performance targets. The Compensation Committee selected these performance targets because they represented the critical business objectives for which the Named Executive Officers are responsible, thereby linking executive compensation with continued long-term success for the company.

During 2019,On September 2, 2020, the Compensation Committee certified the achievement of 2018 PSU Grant #3, which was one of the two commercialclinical development performance targets.goals established for the 2018 PSU awards. Upon such certification, the PSUs vested as to 50% of the original number of shares subject to the award. The remaining 50% of the original number of shares subject to the award will vest on November 15, 2021. The following chart reflects thepre-established commercial clinical development performance targetstarget and the actual results achieved. The remaining three clinical development and pipeline expansion related performance targets are not disclosed for competitive reasons and because the relevant performance periods are ongoing.

 

  2018 PSU
  Grant #
  Business Focus  Pre-Established Performance Target  Achievement
       13  CommercialClinical Development  $250 millionInitiation of 4 label-enabling clinical trials evaluating cabozantinib alone or in cabozantinib global net product revenue1 targetcombination with another therapy, in a single quartereach case sponsored by Exelixis or one or more collaborators  $260.2 million in cabozantinib global net product revenue1 for the quarter ended

COSMIC-313 Initiated May 2019

PDIGREE initiated June 28, 2019

CONTACT-01 initiated June 2020

CONTACT-02 initiated June 2020

       2  Commercial2021 Proxy Statement    $1 billion in cabozantinib global net product revenue1 target over four consecutive quarters$1.0 billion in global net product revenue1 for the four consecutive fiscal quarters ended September 27, 201963


 

1

Includes revenues generated by Ipsen Pharma SAS, our partner in cabozantinib’s development and commercialization outside

2019 Long-Term Incentive Awards Achievements

In 2019, the Compensation Committee granted PSUs to the Named Executive Officers that only vest upon the achievement of regulatory approval of a product in the U.S. On October 22, 2020, following the FDA’s approval of cobimetinib in combination with atezolizumab and vemurafenib as a treatment for patients with BRAF V600 melanoma, the United States and Japan

The Compensation Committee certified 2018the early achievement of the 2019 PSU Grant #1 on September 12,award, representing 150% of the target amount of shares subject to the award. Cobimetinib, which our collaboration partner Genentech commercializes as COTELLIC and which we co-promote in the U.S., is one of the four products discovered previously in Exelixis laboratories, that has progressed through clinical development and received regulatory approval. Upon certification of such early achievement by the Compensation Committee, the 2019 and 2018 PSU Grant #2 on December 4, 2019. Upon such certification, each PSUaward vested as to 50%75% of the originaltarget number of shares subject to the award. The remaining 50%An additional 75% of the originaltarget number of shares subject to eachthe award will vest on the first quarterly vesting date (i.e. FebruaryNovember 15th, May 15th, August 15th and November 15th) following theone-year anniversary of the Compensation Committee’s certification.

74    Exelixis, Inc.


Compensation of Executive Officers | Compensation Discussion and Analysis

2021 based on such early achievement.

Other Compensation Information

Timing of Equity Awards

Annual grants of equity awards to our executive officers, including our Named Executive Officers, are generally determined and approved atpre-scheduled Compensation Committee meetings, with such meeting date typically serving as the grant date. However, the Compensation Committee may sometimes approve the grant of equity awards to executive officers and other employees in advance of its next scheduled meeting, either at a special meeting or by unanimous written consent, in connection with certain new hires, promotions and other circumstances where the Compensation Committee deems it appropriate to make such grants. The grant dates for these equity awards are typically the same date that a newly hired officer begins employment or the effective date of an officer’s promotion, as applicable. Grants made to new hires below the level of Vice President, are approved on a monthly basis by our Equity Award Committee, comprised solely of Dr. Morrissey, acting in his capacity as a director pursuant to authority delegated to him by the Compensation Committee. All stock options are granted with an exercise price that is not less than the closing price of our common stock on The Nasdaq Global Select Market on the grant date. We have no plan or practice to time option grants in coordination with the release ofnon-public information, and we do not time the release ofnon-public information to affect the value of executive compensation.

Stock Ownership Guidelines for Named Executive Officers

The Board maintains Stock Ownership Guidelines for our Named Executive Officers in order to further align their financial interests with those of our stockholders, as well as to promote sound corporate governance. TheFor our Names Executive Officers, we amended our Stock Ownership Guidelines for our Named Executive Officersin February 2021 to establish the following ownership targets and provide for a “lesser of” approach to address stock price volatility often experienced by biotechnology companies:targets:

 

 

Position

  

Ownership Level

Chief Executive Officer

  Lesser of a valueValue equivalent to 5 times annual base salary or 160,000 shares

Other Named Executive Officers

  Lesser of a valueValue equivalent to 1.53 times annual base salary or 25,000 shares

These new ownership targets represent increases from the prior targets of, for the Chief Executive Officer, the lesser of the value equivalent to 5 times the annual base salary or 160,000 shares, and for other Named Executive Officers, the lesser of the value equivalent to 1.5 times annual base salary or 25,000 shares. All Named Executive Officers are expected to achieve their stock ownership targets within five years of becoming subject to these guidelines. The policy includes procedures for granting exemptions in the case of severe financial hardship. In determining ownership levels for each Named Executive Officer under our Stock Ownership Guidelines, credit is provided for shares held outright (including shares owned through trusts, our 401(k) Plan, or by a spouse), as well as 50% of the number of vested, but unexercised, stock options. No credit is provided for RSUs or PSUs until they vest. The values for all shares determined to be held by Named Executive Officers are based on the200-day average stock price as of the measurement date. As of February 10, 2020,5, 2021, all of our Named Executive Officers had met the required ownership targets.

64    Exelixis, Inc.


Compensation of Executive Officers | Compensation Discussion and Analysis

Clawback Policy

We are dedicated to maintaining a culture of high integrity and accountability, and to discourage conduct harmful to our business and the interests of our various stakeholders. On February 28, 2019, upon recommendation from the Compensation Committee, the Board approved theIn response to this dedication, we adopted a Clawback Policy that applies to all forms of compensation, except base salary, granted after the adoption of the Clawback Policy. A triggering event under the Clawback Policy shall occur when a covered employee (which includes all Named Executive Officers):

LOGOLOGO

For clarity, “material harm” includes, but is not limited to, the requirement to prepare an accounting restatement for any fiscal quarter or year commencing after adoption of the Clawback Policy due to our material noncompliance with any financial reporting requirement. If triggered, then to the fullest extent permitted by law, we may recoup all variable compensation granted or paid to the covered employee during each fiscal year in which the covered employee’s “misconduct” occurred.

2020 Proxy Statement    75


Accounting and Tax Considerations

Under FASB ASC 718, we are required to estimate and record an expense for each award of equity compensation (including stock options, RSUs and PSUs) over the vesting period of the award. As long as stock options, RSUs and PSUs remain the sole components of our long-term compensation program, we expect to record stock-based compensation expense on an ongoing basis according to ASC 718. Compensation expense relating to awards subject to performance conditions is recognized if it is probable that the performance goals will be achieved. The probability of achievement of such goals is assessed on a quarterly basis. The Compensation Committee has considered, and may in the future consider, the grant of restricted stock to our executive officers in lieu of stock option grants, RSU and/or PSU awards.

Under Section 162(m) of the Internal Revenue Code as amended by the Tax Cuts and Jobs Act, limits the deductibility for federal income tax purposes to not more than $1 million of(“Section 162(m)”), compensation paid to each of the Company’s “covered employees” in a calendar year. Prior tothat exceeds $1 million per taxable year is generally non-deductible unless the recent enactment ofcompensation qualifies for certain grandfathered exceptions (including the Tax Cuts and Jobs Act, compensation that qualified as “performance-based compensation” under Section 162(m) of the Code was not subject to this deduction limitation. Pursuant to the Tax Cuts and Jobs Act, this exceptionexception) for “performance-based compensation” under Section 162(m) of the Code was repealed with respect to taxable years beginning after December 31, 2017, except that certain transition relief is provided for compensation paid pursuant to a written binding contract which was in effect on November 2, 2017 and which was not materially modified in any material respect on or after such date. As a result, compensation paid to any of our “covered employees” in excess of $1 million per taxable year generally will not be deductible unless, among other requirements, it is intended to qualify, and is eligible to qualify, as “performance-based compensation” under Section 162(m) of the Code pursuant to the transition relief provided by the Tax Cuts and Jobs Act. Certain equity awards issued prior to the transition date were designed to permit us to qualify for the performance-based exception, but because of certain ambiguities and uncertainties as to the application and interpretation of Section 162(m) of the Code and the regulations issued thereunder, as well as other factors beyond the control of the Compensation Committee, no assurance can be given that any compensation paid by the company will be eligible for such transition relief and be deductible by the company in the future. Although the Compensation Committee will continue to consider tax implications as one factor in determining executive compensation, the Compensation Committee also looks at other factors in making its decisions and retains the flexibility to provide compensation for the Named Executive Officers in a manner consistent with the goals of the company’s executive compensation program and the best interests of the company and its stockholders, which may include providing for compensation that is not deductible by the company due to the deduction limit under Section 162(m). The Compensation Committee also retains the flexibility to modify compensation that was initially intended to be exempt from the deduction limit under Section 162(m) if it determines that such modifications are consistent with the company’s business needs.

Compensation Policies and Practices as They Relate to Risk Management

In 2019,2020, the Compensation Committee reviewed our compensation policies and practices and concluded that the mix and design of these policies and practices are not reasonably likely to encourage our employees to take excessive risks. In connection with its evaluation, the Compensation Committee considered, among other things, the structure, philosophy and design characteristics of our primary incentive compensation plans and programs in light of our risk management and governance procedures, as well as other factors that may calibrate or balance potential risk-taking incentives. Based on this assessment, the Compensation Committee concluded that risks arising from our compensation policies and practices for all employees, including executive officers, are not reasonably likely to have a material adverse effect on us.

 

76    Exelixis, Inc.

2021 Proxy Statement    65


Compensation of Executive Officers | Summary of Compensation

 

Summary of Compensation

 

The following table shows for the fiscal years ended January 1, 2021, January 3, 2020 and December 28, 2018 and December 29, 2017 (referred to as fiscal years2020, fiscal 2019 2018 and 2017,fiscal 2018, respectively), compensation awarded to, paid to or earned by our Chief Executive Officer, our Chief Financial Officer, and our other three most highly compensated executive officers in 2019,2020, which we refer to as our “Named Executive Officers.”

Summary Compensation Table

 

Name and Principal Position

 Year
(1)
 Salary
($)(2)
 Bonus
($)(3)
 Stock
Awards
($)(5)
 Option
Awards
($)(6)
 Non-Equity
Incentive Plan
Compensation
($)(4)
 All Other
Compensation
($)
 

Total

($)

  Year
(1)
 Salary
($)(2)
 Bonus
($)(3)
 Stock
Awards
($)(4)
 Option
Awards
($)(5)
 Non-Equity
Incentive  Plan
Compensation
($)(6)
 All Other
Compensation
($)
 

Total

($)

 

Michael M. Morrissey, Ph.D.

  2019   1,005,201            1,118,854   8,500   2,132,555   2020   1,058,216   128,159         1,153,437   10,000   2,349,812 

President and Chief

  2018   945,080         3,111,403   1,000,000   8,500   5,064,983   2019   1,005,201            1,118,854   8,500   2,132,555 

Executive Officer

  2017   891,781   675,750   1,952,800   5,911,152      8,100   9,439,583   2018   945,080         3,111,403   1,000,000   8,500   5,064,983 

Gisela M. Schwab, M.D.

  2019   710,751            409,231   8,500   1,128,482   2020   744,044   37,813         610,409   10,000   1,402,266 

President, Product Development

  2018   672,301         1,227,500   466,156   8,500   2,374,457   2019   710,751            409,231   8,500   1,128,482 

and Medical Affairs and Chief

  2017   629,493   318,000   1,830,750   1,847,235      8,100   4,633,578   2018   672,301         1,227,500   466,156   8,500   2,374,457 

Medical Officer

                  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

Christopher J. Senner

  2019   622,866            310,893   8,500   942,259   2020   648,358   27,434         379,176   10,000   1,064,968 

Executive Vice President and

  2018   594,740         1,227,500   338,074   8,500   2,168,814   2019   622,866            310,893   8,500   942,259 

Chief Financial Officer

  2017   562,120   255,150   1,525,625   1,539,363      8,100   3,890,358   2018   594,740         1,227,500   338,074   8,500   2,168,814 

Jeffrey J. Hessekiel, J.D.

  2019   553,934            276,240   8,500   838,674   2020   576,091   24,376         306,443   10,000   916,910 

Executive Vice President and

  2018   531,880         1,227,500   301,836   8,500   2,069,716   2019   553,934            276,240   8,500   838,674 

General Counsel

  2017   507,067   229,970   1,220,500   1,231,490      7,076   3,196,103   2018   531,880         1,227,500   301,836   8,500   2,069,716 

Peter Lamb, Ph.D.

  2019   517,617            258,589   8,500   784,706 

Patrick J. Haley

  2020   500,953   21,420   763,000(7)      269,280   10,000   1,564,653 

Executive Vice President,

  2018   493,570         1,180,295   311,202   8,500   1,993,567         

Scientific Strategy and Chief

  2017   473,190   214,245   1,342,550   1,354,639      8,100   3,392,724 

Scientific Officer

                

Commercial

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

(1)

The compensation reflected in the Summary Compensation Table reflects a52-week period for fiscal 2020, a 53-week period for fiscal 2019 and a52-week period for each of fiscal 2018 and 2017.2018.

 

(2)

The amount in this column represents the amount actually earned by each Named Executive Officer for the indicated fiscal year. For information regarding 20192020 base salaries, please see “Compensation Discussion and Analysis—20192020 Compensation Decisions—20192020 Base Salaries.Salaries.

 

(3)

The amounts in this column represents the discretionary cash bonuses awarded for services rendered duringportion of the indicated fiscal year by the Named Executive Officers.

(4)

The amounts in this column represent cash bonuses awarded under our Annual Cash Bonus Plan infor fiscal 2018 and 2019 based on the Compensation Committee’s assessment of the achievement ofpre-determined corporate goals.2020. For a description of the company’s Annual Cash Bonus Plan for fiscal 2019,2020 and the discretion applied, see “Compensation Discussion and Analysis—20192020 Compensation Decisions—20192020 Annual Cash BonusesBonuses—2020 Performance Evaluation” above.

 

(5)(4)

Amounts shown in this column reflect the aggregate grant date fair value in the indicated fiscal year for the RSU and PSU awards as computed in accordance with FASB ASC 718. ThereOther than as reflected in footnote 7 to the Summary Compensation Table, there were no time-based RSUs granted to the Named Executive Officers in fiscal 2020, fiscal 2019 or fiscal 2018.

With respect to PSU awards granted to the Named Executive Officers during fiscal 2019,2020, the grant date fair values, as computed in accordance with FASB ASC 718, excluding the estimate of estimated forfeitures, and presented in the table above, are based upon the then-probable outcome of the performance conditions, which was $0 for each Named Executive Officer. Assuming “Threshold Achievement” (i.e. “Threshold Payout”), “Target Achievement” (i.e. “Target Payout”) and “Over Achievement” or “Early Achievement” (i.e. ”Maximum Payout”) of the performance conditions for the PSU awards granted to each Named Executive Officer during fiscal 2019,2020, and in each case other than Dr. Morrissey, assuming a closing

2020 Proxy Statement    77


stock price of $19.56$21.73 per share of our common stock on the September 20, 201911, 2020 grant date (and for Dr. Morrissey, assuming a closing stock price of $21.83 per share of our common stock on the October 22,

66    Exelixis, Inc.


Compensation of Executive Officers | Summary of Compensation

2020 grant date) and excluding estimates of forfeiture, the values of the PSU awards granted to each Named Executive Officer during fiscal 2019 are2020 at the grant date were as follows:

 

Name and Principal Position

  

Target Payout of

PSUs Granted

in 2019

($)

   

Maximum Payout

of PSUs Granted

in 2019

($)

   

Threshold Payout of

PSUs Granted

in 2020

($)

   

Target Payout of

PSUs Granted

in 2020

($)

   

Maximum Payout

of PSUs Granted

in 2020

($)

 

Michael M. Morrissey, Ph.D.

   8,774,107    17,548,215    4,104,149    8,208,298    16,416,597 

Gisela M. Schwab, M.D.

   2,788,982    5,577,964    1,415,384    2,830,767    5,661,534 

Christopher J. Senner

   2,324,139    4,648,278    1,415,384    2,830,767    5,661,534 

Jeffrey J. Hessekiel, J.D.

   2,324,139    4,648,278    1,258,167    2,516,334    5,032,668 

Peter Lamb, Ph.D.

   2,788,982    5,577,964 

Patrick J. Haley

   1,258,167    2,516,334    5,032,668 

For a description of the PSU awards granted during fiscal 2019,2020, see “Compensation Discussion and Analysis—20192020 Compensation Decisions—20192020 Long-Term Incentive Awards” above.

With respect to PSU awards granted to the Named Executive Officers during fiscal 2019, the grant date fair values, as computed in accordance with FASB ASC 718, excluding the estimate of estimated forfeitures, and presented in the table above, are based upon the then-probable outcome of the performance conditions, which was $0 for each Named Executive Officer. Assuming “Target Achievement” (i.e. “Target Payout”) and “Over Achievement” (i.e. “Maximum Payout”) of the performance conditions for the PSU awards granted to each Named Executive Officer during fiscal 2019, and in each case assuming a closing stock price of $19.56 per share of our common stock on the September 20, 2019 grant date and excluding estimates of forfeiture, the values of the PSU awards granted to each Named Executive Officer other than Mr. Haley during fiscal 2019 at the grant date were as follows:

   

Name and Principal Position

  

Target Payout of

PSUs Granted

in 2019

($)

   

Maximum Payout

of PSUs Granted

in 2019

($)

 

Michael M. Morrissey, Ph.D.

   8,774,107    17,548,215 

Gisela M. Schwab, M.D.

   2,788,982    5,577,964 

Christopher J. Senner

   2,324,139    4,648,278 

Jeffrey J. Hessekiel, J.D.

   2,324,139    4,648,278 

With respect to PSU awards granted during fiscal 2018, the grant date fair values, as computed in accordance with FASB ASC 718, excluding the estimate of estimated forfeitures, and presented in the table above, are based upon the then-probable outcome of the performance conditions, which was $0 for each Named Executive Officer. Assuming achievement of the target level of the performance conditions for the PSU awards granted to each Named Executive Officer during fiscal 2018 (which was also the maximum level of performance), and assuming a closing stock price of $18.80 per share of our common stock on the September 10, 2018 grant date and excluding estimates of forfeiture, the values of the PSU awards granted to each Named Executive Officer other than Mr. Haley during fiscal 2018 areat the grant date were as follows:

 

Name and Principal Position

  

Target/Maximum Payout of

PSUs Granted in 2018

($)

 

Michael M. Morrissey, Ph.D.

   2,912,552 

Gisela M. Schwab, M.D.

   1,221,398 

Christopher J. Senner

   1,221,398 

Jeffrey J. Hessekiel, J.D.

   657,680 

Peter Lamb, Ph.D.

1,174,417

The values of the PSU awards granted to each Named Executive Officer during fiscal 2018 were previously disclosed in our proxy statement for the 2019 Annual Meeting of Stockholders under the column “Stock Awards” at the Target/Maximum values presented in the foregoing table.

 

(6)(5)

Amounts shown in this column do not reflect compensation actually received or amounts that may be realized in the future by the Named Executive Officers. The amounts shown reflect the aggregate grant date fair value in the indicated fiscal years for option awards as computed in accordance with FASB ASC 718. The assumptions used to calculate the value of option awards are set forth in Note 8 of the Notes to Consolidated Financial Statements included in our Annual Report on Form10-K for the fiscal year ended January 3, 2020, filed with1, 2021, submitted to the SEC on February 25, 2020.10, 2021. With respect

2021 Proxy Statement    67


to the performance-based option award granted to Dr. Morrissey during fiscal 2018, the grant date fair value, as computed in accordance with FASB ASC 718 and presented in the table above, is based upon the then-probable outcome of achieving the market performance condition and excluding estimates of forfeiture. There can be no assurance that the stock option awards will ever be exercised (in which case no value will actually be realized by the executive) or that the value on exercise will be equal to the FASB ASC 718 value shown in this column.

(6)

The amounts in this column represent the portion of the cash bonuses awarded under our Annual Cash Bonus Plan that was based on the Compensation Committee’s assessment of the achievement of pre-determined corporate goals.

 

(7)

Amounts shown reflect the grant date fair value of the time-based RSU award granted to Mr. Haley in connection with his promotion to Executive Vice President, Commercial as computed in accordance with FASB ASC 718. The grant date fair value of the RSU award was measured based on the closing price of $21.80 per share of our common stock on the February 19, 2020 grant date.

78    Exelixis, Inc.

68    Exelixis, Inc.


Compensation of Executive Officers | Grants of Plan-Based Awards

 

Grants of Plan-Based Awards

 

The following table shows for the fiscal year ended January 3, 2020,1, 2021, certain information regarding grants of plan-based awards to the Named Executive Officers:

Grants of Plan-Based Awards in Fiscal 20192020

 

      Estimated Future
Payouts Under
Non-Equity  Incentive
Plan Awards (1)
   Estimated Future
Payouts Under
Equity Incentive
Plan  Awards
   Grant Date
Fair Value  of
Stock
Awards
($)(2)
        Estimated Future
Payouts  Under
Non-Equity Incentive
Plan Awards (1)
 Estimated Future
Payouts Under
Equity Incentive
Plan  Awards
  All Other
Stock Awards:
Number of
Shares of
Stock or Units
($)(2)
 Grant Date
Fair Value  of
Stock
Awards
($)(3)
 
            
  Grant Date   Threshold
($)
   Target
($)
   Maximum
($)
   Threshold
(#)
   Target
(#)
   Maximum
(#)
  Grant Date Approval
Date
 Threshold
($)
 Target
($)
 Maximum
($)
 Threshold
(#)
 Target
(#)
 Maximum
(#)
 

Michael M. Morrissey, Ph.D.

                          
   09/20/2019              448,574(3)    897,148(3)      

 

10/22/2020

 

 

 

10/22/2020

 

    

 

94,002

 

 

 

188,005

(4) 

 

 

376,010

(4) 

  

 

 

   N/A        1,017,140    2,034,280              

 

10/22/2020

 

 

 

10/22/2020

 

    

 

94,002

 

 

 

188,005

(5) 

 

 

376,010

(5) 

  

 

 

 

 

N/A

 

 

 

N/A

 

 

 

 

 

 

1,067,997

 

 

 

1,553,936

 

          

Gisela M. Schwab, M.D.

                          
 

 

09/11/2020

 

 

 

09/02/2020

 

    

 

32,567

 

 

 

65,135

(4) 

 

 

130,270

(4) 

  

 

 

   09/20/2019              142,586(3)    285,172(3)      

 

09/11/2020

 

 

 

09/02/2020

 

    

 

32,567

 

 

 

65,135

(5) 

 

 

130,270

(5) 

  

 

 

   N/A        358,975    717,949              

 

N/A

 

 

 

N/A

 

 

 

 

 

 

450,154

 

 

 

728,575

 

          

Christopher J. Senner

                          
   09/20/2019              118,821(3)    237,642(3)      

 

09/11/2020

 

 

 

09/02/2020

 

    

 

32,567

 

 

 

65,135

(4) 

 

 

130,270

(4) 

  

 

 

   N/A        282,630    565,260              

 

09/11/2020

 

 

 

09/02/2020

 

    

 

32,567

 

 

 

65,135

(5) 

 

 

130,270

(5) 

  

 

 

 

 

N/A

 

 

 

N/A

 

 

 

 

 

 

326,595

 

 

 

528,593

 

          

Jeffrey J. Hessekiel, J.D.

                          
   09/20/2019              118,821(3)    237,642(3)      

 

09/11/2020

 

 

 

09/02/2020

 

    

 

28,950

 

 

 

57,900

(4) 

 

 

115,800

(4) 

  

 

 

   N/A        251,127    502,255              

 

09/11/2020

 

 

 

09/02/2020

 

    

 

28,950

 

 

 

57,900

(5) 

 

 

115,800

(5) 

  

 

 

Peter Lamb, Ph.D.

                
 

 

N/A

 

 

 

N/A

 

 

 

 

 

 

290,192

 

 

 

469,676

 

          

Patrick J. Haley

          
   09/20/2019              142,586(3)    285,172(3)      

 

02/19/2020

 

 

 

02/19/2020

 

       

 

35,000

 

 

 

763,000

 

   N/A        235,080    470,161              

 

09/11/2020

 

 

 

09/02/2020

 

    

 

28,950

 

 

 

57,900

(4) 

 

 

115,800

(4) 

  

 

 

 

 

09/11/2020

 

 

 

09/02/2020

 

    

 

28,950

 

 

 

57,900

(5) 

 

 

115,800

(5) 

  

 

 

 

 

N/A

 

 

 

N/A

 

 

 

 

 

 

255,000

 

 

 

412,718

 

          

 

(1)

The dollar amount represents the target and maximum amounts of each Named Executive Officer’s potential annual cash bonus award pursuant to our Annual Cash Bonus Plan for the fiscal year ended January 3, 2020.1, 2021. The amounts shown under “Target” reflects the applicable target payment under the Annual Cash Bonus Plan if (i) we achieved 100% of thepre-determined 20192020 corporate goals established by the Compensation, and (ii) as applicable, each Named Executive Officer’s individual performance percentage was assessed at 100% by the Compensation Committee with respect to his or her contributions toward the achievement of our corporate goals and the departmental achievements in each Named Executive Officer’s area of responsibility that drove the achievement of such corporate goals. The amounts shown under “Maximum” reflects the applicable maximum payment under the Annual Cash Bonus Plan if (i) we achieved 200%145.5% of thepre-determined 20192020 corporate goals established by the Compensation Committee, and (ii) as applicable, each Named Executive Officer’s individual performance percentage was assessed at 200% by the Compensation Committee with respect to his or her contributions toward the achievement of our corporate goals and the departmental achievements in each Named Executive Officer’s area of responsibility that drove the achievement of such corporate goals; provided, however, that neither the corporate performance percentage nor the individual performance percentage may exceed 200% in any given year. Since the Annual Cash Bonus PlanThere is entirely performance-based, theno threshold or minimum possible payment under the Annual Cash Bonus Plan is zero.Plan. For more information regarding our Annual Cash Bonus Plan, please see “Compensation Discussion and Analysis—20192020 Compensation Decisions—20192020 Annual Cash Bonuses” above.

 

(2)

The RSU award was granted pursuant to our 2017 Plan. The RSU award will vest as to 1/4th of the shares subject to the RSU award on May 15, 2021 and thereafter as to 1/4th of the number of shares subject to the RSU award on each May 15th until fully vested.

(3)

Amounts shown in this column do not reflect compensation actually received or amounts that may be realized in the future by the Named Executive Officers. The amounts shown in this column reflect the aggregate grant date fair value in fiscal year 20192020 for the RSU and PSU awards as computed in accordance with FASB ASC 718. The assumptions used to calculate the grant date fair value of the PSU awards are set forth in Note 8 of the Notes to Consolidated Financial Statements included in our Annual Report on Form10-K for the fiscal year ended January 3, 2020, filed with1, 2021, submitted to the SEC on February 25, 2020.10, 2021. The grant date fair values of the PSU awards, as computed in accordance with FASB ASC 718, granted to each Named Executive Officer presented in the table above are based upon the then-probable outcome of the performance conditions, which was $0 for each Named

2021 Proxy Statement    69


Executive Officer. For additional information regarding the values of the PSU awards granted to each Named Executive Officer during fiscal 2019,2020, seeFootnote 5 to the Summary Compensation Table above. The grant date fair value of the RSU award was measured based on the closing price of our common stock on the date of grant.

 

(3)(4)

The PSU award was granted pursuant to our 2017 Plan. The PSU award will vest as to (i) 50% of the original number of shares subject to the award2020 PSU Certified Shares upon the Compensation Committee’s certification that the company has obtained approval by the FDA for the commercial sale and marketingachieved positive top-line results of one or more productsclinical trials evaluating a product for which we hold,own, or have licensed to a partner, development andor commercialization rights, inthat provides data that can reasonably support regulatory evaluation of safety and efficacy to determine the U.S. in one or more new indications,risk/benefit profile of the product, and (ii) 50% of the original number of shares subject to the award2020 PSU Certified Shares on the first quarterly vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following theone-year anniversary of the Compensation Committee’s certification. Depending on the level of achievement of such performance target, Named Executive Officers are eligible to vest up to a maximum of 200% of the target number of shares of Exelixis common stock subject to the PSU award. For more information regarding the PSUs granted in 2019,2020, please see “Compensation Discussion and Analysis—20192020 Compensation Decisions—20192020 Long-Term Incentive Awards” above. Failure to achieve the aforementioned performance target by December  31, 20212024 will result in forfeiture of 100% of the PSU award, and vesting is subject to acceleration as described under the caption “—Potential Payments Upon Termination or Change in Control” below.

 

(5)

The PSU award was granted pursuant to our 2017 Plan. The PSU award will vest as to (i) 50% of the 2020 PSU Certified Shares upon the Compensation Committee’s certification that the company has obtained approval by the FDA for the commercial sale and marketing of one or more products for which we own, or have licensed to a partner, development or commercialization rights, in one or more new indications or an indication for which the product has previously received FDA approval, if such product is intended to treat a new, additional or expanded set of patients or is part of a combination therapy, and (ii) 50% of the 2020 PSU Certified Shares on the first quarterly vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Compensation Committee’s certification. Depending on the level of achievement of such performance target, Named Executive Officers are eligible to vest up to a maximum of 200% of the target number of shares of Exelixis common stock subject to the PSU award. For more information regarding the PSUs granted in 2020, please see “Compensation Discussion and Analysis—2020 Compensation Decisions—2020 Long-Term Incentive Awards” above. Failure to achieve the aforementioned performance target by December 31, 2024 will result in forfeiture of 100% of the PSU award, and vesting is subject to acceleration as described under the caption “—Potential Payments Upon Termination or Change in Control” below.

2020 Proxy Statement    79


Compensation Arrangements

 

Base Salaries. For a description of actions taken by the Compensation Committee with respect to base salaries for our Named Executive Officers for fiscal 2019,2020, please see “Compensation Discussion and Analysis—20192020 Compensation Decisions—20192020 Base Salaries” above.

Annual Cash Bonuses. Prior to 2018 the Compensation Committee considered and approved the payment of annual cash bonuses to the Named Executive Officers for services rendered in the prior year. Historically, the payment of bonuses had been entirely within the discretion of the Compensation Committee. Accordingly, we did not consider the bonuses reported in theSummary Compensation Table in fiscal 2017 tobe “Non-Equity Incentive Plan Compensation” within the meaning of applicable SEC rules. In 2018, we adopted our Annual Cash Bonus Plan that provides for annual bonus awards to reward executive officers based on our corporate performance, including achievement ofagainst pre-determined corporate goals and their contribution to the thatindividual contributions of each Named Executive Officer toward the achievement and we consider the bonuses reported in theSummary Compensation Table in fiscal 2018 and fiscal 2019 to be“Non-Equity Incentive Plan Compensation” within the meaning of applicable SEC rules.such corporate goals. For more information regarding our Annual Cash Bonus Plan, please see “Compensation Discussion and Analysis—20192020 Compensation Decisions—20192020 Annual Cash Bonuses” above.

Stock Awards and Option Awards. Our 2017 Plan provides for the grant of RSUs, PSUs and time-based and performance-based stock options to our Named Executive Officers and other employees. In September 2019,2020, we granted PSU awards, which will only vest following our achievement of a certain performance target in line with our longer-term business strategy, to all of our Named Executive Officers. In addition, in February 2020, we granted a time-based RSU award to Mr. Haley. For information regarding PSU and RSU awards granted to the Named Executive Officers in fiscal 2019,2020, including the number of underlying shares and vesting conditions related thereto, please see “Compensation Discussion and Analysis—20192020 Compensation Decisions—20192020 Long-Term Incentive Awards” above.

Employment Agreements.We have no employment agreements with our Named Executive Officers.

Change in Control and Severance Benefit Plan. Each of our Named Executive Officers participates in our Change in Control and Severance Benefit Plan, a description of which is included below under the heading “Potential Payments Upon Termination or Change in Control.

Other Compensatory Arrangements. Please see “Compensation Discussion and Analysis—Compensation Elements—Other Compensation” above for a description of other executive compensatory arrangements, including our 401(k) Plan and other benefits.

 

80    Exelixis, Inc.

70    Exelixis, Inc.


Compensation of Executive Officers | Outstanding Equity Awards at Fiscal Year–End

 

Outstanding Equity Awards at Fiscal Year-End

 

The following table shows certain information regarding outstanding equity awards at January 3, 2020,1, 2021, for the Named Executive Officers.

Outstanding Equity Awards at January 3, 20201, 2021

 

  

 

 Option Awards(1) Stock Awards(2) 
   Option Awards(1) Stock Awards(2) 

Name

 

Grant

Date

 

Number of
Securities
Underlying
Unexercised
Options
(#)

Exercisable

 

Number of
Securities
Underlying
Unexercised
Options
(#)

Unexercisable

 Equity
Incentive
Plan Awards:
Number of
Securities
Underlying
Unexercised
Unearned
Options
(#)
 

Option
Exercise
Price

($)

 

Option
Expiration

Date

 

Number of
Shares or
Units of
Stock That
Have Not
Vested

(#)

 Market
Value of
Shares
or Units
of Stock
That
Have  Not
Vested
($)(3)
 

Equity Incentive

Plan Awards:
Number of
Unearned Shares,
Units or
Other Rights That
Have Not
Vested

(#)

 

Equity Incentive
Plan Awards:
Market or
Payout Value of
Unearned
Shares, Units or
Other Rights
That Have Not
Vested

($)(3)

  

Grant

Date

 

Number of
Securities
Underlying
Unexercised
Options
(#)

Exercisable

 

Number of
Securities
Underlying
Unexercised
Options
(#)

Unexercisable

 

Option
Exercise
Price

($)

 

Option
Expiration

Date

 

Number of
Shares or
Units of
Stock That
Have Not
Vested

(#)

 Market
Value of
Shares
or Units
of Stock
That
Have  Not
Vested
($)(3)
 

Equity Incentive

Plan Awards:
Number of
Unearned Shares,
Units or
Other Rights That
Have Not
Vested

(#)

 

Equity Incentive
Plan Awards:
Market or
Payout Value of
Unearned
Shares, Units or
Other Rights
That Have Not
Vested

($)(3)

 

Michael M. Morrissey, Ph.D.

  9/18/2013   935,000       5.51   9/17/2020          

 

2/11/2016

 

 

 

150,000

 

   

 

4.20

 

 

 

2/10/2023

 

        
 9/19/2014   570,284       1.70   9/18/2021         
  9/16/2015   500,000       6.21   9/15/2022         
  2/11/2016   143,750   6,250(4)     4.20   2/10/2023         
  9/26/2016   292,500   67,500(6)     15.31   9/25/2023          

 

9/26/2016

 

 

 

360,000

 

   

 

15.31

 

 

 

9/25/2023

 

        
  9/26/2016             15,000(7)   255,150      

 

10/3/2017

 

 

 

380,000

 

 

 

100,000

(4) 

 

 

24.41

 

 

 

10/2/2024

 

        
  10/3/2017   270,000   210,000(8)     24.41   10/2/2024          

 

10/3/2017

 

         

 

20,000(5)

 

 

 

401,400

 

    
  10/3/2017        40,000(9)   680,400    

 

9/10/2018

 

 

 

173,455

 

 

 

134,910

(6) 

 

 

18.80

 

 

 

9/9/2025

 

        
  9/10/2018       308,365(10)   18.80   9/9/2025          

 

9/10/2018

 

         

 

18,591(7)

 

 

 

373,121

 

    
  9/10/2018             12,394(11)   210,822      

 

9/10/2018

 

         

 

11,619(8)

 

 

 

233,193

 

    
  9/10/2018             18,591(12)   316,233      

 

9/10/2018

 

             

 

23,238

(9) 

 

 

466,387

 

  9/10/2018                 23,238(13)   395,278  

 

9/10/2018

 

             

 

46,478

(10) 

 

 

932,813

 

  9/10/2018                 23,238(14)   395,278  

 

9/20/2019

 

         

 

336,431

(12) 

 

 

6,752,170

 

 

 

224,287

(12) 

 

 

4,501,440

 

  9/10/2018                 46,478(15)   790,591  

 

10/22/2020

 

             

 

94,002

(13) 

 

 

1,886,620

 

  9/20/2019                 448,574(17)   7,630,244  

 

10/22/2020

 

             

 

94,002

(14) 

 

 

1,886,620

 

Gisela M. Schwab, M.D.

  9/18/2013   140,000       5.51   9/17/2020          

 

9/19/2014

 

 

 

200,000

 

   

 

1.70

 

 

 

9/18/2021

 

        
  9/19/2014   500,000       1.70   9/18/2021          

 

2/5/2015

 

 

 

250,000

 

   

 

1.90

 

 

 

2/4/2022

 

        
  2/5/2015   250,000       1.90   2/4/2022          

 

9/16/2015

 

 

 

245,000

 

   

 

6.21

 

 

 

9/15/2022

 

        
  9/16/2015   245,000       6.21   9/15/2022          

 

2/11/2016

 

 

 

75,000

 

   

 

4.20

 

 

 

2/10/2023

 

        
  2/11/2016   71,875   3,125(4)     4.20   2/10/2023          

 

9/22/2016

 

 

 

120,000

 

   

 

14.74

 

 

 

9/21/2023

 

        
  9/22/2016   97,500   22,500(5)     14.74   9/21/2023          

 

10/3/2017

 

 

 

118,750

 

 

 

31,250

(4) 

 

 

24.41

 

 

 

10/2/2024

 

        
  9/22/2016             5,000(7)   85,050      

 

10/3/2017

 

         

 

18,750

(5) 

 

 

376,313

 

    
  10/3/2017   84,375   65,625(8)     24.41   10/2/2024          

 

9/10/2018

 

 

 

72,738

 

 

 

56,576

(11) 

 

 

18.80

 

 

 

9/9/2025

 

        
  10/3/2017             37,500(9)   637,875      

 

9/10/2018

 

         

 

7,796

(7) 

 

 

156,466

 

    
  9/10/2018   40,410   88,904(16)     18.80   9/9/2025          

 

9/10/2018

 

         

 

4,873

(8) 

 

 

97,801

 

    
  9/10/2018             5,198(11)   88,418      

 

9/10/2018

 

             

 

9,745

(9) 

 

 

195,582

 

  9/10/2018             7,796(12)   132,610      

 

9/10/2018

 

             

 

19,491

(10) 

 

 

391,184

 

  9/10/2018                 9,745(13)   165,762  

 

9/20/2019

 

         

 

106,940

(12) 

 

 

2,146,286

 

 

 

71,293

(12) 

 

 

1,430,851

 

  9/10/2018                 9,745(14)   165,762  

 

9/11/2020

 

             

 

32,567

(13) 

 

 

653,620

 

  9/10/2018                 19,491(15)   331,542  

 

9/11/2020

 

             

 

32,567

(14) 

 

 

653,620

 

  9/20/2019                 142,586(17)   2,425,388 

 

2020 Proxy Statement    81


      Option Awards(1)  Stock Awards(2) 

Name

 

Grant

Date

  

Number of
Securities
Underlying
Unexercised
Options
(#)

Exercisable

  

Number of
Securities
Underlying
Unexercised
Options
(#)

Unexercisable

  Equity
Incentive
Plan Awards:
Number of
Securities
Underlying
Unexercised
Unearned
Options
(#)
  

Option
Exercise
Price

($)

  

Option
Expiration

Date

  

Number of
Shares or
Units of
Stock That
Have Not
Vested

(#)

  Market
Value of
Shares
or Units
of Stock
That
Have Not
Vested
($)(3)
  

Equity Incentive

Plan Awards:
Number of
Unearned Shares,
Units or
Other Rights That
Have Not
Vested

(#)

  

Equity Incentive
Plan Awards:
Market or
Payout Value of
Unearned
Shares, Units or
Other Rights
That Have Not
Vested

($)(3)

 

Christopher J. Senner

  7/15/2015   250,000           3.66   7/14/2022                 
  9/16/2015   225,000           6.21   9/15/2022                 
  9/22/2016   97,500   22,500(5)       14.74   9/21/2023                 
  9/22/2016                       5,000(7)   85,050         
  10/3/2017   70,312   54,688(8)       24.41   10/2/2024                 
  10/3/2017                       31,250(9)   531,563         
  9/10/2018   40,410   88,904(16)       18.80   9/9/2025                 
  9/10/2018                       5,198(11)   88,418         
  9/10/2018                       7,796(12)   132,610         
  9/10/2018                               9,745(13)   165,762 
  9/10/2018                               9,745(14)   165,762 
  9/10/2018                               19,491(15)   331,542 
   9/20/2019                               118,821(17)   2,021,145 

Jeffrey J. Hessekiel, J.D.

  2/10/2014   130,000           7.27   2/9/2021                 
  9/19/2014   25,000           1.70   9/18/2021                 
  2/5/2015   172,698           1.90   2/4/2022                 
  9/16/2015   190,000           6.21   9/15/2022                 
  9/22/2016   79,218   18,282(5)       14.74   9/21/2023                 
  9/22/2016                       4,062(7)   69,094         
  10/3/2017   56,250   43,750(8)       24.41   10/2/2024                 
  10/3/2017                       25,000(9)   425,250         
  9/10/2018   40,410   88,904(16)       18.80   9/9/2025                 
  9/10/2018                       2,999(11)   51,013         
  9/10/2018                       4,498(12)   76,511         
  9/10/2018                               4,998(13)   85,016 
  9/10/2018                               4,998(14)   85,016 
  9/10/2018                               9,994(15)   169,998 
   9/20/2019                               118,821(17)   2,021,145 

Peter Lamb, Ph.D.

  9/18/2013   126,000           5.51   9/17/2020                 
  9/19/2014   320,000           1.70   9/18/2021                 
  2/5/2015   175,000           1.90   2/4/2022                 
  9/16/2015   190,000           6.21   9/15/2022                 
  2/11/2016   38,333   1,667(4)       4.20   2/10/2023                 
  9/22/2016   79,218   18,282(5)       14.74   9/21/2023                 
  9/22/2016                       4,062(7)   69,094         
  10/3/2017   61,875   48,125(8)       24.41   10/2/2014                 
  10/3/2017                       27,500(9)   467,775         
  9/10/2018   38,856   85,485(16)       18.80   9/9/2025                 
  9/10/2018                       4,998(11)   85,016         
  9/10/2018                       7,497(12)   127,524         
  9/10/2018                               9,370(13)   159,384 
  9/10/2018                               9,370(14)   159,384 
  9/10/2018                               18,741(15)   318,784 
   9/20/2019                               142,586(17)   2,425,388 

82    Exelixis, Inc.

2021 Proxy Statement    71


Compensation of Executive Officers | Outstanding Equity Awards at Fiscal Year–End

  

 

  

 

  Option Awards(1)  Stock Awards(2) 

Name

 

Grant

Date

  

Number of
Securities
Underlying
Unexercised
Options
(#)

Exercisable

  

Number of
Securities
Underlying
Unexercised
Options
(#)

Unexercisable

  

Option
Exercise
Price

($)

  

Option
Expiration

Date

  

Number of
Shares or
Units of
Stock That
Have Not
Vested

(#)

  Market
Value of
Shares
or Units
of Stock
That
Have  Not
Vested
($)(3)
  

Equity Incentive

Plan Awards:
Number of
Unearned Shares,
Units or
Other Rights That
Have Not
Vested

(#)

  

Equity Incentive
Plan Awards:
Market or
Payout Value of
Unearned
Shares, Units or
Other Rights
That Have Not
Vested

($)(3)

 

Christopher J. Senner

 

 

7/15/2015

 

 

 

120,000

 

     

 

3.66

 

 

 

7/14/2022

 

                
 

 

9/16/2015

 

 

 

225,000

 

     

 

6.21

 

 

 

9/15/2022

 

                
 

 

9/22/2016

 

 

 

120,000

 

     

 

14.74

 

 

 

9/21/2023

 

                
 

 

10/3/2017

 

 

 

98,958

 

 

 

26,042

(4) 

 

 

24.41

 

 

 

10/2/2024

 

                
 

 

10/3/2017

 

                 

 

15,625

(5) 

 

 

313,594

 

        
 

 

9/10/2018

 

 

 

72,738

 

 

 

56,576

(11) 

 

 

18.80

 

 

 

9/9/2025

 

                
 

 

9/10/2018

 

                 

 

7,796

(7) 

 

 

156,466

 

        
 

 

9/10/2018

 

                 

 

4,873

(8) 

 

 

97,801

 

        
 

 

9/10/2018

 

                         

 

9,745

(9) 

 

 

195,582

 

 

 

9/10/2018

 

                         

 

19,491

(10) 

 

 

391,184

 

 

 

9/20/2019

 

                 

 

89,116

(12) 

 

 

1,788,558

 

 

 

59,411

(12) 

 

 

1,192,379

 

 

 

9/11/2020

 

                         

 

32,567

(13) 

 

 

653,620

 

  

 

9/11/2020

 

                         

 

32,567

(14) 

 

 

653,620

 

Jeffrey J. Hessekiel, J.D.

 

 

2/10/2014

 

 

 

30,000

 

     

 

7.27

 

 

 

2/9/2021

 

                
 

 

2/5/2015

 

 

 

20,000

 

     

 

1.90

 

 

 

2/4/2022

 

                
 

 

9/22/2016

 

 

 

97,500

 

     

 

14.74

 

 

 

9/21/2023

 

                
 

 

10/3/2017

 

 

 

79,166

 

 

 

20,834

(4) 

 

 

24.41

 

 

 

10/2/2024

 

                
 

 

10/3/2017

 

                 

 

12,500

(5) 

 

 

250,875

 

        
 

 

9/10/2018

 

 

 

72,738

 

 

 

56,576

(11) 

 

 

18.80

 

 

 

9/9/2025

 

                
 

 

9/10/2018

 

                 

 

4,498

(7) 

 

 

90,275

 

        
 

 

9/10/2018

 

                 

 

2,499

(8) 

 

 

50,155

 

        
 

 

9/10/2018

 

                         

 

4,998

(9) 

 

 

100,310

 

 

 

9/10/2018

 

                         

 

9,994

(10) 

 

 

200,580

 

 

 

9/20/2019

 

                 

 

89,116

(12) 

 

 

1,788,558

 

 

 

59,411

(12) 

 

 

1,192,379

 

 

 

9/11/2020

 

                         

 

28,950

(13) 

 

 

581,027

 

  

 

9/11/2020

 

                         

 

28,950

(14) 

 

 

581,027

 

Patrick J. Haley.

 

 

9/19/2014

 

 

 

25,000

 

     

 

1.70

 

 

 

9/18/2021

 

                
 

 

2/5/2015

 

 

 

60,000

 

     

 

1.90

 

 

 

2/4/2022

 

                
 

 

9/16/2015

 

 

 

60,000

 

     

 

6.21

 

 

 

9/15/2022

 

                
 

 

2/11/2016

 

 

 

25,000

 

     

 

4.20

 

 

 

2/10/2023

 

                
 

 

12/19/2016

 

 

 

50,000

 

     

 

16.29

 

 

 

12/18/2023

 

                
 

 

10/3/2017

 

 

 

79,166

 

 

 

20,834

(4) 

 

 

24.41

 

 

 

10/2/2024

 

                
 

 

10/3/2017

 

                 

 

12,500

(5) 

 

 

250,875

 

        
 

 

9/10/2018

 

 

 

65,465

 

 

 

50,918

(11) 

 

 

18.80

 

 

 

9/9/2025

 

                
 

 

9/10/2018

 

                 

 

4,048

(7) 

 

 

81,243

 

        
 

 

9/10/2018

 

                 

 

2,249

(8) 

 

 

45,137

 

        
 

 

9/10/2018

 

                         

 

4,498

(9) 

 

 

90,275

 

 

 

9/10/2018

 

                         

 

8,995

(10) 

 

 

180,530

 

 

 

9/20/2019

 

                 

 

89,116

(12) 

 

 

1,788,558

 

 

 

59,411

(12) 

 

 

1,192,379

 

 

 

2/19/2020

 

                 

 

35,000

(15) 

 

 

702,450

 

        
 

 

9/11/2020

 

                         

 

28,950

(13) 

 

 

581,027

 

  

 

9/11/2020

 

                         

 

28,950

(14) 

 

 

581,027

 

 

(1)

Option awards granted on or after May 18, 2011, and prior to May 28, 2014, were issued under our 2011 Equity Incentive Plan (2011 Plan) and were either subject to time-based vesting or were subject to performance-based vesting and expire seven years from the date of grant or earlier upon

72    Exelixis, Inc.


Compensation of Executive Officers | Outstanding Equity Awards at Fiscal Year–End

termination of continuous service. Option awards granted on or after May 28, 2014, and prior to May 24, 2017, were issued under our 2014 Equity Incentive Plan (2014 Plan) and are either subject to time-based vesting or were subject to performance-based vesting and expire seven years from the date of grant or earlier upon termination of continuous service. Vesting of option awards granted under the 2014 Plan is set forth in the applicable footnote accompanying the entry. Option awards granted pursuant to our 2014 Plan subject to time-based vesting vest as to 1/4th of the original number of shares subject to the option on theone-year anniversary of the vesting commencement date and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the vesting commencement date. Option awards granted pursuant to our 2014 Plan subject to performance-based vesting are vested in full. Option awards granted on or after May 24, 2017 were issued under our 2017 Plan and are subject to time-based vesting and expire seven years from the date of grant or earlier upon termination of continuous service. Vesting of option awards granted under the 2017 Plan is set forth in the applicable footnote accompanying the entry. Option awards granted pursuant to our 2017 Plan subject to time-based vesting vest as to 1/4th of the original number of shares subject to the option on theone-year anniversary of the vesting commencement date and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the vesting commencement date. One option award granted pursuant to our 2017 Plan subject to performance-based vesting, in addition to time-based vesting, will not be exercisable until the achievement of the stock price target set by the Compensation Committee, as described below in Footnote 12. Vesting of all options issued to our Named Executive Officers are subject to acceleration as described under the caption “Potential Payments Upon Termination or Change in Control” below.

 

(2)

RSU awards granted on or after May 28, 2014 and prior to May 24, 2017 were issued under our 2014 Plan, and RSU awards granted on or after May 24, 2017 were issued under our 2017 Plan. RSU awards generally vest as to 1/4th of the original number of shares subject to the RSU award on the first established RSU vesting date following the one year anniversary of the grant date and thereafter as to 1/4th of the original number of shares subject to the RSU award on each anniversary of the first established RSU vesting date following the one year anniversary of the grant date, until fully vested. We have established February 15th, May 15th, August 15th and November 15th as quarterly vesting dates. Vested shares will be delivered to the Named Executive Officer on the applicable quarterly vesting date, provided that delivery may be delayed pursuant to the terms of the award agreement. In addition, PSU awards granted pursuant to our 2017 Plan vest based on the achievement of certain performance targets set by the Compensation Committee as described below in Footnotes 11,7, 8, 9, 10, 12, 13 14, 15 and 17.14. Vesting of all RSU awards and PSU awards issued to our Named Executive Officers is subject to acceleration as described under the caption “Potential Payments Upon Termination or Change in Control” below.

 

(3)

For purposes of determining market value, we assumed a stock price of $17.01,$20.07, the closing sale price per share of our common stock on January 3,December 31, 2020, the last business day of our last fiscal year.

 

(4)

Option vests as to 1/4th of the original number of shares subject to the option on theone-year anniversary of the grant date and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the grant date with a final vesting date of February 11, 2020 (assuming that such options are not accelerated).

(5)

Option vests as to 1/4th of the original number of shares subject to the option on theone-year anniversary of the grant date and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the grant date with a final vesting date of September 22, 2020 (assuming that such options are not accelerated).

(6)

Option vests as to 1/4th of the original number of shares subject to the option on theone-year anniversary of the grant date and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the grant date with a final vesting date of September 26, 2020 (assuming that such options are not accelerated).

(7)

RSUs vest as to 1/4th of the original number of shares subject to the RSU award on each November 15th with a final vesting date of November 15, 2020 (assuming that such RSUs are not accelerated).

(8)

Option vests as to 1/4th of the original number of shares subject to the option on theone-year anniversary of the grant date and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the grant date with a final vesting date of October 3, 2021 (assuming that such options are not accelerated).

 

(9)(5)

RSUs vest as to 1/4th of the original number of shares subject to the RSU award on each November 15th with a final vesting date of November 15, 2021 (assuming that such RSUs are not accelerated).

 

(10)(6)

Option vests as to 1/4th of the original number of shares subject to the option on theone-year anniversary of the grant date and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the grant date with a final vesting date of September 10, 2022 (assuming that such options are not accelerated). However,The option became exercisable upon the option will not be exercisable untilachievement of the performance condition that required the closing market price of our common stock isto be equal to or greater than 125% of the exercise price of the option over a period of at least 30 consecutive calendar days.

 

(11)

PSUs vest as to (i) 50% of the original number of shares subject to the award upon the Compensation Committee’s certification that Exelixis has achieved a quarterly net product revenue target, and (ii) 50% of the original number of shares subject to the award on the first quarterly vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following theone-year anniversary of the Compensation Committee’s certification (assuming that such PSUs are not accelerated). On September 12, 2019, the Compensation Committee convened to determine that the quarterly net product revenue target had been achieved during the three months ended June 28, 2019, resulting in the immediate vesting of 50% of the PSU award, and the remaining 50% (reported in the table) will vest on November 15, 2020 (assuming that such PSUs are not accelerated).

(12)(7)

PSUs vest as to (i) 50% of the original number of shares subject to the award upon the Compensation Committee’s certification that Exelixis has achieved a net product revenue target over four consecutive fiscal quarters, and (ii) 50% of the original number of shares subject to the award on the first quarterly vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following theone-year anniversary of the Compensation Committee’s certification (assuming that such PSUs are not accelerated). On December 4, 2019, the Compensation Committee convened to determine that the net product revenue target over four consecutive fiscal quarters had been achieved during the three months ended September 27, 2019, resulting in the immediate vesting of 50% of the PSU award, and the remaining 50% (reported in the table) will vestvested on February 15, 2021 (assuming that(reported in the table as unvested, since such PSUs are not accelerated)were still unvested as of January 1, 2021).

 

2020 Proxy Statement    83


(13)(8)

PSUs vest as to (i) 50% of the original number of shares subject to the award upon the Compensation Committee’s certification that Exelixis has initiated a target number of potentially label-enabling clinical trials for cabozantinib (both alone or in combination with another therapy), and (ii) 50% of the original number of shares subject to the award on the first quarterly vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following theone-year anniversary of the Compensation Committee’s certification (assuming that such PSUs are not accelerated). FailureOn September 2, 2020, the Compensation Committee convened to achievedetermine that the aforementioned performance target by December 31, 2021 will resultnumber of potentially label-enabling clinical trials had been achieved, resulting in forfeiturethe immediate vesting of 100%50% of the PSU award.award, and the remaining 50% (reported in the table) will vest on November 15, 2021 (assuming such PSUs are not accelerated).

 

(14)(9)

PSUs vest as to (i) 50% of the original number of shares subject to the award upon the Compensation Committee’s certification that Exelixis has achieved either (x) full target enrollment, as specified in the applicable clinical trial protocol, or (y) positivetop-line results, in each case with respect to a target number of potentially label-enabling clinical trials for cabozantinib (both alone or in combination with another therapy), and (ii) 50% of the original number of shares subject to the award on the first quarterly vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following theone-year anniversary of the Compensation Committee’s certification (assuming that such PSUs are not accelerated). FailureOn February 3, 2021, the Compensation Committee convened to achievedetermine that full target enrollment and/or positive top-line results from the aforementioned performance target by December 31, 2021 will resultnumber of potentially label-enabling clinical trials had been achieved, resulting in forfeiturethe immediate vesting of 100%50% of the PSU award.award, and the remaining 50% (reported in the table) will vest on February 15, 2022 (assuming such PSUs are not accelerated); however, because the Compensation Committee had not yet certified the achievement of the performance criteria as of January 1, 2021, this PSU award is reported as “unearned” in the table above.

 

(15)(10)

PSUs vest as to (i) 50% of the original number of shares subject to the award upon the Compensation Committee’s certification that a target number of IND applications or equivalent filings with foreign governmental authorities have been approved or otherwise become effective with respect to product candidates that have either (x) been discovered by Exelixis or(y) in-licensed or acquired by Exelixis, and (ii) 50% of the original number of shares subject to the award on the first quarterly vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following theone-year anniversary of the Compensation Committee’s certification (assuming that such PSUs are not accelerated). Failure to achieve the aforementioned performance target by December 31, 2021 will result in forfeiture of 100% of the PSU award.

 

(16)
2021 Proxy Statement    73


(11)

Option vests as to 1/4th of the original number of shares subject to the option on theone-year anniversary of the grant date and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the grant date with a final vesting date of September 10, 2022 (assuming that such options are not accelerated).

 

(17)(12)

PSUs vest as to (i) 50% of the original number of shares subject to the award that are entitled to vest based upon the Compensation Committee’s certification that the Companycompany has obtained approval by the FDA for the commercial sale and marketing of one or more products for which we hold, or have licensed to a partner, development and commercialization rights in the U.S. in one or more new indications, on the date of such certification, and (ii) 50% of the original number of shares subject to the award that are entitled to vest based on such certification on the first quarterly vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following theone-year anniversary of the Compensation Committee’s certification (assuming that such PSUs are not accelerated). On October 22, 2020, the Compensation Committee convened to determine that certain performance criteria had been achieved early, resulting in the immediate vesting of 75% of the target number of shares subject to the PSU award, and an additional 75% of the target number of shares subject to the PSU award (reported in the table) will vest on November 15, 2021 (assuming such PSUs are not accelerated). On February 3, 2021, the Compensation Committee convened to determine that the maximum performance criteria had been achieved, resulting in the immediate vesting of an additional 25% of the target number of shares subject to the PSU award, and an additional 25% of the target number of shares subject to the PSU award will vest on February 15, 2022 (assuming such PSUs are not accelerated); however, because the Compensation Committee had not yet certified the maximum achievement of the performance criteria as of January 1, 2021, this portion of the PSU award (representing 50% of the target number of shares of Exelixis common stock) is reported as “unearned” in the table above.

(13)

PSUs vest as to (i) 50% of the 2020 PSU Certified Shares upon the Compensation Committee’s certification that the company has achieved positive top-line results of one or more clinical trials evaluating a product for which we own, or have licensed to a partner, development or commercialization rights, that provides data that can reasonably support regulatory evaluation of safety and efficacy to determine the risk/benefit profile of the product, and (ii) 50% of the 2020 PSU Certified Shares on the first quarterly vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Compensation Committee’s certification (assuming that such PSUs are not accelerated). The number of shares reported in the table above representrepresents threshold achievement, or 50% of the target number of shares of Exelixis common stock subject to the PSU award. Depending on the level of achievement of such performance target, Named Executive Officers are eligible to vest up to a maximum of 200% of the target number of shares of Exelixis common stock subject to the PSU award. Failure to achieve the aforementioned performance target by December 31, 20212024 will result in forfeiture of 100% of the PSU award.

(14)

PSUs vest as to (i) 50% of the 2020 PSU Certified Shares upon the Compensation Committee’s certification that the company has obtained approval by the FDA for the commercial sale and marketing of one or more products for which we own, or have licensed to a partner, development or commercialization rights, in one or more new indications or an indication for which the product has previously received FDA approval, if such product is intended to treat a new, additional or expanded set of patients or is part of a combination therapy, and (ii) 50% of the 2020 PSU Certified Shares on the first quarterly vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Compensation Committee’s certification (assuming that such PSUs are not accelerated). The number of shares reported in the table above represents threshold achievement, or 50% of the target number of shares of Exelixis common stock subject to the PSU award. Depending on the level of achievement of such performance target, Named Executive Officers are eligible to vest up to a maximum of 200% of the target number of shares of Exelixis common stock subject to the PSU award. Failure to achieve the aforementioned performance target by December 31, 2024 will result in forfeiture of 100% of the PSU award.

(15)

RSUs vest as to 1/4th of the original number of shares subject to the RSU award on each May 15th with a final vesting date of May 15, 2024 (assuming that such RSUs are not accelerated).

Option Exercises and Stock Vested

 

The following table includes certain information with respect to stock options exercised and stock awards that vested during the fiscal year ended January 3, 2020.1, 2021.

Options Exercised and Stock Vested in Fiscal 20192020

 

  Option Awards   Stock Awards   Option Awards   Stock Awards 

Name

  Number of
Shares
Acquired on
Exercise(#)
   

Value

Realized on
Exercise($)(1)

   

Number of

Shares

Acquired on

Vesting(#)

   

Value

Realized on

Vesting($)(2)

   Number of
Shares
Acquired on
Exercise(#)
   

Value

Realized on
Exercise($)(1)

   

Number of

Shares

Acquired on

Vesting(#)

   

Value

Realized on

Vesting($)(2)

 

Michael M. Morrissey, Ph.D.

   727,000    10,950,945    65,984    1,145,044    2,005,284    40,643,720    395,443    8,537,011 

Gisela M. Schwab, M.D.

   416,109    6,144,439    36,743    629,962    440,000    8,230,955    140,759    3,018,930 

Christopher J. Senner

           33,618    578,368    130,000    2,855,222    119,810    2,567,545 

Jeffrey J. Hessekiel

   95,000    1,901,892    24,058    410,660    467,698    8,283,166    111,175    2,390,094 

Peter Lamb, Ph.D.

   245,000    3,979,169    30,305    522,773 

Patrick J. Haley

   41,055    944,743    112,430    2,415,040 

 

(1)

“Value Realized on Exercise” reflects the closing market price of our common stock on the applicable exercise date, net of the applicable exercise price, multiplied by the number of shares acquired upon exercise of stock options.

 

(2)

“Value Realized on Vesting” reflects the closing market price of our common stock on the applicable vesting date, multiplied by the number of units vested.

74    Exelixis, Inc.


Compensation of Executive Officers | Potential Payments Upon Termination or Change in Control

Potential Payments Upon Termination or Change in Control

 

Change in Control and Severance Benefit Plan

The Board, upon recommendation of the Compensation Committee, has adopted a Change in Control and Severance Benefit Plan that provides for certain severance benefits to our officers in connection with specified termination events. Eligible plan participants may include any employee having a rank of vice president or above, which includes the Named Executive Officers.

84    Exelixis, Inc.


Compensation of Executive Officers | Potential Payments Upon Termination or Change in Control

If a Named Executive Officer’s employment terminates due to an involuntary termination without cause or a constructive termination (Covered Termination) during a period starting one month prior to and ending 13 months following a change in control (Change in Control Termination), then the Named Executive Officer would be entitled to the following benefits under the plan:

 

 

a cash payment paid in installments pursuant to our regularly scheduled payroll periods equal to the sum of the Named Executive Officer’s base salary and target bonus for (i) 18 months for Named Executive Officers (other than the Chief Executive Officer) and (ii) 24 months for the Chief Executive Officer;

 

 

the vesting of up to all of the Named Executive Officer’s options, RSUs and PSUs will accelerate in full, and the exercise period of such options will be extended to the later of: (i) 12 months after the later of (x) the participant’s termination date, or (y) the change in control; and (ii) the post-termination exercise period provided for in the applicable option agreement; the plan also provides that any reacquisition or repurchase rights held by us in respect of common stock issued or issuable pursuant to any stock awards granted under any of our equity incentive plans shall lapse;

 

 

payment of COBRA premiums, or the cash equivalent thereof, for any health, dental or vision plan sponsored by Exelixis for a period of up to (i) 18 months for Named Executive Officers (other than the Chief Executive Officer) and (ii) 24 months for the Chief Executive Officer; and

 

 

payment of outplacement services for (i) 18 months for Named Executive Officers (other than the Chief Executive Officer), subject to a $30,000 limit and (ii) 24 months for the Chief Executive Officer, subject to a $50,000 limit.

In the event of a Covered Termination of a Named Executive Officer that is not also a Change in Control Termination, such Named Executive Officer would be entitled to receive a cash severance benefit under the plan equal to 12 months of base salary paid in installments pursuant to our regularly scheduled payroll periods. In such circumstances, we would also pay for a period of up to 12 months of such Named Executive Officer’s COBRA premiums, or the cash equivalent thereof, for any health, dental or vision plan that we sponsored and that the Named Executive Officer is enrolled in. However, such Named Executive Officer would not be entitled to any vesting acceleration benefits by virtue of such termination.

The payments and benefits described above are subject to certain reductions and offsets if, for example, the Named Executive Officer received other severance benefits from us pursuant to a written employment agreement. In addition, if any of the severance benefits payable under the plan would constitute a “parachute payment” subject to the excise tax imposed by Section 4999 of the Code, a Named Executive Officer may receive a reduced amount of the affected severance benefits. The plan does not provide for the gross up of any excise taxes imposed by Section 4999 of the Code. No Named Executive Officer would receive benefits under the plan if (i) the Named Executive Officer has entered into an individually negotiated employment agreement that provides for severance or change in control benefits, (ii) the Named Executive Officer voluntarily terminates employment with us to accept employment with another entity that is controlled by us or is otherwise affiliated with us or (iii) the Named Executive Officer does not confirm in writing that he or she is subject to agreements with us relating to proprietary and confidential information. In addition, as a general matter, to be eligible to receive benefits under the plan and if requested by Exelixis, a Named Executive Officer must execute a general waiver and release of claims, and such release must become effective in accordance with its terms. A Named Executive Officer’s right to receive payment of benefits under the plan will immediately terminate if, at any time prior to or during the period the Named Executive Officer is receiving such benefits, the Named Executive Officer, without the prior written approval of Exelixis, (i) willfully breaches a material provision of a proprietary and confidential information agreement with Exelixis or (ii) willfully encourages or solicits any of Exelixis’ then current employees to leave Exelixis’ employ.

Treatment of Equity Awards

Pursuant to our 2011 Plan, 2014 Plan and 2017 Plan, in the event of an asset sale, merger or consolidation in which we are not the surviving corporation, or a reverse merger in which we are the surviving corporation but our common stock is

2021 Proxy Statement    75


converted by virtue of the merger into other property, then any surviving or acquiring corporation may assume outstanding stock awards or substitute similar stock awards for those under the plan. If any surviving or acquiring corporation refuses to assume such outstanding stock awards or substitute similar stock awards, stock awards held by participants whose service has not terminated will be accelerated in full. In addition, if any person, entity or group acquires beneficial ownership of more than 50% of our combined voting power, then stock awards held by participants whose service has not terminated will be accelerated in full.

2020 Proxy Statement    85


The following table sets forth the potential severance payments and benefits under our Change in Control and Severance Benefit Plan to which a Named Executive Officer would be entitled in connection with specified termination events, as if such Named Executive Officers’ employment terminated as of January 3, 2020,1, 2021, the last day of our last fiscal year. In addition, the table sets forth the amounts to which such Named Executive Officers would be entitled under our equity plans either (i) in connection with a change in control transaction in which the successor corporation did not assume or substitute outstanding stock awards (and with respect to PSU awards granted to each Named Executive Officer, a change in control transaction in which a successor corporation does assume outstanding stock awards), or (ii) an entity or group acquired more than 50% of our combined voting power, in each case, as of January 3, 2020.1, 2021. There are no other agreements, arrangements or plans that entitle any of the above-mentioned Named Executive Officers to severance, perquisites or other enhanced benefits upon termination of employment, other than certain extensions of the termination date to avoid violation of registration requirements under the Securities Act of 1933, as amended, or for such Named Executive Officer’s death or disability.

Potential Payments Table

The following table shows the potential payments upon termination of employment or a change in control for the Named Executive Officers. The table assumes that the triggering event took place on January 3, 2020,1, 2021, the last day of our 20192020 fiscal year.

Potential Payments Upon Termination or Change in Control Table

 

Name

  Benefit  Change in Control and Severance
Benefit Plan
   Equity Plans   Benefit  Change in Control and Severance
Benefit Plan
   Equity Plans 

Involuntary

Termination

Without

Cause or

Constructive

Termination in

Connection

with a Change

of Control ($)(1)

   

Involuntary

Termination

Without

Cause or

Constructive

Termination Not

in Connection

with a Change

in Control ($)(2)

   

Certain

Change of

Control

Transactions

without

Termination

($)(3)

 

 

Involuntary

Termination

Without

Cause or

Constructive

Termination in

Connection

with a Change

of Control ($)(1)

   

 

Involuntary

Termination

Without

Cause or

Constructive

Termination Not

in Connection

with a Change

in Control ($)(2)

   

Certain

Change of

Control

Transactions

without

Termination

($)(3)

 

Michael M. Morrissey, Ph.D.

  Base Salary   2,034,280    1,017,140       Base Salary   2,135,994    1,067,997     
  Bonus   2,034,280           Bonus   2,135,994         
  Vesting Acceleration (4)   10,868,809        10,868,809   Vesting Acceleration (4)   21,420,249        21,420,249 
  COBRA Payments   71,067    35,533       COBRA Payments   71,067    35,533     
  Outplacement Services   50,000           Outplacement Services   50,000         

Benefit Total

      15,058,436    1,052,673    10,868,809       25,813,304    1,103,530    21,420,249 

Gisela M. Schwab, M.D.

  Base Salary   1,076,924    717,949       Base Salary   1,125,386    750,257     
  Bonus   538,461           Bonus   675,231         
  Vesting Acceleration (4)   4,123,514        4,123,514   Vesting Acceleration (4)   7,740,818        7,740,818 
  COBRA Payments   34,482    22,988       COBRA Payments   34,482    22,988     
  Outplacement Services   30,000           Outplacement Services   30,000         

Benefit Total

      5,803,381    740,937    4,123,514       9,605,917    773,245    7,740,818 

Christopher J. Senner

  Base Salary   942,101    628,067       Base Salary   979,784    653,189     
  Bonus   423,945           Bonus   489,892         
  Vesting Acceleration (4)   3,572,927        3,572,927   Vesting Acceleration (4)   7,215,847        7,215,847 
  COBRA Payments   53,300    35,533       COBRA Payments   53,300    35,533     
  Outplacement Services   30,000           Outplacement Services   30,000         

Benefit Total

      5,022,273    663,600    3,572,927       8,768,823    688,722    7,215,847 

Jeffrey J. Hessekiel, J.D.

  Base Salary   837,092    558,061     
  Bonus   376,691         
  Vesting Acceleration (4)   3,024,544        3,024,544 
  COBRA Payments   53,300    35,533     
  Outplacement Services   30,000         

Benefit Total

      4,321,627    593,594    3,024,544 

 

86    Exelixis, Inc.

76    Exelixis, Inc.


Compensation of Executive Officers | Potential Payments Upon Termination or Change in Control

 

Name

  Benefit  Change in Control and Severance
Benefit Plan
   Equity Plans   Benefit  Change in Control and Severance
Benefit Plan
   Equity Plans 

Involuntary

Termination

Without

Cause or

Constructive

Termination in

Connection

with a Change

of Control

($)(1)

   

Involuntary

Termination

Without

Cause or

Constructive

Termination Not

in Connection

with a Change

in Control

($)(2)

   

Certain

Change of

Control

Transactions

without

Termination

($)(3)

 

 

Involuntary

Termination

Without

Cause or

Constructive

Termination in

Connection

with a Change

of Control ($)(1)

   

 

Involuntary

Termination

Without

Cause or

Constructive

Termination Not

in Connection

with a Change

in Control ($)(2)

   

Certain

Change of

Control

Transactions

without

Termination

($)(3)

 

Peter Lamb, Ph.D.

  Base Salary   783,602    522,401     

Jeffrey J. Hessekiel, J.D.

  Base Salary   870,576    580,384     
  Bonus   352,620           Bonus   435,288         
  Vesting Acceleration (4)   3,875,204        3,875,204   Vesting Acceleration (4)   6,358,477        6,358,477 
  COBRA Payments   20,271    13,514       COBRA Payments   53,300    35,533     
  Outplacement Services   30,000           Outplacement Services   30,000         

Benefit Total

      5,061,697    535,915    3,875,204       7,747,641    615,917    6,358,477 

Patrick J. Haley

  Base Salary   765,000    510,000     
  Bonus   382,500         
  Vesting Acceleration (4)   6,903,237        6,903,237 
  COBRA Payments   93,068    62,045     
  Outplacement Services   30,000         

Benefit Total

      8,173,805    572,045    6,903,237 

 

(1)

These benefits would be payable under the Change in Control and Severance Benefit Plan if the involuntary termination without cause or constructive termination occurred during a period starting one month prior to and ending 13 months following the change in control. The amounts shown in this column do not include any value associated with the extension, if any, of the post-termination exercise period provided for in the Change in Control and Severance Benefit Plan.

 

(2)

These benefits would be payable under the Change in Control and Severance Benefit Plan if the involuntary termination without cause occurred more than one month before the change in control or if the involuntary termination without cause or a constructive termination occurred more than 13 months following the change in control.

 

(3)

These benefits would be payable under the 2011 Plan and/or the 2014 Plan and/or the 2017 Plan if either (i) a successor corporation does not assume outstanding stock awards in a change in control transaction or (ii) a person, entity or group acquires beneficial ownership of more than 50% of our combined voting power, and, in each case, the Named Executive Officers do not terminate employment in connection with such a transaction or event.

 

2021 Proxy Statement    77


  

In addition, if a successor corporation does assume outstanding stock awards in a change in control transaction and the Named Executive Officers do not terminate employment in connection with such a transaction, then each Named Executive Officer’s then outstanding PSUs will be revised in a manner as the though target number of shares subject to such PSUs had been subject solely to a time-based vesting schedule pursuant to which one third of the target number of shares subject to such PSUs (and for the PSUs granted during fiscal 2020, one fourth) would have vested on each of the first three anniversaries (and for the PSUs granted during fiscal 2020, each of the first four anniversaries) of the date the PSUs were granted, subject to the Named Executive Officer’s continuous service through the applicable vesting date.date (with any portion that would have vested on or prior to the change in control transaction under such vesting schedule becoming vested on the date of the change in control transaction and any portion that is unvested following the date of the change in control transaction vesting in accordance with such vesting schedule). With respect to PSU awards granted during fiscal 2020, the vesting acceleration benefit for each Named Executive Officer would be $0 because the first anniversary of the grant date will not yet have occurred as of January 1, 2021. With respect to PSU awards granted during fiscal 2019, the vesting acceleration benefit for each Named Executive Officer would be $0.$0, because the performance criteria for the target number of such PSUs had already been achieved as of January 1, 2021. With respect to PSU awards granted during fiscal 2018, the vesting acceleration benefit for each Named Executive Officer would be as follows:

 

Name and Principal Position

  

Vesting Acceleration Benefit for  Outstanding

PSUs Granted in 2018

($)

 

Michael M. Morrissey, Ph.D.

   527,038932,793 

Gisela M. Schwab, M.D.

   221,011391,164 

Christopher J. Senner

   221,011391,164 

Jeffrey J. Hessekiel, J.D.

   113,338200,580 

Peter Lamb, Ph.D.Patrick J. Haley

   212,506180,510 

 

(4)

Assumes that the triggering event occurred on January 3,December 31, 2020, the last business day of our last fiscal year, when the closing sale price per share of our common stock was $17.01.$20.07. The amount of the vesting acceleration is determined by: (i) aggregating for all accelerated options, the amount equal to (A) the excess, if any, of $17.01$20.07 over the relevant exercise price of the option, multiplied by (B) the number of shares underlying unvested options at such exercise price as of January 3,December 31, 2020; and (ii) aggregating for all accelerated RSUs and PSUs, the amount equal to (X) $17.01$20.07 multiplied by (Y) the number of shares underlying the unvested RSUs and PSUs. There can be no assurance that a similar triggering event would produce the same or similar results as those estimated if such event occurs on any other date or at a time when our closing sale price is different.

2020 Proxy Statement    87


CEO Pay Ratio

 

We believe that we provide fair and equitable compensation to our employees through a combination of competitive base pay, incentives, retirement plans and other benefits. In accordance with Item 402(u) of RegulationS-K, promulgated by the Dodd Frank Act, we determined the ratio of: (a) the annual total compensation of our Chief Executive Officer; to (b) the median of the annual total compensation of all of our employees, except for our Chief Executive Officer, both calculated in accordance with the requirements of Item 402(c)(2)(x) of RegulationS-K (CEO Pay Ratio).

In order to determine the median of the annual total compensation of all of our employees, we were required to identify the “median employee” of our workforce, without regard to his or her location or employment status (full-time or part-time). The applicable SEC rules require us to identify a median employee only once every three years, as long as there have been no material changes in our employee population or employee compensation arrangements that we believe would significantly impact the calculation of our CEO Pay Ratio. However, because there was a significant increase in our employee population between October 2018,2019, when we identified our median employee to calculate our CEO Pay Ratio for fiscal 2018,2019, and October 2019,2020, we decided to identify a new median employee for purposes of calculating our CEO Pay Ratio for fiscal 2019.2020.

Consistent with the process we adopted for prior fiscal 2017 and fiscal 2018,years, to determine the median of the annual total compensation of all of our employees, except for our Chief Executive Officer, we used the following methodology:

 

 

To identify our employee population, we used tax and payroll records to determine all full-time and part-time employees, excluding our Chief Executive Officer, who were employed as of October 31, 2019.2020.

 

 

To identify the median employee with respect to annual total compensation of all of our employees, we calculated each employee’s “target total direct compensation,” which consists of: (i) fiscal 20192020 base salary (using a reasonable

78    Exelixis, Inc.


Compensation of Executive Officers | CEO Pay Ratio

estimate of the hours worked and overtime actually paid during fiscal 20192020 for hourly employees); (ii) target cash bonus; and (iii) the grant date fair value of any equity awards granted during fiscal 20192020 (using the same methodology that we use for estimating the value of the equity awards granted to our Named Executive Officers and reported in ourSummary Compensation Table).

 

 

In making this determination, we annualized the base salary and target cash bonus for all full-time and part-time employees who were employed by us for less than the entirety of fiscal 2019. Because there was an even number of employees, two individuals were identified at the median. We selected from among these two individuals a continuing employee whose actual compensation was within 5% of the compensation estimate used to identify the median.2020.

Once our representative median employee was identified in the manner described above, we calculated the annual total compensation of the representative median employee using the same methodology that we used to determine the annual total compensation of our Chief Executive Officer, as reported in theSummary Compensation Table included in this Proxy Statement. For fiscal 2019,2020, the median of the annual total compensation of our employees (other than our Chief Executive Officer) was $241,154$297,489 and the annual total compensation of our Chief Executive Officer, as reported in theSummary Compensation Table included in this Proxy Statement, was $2,132,555.$2,349,812. Based on this information, our CEO Pay Ratio for fiscal 20192020 was 98 to 1.

This CEO Pay Ratio represents our reasonable estimate calculated in a manner consistent with Item 402(u) of RegulationS-K and applicable guidance, which provide significant flexibility in how companies identify the median employee. Each company may use a different methodology and make different assumptions particular to that company. As a result, and as explained by the SEC when it adopted these rules, in considering this CEO Pay Ratio disclosure, stockholders should keep in mind that the rule was not designed to facilitate comparisons of CEO Pay Ratios among different companies, even companies within the same industry, but rather to allow stockholders to better understand and assess each particular company’s compensation practices and CEO Pay Ratio disclosures. Neither the Compensation Committee nor our management used our fiscal CEO Pay Ratio for fiscal 20192020 in making compensation decisions.

 

88    Exelixis, Inc.

2021 Proxy Statement    79


Compensation Committee Interlocks and Insider Participation

 

COMPENSATION COMMITTEE REPORT

The material in this report is not “soliciting material,” is not deemed “filed” with the Securities and Exchange Commission and is not deemed to be incorporated by reference in any filing of Exelixis under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.

The Compensation Committee of the Board of Directors of Exelixis, Inc., consisting solely of independent directors, has reviewed and discussed with management the Compensation Discussion and Analysis contained in this Proxy Statement and, based on this review and discussion, the Compensation Committee recommended to the Board of Directors that the Compensation Discussion and Analysis be included in this Proxy Statement and incorporated into our Annual Report on Form10-K for the year ended January 3, 2020.1, 2021.

Compensation Committee:

Charles Cohen, Chair

Vincent T. Marchesi

Julie A. Smith

Lance Willsey

COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION

During 2019,2020, the Compensation Committee comprised Drs. Cohen, Marchesi and Willsey Mr. Feldbaum (who transitioned off of the Compensation Committee on December 5, 2019) and Ms. Smith. None of the members of the Compensation Committee during 20192020 has at any time been an officer or employee of Exelixis, except that Dr. Cohen served as our acting Chief Scientific Officer from December 1995 to April 1997, and was named an officer of one of our former subsidiaries from 2001 through March 2005, for which he did not receive any compensation. No interlocking relationship exists between the Board or Compensation Committee and the board of directors or compensation committee of any other company, nor has any interlocking relationship existed in the past.

DELINQUENT SECTION 16(a) REPORTS

Section 16(a) of the Securities Exchange Act of 1934, as amended, requires our directors and executive officers and persons who own more than ten percent of a registered class of our equity securities to file with the SEC initial reports of ownership and reports of changes in ownership of our common stock and other equity securities of Exelixis. Officers, directors and greater than ten percent stockholders are required by SEC regulation to furnish us with copies of all Section 16(a) forms they file.

To our knowledge, based solely on a review of the copies of such reports furnished to us and written representations that no other reports were required, during the fiscal year ended January 3, 2021, all Section 16(a) filing requirements applicable to our officers, directors and greater than ten percent beneficial owners were complied with, except as follows: a Form 4 relating to a Rule 10b5-1 trading plan transaction by George A. Scangos, then a director, in which fifty thousand (50,000) shares of our common stock were sold on February 18, 2020 was not timely filed. A Form 4 reporting the transaction was subsequently filed on February 21, 2020.

CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

The Board recognizes that related party transactions can present a heightened risk of potential or actual conflicts of interests. The Board adopted a written Statement of Policy with respect to Related Person Transactions entered into with related parties. Under this policy, the Audit Committee has been tasked with responsibility to review and approve related party transactions. The policy provides that management shall present related party transactions to the Audit Committee for approval. The policy does not prevent management from entering into any related party transaction without prior approval of the Audit Committee, so long as such related party transaction is thereafter presented to the Audit Committee for ratification. If ratification is not forthcoming, then management shall make all reasonable efforts to cancel or annul such transaction.

80    Exelixis, Inc.


Certain Relationships and Related Party Transactions

Under the policy, a “related party” includes: any senior officer (including each executive officer or officer subject to Section 16 of the Exchange Act) or director of Exelixis; a person who is an immediate family member of a senior officer, director or director nominee; a security holder who is known to own of record or beneficially more than 5% percent of any class of our securities; a person who is an immediate family member of such security holder; or an entity which is owned or controlled by one of the aforementioned persons, or an entity in which one of the aforementioned persons has a substantial ownership interest in or control over such entity.

2020 Proxy Statement    89


All related party transactions shall be disclosed in our applicable filings with the SEC as required under SEC rules. There were no related party transactions reportable under the SEC rules during fiscal 2019, other than as follows:

During 2019,2020, BlackRock, Inc. (BlackRock), a global provider of investment, advisory and risk management solutions and a greater than 5% holder of our common stock, managed a portion of our cash and investments portfolio. As of January 1, 2021 and January 3, 2020, and December 28, 2018, respectively, the fair value of cash and investments managed by BlackRock was $515.1$574.6 million and $298.5$515.1 million, which included $1.4 million$10.3 and $3.0$1.4 million invested in the BlackRock Liquidity Money Market Fund. We incurred $0.3 million in fees for BlackRock advisory services performed during the year ended January 3, 2020.1, 2021.

HOUSEHOLDING OF PROXY MATERIALS

The SEC has adopted rules that permit companies and intermediaries (e.g., brokers, banks and other fiduciaries) to satisfy the delivery requirements for Notices of Internet Availability of Proxy Materials or other Annual Meeting materials with respect to two or more stockholders sharing the same address by delivering a single Notice or other Annual Meeting materials addressed to those stockholders. This process, which is commonly referred to as “householding,” potentially means extra convenience for stockholders and cost savings for companies.

This year, a number of brokers with account holders who are our stockholders will be householding proxy materials. A single Notice will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be householding communications to your address, householding will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in householding and would prefer to receive a separate Notice, please notify your broker or direct your written request to Investor Relations, Exelixis, Inc., 1851 Harbor Bay Parkway, Alameda, California 94502 or contact Exelixis, Inc., Investor Relations at(650) 837-7000. Stockholders who currently receive multiple copies of the Notice at their address and would like to request householding of their communications should contact their broker.

ANNUAL REPORT ON FORM10-K

A copy of our Annual Report on Form10-K for the fiscal year ended January 3, 2020,1, 2021, including the consolidated financial statements, schedules and list of exhibits, and any particular exhibit specifically requested, is available without charge upon written request to: Investor Relations, Exelixis, Inc., 1851 Harbor Bay Parkway, Alameda, California 94502.

OTHER MATTERS

The Board knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly brought before the meeting, it is the intention of the persons named in the accompanying proxy to vote on such matters in accordance with their best judgment.

By Order of the Board of Directors

 

LOGO

JEFFREY J. HESSEKIEL

Executive Vice President and General Counsel

Alameda, California

April 9, 202015, 2021

 

90    Exelixis, Inc.

2021 Proxy Statement    81


Appendix A

EXELIXIS, INC.

2017 EQUITY INCENTIVE PLAN

ADOPTEDBYTHE BOARDOF DIRECTORS: FEBRUARY 23, 2017

AMENDEDBYTHE COMPENSATION COMMITTEE: MARCH 22, 2017

APPROVEDBYTHE STOCKHOLDERS: MAY 24, 2017

AMENDEDBYTHE COMPANY: DECEMBER 18, 2017

AMENDEDBYTHE COMPENSATION COMMITTEE: MARCH 18, 2020

[APPROVEDBYTHE STOCKHOLDERS: MAY 20, 2020]

1.    GENERAL.

(a)Successor to and Continuation of 2014 Plan. The Plan is intended as the successor to and continuation of the Exelixis, Inc. 2014 Equity Incentive Plan (the “2014 Plan”). Following the Effective Date, no additional stock awards may be granted under the 2014 Plan. Any unallocated shares remaining available for grant under the 2014 Plan as of 12:01 a.m. Pacific time on the Effective Date (the “2014 Plans Available Reserve”) will cease to be available under the 2014 Plan at such time and will be added to the Share Reserve (as further described in Section 3(a) below) and be then immediately available for grant and issuance pursuant to Stock Awards granted under the Plan. In addition, from and after 12:01 a.m. Pacific timeon the Effective Date, all outstanding stock awards granted under the 2014 Plan, the Exelixis, Inc. 2000 Equity Incentive Plan, as amended and restated (the “2000 Plan”), the Exelixis, Inc. 2000Non-Employee Directors’ Stock Option Plan (the “2000Non-Employee Directors Plan”), the Exelixis, Inc. 2011 Equity Incentive Plan (the “2011 Plan”), and the Exelixis, Inc. 2016 Inducement Award Plan (the “2016 Inducement Plan”) will remain subject to the terms of the 2014 Plan, the 2000 Plan, the 2000Non-Employee Directors’ Plan, the 2011 Plan or the 2016 Inducement Plan, as applicable;provided, however, that any shares subject to outstanding stock awards granted under the 2014 Plan, the 2000 Plan, the 2000Non-Employee Directors’ Plan, the 2011 Plan or the 2016 Inducement Plan that (i) expire or terminate for any reason prior to exercise or settlement, (ii) are forfeited, cancelled or otherwise returned to the Company because of the failure to meet a contingency or condition required for the vesting of such shares, or (iii) other than with respect to outstanding options and stock appreciation rights granted under the 2014 Plan, the 2000 Plan, the 2000 Nonemployee Directors’ Plan, the 2011 Plan or the 2016 Inducement Plan with respect to which the exercise or strike price is at least one hundred percent (100%) of the Fair Market Value of the Common Stock subject to the option or stock appreciation right on the date of grant (the “Prior Plans Appreciation Awards”), are reacquired or withheld (or not issued) by the Company to satisfy a tax withholding obligation in connection with a stock award (collectively, the “Prior Plans Returning Shares”) will immediately be added to the Share Reserve (as further described in Section 3(a) below) as and when such shares become Prior Plans’ Returning Shares and become available for issuance pursuant to Awards granted hereunder. All Awards granted on or after 12:01 a.m. Pacific timeon the Effective Date will be subject to the terms of this Plan, as amended from time to time.

(b)Eligible Award Recipients. Subject to Section 4, Employees, Directors and Consultants are eligible to receive Awards.

(c)Available Awards. The Plan provides for the grant of the following types of Awards: (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Stock Appreciation Rights, (iv) Restricted Stock Awards, (v) Restricted Stock Unit Awards, (vi) Performance Stock Awards, (vii) Performance Cash Awards, and (viii) Other Stock Awards.

(d)Purpose. The Plan, through the granting of Awards, is intended to help the Company and any Affiliate secure and retain the services of eligible award recipients, provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and provide a means by which the eligible recipients may benefit from increases in value of the Common Stock.

2.    ADMINISTRATION.

(a)Administration by Board. The Board will administer the Plan. The Board may delegate administration of the Plan to a Committee or Committees, as provided in Section 2(c).

(b)Powers of Board. The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan:

(i)    To determine (A) who will be granted Awards; (B) when and how each Award will be granted; (C) what type of Award will be granted; (D) the provisions of each Award (which need not be identical), including when a person will be permitted to exercise or otherwise receive cash or Common Stock under the Award; (E) the number of shares of Common Stock subject to, or the cash value of, an Award; and (F) the Fair Market Value applicable to a Stock Award.

(ii)    To construe and interpret the Plan and Awards granted under it, and to establish, amend and revoke rules and regulations for administration of the Plan and Awards. The Board, in the exercise of these powers, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement, in a manner and to the extent it will deem necessary or expedient to make the Plan or Award fully effective.

(iii)    To settle all controversies regarding the Plan and Awards granted under it.

(iv)    To accelerate, in whole or in part, the time at which an Award may be exercised or vest (or the time at which cash or shares of Common Stock may be issued in settlement thereof).

(v)    To suspend or terminate the Plan at any time. Except as otherwise provided in the Plan or an Award Agreement, suspension or termination of the Plan will not materially impair a Participant’s rights under his or her then-outstanding Award without his or her written consent except as provided in subsection (viii) below.

(vi)    To amend the Plan in any respect the Board deems necessary or advisable, including, without limitation, by adopting amendments relating to Incentive Stock Options and certain nonqualified deferred compensation under Section 409A of the Code and/or to make the Plan or Awards granted under the Plan compliant with the requirements for Incentive Stock Options or exempt from or compliant with the requirements for nonqualified deferred compensation under Section 409A of the Code, subject to the limitations, if any, of applicable law. However, if required by applicable law or listing requirements, and except as provided in Section 9(a) relating to Capitalization Adjustments, the Company will seek stockholder approval of any amendment of the Plan that (A) materially increases the number of shares of Common Stock available for issuance under the Plan, (B) materially expands the class of individuals eligible to receive Awards under the Plan, (C) materially increases the benefits accruing to Participants under the Plan, (D) materially reduces the price at which shares of Common Stock may be issued or purchased under the Plan, or (E) materially expands the types of Awards available for issuance under the Plan. Except as otherwise provided in the Plan (including Section 2(b)(viii)) or an Award Agreement, no amendment of the Plan will materially impair a Participant’s rights under an outstanding Award without the Participant’s written consent.

(vii)    To submit any amendment to the Plan for stockholder approval, including, but not limited to, amendments to the Plan intended to satisfy the requirements of (A) Section 162(m) of the Code regarding the exclusion of performance-based compensation from the limit on corporate deductibility of compensation paid to Covered Employees, (B) Section 422 of the Code regarding incentive stock options or (C) Rule16b-3.

(viii)    To approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion;provided, however, that a Participant’s rights under any Award will not be impaired by any such amendment unless (A) the Company requests the consent of the affected Participant, and (B) such Participant consents in writing. Notwithstanding the foregoing, (1) a Participant’s rights will not be deemed to have been impaired by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as a whole, does not materially impair the Participant’s rights, and (2) subject to the limitations of applicable law, if any, the Board may amend the terms of any one or more Awards without the affected Participant’s consent (A) to maintain the qualified status of the Award as an Incentive Stock Option under Section 422 of the Code; (B) to change the terms of an Incentive Stock Option, if such change results in impairment of the Award solely because it impairs the qualified status of the Award as an Incentive Stock Option under Section 422 of the Code; (C) to clarify the manner of exemption from, or to bring the Award into compliance with, Section 409A of the Code; or (D) to comply with other applicable laws or listing requirements.

(ix)    Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Awards.

(x)    To adopt such procedures andsub-plans as are necessary or appropriate to permit participation in the Plan by Employees, Directors or Consultants who are foreign nationals or employed outside the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Award Agreement that are required for compliance with the laws of the relevant foreign jurisdiction).

(c)    Delegation to Committee.

(i)General. The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee, as applicable). Any delegation of administrative powers will be reflected in resolutions, not inconsistent with the provisions of the Plan, adopted from time to time by the Board or Committee (as applicable). The Committee may, at any time, abolish the subcommittee and/or revest in the Committee any powers delegated to the subcommittee. The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated.

(ii)Section 162(m) and Rule16b-3 Compliance. The Committee may consist solely of two or more Outside Directors, in accordance with Section 162(m) of the Code, or solely of two or moreNon-Employee Directors, in accordance with Rule16b-3.

(d)Delegation to an Officer. The Board may delegate to one or more Officers the authority to do one or both of the following: (i) designate Employees who are not Officers to be recipients of Options and SARs (and, to the extent permitted by applicable law, other Stock Awards) and, to the extent permitted by applicable law, the terms of such Awards, and (ii) determine the number of shares of Common Stock to be subject to such Stock Awards granted to such Employees;provided, however, that the Board resolutions regarding such delegation will specify the total number of shares of Common Stock that may be subject to the Stock Awards granted by such Officer and that such Officer may not grant a Stock Award to himself or herself. Any such Stock Awards will be granted on the form of Award Agreement most recently approved for use by the Committee or the Board, unless otherwise provided in the resolutions approving the delegation of authority. The Board may not delegate authority to an Officer who is acting solely in the capacity of an Officer (and not also as a Director) to determine the Fair Market Value pursuant to Section 13(w)(iii) below.

(e)Effect of Board’s Decision. All determinations, interpretations and constructions made by the Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons.

(f)Repricing; Cancellation andRe-Grant of Awards. Neither the Board nor any Committee will have the authority to (i) reduce the exercise, purchase or strike price of any

outstanding Option or SAR under the Plan, or (ii) cancel any outstanding Option or SAR that has an exercise price or strike price greater than the then-current Fair Market Value of the Common Stock in exchange for cash or other Awards under the Plan, unless the stockholders of the Company have approved such an action within 12 months prior to such an event.

(g)Minimum Vesting Requirements. No Award may vest until at least twelve (12) months following the date of grant of the Award;provided, however, that shares of Common Stock up to five percent (5%) of the Share Reserve (as defined in Section 3(a)) may be issued pursuant to Awards which do not meet such vesting requirement.

(h)Dividends and Dividend Equivalents.Dividends or dividend equivalents may be paid or credited, as applicable, with respect to any shares of Common Stock subject to an Award, as determined by the Board and contained in the applicable Award Agreement;provided, however, that (i) no dividends or dividend equivalents may be paid with respect to any such shares before the date such shares have vested under the terms of such Award Agreement, (ii) any dividends or dividend equivalents that are credited with respect to any such shares will be subject to all of the terms and conditions applicable to such shares under the terms of such Award Agreement (including, but not limited to, any vesting conditions), and (iii) any dividends or dividend equivalents that are credited with respect to any such shares will be forfeited to the Company on the date, if any, such shares are forfeited to or repurchased by the Company due to a failure to meet any vesting conditions under the terms of such Award Agreement.

3.    SHARES SUBJECTTOTHE PLAN.

(a)    Share Reserve.

(i)    Subject to Sections 3(b)(i) and 9(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Stock Awards from and after the Effective Date will not exceed (A) 45,453,064 shares (which number is the sum of (i) the number of shares (453,064) subject to the 2014 Plan’s Available Reserve, (ii) an additional 24,000,000 shares that were approved at the annual meeting of stockholders of the Company held in 2017, and (iii) an additional 21,000,000 shares that were approved at the annual meeting of stockholders of the Company held in 2020),plus (B) the Prior Plans’ Returning Shares, if any, which become available for issuance under this Plan from time to time (such aggregate number of shares described in (A) and (B) above, the “Share Reserve”).

(ii)    For clarity, the Share Reserve in this Section 3(a) is a limitation on the number of shares of Common Stock that may be issued pursuant to the Plan. Accordingly, this Section 3(a) does not limit the granting of Stock Awards except as provided in Section 7(a). Shares may be issued in connection with a merger or acquisition as permitted by Nasdaq Listing Rule 5635(c) or, if applicable, NYSE Listed Company Manual Section 303A.08, AMEX Company Guide Section 711 or other applicable rule, and such issuance will not reduce the number of shares available for issuance under the Plan.

(iii)    Subject to Section 3(b), the number of shares of Common Stock available for issuance under the Plan will be reduced by: (A) one share for each share of Common Stock issued pursuant to an Option or SAR with respect to which the exercise or strike price is at least 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date of grant; and (B) 1.5 shares for each share of Common Stock issued pursuant to a Full Value Award.

(b)    Reversion of Shares to the Share Reserve.

(i)Shares Available For Subsequent Issuance.If (A) any shares of Common Stock subject to a Stock Award are not issued because such Stock Award or any portion thereof expires or otherwise terminates without all of the shares covered by such Stock Award having been issued or is settled in cash (i.e., the Participant receives cash rather than stock), (B) any shares of Common Stock issued pursuant to a Stock Award are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required for the vesting of such shares, or (C) with respect to a Full Value Award, any shares of Common Stock are reacquired or withheld (or not issued) by the Company to satisfy a tax withholding obligation in connection with such Full Value Award, such shares will again become available for issuance under the Plan (collectively, the “2017 Plan Returning Shares”). For each (1) 2017 Plan Returning Share subject to a Full Value Award or (2) Prior Plans’ Returning Share subject to a stock award other than a Prior Plans’ Appreciation Award, the number of shares of Common Stock available for issuance under the Plan will increase by 1.5 shares.

(ii)Shares Not Available For Subsequent Issuance.Any shares of Common Stock reacquired or withheld (or not issued) by the Company to satisfy the exercise or purchase price of a Stock Award or a Prior Plans’ Award will no longer be available for issuance under the Plan, including any shares subject to a Stock Award or a Prior Plans’ Award that are not delivered to a Participant because such Stock Award or Prior Plans’ Award is exercised through a reduction of shares subject to such Stock Award or Prior Plans’ Award (i.e., “net exercised”). In addition, any shares reacquired or withheld (or not issued) by the Company to satisfy a tax withholding obligation in connection with an Option or Stock Appreciation Right or a Prior Plans’ Appreciation Award, or any shares repurchased by the Company on the open market with the proceeds of the exercise or strike price of an Option or Stock Appreciation Right or a Prior Plans’ Appreciation Award will no longer be available for issuance under the Plan. In the event that a Stock Appreciation Right or a Prior Plans’ Award that is a stock appreciation right is settled in shares of Common Stock, the gross number of shares of Common Stock subject to such award will no longer be available for issuance under the Plan.

(c)Incentive Stock Option Limit.Subject to the Share Reserve and Section 9(a) relating to Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options will be 50,000,000 shares of Common Stock.

(d)Individual Award Limitations. Subject to the Share Reserve and Section 9(a) relating to Capitalization Adjustments:

(i)    A maximum of 5,000,000 shares of Common Stock subject to Options, SARs and Other Stock Awards whose value is determined by reference to an increase over an exercise or strike price of at least 100% of the Fair Market Value on the date any such Stock Award is granted may be granted to any one Participant during any one calendar year.

(ii)    A maximum of 5,000,000 shares of Common Stock subject to Performance Stock Awards may be granted to any one Participant during any one calendar year (whether the grant, vesting or exercise is contingent upon the attainment during the Performance Period of the Performance Goals).

(iii)    A maximum of $10,000,000 subject to Performance Cash Awards may be granted to any one Participant during any one calendar year.

(e)Limitation on Grants toNon-Employee Directors.The (i) maximum number of shares of Common Stock subject to Stock Awards granted under the Plan or otherwise during any one calendar year (beginning with the 2017 calendar year) to anyNon-Employee Director, taken together with the (ii) cash fees paid by the Company to suchNon-Employee Director during such calendar year, and in both cases for service on the Board, will not exceed $750,000 in total value (calculating the value of any such Stock Awards based on the grant date fair value of such Stock Awards for financial reporting purposes), or, with respect to the calendar year in which aNon-Employee Director is first appointed or elected to the Board, $1,500,000.

(f)Source of Shares. The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise.

4.    ELIGIBILITY.

(a)Eligibility for Specific Stock Awards. Incentive Stock Options may be granted only to employees of the Company or a “parent corporation” or “subsidiary corporation” thereof (as such terms are defined in Sections 424(e) and 424(f) of the Code). Stock Awards other than Incentive Stock Options may be granted to Employees, Directors and Consultants;provided, however, that Stock Awards may not be granted to Employees, Directors and Consultants who are providing Continuous Service only to any “parent” of the Company, as such term is defined in Rule 405, unless (i) the stock underlying such Stock Awards is treated as “service recipient stock” under Section 409A of the Code (for example, because the Stock Awards are granted pursuant to a corporate transaction such as a spin off transaction) or (ii) the Company, in consultation with its legal counsel, has determined that such Stock Awards are otherwise exempt from or alternatively comply with the requirements of Section 409A of the Code.

(b)Ten Percent Stockholders. A Ten Percent Stockholder will not be granted an Incentive Stock Option unless the exercise price of such Option is at least 110% of the Fair Market Value on the date of grant and the Option is not exercisable after the expiration of five years from the date of grant.

5.    PROVISIONS RELATINGTO OPTIONSAND STOCK APPRECIATION RIGHTS.

Each Option or Stock Appreciation Right Agreement will be in such form and will contain such terms and conditions as the Board deems appropriate. All Options will be separately designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates are issued, a separate certificate or certificates will be issued for shares of Common Stock purchased on exercise of each type of Option. If an Option is not specifically designated as an Incentive Stock Option, or if an Option is designated as an Incentive Stock Option but some portion or all of the Option fails to qualify as an Incentive Stock Option under the applicable rules, then the Option (or portion thereof) will be a Nonstatutory Stock Option. The provisions of separate Option or Stock Appreciation Right Agreements need not be identical;provided, however, that each Award Agreement will conform to (through incorporation of provisions hereof by reference in the applicable Award Agreement or otherwise) the substance of each of the following provisions:

(a)Term. Subject to the provisions of Section 4(b) regarding Ten Percent Stockholders, no Option or SAR will be exercisable after the expiration of seven years from the date of its grant or such shorter period specified in the Award Agreement.

(b)Exercise Price. Subject to the provisions of Section 4(b) regarding Ten Percent Stockholders, the exercise or strike price of each Option or SAR will be not less than 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date the Award is granted. Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value of the Common Stock subject to the Award on the date the Award is granted if such Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Transaction and in a manner consistent with the provisions of Section 409A of the Code and, if applicable, Section 424(a) of the Code. Each SAR will be denominated in shares of Common Stock equivalents.

(c)Purchase Price for Options. The purchase price of Common Stock acquired pursuant to the exercise of an Option may be paid, to the extent permitted by applicable law and as determined by the Board in its sole discretion, by any combination of the methods of payment set forth below. The Board will have the authority to grant Options that do not permit all of the following methods of payment (or that otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to use a particular method of payment. The permitted methods of payment are as follows:

(i)    by cash, check, bank draft or money order payable to the Company;

(ii)    pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of the Common Stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds;

(iii)    by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock;

(iv)    if an Option is a Nonstatutory Stock Option, by a “net exercise” arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price;provided, however, that the Company will accept a cash or other payment from the Participant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole shares to be issued. Shares of Common Stock will no longer be subject to an Option and will not be exercisable thereafter to the extent that (A) shares issuable upon exercise are used to pay the exercise price pursuant to the “net exercise,” (B) shares are delivered to the Participant as a result of such exercise, and (C) shares are withheld to satisfy tax withholding obligations; or

(v)    in any other form of legal consideration that may be acceptable to the Board and specified in the applicable Award Agreement.

(d)Exercise and Payment of a SAR. To exercise any outstanding SAR, the Participant must provide written notice of exercise to the Company in compliance with the provisions of the Award Agreement evidencing such SAR. The appreciation distribution payable on the exercise of a SAR will be not greater than an amount equal to the excess of (A) the aggregate Fair Market Value (on the date of the exercise of the SAR) of a number of shares of Common Stock equal to the number of Common Stock equivalents in which the Participant is vested under such SAR, and with respect to which the Participant is exercising the SAR on such date, over (B) the aggregate strike price of the number of Common Stock equivalents with respect to which the Participant is exercising the SAR on such date. The appreciation distribution may be paid in Common Stock, in cash, in any combination of the two or in any other form of consideration, as determined by the Board and contained in the Award Agreement evidencing such SAR.

(e)Transferability of Options and SARs. The Board may, in its sole discretion, impose such limitations on the transferability of Options and SARs as the Board will determine. In the absence of such a determination by the Board to the contrary, the restrictions set forth in this Section 5(e) on the transferability of Options and SARs will apply. Notwithstanding the foregoing or anything in the Plan or an Award Agreement to the contrary, no Option or SAR may be transferred to any financial institution without prior stockholder approval.

(i)Restrictions on Transfer. An Option or SAR will not be transferable except by will or by the laws of descent and distribution (and pursuant to Sections 5(e)(ii) and 5(e)(iii) below) and will be exercisable during the lifetime of the Participant only by the Participant. Subject to the foregoing paragraph, the Board may permit transfer of the Option or SAR in a manner that is not prohibited by applicable tax and securities laws. Except as explicitly provided in the Plan, neither an Option nor a SAR may be transferred for consideration.

(ii)Domestic Relations Orders. Subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant to the terms of a domestic

relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury RegulationsSection 1.421-1(b)(2). If an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer.

(iii)Beneficiary Designation. Subject to the approval of the Board or a duly authorized Officer, a Participant may, by delivering written notice to the Company, in a form approved by the Company (or the designated broker), designate a third party who, upon the death of the Participant, will thereafter be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise. In the absence of such a designation, upon the death of the Participant, the executor or administrator of the Participant’s estate will be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise. However, the Company may prohibit designation of a beneficiary at any time, including due to any conclusion by the Company that such designation would be inconsistent with the provisions of applicable laws.

(f)Vesting Generally. The total number of shares of Common Stock subject to an Option or SAR may vest and become exercisable in periodic installments that may or may not be equal. The Option or SAR may be subject to such other terms and conditions on the time or times when it may or may not be exercised (which may be based on the satisfaction of Performance Goals or other criteria) as the Board may deem appropriate. The vesting provisions of individual Options or SARs may vary. The provisions of this Section 5(f) are subject to Section 2(g) and any Option or SAR provisions governing the minimum number of shares of Common Stock as to which an Option or SAR may be exercised.

(g)Termination of Continuous Service. Except as otherwise provided in the applicable Award Agreement or other written agreement between the Participant and the Company or an Affiliate, if a Participant’s Continuous Service terminates (other than for Cause and other than upon the Participant’s death or Disability), the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i) the date three months following such termination of Continuous Service (or such longer or shorter period specified in the Award Agreement), and (ii) the expiration of the term of the Option or SAR as set forth in the Award Agreement. If, after such termination of Continuous Service, the Participant does not exercise his or her Option or SAR (as applicable) within the applicable time frame, the Option or SAR (as applicable) will terminate.

(h)Extension of Termination Date. Except as otherwise provided in the applicable Award Agreement or other written agreement between the Participant and the Company or an Affiliate,if the exercise of an Option or SAR following the termination of the Participant’s Continuous Service (other than for Cause and other than upon the Participant’s death or Disability) would be prohibited at any time solely because the issuance of shares of Common Stock would violate the registration requirements under the Securities Act, then the Option or SAR will terminate on the earlier of (i) the expiration of a total period of time (that need not be

consecutive) equal to the applicable post-termination exercise period after the termination of the Participant’s Continuous Service during which the exercise of the Option or SAR would not be in violation of such registration requirements, or (ii) the expiration of the term of the Option or SAR as set forth in the applicable Award Agreement. In addition, unless otherwise provided in a Participant’s Award Agreement or other written agreement between the Participant and the Company or an Affiliate, if the sale of any Common Stock received upon exercise of an Option or SAR following the termination of the Participant’s Continuous Service (other than for Cause) would violate the Company’s insider trading policy, then the Option or SAR will terminate on the earlier of (i) the expiration of a period of time (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant’s Continuous Service during which the sale of the Common Stock received upon exercise of the Option or SAR would not be in violation of the Company’s insider trading policy, or (ii) the expiration of the term of the Option or SAR as set forth in the applicable Award Agreement.

(i)Disability of Participant. Except as otherwise provided in the applicable Award Agreement or other written agreement between the Participant and the Company or an Affiliate, if a Participant’s Continuous Service terminates as a result of the Participant’s Disability, the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i) the date 12 months following such termination of Continuous Service (or such longer or shorter period specified in the Award Agreement), and (ii) the expiration of the term of the Option or SAR as set forth in the Award Agreement. If, after such termination of Continuous Service, the Participant does not exercise his or her Option or SAR (as applicable) within the applicable time frame, the Option or SAR (as applicable) will terminate.

(j)Death of Participant. Except as otherwise provided in the applicable Award Agreement or other written agreement between the Participant and the Company or an Affiliate, if (i) a Participant’s Continuous Service terminates as a result of the Participant’s death, or (ii) the Participant dies within the period (if any) specified in the Award Agreement for exercisability after the termination of the Participant’s Continuous Service (for a reason other than death), then the Participant’s Option or SAR may be exercised (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of death) by the Participant’s estate, by a person who acquired the right to exercise the Option or SAR by bequest or inheritance or by a person designated to exercise the Option or SAR upon the Participant’s death, but only within such period of time ending on the earlier of (i) the date 18 months following the date of death (or such longer or shorter period specified in the Award Agreement), and (ii) the expiration of the term of such Option or SAR as set forth in the Award Agreement. If, after the Participant’s death, the Option or SAR (as applicable) is not exercised within the applicable time frame, the Option or SAR (as applicable) will terminate.

(k)Termination for Cause. Except as explicitly provided otherwise in a Participant’s Award Agreement or other individual written agreement between the Participant and the Company or an Affiliate, if a Participant’s Continuous Service is terminated for Cause, the

Participant’s Option or SAR will terminate immediately upon such termination of Continuous Service, and the Participant will be prohibited from exercising his or her Option or SAR from and after the time of such termination of Continuous Service.

(l)Non-Exempt Employees. If an Option or SAR is granted to an Employee who is anon-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, the Option or SAR will not be first exercisable for any shares of Common Stock until at least six months following the date of grant of the Option or SAR (although the Award may vest prior to such date). Consistent with the provisions of the Worker Economic Opportunity Act, (i) if suchnon-exempt employee dies or suffers a Disability, (ii) upon a Transaction in which such Option or SAR is not assumed, continued, or substituted, (iii) upon a Change in Control, or (iv) upon the Participant’s retirement (as such term may be defined in the Participant’s Award Agreement, in another written agreement between the Participant and the Company or an Affiliate, or, if no such definition, in accordance with the Company’s or Affiliate’s then current employment policies and guidelines), the vested portion of any Options and SARs may be exercised earlier than six months following the date of grant. The foregoing provision is intended to operate so that any income derived by anon-exempt employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay. To the extent permitted and/or required for compliance with the Worker Economic Opportunity Act to ensure that any income derived by anon-exempt employee in connection with the exercise, vesting or issuance of any shares under any other Stock Award will be exempt from the employee’s regular rate of pay, the provisions of this Section 5(l) will apply to all Stock Awards and are hereby incorporated by reference into such Stock Award Agreements.

6.    PROVISIONSOF AWARDS OTHERTHAN OPTIONSAND SARS.

(a)Restricted Stock Awards. Each Restricted Stock Award Agreement will be in such form and will contain such terms and conditions as the Board deems appropriate. To the extent consistent with the Company’s bylaws, at the Board’s election, shares of Common Stock underlying a Restricted Stock Award may be (i) held in book entry form subject to the Company’s instructions until any restrictions relating to the Restricted Stock Award lapse, or (ii) evidenced by a certificate, which certificate will be held in such form and manner as determined by the Board. The terms and conditions of Restricted Stock Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Award Agreements need not be identical.Each Restricted Stock Award Agreement will conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions:

(i)Consideration. A Restricted Stock Award may be awarded in consideration for (A) cash, check, bank draft or money order payable to the Company, (B) past services to the Company or an Affiliate, or (C) any other form of legal consideration (including future services) that may be acceptable to the Board, in its sole discretion, and permissible under applicable law.

(ii)Vesting.Subject to Section 2(g), shares of Common Stock awarded under the Restricted Stock Award Agreement may be subject to forfeiture to the Company in accordance with a vesting schedule to be determined by the Board.

(iii)Termination of Participant’s Continuous Service. If a Participant’s Continuous Service terminates, the Company may receive through a forfeiture condition or a repurchase right any or all of the shares of Common Stock held by the Participant that have not vested as of the date of such termination of Continuous Service under the terms of the Restricted Stock Award Agreement.

(iv)Transferability. Rights to acquire shares of Common Stock under the Restricted Stock Award Agreement will be transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock Award Agreement, as the Board will determine in its sole discretion, so long as Common Stock awarded under the Restricted Stock Award Agreement remains subject to the terms of the Restricted Stock Award Agreement. Notwithstanding the foregoing or anything in the Plan or a Restricted Stock Award Agreement to the contrary, no Restricted Stock Award may be transferred to any financial institution without prior stockholder approval.

(b)Restricted Stock Unit Awards.Each Restricted Stock Unit Award Agreement will be in such form and will contain such terms and conditions as the Board deems appropriate. The terms and conditions of Restricted Stock Unit Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Unit Award Agreements need not be identical. Each Restricted Stock Unit Award Agreement will conform to (through incorporation of the provisions hereof by reference in the Agreement or otherwise) the substance of each of the following provisions:

(i)Consideration. At the time of grant of a Restricted Stock Unit Award, the Board will determine the consideration, if any, to be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award. The consideration to be paid (if any) by the Participant for each share of Common Stock subject to a Restricted Stock Unit Award may be paid in any form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law.

(ii)Vesting.Subject to Section 2(g), at the time of the grant of a Restricted Stock Unit Award, the Board may impose such restrictions on or conditions to the vesting of the Restricted Stock Unit Award as it, in its sole discretion, deems appropriate.

(iii)Payment. A Restricted Stock Unit Award may be settled by the delivery of shares of Common Stock, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board and contained in the Restricted Stock Unit Award Agreement.

(iv)Additional Restrictions.At the time of the grant of a Restricted Stock Unit Award, the Board, as it deems appropriate, may impose such restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to a Restricted Stock Unit Award to a time after the vesting of such Restricted Stock Unit Award.

(v)Termination of Participant’s Continuous Service.Except as otherwise provided in the applicable Restricted Stock Unit Award Agreement or other written agreement between the Participant and the Company or an Affiliate, such portion of the Restricted Stock Unit Award that has not vested will be forfeited upon the Participant’s termination of Continuous Service.

(c)    Performance Awards.

(i)Performance Stock Awards. A Performance Stock Award is a Stock Award (covering a number of shares not in excess of that set forth in Section 3(d)(ii)) that is payable (including that may be granted, vest or be exercised) contingent upon the attainment during a Performance Period of certain Performance Goals. A Performance Stock Award may, but need not, require the Participant’s completion of a specified period of Continuous Service. Subject to Section 2(g), the length of any Performance Period, the Performance Goals to be achieved during the Performance Period, and the measure of whether and to what degree such Performance Goals have been attained will be conclusively determined by the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee), in its sole discretion. In addition, to the extent permitted by applicable law and the applicable Award Agreement, the Board may determine that cash may be used in payment of Performance Stock Awards.

(ii)Performance Cash Awards. A Performance Cash Award is a cash award (for a dollar value not in excess of that set forth in Section 3(d)(iii)) that is payable contingent upon the attainment during a Performance Period of certain Performance Goals. A Performance Cash Award may, but need not, require the Participant’s completion of a specified period of Continuous Service. Subject to Section 2(g), the length of any Performance Period, the Performance Goals to be achieved during the Performance Period, and the measure of whether and to what degree such Performance Goals have been attained will be conclusively determined by the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee), in its sole discretion. The Board may specify the form of payment of Performance Cash Awards, which may be cash or other property, or may provide for a Participant to have the option for his or her Performance Cash Award, or such portion thereof as the Board may specify, to be paid in whole or in part in cash or other property.

(iii)Committee and Board Discretion. The Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee) retains the discretion to reduce or eliminate the compensation or economic benefit due upon the attainment of any Performance Goals and to define the manner of calculating the Performance Criteria it selects to use for a Performance Period.

(iv)Section 162(m) Compliance. Unless otherwise permitted in compliance with Section 162(m) of the Code with respect to an Award intended to qualify as “performance-based

compensation” thereunder, the Committee will establish the Performance Goals applicable to, and the formula for calculating the amount payable under, the Award no later than the earlier of (A) the date 90 days after the commencement of the applicable Performance Period, and (B) the date on which 25% of the Performance Period has elapsed, and in any event at a time when the achievement of the applicable Performance Goals remains substantially uncertain. Prior to the payment of any compensation under an Award intended to qualify as “performance-based compensation” under Section 162(m) of the Code, the Committee will certify the extent to which any Performance Goals and any other material terms under such Award have been satisfied (other than in cases where the Performance Goals relate solely to the increase in the value of the Common Stock). Notwithstanding satisfaction or any completion of any Performance Goals, shares subject to Options, cash or other benefits granted, issued, retainable and/or vested under an Award on account of satisfaction of such Performance Goals may be reduced by the Committee on the basis of any further considerations as the Committee, in its sole discretion, will determine.

(v)Section 162(m) Transition Relief. Notwithstanding anything in the Plan to the contrary, any provision in the Plan that refers to “performance-based compensation” under Section 162(m) of the Code will only apply to any Award that is intended to qualify, and is eligible to qualify, as “performance-based compensation” under Section 162(m) of the Code pursuant to the transition relief provided by the Tax Cuts and Jobs Act (the “TCJA”) for remuneration provided pursuant to a written binding contract which was in effect on November 2, 2017 and which was not modified in any material respect on or after such date, as determined by the Board, in its sole discretion, in accordance with the TCJA and any applicable guidance, rulings or regulations issued by the U.S. Department of the Treasury, the Internal Revenue Service or any other governmental authority.

(d)Other Stock Awards. Other forms of Stock Awards valued in whole or in part by reference to, or otherwise based on, Common Stock may be granted either alone or in addition to Stock Awards granted under Section 5 and this Section 6. Subject to the provisions of the Plan (including, but not limited to, Sections 2(g) and 2(h)), the Board will have sole and complete authority to determine the persons to whom and the time or times at which such Other Stock Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Stock Awards and all other terms and conditions of such Other Stock Awards.

7.    COVENANTSOFTHE COMPANY.

(a)Availability of Shares. The Company will keep available at all times the number of shares of Common Stock reasonably required to satisfy then-outstanding Stock Awards.

(b)Securities Law Compliance. The Company will seek to obtain from each regulatory commission or agency having jurisdiction over the Plan the authority required to grant Stock Awards and to issue and sell shares of Common Stock upon exercise of the Stock Awards;provided, however, that this undertaking will not require the Company to register under the Securities Act the Plan, any Stock Award or any Common Stock issued or issuable pursuant to any

such Stock Award. If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Common Stock upon exercise of such Stock Awards unless and until such authority is obtained. A Participant will not be eligible for the grant of an Award or the subsequent issuance of cash or Common Stock pursuant to the Award if such grant or issuance would be in violation of any applicable securities law.

(c)No Obligation to Notify or Minimize Taxes.The Company will have no duty or obligation to any Participant to advise such holder as to the time or manner of exercising a Stock Award. Furthermore, the Company will have no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of an Award or a possible period in which the Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of an Award to the holder of such Award.

8.    MISCELLANEOUS.

(a)Use of Proceeds from Sales of Common Stock.Proceeds from the sale of shares of Common Stock issued pursuant to Stock Awards will constitute general funds of the Company.

(b)Corporate Action Constituting Grant of Awards. Corporate action constituting a grant by the Company of an Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Award is communicated to, or actually received or accepted by, the Participant. In the event that the corporate records (e.g., Board consents, resolutions or minutes) documenting the corporate action constituting the grant contain terms (e.g., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or related grant documents as a result of a clerical error in the papering of the Award Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect terms in the Award Agreement or related grant documents.

(c)Stockholder Rights. No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to an Award unless and until (i) such Participant has satisfied all requirements for exercise of, or the issuance of shares of Common Stock under, the Award pursuant to its terms, and (ii) the issuance of the Common Stock subject to such Award has been entered into the books and records of the Company.

(d)No Employment or Other Service Rights. Nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Award was granted or will affect the right of the Company or an Affiliate to terminate (i) the employment of an Employee with or

without notice and with or without cause, (ii) the service of a Consultant pursuant to the terms of such Consultant’s agreement with the Company or an Affiliate, or (iii) the service of a Director pursuant to the bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be.

(e)Change in Time Commitment. In the event a Participant’s regular level of time commitment in the performance of his or her services for the Company or any Affiliate is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee) after the date of grant of any Award to the Participant, the Board has the right in its sole discretion to (x) make a corresponding reduction in the number of shares or cash amount subject to any portion of such Award that is scheduled to vest or become payable after the date of such change in time commitment, and (y) in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Award. In the event of any such reduction, the Participant will have no right with respect to any portion of the Award that is so reduced or extended.

(f)Incentive Stock Option Limitations. To the extent that the aggregate Fair Market Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any Affiliates) exceeds $100,000 (or such other limit established in the Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with such rules will be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s).

(g)Investment Assurances. The Company may require a Participant, as a condition of exercising or acquiring Common Stock under any Award, (i) to give written assurances satisfactory to the Company as to the Participant’s knowledge and experience in financial and business matters and/or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and business matters and that he or she is capable of evaluating, alone or together with the purchaser representative, the merits and risks of exercising the Award; and (ii) to give written assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Award for the Participant’s own account and not with any present intention of selling or otherwise distributing the Common Stock. The foregoing requirements, and any assurances given pursuant to such requirements, will be inoperative if (A) the issuance of the shares upon the exercise or acquisition of Common Stock under the Stock Award has been registered under a then currently effective registration statement under the Securities Act, or (B) as to any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in the circumstances under the then applicable securities laws. The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock.

(h)Withholding Obligations. Unless prohibited by the terms of an Award Agreement, the Company may, in its sole discretion, satisfy any federal, state, local or foreign tax withholding obligation relating to an Award by any of the following means or by a combination of such means: (i) causing the Participant to tender a cash payment; (ii) withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Stock Award, provided that notwithstanding anything to the contrary in the terms of an Award Agreement, the Company will have the discretion to determine the basis upon which the number of shares to be withheld will be calculated;provided, however,that no shares of Common Stock are withheld with a value exceeding the maximum amount of tax that may be required to be withheld by law (or such other amount as may be permitted while still avoiding classification of the Stock Award as a liability for financial accounting purposes); (iii) withholding cash from an Award settled in cash; (iv) withholding payment from any amounts otherwise payable to the Participant; or (v) by such other method as may be set forth in the Award Agreement.

(i)Electronic Delivery. Any reference herein to a “written” agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company’s intranet (or other shared electronic medium controlled by the Company to which the Participant has access).

(j)Deferrals. To the extent permitted by applicable law, the Board, in its sole discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may establish programs and procedures for deferral elections to be made by Participants. Deferrals by Participants will be made in accordance with Section 409A of the Code. Consistent with Section 409A of the Code, the Board may provide for distributions while a Participant is still an employee or otherwise providing services to the Company or an Affiliate. The Board is authorized to make deferrals of Awards and determine when, and in what annual percentages, Participants may receive payments, including lump sum payments, following the Participant’s termination of Continuous Service, and implement such other terms and conditions consistent with the provisions of the Plan and in accordance with applicable law.

(k)Compliance with Section 409A of the Code.Unless otherwise expressly provided for in an Award Agreement, the Plan and Award Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section 409A of the Code, and, to the extent not so exempt, in compliance with Section 409A of the Code. To the extent that the Board determines that any Award granted hereunder is not exempt from and is therefore subject to Section 409A of the Code, the Award Agreement evidencing such Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section 409A(a)(1) of the Code, and, to the extent applicable, the Plan and Award Agreements will be interpreted in accordance with the requirements of Section 409A of the Code. Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded and a Participant holding an Award that constitutes “deferred compensation” under Section 409A of the Code is a “specified employee” for purposes of Section 409A of the Code, no

distribution or payment of any amount will be made upon a “separation from service” before a date that is six months following the date of such Participant’s “separation from service” (as defined in Section 409A of the Code without regard to alternative definitions thereunder) or, if earlier, the date of the Participant’s death, unless such distribution or payment may be made in a manner that complies with Section 409A of the Code.

(l)Clawback/Recovery. All Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company’s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law, and any other clawback policy that the Company adopts. In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of Cause. No recovery of compensation under such a clawback policy will be an event giving rise to a right to resign for “good reason” or “constructive termination” (or similar term) under any agreement with the Company or an Affiliate.

9.    ADJUSTMENTSUPON CHANGESIN COMMON STOCK; OTHER CORPORATE EVENTS.

(a)Capitalization Adjustments. In the event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i) the class(es) and maximum number of securities subject to the Plan pursuant to Section 3(a), (ii) the class(es) and maximum number of securities that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section 3(c), (iii) the class(es) and maximum number of securities that may be awarded to any person pursuant to Section 3(d), and (iv) the class(es) and number of securities and price per share of stock subject to outstanding Stock Awards. The Board will make such adjustments, and its determination will be final, binding and conclusive.

(b)Dissolution or Liquidation. Except as otherwise provided in the Stock Award Agreement or any other written agreement between the Company or any Affiliate and the Participant, in the event of a dissolution or liquidation of the Company, all outstanding Stock Awards (other than Stock Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company’s right of repurchase) will terminate immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company’s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company notwithstanding the fact that the holder of such Stock Award is providing Continuous Service.

(c)Transaction. The provisions of this Section 9(c) will apply to Stock Awards in the event of a Transaction unless otherwise provided in the instrument evidencing the Stock Award or any other written arrangement between the Company or any Affiliate and the Participant or in any director compensation policy of the Company.

(i)Stock Awards May Be Assumed. In the event of a Transaction, any surviving corporation or acquiring corporation (or the surviving or acquiring corporation’s parent company) may assume or continue any or all Stock Awards outstanding under the Plan or may substitute similar stock awards for Stock Awards outstanding under the Plan (including but not limited to, awards to acquire the same consideration paid to the stockholders of the Company pursuant to the Transaction), and any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to Stock Awards may be assigned by the Company to the successor of the Company (or the successor’s parent company, if any), in connection with such Transaction. A surviving corporation or acquiring corporation (or its parent) may choose to assume or continue only a portion of a Stock Award or substitute a similar stock award for only a portion of a Stock Award, or may choose to assume or continue, or substitute similar stock awards for, the Stock Awards held by some, but not all Participants. The terms of any assumption, continuation or substitution will be set by the Board.

(ii)Stock Awards Held by Current Participants. In the event of a Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Stock Awards or substitute similar stock awards for such outstanding Stock Awards, then with respect to Stock Awards that have not been assumed, continued or substituted and that are held by Participants whose Continuous Service has not terminated prior to the effective time of the Transaction (referred to as the “Current Participants”), the vesting of such Stock Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Stock Awards may be exercised) will be accelerated in full (and with respect to any such Stock Awards that are subject to performance-based vesting conditions or requirements, vesting will be deemed to be satisfied at the target level of performance) to a date prior to the effective time of such Transaction (contingent upon the effectiveness of the Transaction) as the Board will determine (or, if the Board does not determine such a date, to the date that is five days prior to the effective time of the Transaction), and such Stock Awards will terminate if not exercised (if applicable) at or prior to the effective time of the Transaction, and any reacquisition or repurchase rights held by the Company with respect to such Stock Awards will lapse (contingent upon the effectiveness of the Transaction).

(iii)Stock Awards Held by Current Participants in Certain Control Acquisitions. In the event of a Control Acquisition that was not approved by the Board prior to the consummation of such transaction, then with respect to Stock Awards that are held by Current Participants, the vesting of such Stock Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Stock Awards may be exercised) will be accelerated in full (and with respect to any such Stock Awards that are subject to performance-based vesting conditions or requirements, vesting will be deemed to be satisfied at the target level of performance) to a date prior to the effective time of such Control Acquisition (contingent upon the effectiveness of the Control Acquisition) as the Board will determine (or, if the Board does not determine such a date, to the date that is five days prior to the effective time of the Control Acquisition) and any reacquisition or repurchase rights held by the Company with respect to such Stock Awards will lapse (contingent upon the effectiveness of the Control Acquisition).

(iv)Stock Awards Held by Persons other than Current Participants. In the event of a Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Stock Awards or substitute similar stock awards for such outstanding Stock Awards, then with respect to Stock Awards that have not been assumed, continued or substituted and that are held by persons other than Current Participants, such Stock Awards will terminate if not exercised (if applicable) prior to the effective time of the Transaction;provided,however, that any reacquisition or repurchase rights held by the Company with respect to such Stock Awards will not terminate and may continue to be exercised notwithstanding the Transaction.

(v)Payment for Stock Awards in Lieu of Exercise. Notwithstanding the foregoing, in the event a Stock Award will terminate if not exercised prior to the effective time of a Transaction, the Board may provide that the holder of such Stock Award may not exercise such Stock Award but instead will receive a payment, in such form as may be determined by the Board, equal in value to the excess, if any, of (A) the value of the property the Participant would have received upon the exercise of the Stock Award immediately prior to the effective time of the Transaction, over (B) any exercise price payable by such holder in connection with such exercise. For clarity, this payment may be zero if the value of the property is equal to or less than the exercise price. Payments under this provision may be delayed to the same extent that payment of consideration to the holders of the Company’s Common Stock in connection with the Transaction is delayed as a result of escrows, earn outs, holdbacks or any other contingencies.

(d)Change in Control. The provisions of this Section 9(d) will apply to Stock Awards in the event of a Change in Control unless otherwise provided in the instrument evidencing the Stock Award or any other written arrangement between the Company or any Affiliate and the Participant or in any director compensation policy of the Company.

(i)    If a Change in Control occurs and within one month before, as of, or within thirteen months after, the effective time of such Change in Control a Participant’s Continuous Service terminates due to an involuntary termination (not including death or Disability) without Cause or due to a voluntary termination with Good Reason, then the vesting of such Stock Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Stock Awards may be exercised) will be accelerated in accordance with the vesting schedule applicable to such Stock Awards as if (A) with respect to any such Stock Awards that are subject to vesting conditions or requirements based solely on such Participant’s Continuous Service, such Participant’s Continuous Service had continued for twelve months following the date of termination of Continuous Service, and (B) with respect to any such Stock Awards that are subject to performance-based vesting conditions or requirements, vesting has been satisfied at the target level of performance. Such vesting acceleration will occur on the date of termination of such Participant’s Continuous Service, or if later, the effective date of the Change in Control (if the Participant’s termination of Continuous Service occurs prior to the Change in Control).

(ii)    If any payment or benefit a Participant will or may receive from the Company or otherwise (a “280GPayment”) would (i) constitute a “parachute payment” within

the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then any such 280G Payment (a “Payment”) will be equal to the Reduced Amount. The “Reduced Amount” will be either (x) the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined by clause (x) or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in the Participant’s receipt, on anafter-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction will occur in the manner (the “Reduction Method”) that results in the greatest economic benefit for the Participant. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the “Pro Rata Reduction Method”).

Notwithstanding any provision of the foregoing paragraph to the contrary, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A of the Code that would not otherwise be subject to taxes pursuant to Section 409A of the Code, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, will be modified so as to avoid the imposition of taxes pursuant to Section 409A of the Code as follows: (A) as a first priority, the modification will preserve to the greatest extent possible, the greatest economic benefit for the Participant as determined on anafter-tax basis; (B) as a second priority, Payments that are contingent on future events (e.g., being terminated without Cause), will be reduced (or eliminated) before Payments that are not contingent on future events; and (C) as a third priority, Payments that are “deferred compensation” within the meaning of Section 409A of the Code will be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section 409A of the Code.

If a Participant receives a Payment for which the Reduced Amount was determined pursuant to clause (x) of the first paragraph of this Section 9(d)(ii) and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, the Participant agrees to promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x) of the first paragraph of this Section 9(d)(ii)) so that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y) of the first paragraph of this Section 9(d)(ii), the Participant will have no obligation to return any portion of the Payment pursuant to the preceding sentence.

Unless the Participant and the Company agree on an alternative accounting firm or law firm, the accounting firm engaged by the Company for general tax compliance purposes as of the day prior to the effective date of the Change in Control will perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the

individual, entity or group effecting the Change in Control, the Company will appoint a nationally recognized accounting or law firm to make the determinations required hereunder. The Company will bear all expenses with respect to the determinations by such accounting or law firm required to be made hereunder.

The Company will use commercially reasonable efforts to cause the accounting or law firm engaged to make the determinations hereunder to provide its calculations, together with detailed supporting documentation, to the Participant and the Company within 15 calendar days after the date on which the Participant’s right to a 280G Payment becomes reasonably likely to occur (if requested at that time by the Participant or the Company) or such other time as requested by the Participant or the Company.

10.    TERMINATIONOR SUSPENSIONOFTHE PLAN.

(a)Termination or Suspension. The Board may suspend or terminate the Plan at any time. No Incentive Stock Option will be granted afterthe tenth anniversary of the earlier of (i) the date the Plan is adopted by the Board, or (ii) the date the Plan is approved by the stockholders of the Company. No Awards may be granted under the Plan while the Plan is suspended or after it is terminated.

(b)No Impairment of Rights.Suspension or termination of the Plan will not materially impair rights and obligations under any Award granted while the Plan is in effect except with the written consent of the affected Participant or as otherwise permitted in the Plan.

11.    EFFECTIVE DATEOF PLAN.

This Plan will become effective on the Effective Date.

12.    CHOICEOF LAW.

The laws of the State of California will govern all questions concerning the construction, validity and interpretation of this Plan, without regard to that state’s conflict of laws rules.

13.DEFINITIONS.As used in the Plan, the following definitions will apply to the capitalized terms indicated below:

(a)     “Affiliate” means, at the time of determination, any “parent” or “subsidiary” of the Company as such terms are defined in Rule 405. The Board will have the authority to determine the time or times at which “parent” or “subsidiary” status is determined within the foregoing definition.

(b)    “Award” means a Stock Award or a Performance Cash Award.

(c)    “Award Agreement” means a written agreement between the Company and a Participant evidencing the terms and conditions of an Award.

(d)    “Board” means the Board of Directors of the Company.

(e)    “Capitalization Adjustment” means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Stock Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment.

(f)    “Causewill have the meaning ascribed to such term in any written agreement between the Participant and the Company or an Affiliate defining such term and, in the absence of such agreement, such term will mean, with respect to a Participant, the occurrence of any of the following events: (i) such Participant’s conviction of, or plea of no contest with respect to, any crime involving fraud, dishonesty or moral turpitude; (ii) such Participant’s attempted commission of or participation in a fraud or act of dishonesty against the Company or an Affiliate that results in (or might have reasonably resulted in) material harm to the business of the Company or an Affiliate; (iii) such Participant’s intentional, material violation of any contract or agreement between the Participant and the Company or an Affiliate, or any statutory duty the Participant owes to the Company or an Affiliate; or (iv) such Participant’s conduct that constitutes gross misconduct, insubordination, incompetence or habitual neglect of duties and that results in (or might have reasonably resulted in) material harm to the business of the Company or an Affiliate. The determination that a termination of a Participant’s Continuous Service is for Cause will not be made unless and until there will have been delivered to such Participant a copy of a resolution duly adopted by the affirmative vote of at least a majority of the Board at a meeting of the Board called and held for such purpose (after reasonable notice to such Participant and an opportunity for such Participant, together with such Participant’s counsel, to be heard before the Board), finding that in the good faith opinion of the Board, such Participant was guilty of the conduct constituting “Cause” and specifying the particulars. Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Company or an Affiliate or such Participant for any other purpose.

(g)    “Change in Control” means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events:

(i)    a sale, lease or other disposition of all or substantially all of the assets of the Company;

(ii)    an acquisition by any Exchange Act Person of the beneficial ownership (within the meaning of Rule13d-3 promulgated under the Exchange Act, or comparable

successor rule) of securities of the Company representing at least 50% of the combined voting power entitled to vote in the election of Directors other than by virtue of a merger, consolidation or similar transaction;

(iii)    a merger, consolidation or similar transaction in which the Company is not the surviving corporation; or

(iv)    a reverse merger, consolidation or similar transaction in which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.

Notwithstanding the foregoing definition or any other provision of this Plan, the term Change in Control will not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company.

(h)    “Code” means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.

(i)    “Committee” means a committee of one or more Directors to whom authority has been delegated by the Board in accordance with Section 2(c).

(j)    “Common Stock” means the common stock of the Company.

(k)    “Company” means Exelixis, Inc., a Delaware corporation.

(l)    “Consultant” means any person, including an advisor, who is (i) engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii) serving as a member of the board of directors of an Affiliate and is compensated for such services. However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a “Consultant” for purposes of the Plan.Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only if a FormS-8 Registration Statement under the Securities Act is available to register either the offer or the sale of the Company’s securities to such person.

(m)    “Continuous Service” means that the Participant’s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Director or Consultant or a change in the Entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant’s service with the Company or an Affiliate, will not terminate a Participant’s Continuous Service;provided, however, thatif the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, in its sole discretion, such Participant’s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate.

For example, a change in status from an Employee of the Company to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service. To the extent permitted by law, the Board or the chief executive officer of the Company, in that party’s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i) any leave of absence approved by the Board or chief executive officer, including sick leave, military leave or any other personal leave, or (ii) transfers between the Company, an Affiliate, or their successors. Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in a Stock Award only to such extent as may be provided in the Company’s or Affiliate’s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law.

(n)    “Corporate Transaction” means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events:

(i)    a sale, lease or other disposition of all or substantially all of the assets of the Company;

(ii)    an acquisition by any Exchange Act Person of the beneficial ownership (within the meaning of Rule13d-3 promulgated under the Exchange Act, or comparable successor rule) of securities of the Company representing at least 50% of the combined voting power entitled to vote in the election of Directors (a “Control Acquisition”);

(iii)    a merger, consolidation or similar transaction in which the Company is not the surviving corporation; or

(iv)    a reverse merger, consolidation or similar transaction in which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.

Notwithstanding the foregoing definition or any other provision of this Plan, the terms Corporate Transaction and Control Acquisition will not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company.

(o)    “Covered Employee” will have the meaning provided in Section 162(m)(3) of the Code.

(p)    “Director” means a member of the Board.

(q)    “Disability” means, with respect to a Participant, the inability of such Participant to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to last for a continuous period of not less than 12 months, as provided in Sections 22(e)(3) and 409A(a)(2)(c)(i) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances.

(r)    “Effective Date” means the effective date of this Plan document, which is the date of the annual meeting of stockholders of the Company held in 2017, provided this Plan is approved by the Company’s stockholders at such meeting.

(s)    “Employee” means any person employed by the Company or an Affiliate. However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an “Employee” for purposes of the Plan.

(t)    “Entity” means a corporation, partnership, limited liability company or other entity.

(u)    “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

(v)    “Exchange Act Personmeans any natural person, Entity or “group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act), except that “Exchange Act Person” will not include (i) the Company or any Subsidiary of the Company, (ii) any employee benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities, (iv) an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; or (v) any natural person, Entity or “group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company’s then outstanding securities.

(w)    “Fair Market Value” means, as of any date, the value of the Common Stock determined as follows:

(i)    If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value of a share of Common Stock will be, unless otherwise determined by the Board, the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable.

(ii)    Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing selling price on the last preceding date for which such quotation exists.

(iii)    In the absence of such markets for the Common Stock, the Fair Market Value will be determined by the Board in good faith and in a manner that complies with Sections 409A and 422 of the Code.

(x)    “Full Value Award” means a Stock Award that is not an Option or SAR with respect to which the exercise or strike price is at least 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date of grant.

(y)    “Good Reason” means that one or more of the following are undertaken by the Company or an Affiliate without the Participant’s express written consent:

(i)    reduction of such Participant’s rate of compensation as in effect immediately prior to a Change in Control by greater than 10%, except to the extent the compensation of other similarly situated persons are accordingly reduced;

(ii)    failure to provide a package of welfare benefit plans that, taken as a whole, provide substantially similar benefits to those in which such Participant is entitled to participate immediately prior to a Change in Control (except that such Participant’s contributions may be raised to the extent of any cost increases imposed by third parties) or any action by the Company or an Affiliate that would adversely affect such Participant’s participation or reduce such Participant’s benefits under any of such plans;

(iii)    a change in such Participant’s responsibilities, authority, titles or offices resulting in diminution of position, excluding for this purpose an isolated, insubstantial and inadvertent action not taken in bad faith that is remedied by the Company or an Affiliate promptly after notice thereof is given by such person;

(iv)    a request that such Participant relocate to a worksite that is more than 50 miles from such Participant’s prior worksite, unless such person accepts such relocation opportunity;

(v)    a material reduction in duties;

(vi)    a failure or refusal of any successor company to assume the obligations of the Company or an Affiliate under an agreement with such Participant; or

(vii)    a material breach by the Company or an Affiliate of any of the material provisions of an agreement with such Participant.

Notwithstanding the foregoing, a Participant will have “Good Reason” for his or her resignation only if: (a) such Participant notifies the Company in writing, within 30 days after the occurrence of one of the foregoing event(s), specifying the event(s) constituting Good Reason and that he or she intends to terminate his or her employment no earlier than 30 days after providing such notice; (b) the Company does not cure such condition within 30 days following its receipt of such notice or states unequivocally in writing that it does not intend to attempt to cure such condition; and (c) the Participant resigns from employment within 30 days following the end of the period within which the Company was entitled to remedy the condition constituting Good Reason but failed to do so.

(z)     “Incentive Stock Option” means an option granted pursuant to Section 5 that is intended to be, and that qualifies as, an “incentive stock option” within the meaning of Section 422 of the Code.

(aa)    “Non-Employee Director”means a Director who either (i) is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item 404(a) of RegulationS-K promulgated pursuant to the Securities Act (“RegulationS-K”)), does not possess an interest in any other transaction for which disclosure would be required under Item 404(a) of RegulationS-K, and is not engaged in a business relationship for which disclosure would be required pursuant to Item 404(b) of RegulationS-K; or (ii) is otherwise considered a“non-employee director” for purposes of Rule16b-3.

(bb)    “Nonstatutory Stock Option” means any option granted pursuant to Section 5 that does not qualify as an Incentive Stock Option.

(cc)    “Officer” means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act.

(dd)    “Option” means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan.

(ee)    “Option Agreement” means a written agreement between the Company and an Optionholder evidencing the terms and conditions of an Option grant. Each Option Agreement will be subject to the terms and conditions of the Plan.

(ff)    “Optionholder” means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.

(gg)    “Other Stock Award” means an award based in whole or in part by reference to the Common Stock which is granted pursuant to the terms and conditions of Section 6(d).

(hh)    “Other Stock Award Agreementmeans a written agreement between the Company and a holder of an Other Stock Award evidencing the terms and conditions of an Other Stock Award grant. Each Other Stock Award Agreement will be subject to the terms and conditions of the Plan.

(ii)    “Outside Director” means a Director who either (i) is not a current employee of the Company or an “affiliated corporation” (within the meaning of Treasury Regulations promulgated under Section 162(m) of the Code), is not a former employee of the Company or an “affiliated corporation” who receives compensation for prior services (other than benefits under atax-qualified retirement plan) during the taxable year, has not been an officer of the Company or an “affiliated corporation,” and does not receive remuneration from the Company or an “affiliated corporation,” either directly or indirectly, in any capacity other than as a Director, or (ii) is otherwise considered an “outside director” for purposes of Section 162(m) of the Code.

(jj)    “Own,Owned,Owner,Ownership”A person or Entity will be deemed to “Own,” to have “Owned,” to be the “Owner” of, or to have acquired “Ownership” of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.

(kk)    “Participant” means a person to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Stock Award.

(ll)    “Performance Cash Award” means an award of cash granted pursuant to the terms and conditions of Section 6(c)(ii).

(mm)    “Performance Criteria” means the one or more criteria that the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee) will select for purposes of establishing the Performance Goals for a Performance Period. The Performance Criteria that will be used to establish such Performance Goals may be based on any one of, or combination of, the following as determined by the Committee (or Board, if applicable): (1) earnings (including earnings per share and net earnings); (2) earnings before interest, taxes and depreciation; (3) earnings before interest, taxes, depreciation and amortization; (4) total stockholder return; (5) return on equity or average stockholder’s equity; (6) return on assets, investment, or capital employed; (7) stock price; (8) margin (including gross margin); (9) income (before or after taxes); (10) operating income; (11) operating income after taxes;(12) pre-tax profit; (13) operating cash flow; (14) sales or revenue targets; (15) increases in revenue or product revenue; (16) expenses and cost reduction goals; (17) improvement in or attainment of working capital levels; (18) economic value added (or an equivalent metric); (19) market share; (20) cash flow; (21) cash flow per share; (22) share price performance; (23) debt reduction; (24) implementation or completion of projects or processes; (25) customer satisfaction; (26) stockholders’ equity; (27) capital expenditures; (28) debt levels; (29) operating profit or net operating profit; (30) workforce diversity; (31) growth of net income or operating income; (32) billings; and (33) to the extent that an Award is not intended to comply with Section 162(m) of the Code, other measures of performance selected by the Committee or Board.

(nn)    “Performance Goals” means, for a Performance Period, the one or more goals established by the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee) for the Performance Period based upon the Performance Criteria. Performance Goals may be based on a Company-wide basis, with respect to one or more business units, divisions, Affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise by the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee) (i) in the Award Agreement at the time the Award is granted or (ii) in such other document setting forth the Performance Goals at the time the Performance Goals are established, the Committee (or Board, if applicable) will

appropriately make adjustments in the method of calculating the attainment of Performance Goals for a Performance Period as follows: (1) to exclude restructuring and/or other nonrecurring charges; (2) to exclude exchange rate effects, as applicable, fornon-U.S. dollar denominated Performance Goals; (3) to exclude the effects of changes to generally accepted accounting principles; (4) to exclude the effects of any statutory adjustments to corporate tax rates; and (5) to exclude the effects of any items that are “unusual” in nature or occur “infrequently” as determined under generally accepted accounting principles.    

(oo)    “Performance Period” means the period of time selected by the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee) over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant’s right to and the payment of a Performance Stock Award or a Performance Cash Award. Performance Periods may be of varying and overlapping duration, at the sole discretion of the Committee (or Board, if applicable).

(pp)    “Performance Stock Award” means a Stock Award granted under the terms and conditions of Section 6(c)(i).

(qq)    “Plan” means this Exelixis, Inc. 2017 Equity Incentive Plan.

(rr)    “Prior Plans’ Award” means any stock award granted under the 2014 Plan, the 2000 Plan, the 2000Non-Employee Directors’ Plan, the 2011 Plan or the 2016 Inducement Plan, in each case that was outstanding as of the Effective Date.

(ss)    “Restricted Stock Award” means an award of shares of Common Stock which is granted pursuant to the terms and conditions of Section 6(a).

(tt)    “Restricted Stock Award Agreement” means a written agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan.

(uu)    “Restricted Stock Unit Awardmeans a right to receive shares of Common Stock which is granted pursuant to the terms and conditions of Section 6(b).

(vv)    “Restricted Stock Unit Award Agreementmeans a written agreement between the Company and a holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant. Each Restricted Stock Unit Award Agreement will be subject to the terms and conditions of the Plan.

(ww)    “Rule16b-3” means Rule16b-3 promulgated under the Exchange Act or any successor to Rule16b-3, as in effect from time to time.

(xx)    “Rule 405” means Rule 405 promulgated under the Securities Act.

(yy)    “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

(zz)    “Stock Appreciation Right” or “SARmeans a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section 5.

(aaa)    “Stock Appreciation Right Agreement” means a written agreement between the Company and a holder of a Stock Appreciation Right evidencing the terms and conditions of a Stock Appreciation Right grant. Each Stock Appreciation Right Agreement will be subject to the terms and conditions of the Plan.

(bbb)    “Stock Award” means any right to receive Common Stock granted under the Plan, including an Incentive Stock Option, a Nonstatutory Stock Option, a Stock Appreciation Right, a Restricted Stock Award, a Restricted Stock Unit Award, a Performance Stock Award or any Other Stock Award.

(ccc)    “Stock Award Agreement” means a written agreement between the Company and a Participant evidencing the terms and conditions of a Stock Award grant. Each Stock Award Agreement will be subject to the terms and conditions of the Plan.

(ddd)    “Subsidiary” means, with respect to the Company, (i) any corporation of which more than 50% of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii) any partnership, limited liability company or other entity in which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than 50%.

(eee)    “Ten Percent Stockholder” means a person who Owns (or is deemed to Own pursuant to Section 424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate.

(fff)    “Transaction” means a Corporate Transaction or a Change in Control.

EXELIXIS, INC.

1851 HARBOR BAY PARKWAY

ALAMEDA, CA 94502

VOTE BY INTERNET

Before The Meeting- Go towww.proxyvote.com

Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time on May 19, 2020.25, 2021. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form.

During The Meeting - Go towww.virtualshareholdermeeting.com/EXEL2020EXEL2021

You may attend the meeting via the Internet and vote during the meeting. Have the information that is printed in the box marked by the arrow available and follow the instructions.

VOTE BY PHONE - 1-800-690-6903

Use any touch-tone telephone to transmit your voting instructions up until 11:59 p.m. Eastern Time on May 19, 2020.25, 2021. Have your proxy card in hand when you call and then follow the instructions.

VOTE BY MAIL

Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717.

 

 

 

TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS:    
  D09343-Z76910D49740-P53795  KEEP THIS PORTION FOR YOUR RECORDS

 

DETACH AND RETURN THIS PORTION ONLY

THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED.

 

 

    EXELIXIS, INC.

        
 
 

The Board of Directors recommend a voteFOR all the nominees listed in Proposal 1 andFOR Proposals 2 3 and 4.3.

            
 1. 

To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders.

 For Against Abstain        
  

Nominees:

           
  

 

1a.

 

 

Charles Cohen, Ph.D.

 

 

 

 

 

 

     For Against Abstain 
  

 

1b.

 

 

 

Carl B. Feldbaum, Esq.

 

 

 

 

 

 

 

 

 

 

  2. 1h.      George Poste, DVM, Ph.D., FRSTo ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Exelixis’ independent registered public accounting firm for the fiscal year ending December 31, 2021.     
  

 

1c.

 

 

Maria C. Freire, Ph.D.

 

 

 

 

 

 

   1i.       Julie Anne Smith     
  

 

 

1d.

 

 

 

Alan M. Garber, M.D., Ph.D.

 

 

 

 

 

 

 

 

 

  3. 1j.       Lance Willsey, M.D.To approve, on an advisory basis, the compensation of Exelixis’ named executive officers, as disclosed in the accompanying Proxy Statement.     
      

 

1e.

 

 

Vincent T. Marchesi, M.D., Ph.D.

 

 

 

 

 

 

   

1k.      Jack L. Wyszomierski

  

 

 

 
  

 

1f.

 

 

Michael M. Morrissey, Ph.D.

 

 

 

 

 

 

  

2.

 

 

To ratifyNOTE: Such other business as may properly come before the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Exelixis’ independent registered public accounting firm for the fiscal year ending January 1, 2021.meeting or any adjournment thereof.

  

 

 

  

 

1g.

 

 

Stelios Papadopoulos, Ph.D.

 

 

 

 

 

 

       
 

For address changes and/or comments, please check this box and write them on the back where indicated.

  

 

3.1h.

 

 

To amend and restate the Exelixis 2017 Equity Incentive Plan to, among other things, increase the number of shares authorized for issuance by 21,000,000 shares.George Poste, DVM, Ph.D., FRS

 

 

 

 

 

 

        

 

4.1i.

 

 

To approve, on an advisory basis, the compensation of Exelixis’ named executive officers, as disclosed in the accompanying Proxy Statement.Julie Anne Smith

 

 

 

 

 

 

        

 

NOTE: Such other business as may properly come before the meeting or any adjournment thereof.1j.

Lance Willsey, M.D.

1k.

Jack L. Wyszomierski

     
 

Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name by authorized officer.

 

    
         
                      
 Signature [PLEASE SIGN WITHIN BOX] Date   Signature (Joint Owners) Date   


 

Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting:

The Notice and Proxy Statement and Annual Report are available at www.proxyvote.com.

 

 

 

D09344-Z76910D49741-P53795         

 

 

EXELIXIS, INC.

Annual Meeting of Stockholders

May 20, 2020 10:26, 2021 9:00 AM

This proxy is solicited by the Board of Directors

 

The undersigned hereby appoints Michael M. Morrissey, Christopher J. Senner and Jeffrey J. Hessekiel, and each of them, as attorneys and proxies of the undersigned, with full power of substitution, to vote all of the shares of stock of Exelixis, Inc. that the undersigned may be entitled to vote at the Annual Meeting of Stockholders of Exelixis, Inc. to be held at www.virtualshareholdermeeting.com/EXEL2020EXEL2021 on Wednesday, May 20, 2020,26, 2021, at 10:9:00 a.m. Pacific Time, and at any and all postponements, continuations and adjournments thereof, with all powers that the undersigned would possess if personally present, upon and in respect of the following matters and in accordance with the following instructions, with discretionary authority as to any and all other matters that may properly come before the meeting.

UNLESS A CONTRARY DIRECTION IS INDICATED, THIS PROXY WILL BE VOTED “FOR” ALL NOMINEES LISTED IN PROPOSAL 1 AND “FOR” PROPOSALS 2 3 AND 4,3, AS MORE SPECIFICALLY DESCRIBED IN THE PROXY STATEMENT. IF SPECIFIC INSTRUCTIONS ARE INDICATED, THIS PROXY WILL BE VOTED IN ACCORDANCE THEREWITH.

  
Address Changes/Comments: 
(If you noted any Address Changes/Comments above, please mark corresponding box on the reverse side.)
 Continued and to be signed on reverse side.